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Abstract 
 
The concept of lead-oriented synthesis (LOS) seeks to address to the paucity of 
diverse compounds with appropriate properties for biological screening. This 
thesis focuses on the preparation of diverse scaffolds, which, following 
decoration, may provide access to lead-like compounds. Key polyfunctionalised 
building blocks were prepared to enable the synthesis of such scaffolds by 
applying small tool-kits of robust synthetic methodologies. Computational tools 
were used to guide the development of key methodologies and to target the 
preparation of specific scaffolds. In addition, computational tools were used to 
retrospectively analyse the ability of the scaffolds prepared to provide access to 
lead-like space. 
 
Chapter 1 discusses ideal molecular properties for drugs and leads, modern 
synthetic approaches to the preparation of diverse screening compounds, and 
the emergence of LOS as a concept to resolve the challenge of sourcing large 
numbers of ideal screening compounds.  
 
Chapter 2 details the preparation of small polyfunctionalised building blocks 
through the allylation of amino acid-derivatives. A building-up (‘bottom-up’) 
approach was used to prepare scaffolds, exploiting the intramolecular capture of 
pendant nucleophiles at alkene or ester functionalities, and the use of transition 
metal-catalysed cyclisations. Four building blocks were used to prepare 22 
scaffolds. A virtual library of 1110 compounds was enumerated from the 
scaffolds, of which 66% were found to be lead-like. 
 
Chapter 3 describes the preparation of larger polycycles using an intramolecular 
[5+2] oxidopyrylium cycloaddition. The two polycyclic assemblies prepared were 
deconstructed using a ‘top-down’ approach to give six scaffolds. A virtual library 
of 798 compounds was enumerated from the scaffolds, of which 72% would be 
lead-like. 
 
Chapter 4 compares the value of the different LOS approaches developed, this 
considers the ability of the scaffolds to provide access to lead-like space, their 
three-dimensionality, and the synthetic economy of their preparation. 
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1.0 Introduction 
 
1.1 Challenges facing the pharmaceutical industry 
In 2010, the pharmaceutical industry was the largest investor (~£4.5bn) in 
research and development in the UK, and furthermore, contributed £17bn to 
exports.1 The challenges facing the sector are numerous2 and, amongst others, 
include long and costly campaigns to prepare new drug candidates,3 income 
losses from expiring patents,4 diminishing drug pipelines,2 healthcare systems 
that are increasingly cost-constrained,5 and tightened regulations.6–8 It is no 
surprise then that improving productivity in drug discovery has been framed as 
the sector’s “grand challenge”.3 However, perhaps most importantly, the high 
attrition rate of drug candidates in clinical trials has been marked as the biggest 
roadblock to the delivery of new treatments.3 The overall attrition rate (~96%) in 
early-stage drug discovery is crippling, and has ultimately been associated with 
poorly defined physical property constraints for the lead compounds from which 
drug candidates are derived.3,9–12 
 
1.2 An overview of the drug discovery process 
Bioactive small molecules continue to dominate Man’s ability to treat disease;13 
of the 41 new molecular entities (NMEs) approved by the US Food and Drug 
Administration (FDA) in 2014, 29 were small molecules.14 Furthermore, this figure 
may underestimate the overall benefit of small drugs to patients.15  
 
The purpose of drug discovery is to identify safe and effective new candidates for 
medical treatments. Drug discovery is currently a risky, lengthy (on average 13.5 
years) and expensive (on average £1.8bn) process (Figure 1).3 
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Figure 1 A summary of the key stages in drug discovery and their associated success rates, cycle times and costs. Does not include costs for target identification and validation, or for salaries for employees 
not involved in R&D but who are essential to support the organisation (accounts for an additional 20-30% in cost). *The cost for lead optimisation takes attrition into account. Image adapted from work by Paul.3 
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The drug discovery process starts with the identification of a druggable target 
(protein, gene, RNA etc.), which is validated using a range of chemical, biological 
and biophysical techniques.16 Typically, high-throughput screening (HTS) of large 
(>105) libraries of diverse molecules is used to identify compounds which interact 
with the target.17 A compound which binds and inhibits (or activates) the target is 
called a “hit”. High-quality hits may be developed into “leads”. These leads are 
optimised (through the synthesis of analogues) to improve their affinity, selectivity 
and safety. The resulting final compound is termed a “drug candidate”, which 
must then successfully navigate clinical trials to become a marketable 
medication.16 An alternative method for small molecule drug discovery is to 
screen fragments (‘fragment-based drug discovery’, FBDD) and is discussed in 
Section 1.5.2. 
 
Drug candidates are often prone to failure in clinical trials due to unforeseen 
complications, such as poor bioavailability, poor pharmacokinetic properties or 
unwanted toxicological effects. Attrition in phase II (66% of compounds) and 
phase III (30% of compounds) are the most important contributing factors for 
efficiency in R&D.3 Advances in cheminformatics in recent years have exposed 
an intrinsic link between the success of drug candidates in clinical trials and the 
molecular properties of the leads from which these candidates are derived.3,9,10 
By preparing leads with more appropriate screening properties, it may be possible 
to reduce the failure rate,10 leading to substantial increases in productivity, a 
reduction in costs, and an increase in the likelihood of more new molecular 
entities (NMEs) reaching the market. 
 
1.2.1 The role of synthesis in drug discovery 
The early stages of drug discovery (hit-to-lead; lead optimisation) are heavily 
reliant on the availability of appropriate synthetic methods to deliver compounds 
for high-throughput screening. In recent years, synthetic efforts in the lead 
generation process have particularly focused on the preparation of small libraries 
(10-100 compounds) of drug-like molecules called “arrays”.18 However, a recent 
study by Macdonald found that of ~5000 reactions used to prepare arrays at 
GlaxoSmithKline (GSK), 63% of these reactions fell into just four reaction classes 
(alkylations, condensations, palladium-catalysed couplings, and protecting-group 
manipulations).18 A lack of methodologies that introduce new stereocentres was 
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also reported, despite evidence that lower attrition rates may be associated with 
clinical candidates containing more stereocentres.19 In addition, many reactions 
have limited success rates with building blocks containing polar medicinal 
chemistry motifs, prompting the need to re-tool methodologies for use in array 
synthesis.20,21 
 
As a result of the routine use of a limited number of reactions in medicinal 
chemistry,22,23 compounds prepared by medicinal chemists have typically only 
explored a limited area of chemical space. The lack of diversity in screening 
collections24,25 reflects the wider uneven and unsystematic exploration of 
chemical space: ~50% of all known compounds are based on just 0.25% of all 
the known small molecular scaffolds.26 The introduction of multiple new 
methodologies that are broad in scope, robust,27 and functional group tolerant will 
play a key role in allowing chemists to access more diverse screening collections 
in years to come.13 
 
1.3 Characteristics of drug-like molecules 
In recent decades chemists have developed criteria to assess the drug-likeness 
of small molecules;28–40 these analyses consider a range of physicochemical 
properties (molecular weight, partition coefficient (logP), number of 
hydrogen-bond donors and acceptors, polar surface area etc.). Most famously, in 
1997 Lipinski’s seminal ‘rule of five’ (RO5) paper introduced ideal 
physicochemical parameters to increase the bioavailability of orally available 
drugs (Table 1).28 Such parameters can help guide medicinal chemists towards 
drug-relevant chemical space. 
Entry Physicochemical property Ideal value 
1 Molecular weight ≤500 
2 logP ≤5 
3 H-bond donors ≤5 
4 H-bond acceptors ≤10 
Table 1 Summary of Lipinski’s ‘rule of five’ parameters.28,31 
 
It should be noted that any molecular property criteria for drug discovery are 
intended only as guidelines, but aim to represent chemical space that is known 
to give rise to safe and effective drugs. There are outliers to any defined drug 
space, and indeed preferred parameters for drug-like space differ between 
organisations as well as against different biological targets (for instance, to 
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modulate protein-protein interactions;41 and to penetrate the blood-brain 
barrier42). 
 
Molecular properties have a significant effect on the likelihood of success in drug 
discovery.3,9,10 Recent studies have shown that logP is generally the most 
important parameter to control.43–46 Parameters such as molecular weight, 
polarity, and the potential to hydrogen bond to a target are also extremely 
important,47 but are ultimately entangled to some degree within the composite 
nature of logP. Molecules with high lipophilicities (clogp >3) generally experience 
increased binding to the biological target but also exhibit promiscuous and 
uncontrollable off-target binding. This off-target activity can amplify toxicological 
effects and markedly reduce the safety of the drug.9 
 
Recently, the importance of shape in drug discovery has come to the fore.19,48 
Compounds with higher fractions of sp3-hybridised carbons (Fsp3) have been 
found to have higher success rates in clinical testing and often have more 
favourable solubility properties than flatter molecules of similar size and logP.19 
Furthermore, as drug candidates pass through development, those containing a 
large number of aromatic rings (≥3) are more likely to fail.48 
 
1.4 Characteristics of lead-like molecules 
If chemists want to systematically target drug candidates that fall within typical 
drug-like space (e.g. Lipinski RO5 space, or similar), they must first be able to 
prepare leads which have appropriate properties to allow for the tendency for 
increases in lipophilicity, molecular weight and molecular complexity as the lead 
is optimised towards a drug candidate.49–53 A recent study of 62 lead/drug pairs 
showed that compared to leads, drugs have higher complexity, molecular weight 
and cLogP, and have more rotatable bonds, hydrogen-bond donors and 
acceptors.49 
 
A group of chemists at GlaxoSmithKline, led by Churcher, recently defined an 
ideal lead-like chemical space to facilitate the preparation of leads which allow 
greater flexibility in the optimisation stage of drug discovery (Figure 2, Table 2).10 
In addition to constraints on lipophilicity, molecular weight and number of 
aromatic rings, the highlighted parameters also include filters to remove 
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undesirable substructures (chemically-reactive, electrophilic, or redox-active 
groups). 
 
Figure 2 A Venn diagram showing lead-like space in relation to drug-like space. The pink arrow shows the typical drift in 
clogP and molecular weight as a hit is optimised towards a drug. Image adapted from work by Churcher.10 
 
Entry Physicochemical property Ideal value 
1 Molecular size 
14 ≤ Heavy atoms ≤ 26 
~200 ≤ mw ≤350 Da 
2 Lipophilicity −1 < clogP < +3 
3 No. aromatic rings 1-2 a 
4 Shape High Fsp3 a 
5 Substructures 
Absence of chemically-reactive, 
electrophilic or redox-active groups 
Table 2 Summary of Churcher’s lead-likeness rules.10 aInterpreted from discussion in the text. 
 
The above study also assessed the lead-likeness of 4.9×106 commercially 
available compounds and found that just 2.6% fell within the desired parameters. 
In addition, all of the reaction products formed in The Journal of Organic 
Chemistry in 2009 were assessed. Just 2.0% of the 32,700 compounds assessed 
were found to be lead-like. Consequently, it was inferred that sourcing large 
numbers of diverse compounds with the desired lead-like properties for screening 
would be a major challenge.  
 
A logP drift in array chemistry was also noted, whereby final compound libraries 
were often found to be more lipophilic than intended. This was attributed to the 
poor tolerance of many methodologies towards polar functionalities, with the less 
polar array compounds having a better chance of being prepared and isolated. 
The concept of lead-oriented synthesis (LOS) was introduced to develop 
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synthetic methodologies that are robust towards polar functionalities and that 
systematically allow for the preparation of diverse new leads using array 
approaches (discussed further in Section 1.5.3). It remains a significant and 
largely unmet challenge.10 
 
1.4.1 Diversity considerations 
The diversity of a library of compounds can be considered from many points of 
view.54 Here particular value is placed on skeletal diversity between compounds, 
as this is the most important factor when it comes to delivering molecules with 
diverse biological functions.24,55,56 Natural products arguably represent the most 
diverse collection of molecules currently available. Nature has produced vast 
numbers of stereochemically-complex secondary metabolites which have 
evolved through natural selection to modulate specific biological functions. 
Screening of natural products has historically generated several starting points 
for drug discovery.57 However, there are several drawbacks associated with 
preparing screening collections based solely on natural products. As well as 
challenges in sourcing and isolating large numbers of natural products, they are 
not always susceptible to chemical modification and often their structures are not 
initially known. Furthermore many features of modern drugs (for instance 
polyfluorination) are typically not observed in natural products. A recent study by 
Ertl assigned ‘natural product-likeness’ scores to drugs, natural products and 
synthetic molecules.58 Interestingly, while a lack of similarity between synthetic 
molecules and natural products was apparent, the largest proportion of drugs 
were found at the node between synthetic molecule space and natural product 
space (Figure 3).  
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Figure 3 Ertl’s natural product-likeness scores for drugs (red), natural products (green) and synthetic molecules (blue). 
The compound catalogues used for analysis of the synthetic molecules are shown in light grey. Image: Ertl et al., J. Chem. 
Inf. Model. Copyright © 2008 American Chemical Society.58 
 
The above study suggests that the preparation of synthetic molecules which 
exhibit some features associated with natural products (such as the number of 
stereocentres, aromatic rings, nitrogen and oxygen atoms) may be of particular 
value to maintaining high-quality screening collections. 
 
1.5 Approaches to the synthesis of diverse screening libraries 
As discussed earlier, the exploration of chemical space has been uneven and 
unsystematic.26 Recent decades have seen chemists begin to address the 
problem of diversity in screening libraries.11,59,60 This section will discuss a range 
of modern synthetic techniques which have been developed to address the lack 
of diversity in screening collections, with the overall aim of systematically 
targeting new leads, drugs, and/or tool compounds. 
 
1.5.1 Diversity-oriented Synthesis (DOS) 
Diversity-oriented synthesis, first introduced by Schreiber,61 aims to prepare a 
large number of structurally diverse compounds for use in HTS against untried 
targets with a view to identifying new leads, drugs, or chemical probes.60 A range 
of synthetic strategies have been developed to prepare diverse libraries of 
compounds,54,62,63 and the most successful of these approaches is the 
‘build-couple-pair’ strategy (Figure 4).64 In this approach building blocks are 
prepared (‘built’), linked together (‘coupled’) and subsequently cyclised (‘paired’). 
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Figure 4 Build-couple-pair strategies in which coupling functional groups (red dots) are used to link together building 
blocks, the resulting assemblies are then cyclised through pairing functional groups (green and blue dots). Panel A: 
folding (substrate-based) diversification. Panel B: branching (reagent-based) diversification. Image reproduced from work 
by Spring.54 
 
Key examples of the ‘build-couple-pair’ strategy will be discussed herein. 
 
1.5.1.1 Substrate-based DOS: Folding pathways 
In ‘folding’ pathways, the application of a key common reaction to alternative 
building blocks provides access to different scaffolds.65,66 For instance, through 
the use of a unifying Rh(II)-catalysed tandem cyclisation-cycloaddition, Schreiber 
demonstrated that the careful choice of substrates 1 enabled the preparation of 
three distinct molecular architectures (Table 3).66 
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Entry Starting material 1 Product 
1 
 
 
2 
 
 
3 
 
 
Table 3 Schreiber’s folding approach to DOS.66 
 
Some other approaches which exploit the folding pathway are based on the 
Achmatowicz reaction,65,67 three-component coupling reactions,68 and, 
ring-closing metathesis cascades.69  
 
1.5.1.2 Reagent-based DOS: Branching pathways 
In ‘branching’ pathways, the design of key polyfunctionalised intermediates 
enables downstream conversion to a range of molecular scaffolds through the 
use of different methodologies.70–72 For example, Stockman showed that the key 
intermediate 2 could undergo a range of cyclisation reactions to give access to 
diverse ring systems (Scheme 1).72 This strategy is especially efficient because 
in each case, a new molecular scaffold is prepared in ≤2 steps. 
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Scheme 1 Stockman’s branching pathway.72 Reagents and conditions: (a) (i) NH2OH•HCl, NaOAc, MeCN. (ii) PhMe, 
µW 140 °C, 36%; (b) NH2OH•HCl, NaOAc, MeCN, 60 °C, 68%; (c) NH2OH•HCl, NaOEt, EtOH, 12%; (d) (i) NaBH4, NH3, 
EtOH, Ti(OEt)4, 74%. (ii) AcOH; (e) PhNH2, TiCl4, CH2Cl2, rt, 65%.; (f) DIPEA, H2NCH2CO2Et, 71%; (g) NH2NHTs, PhMe, 
reflux, 41%; (h) NaH, THF, 70%; (i) SmI2 (2 eq.), THF, MeOH, −78 °C, 70%; (j) SmI2 (5 eq.), THF, MeOH, −78 °C, 70%; 
(k) superhydride, THF, 50%. 
 
Other branching pathways exploit cyclisations of enynes,73 N-allyl amino 
propargylic alcohols,74 building blocks derived from the Petasis reaction,71 
polymer-supported building blocks,75,76 and a fluorous-tagged diazoacetate.70  
 
1.5.1.3 Oligomer-based approaches 
In an oligomer-based folding approach by Nelson, carefully designed 
fluorous-tagged unsaturated building blocks (e.g. 3, 4) were subjected to 
ring-closing metathesis (RCM) cascade reactions (Scheme 2).77 The use of 
fluorous tags allowed rapid purification of intermediates and final compounds via 
fluorous solid phase extraction (SPE). Through variation of different unsaturated 
linkers in the building blocks, a library of over 80 distinct molecular scaffolds was 
prepared. 
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Scheme 2 Nelson’s oligomer based approach to DOS.77 RF= fluorous tag.  
Illustrative examples from a review by Nelson and Marsden.12 
 
Spring pioneered the use of oligomer-based approaches to prepare libraries of 
diverse macrocycles (Scheme 3).78–80 The iterative preparation of oligomers 
(e.g. 5, 6) terminating in alkenes, alkynes and azides enabled macrocyclisation 
through the use of enyne metathesis (equation 1), and both Cu- and Ru-catalysed 
1,3-dipolar cycloadditions (equations 2 and 3).79 In this way over 200 
peptidomimetic compounds were prepared, which showed great diversity in 
molecular shape.78  
 
Scheme 3 Spring’s oligomer based approach to the synthesis of diverse macrocycles.79 RF= fluorous tag. 
 
1.5.1.4 DOS: A summary 
Diversity-oriented synthesis has played a crucial role in the development of 
effective strategies to prepare diverse compound libraries. However, there has 
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not been deliberate consideration of molecular property constraints in DOS 
approaches to focus synthetic efforts towards drug-like or lead-like compounds. 
In addition, because the number of possible molecules rises exponentially as 
molecular weight increases,81 the efficiency of the exploration of molecular shape 
is often poor for typical DOS compounds, which are frequently large.  
 
Fortunately, DOS is reaching maturity and the key strategies developed in the 
last two decades are now being shown to be readily refitted for use towards lead 
generation. Lead-oriented synthesis (LOS) incorporates elements of DOS to 
target the generation of new leads that efficiently sample chemical space and 
allow room for combinatorial variation of scaffolds (see Section 1.5.3 for further 
discussion).11,12,82  
 
1.5.2 Fragment-based drug discovery (FBDD) 
Fragment-based drug discovery relies on the screening of smaller libraries (~103) 
of small molecules (“fragments”). In contrast to DOS, a relatively small number of 
fragments are needed to efficiently cover a large area of chemical space.83 The 
viability of this approach has been proven and has already resulted in a marketed 
drug (Vermurafenib). ‘Rule of three’ molecular property constraints (mw <300; 
clogP <3) are often used to guide the preparation of high-quality fragments.80 
However, a drawback of FBDD is that high-quality structural data is generally 
required to determine binding of a fragment to a target. X-ray diffraction of 
co-crystals of the fragment bound to the target, and/or NMR spectroscopy, is 
typically used to confirm binding. Due to their modest affinities (~1 mM) fragments 
are unlikely to be of use in phenotypic screens.84 However, when measurable, 
affinities of the order of just ~1 mM can indicate high-quality interactions between 
a fragment and a target, since smaller molecules have fewer atoms with which to 
form favourable interactions with a target.85 Fragment hits can be ‘grown’ into 
high affinity drugs through linkage to fragments which bind to other sites on the 
target, and through combinatorial modification.86  
 
FBDD and DOS can be combined in a complementary way. A folding DOS 
approach was recently used by Young to prepare three-dimensional fragments 
(Scheme 4).87 Proline-derived building block 7 was armed with a variety of 
alkene-containing handles to facilitate cyclisation by ring-closing metathesis, 
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giving rise to a wide variety of bicyclic scaffolds. Although the authors prepared 
the scaffolds with a view towards fragment-based screening, there are several 
sites on the scaffolds which could be used for combinatorial derivatisation, which 
may give access to lead-like compounds.  
 
Scheme 4 Young’s DOS approach to 3-D fragments.87 Reagents and conditions: (a) prop-2-ene-1-sulfonyl chloride, 
Et3N, CH2Cl2, 44%; (b) vinylsulfonyl chloride, Et3N, CH2Cl2, 62%; (c) (S)-N-Boc-allylglycine, EDCI, Oxyma, Et3N, CH2Cl2, 
48%; (d) (S)-allylglycine methyl ester, EDCI, Oxyma, Et3N, CH2Cl2, 89%; (e) (i) allylamine, EDCI, Oxyma, Et3N, CH2Cl2, 
91%; (ii) NaH, MeI, dimethylformamide (DMF), 72%; (f) GII, various conditions, 34-96%. (g) LiOH, THF, 53-71%. 
 
1.5.3 Lead-oriented synthesis (LOS) 
The concept of lead-oriented synthesis (LOS) was introduced to promote the 
development of synthetic methodologies that systematically allow for the 
preparation of diverse compounds within lead-like space. Particular value was 
placed on efficiency, appropriateness for array synthesis, compatibility with polar 
functional groups and avoidance of logP drift in the compounds prepared.10 The 
utility of LOS approaches may be evaluated in terms of the diversity of the 
scaffolds prepared and the molecular properties of accessible derivative 
compounds. The strategies herein focus on the preparation of specific and/or 
diverse scaffolds which lend themselves to further diversification with medicinal 
chemistry capping groups to give lead-like compounds. 
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1.5.3.1 Combinatorial considerations 
In order to prepare large numbers of screening compounds based on specific 
scaffolds it is important to maintain the availability of high-quality medicinal 
chemistry capping groups for use in the combinatorial decoration of leads. For 
instance, against protein targets, capping groups can dictate which amino acid 
moieties a compound interacts with.88 
 
A recent study by Goldberg underlined the importance of capping groups to 
medicinal chemistry programmes. Data mining and the opinions of expert 
medicinal chemists were used to design a library of ~3000 custom capping 
reagents that were not found in the Available Chemicals Directory (ACD).89 
Particular focus was given to the preparation reagents (~20 g scale) that would 
provide broad utility against a range of target classes. Reagents were designed 
so that they would not add more than 200 Da in molecular weight, or alter the 
overall logP by more than 2 units, and had ≤2 hydrogen-bond donors and ≤4 
hydrogen-bond acceptors (examples shown in Figure 5). Analysis of uptake of 
these reagents by medicinal chemists at AstraZeneca found that amine 
(especially secondary amine), carboxylic acid and boronic acid capping groups 
were most commonly used by medicinal chemists. Ultimately, since 2009 at 
AstraZeneca this initiative has resulted in incorporation of the reagents in three 
drug candidates, along with numerous short-listed candidates. 
 
Figure 5 Examples of novel capping groups that were found to have ‘unusually popular’ uptake (used in >200 reactions) 
by medicinal chemists at AstraZeneca.88 
 
1.5.3.2 Lead-like arrays based on specific scaffolds 
Making lead-like compound libraries is not necessarily difficult per se, but without 
careful planning comes at the expense of diversity. A number of methodologies 
are already in existence that would be appropriate to allow the preparation of 
specific classes of scaffolds.11,12 Combinatorial decoration of such scaffolds gives 
expedient access to arrays of lead-like compounds.90–93  
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For instance, Nelson recently described the synthesis of piperazines 8 using a 
modular Au-catalysed approach (Scheme 5, Panel A, equation 1).90,92 The 
potential to prepare lead-like compounds from the scaffolds 8 was shown through 
(i) reduction using TFA/triethylsilane (Panel B, equation 2); and (ii) a 
multicomponent reaction with an isocyanide (Panel B, equation 3).90 
 
 
Scheme 5 Nelson’s Au-catalysed piperzine synthesis (Panel A) and exemplar decorations to give compounds which may 
find value as leads (Panel B).90 
 
1.5.3.3 Unified approaches to diverse lead-like compounds 
In order to fully realise the potential of LOS, the targeted preparation of 
compounds with lead-like properties must be incorporated into strategies 
(e.g from DOS) that enable access to diverse scaffolds. Sites for further 
decoration on the scaffolds would potentially give access to diverse screening 
compounds. 
 
The candidate was recently involved in a LOS study led by Richard Doveston, 
Stephen Marsden and Adam Nelson which ran concurrently with the work 
described in this thesis.82 The preparation of a library of over 50 molecular 
scaffolds was realised by using a unified LOS approach. Ir-catalysed allylic 
amination, which was recently re-tooled for use with highly polar functionalities 
by Paolo Tosatti, Nelson and Marsden20,21 was used as a connective reaction to 
prepare 13 building blocks 9 as pre-cursors for cyclisation (Scheme 6). 
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Scheme 6 Ir-catalysed allylic amination of polar substrates to prepare building blocks 9 for later cyclisation.82 
a(S,S,aS)-L1 used. bPrNH2 and THF used. 
cThe amine HCl salt and K3PO4 (1.3 eq) were used. 
 
The building blocks 9 were exposed to a toolkit of just six distinct cyclisation 
strategies (ring-closing metathesis, iodocyclisations, urea/oxazolidinone 
formation, ketopiperazine/morpholine formation, aminoarylations, lactamisations) 
to form scaffolds (Scheme 7). In several instances the initial cyclisation products 
could be cyclised again, using the same toolkit of reactions, to give additional 
scaffolds. In total 52 diverse scaffolds were prepared in an average of two steps 
per scaffold.  
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Scheme 7 Exemplar scaffolds prepared from the building blocks 9 using a focused toolkit of cyclisation methodologies: (a) ring-closing metathesis; (b) iodocyclisations; (c) urea/oxazolidinone formation; 
(d) ketopiperazine/morpholine formation; (e) aminoarylations; (f) lactamisations.82 Ar= 3-pyrimidyl.
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Virtual decoration of the compounds with 59 medicinal chemistry capping groups 
suggested that significant lead-like space may be accessed through 
combinatorial decoration of the compounds. Each compound was decorated 
twice with the 59 medicinal chemistry capping groups (except where a decoration 
step was used as part of the scaffold forming reaction [i.e. where the 
aminoarylation reaction was used]). In all, 59% (11,468) of the 19,530 derivatives 
enumerated would be lead-like, underscoring the value of our approach.  
 
A recent study by O’Brien described the use of N-Boc-directed α-lithiation of 
amines to prepare six novel lead-like scaffolds that would be appropriate for 
combinatorial decoration to give screening compounds.94 Reaction of the lithium 
carbanions generated from compounds 10-11, with heterocyclic ketones 12a-b, 
gave carbamates 13-14 (Scheme 8, Panel A). Alternatively, aminoalcohols 15 
underwent a ring-expansion reaction, mediated by trifluoroacetic anhydride, to 
give scaffolds 16-17 (Panel B). Orthogonal deprotection of the scaffolds was 
demonstrated, then virtual decoration of the compounds with chosen capping 
groups enumerated a library of 190 potential screening compounds, of which 48% 
would be lead-like according to Churcher’s criteria. In addition, 24% of the 190 
derivatives were found to access underrepresented three-dimensional shape 
space compared to traditional pharmaceutically-relevant space.  
 
Scheme 8 Synthesis of lead-like scaffolds using O’Brien’s lithiation strategy.94 
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In summary, robust methods for the preparation of large numbers of diverse 
lead-like compounds are beginning to emerge, but such studies still remain 
under-represented in the literature. As such there is still a substantial demand to 
increase the arsenal of complementary methodologies for LOS. 
 
1.6 Project aims and thesis outline 
The research described in this thesis is targeted towards the synthesis of large 
numbers of cyclic molecular scaffolds which, upon decoration, would provide 
access to broad regions of lead-like chemical space. In order to achieve this, 
strategies were devised relying upon the careful selection and synthetic 
preparation of specific classes of polyfunctional substrates. The modular 
application of small toolkits of broadly applicable cyclisation methodologies to 
these substrates allowed the generation of novel and diverse molecular scaffolds.  
 
Chapter two describes the preparation of small polyfunctionalised precursors and 
their use in a building-up (‘bottom-up’) approach to synthesise scaffolds. 
Strategically this is analogous to the allylic amination strategy described in 
Section 1.5.3.3. In contrast, chapter three describes the preparation of larger 
polycycles which were deconstructed in a ‘top-down’ approach to give scaffolds. 
Chapter four goes on to compare the value of the different LOS approaches 
developed. 
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2.0 Results and discussion 1: A bottom-up approach to LOS 
 
Our ‘bottom-up’ strategy for lead-oriented synthesis depended upon the synthetic 
accessibility of specific classes of small polyfunctionalised substrates which could 
be cyclised to afford scaffolds. We proposed to prepare quaternary amino acid 
derivatives as a representative class of such building blocks to meet this end. 
These substrates would bear four branch points which may be exploited to form 
scaffolds, or may later serve as points for further derivatisation to enable the 
preparation of subsequent compound libraries. 
  
2.1 The selection of a connective reaction for LOS 
The allylic alkylation of amino acid derivatives 18 was put forward as an 
established transformation which could deliver α-allyl, α-amino acid building 
blocks 19 (Figure 6). Inherent in these building blocks is an assortment of different 
functionalities which may be exploited in order to form scaffolds: alkenes can 
undergo a variety of cyclisation reactions and redox chemistry, esters are prone 
to nucleophilic substitution, amines can potentially be capped with a variety of 
different functionalised tethers, and there was also the possibility of introducing 
variable functionality through the amino acid side-chain. 
 
Figure 6 The proposed synthetic transformation to prepare polyfunctionalised building blocks.  
The coloured dots represent functionalities that may potentially be exploited to form scaffolds. 
 
We envisioned a synergistic approach to LOS where computational tools could 
be used to direct synthetic chemistry. In order to systematically target lead-like 
compounds, we needed to assess the ability of known and speculative synthetic 
transformations to provide access to lead-like chemical space. A computational 
protocol was developed by Richard Doveston using Accelrys Pipeline Pilot to 
identify valuable methodologies for LOS which would then be exemplified 
synthetically (Figure 7).95 Such tools were used throughout the course of the 
project to aid the decision making process, including: (i) the selection of 
appropriate connective reactions to prepare building blocks for LOS, and (ii) the 
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selection of appropriate methodologies to cyclise the building blocks to form 
scaffolds.  
 
An illustrative example to show how Pipeline Pilot was used to identify 
methodologies for LOS is shown below (Figure 7): (i) the connective reaction of 
interest (in this case allylic alkylation) was performed; (ii) the cyclisation precursor 
was armed with a variety of different functionalised handles; (iii) chosen 
cyclisation methodologies were performed (these were typically based on good 
literature precedence, but more speculative transformations were also 
programmed); (iv) any latent functionality was cleaved using well-established 
functional group interconversions, especially with a view to removing any 
undesired substructures (the ‘GSK B’ filter described by Churcher was used10), 
and to generate points for further diversification; (v) the novelty of the scaffold 
was assessed against the ZINC database96 of commercially available 
compounds (Murcko-assemblies97 with and without substitution were mapped); 
(vi) each point for further diversification was decorated with medicinal chemistry 
capping groups (from a list provided by GSK) to generate a structurally diverse 
compound library; (vii) the properties of the compound library were assessed and 
a penalty point scoring system (Table 4) was assigned to the scaffold to give an 
indication of its ability to provide access to lead-like molecules. 
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Figure 7 An illustrative example to show how Pipeline Pilot was used to identify methodologies for LOS: i) the connective 
reaction was performed; ii) the cyclisation precursor was armed with different functionalised handles; iii) chosen cyclisation 
methodologies were performed; iv) any latent functionality was cleaved using FGIs; v) the novelty of the scaffold was 
assessed; vi) each point for further diversification was decorated with medicinal chemistry capping groups; vii) the 
properties of the compound library were assessed (Table 4) and an average score was assigned to the scaffold to indicate 
its ability to provide access to lead-like molecules. 
 
Property Value Penalty Score 
Heavy Atom Count 
17-24 0 
25 and 16 1 
26 and 15 2 
27 and 14 3 
Lipophilicity (AlogP) 
–1.0 - +3.0 0 
>3.0 and <–1.0 1 
>3.5 and <–1.5 2 
>4.0 and <–2.0 3 
No. aromatic rings 
1, 2 0 
0, 3 1 
4 2 
5 3 
Biological interaction 
(sum of N and O atoms) 
<4 2 
Undesirable functionality n/a 5 
Table 4 A penalty point system was applied to determine how well the final decorated compounds map onto the lead-like 
parameters outlined by Churcher.10 This score was averaged over all of the decorated compounds that can be prepared 
from each scaffold, providing a mean score per scaffold. This score gives a good indication about whether a scaffold can 
readily access lead-like space (the lower the score, the more lead-like the scaffold is).95 
 
Using highly interactive data visualisation software (Dotmatics Vortex) we were 
able to determine which methodologies and building blocks may potentially 
prepare the most lead-like scaffolds (Figure 8), and we could then investigate the 
most promising methodologies synthetically. For instance, the bicyclic carbamate 
20 is an example of an attractive scaffold to target synthetically, as it is novel (no 
substructure hits) and has the potential to access ca. 200 lead-like derivative 
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compounds (the average lead-likeness penalty for the decorated scaffolds ≈2). 
In contrast, the piperazine 21 is an example of a scaffold that is extremely well 
represented in commercially available compound libraries (17K substructure 
hits!) and was therefore not of interest as a synthetic target. Compounds derived 
from the scaffold 22 would have extremely poor lead-like properties due to high 
molecular weights and low ALogP, hence this scaffold may not be useful in a LOS 
programme. 
 
Figure 8 A useful plot to generate in Dotmatics Vortex was the log of the number of final decorated compounds that can 
be derived from each scaffold (y-axis) versus the average scaffold lead-likeness penalty (x-axis, see also Table 4). The 
data were coloured depending on the novelty of the scaffold (following a sub-structure search against the ZINC database 
[green= novel; red= known substructure]). The most interesting compounds fall at the top-left corner of the graph (marked 
by the blue box) where a scaffold can deliver large numbers of highly lead-like scaffolds. This highly interactive software 
enabled the candidate to identify which methodologies were associated with preparing the scaffolds found in this area of 
the graph. Substructure hits are for the Murcko fragment. The substructure hits for the Murcko fragment with 
alpha-attachments are shown in parentheses. 
 
The significance of this computational protocol lies in the ability of the user to 
relate a potentially valuable scaffold to synthetically plausible routes. We 
inevitably programmed more hypothetical reactions than were ever successfully 
developed synthetically, but the tools helped us semi-quantitatively rank 
methodologies for development based on (i) their general ability to provide 
access to lead-like molecules and (ii) literature precedence. For instance, the tool 
indicated that both the oxyiodination reaction to form carbamates 23 (equation 1) 
and the aminoiodination to form diazepanes 24 (equation 2) would form scaffolds 
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that would be valuable in a LOS programme (Figure 9). However, when deciding 
which chemistry to apply synthetically, the oxyiodination was found to have good 
literature precedence,98–103 whereas the aminoiodination had no literature 
precedence. The development of the oxyiodination chemistry was therefore 
prioritised (see Section 2.3.1.1).  
 
Figure 9 Proposed synthetic transformations for LOS. 
 
Another important aspect of the computational tool is that it allows the user to 
identify unknown transformations that would broadly allow access to lead-like 
compounds (such as formation of diazepanes 24, equation 2). Valuable new 
methodologies may then be developed based on their ability to target novel areas 
of chemical space. 
 
In summary, we were able to semi-quantitatively determine that our proposed 
strategy involving the cyclisation of allylated amino acid derivatives had the 
potential to access many useful scaffolds for LOS, if some of the transformations 
that were shown to be valuable by the synthetic tools could be synthetically 
validated. Ultimately the computational tools are only as useful as the sum of the 
successfully developed chemistries that they directed. As a result of this, to 
provide clear evidence of success from an academic standpoint, it is perhaps 
more useful to retrospectively analyse the scaffolds that we found to be 
synthetically accessible and interrogate their potential ability to access lead-like 
space. Indeed such an analysis is included towards the end of the chapter 
(Section 2.5), following the discussion of the development of the suite of synthetic 
chemistry. 
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2.2 Selection of a suitable methodology for the allylic alkylation of amino 
acid derivatives 
In order to demonstrate that the allylic alkylation of amino acid derivatives was 
indeed a suitable reaction for delivering exemplar polyfunctionalised cyclisation 
precursors, we needed to establish an appropriate synthetic strategy for their 
preparation. Ideally this approach would be high yielding, synthetically tractable 
and scalable. An enantioselective synthesis would be attractive, but not essential, 
since it can be advantageous to initially screen drug leads as racemates.104 
 
2.2.1 The asymmetric allylic alkylation (AAA) reaction 
Transition metal-catalysed allylic substitutions are an extremely important and 
extensively studied class of transformations in organic synthesis (Figure 
10).105,106 Allyl-metal complexes 25 undergo SN2 or SN2’ substitutions with a 
range of nucleophiles to form new C-H, C-C, C-F, C-O, C-N and C-S bonds. 
These processes are catalysed by a range of transition metals including Cu, Ir, 
Ni, Mo, Pd, Pt, Rh, Ru and W. The nature of the metal has a profound effect on 
the regioselectivity of the reaction, whilst the use of chiral ligands can enable high 
levels of asymmetric induction. 
 
Figure 10 Regioselectivity in metal-catalysed allylic substitution reactions of terminal allylic electrophiles.105 
 
2.2.1.1 Asymmetric allylic alkylation (AAA) of amino acid derivatives: The 
Tsuji–Trost reaction 
The Pd-catalysed allylation of nucleophiles (e.g. enolates [and equivalents], 
amines, phenols) by allylic acetates, bromides and carbonates to give linear 
products 26 was extensively developed by Trost from earlier work described by 
Tsuji (Figure 11).105 
 
Figure 11 General conditions for the Tsuji–Trost reaction.105 
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In one variant of the reaction, Trost developed the Pd-catalysed asymmetric 
allylic alkylation (AAA) of azlactones 27, which are derivatives of amino 
acids.107,108 In the presence of the chiral ligand (R,R)-DACH-phenyl L2 the 
reaction affords the linearly allylated quaternary azlactones 28 with a high degree 
of enantioselectivity (Table 5). Prenylation with either linear (entry 1) or branched 
(entry 2) prenyl acetate gave the linearly alkylated azlactones in good yields and 
with excellent enantioselectivity. Curiously, while linear cinnamyl acetate (entry 3) 
gave linearly alkylated azlactones, branched cinnamyl acetate (entry 4) gave a 
mixture of linear and branched products. The reaction also tolerated cyclic 
acetates (entry 5) and diacetylated starting materials (entry 6), proceeding to give 
the respective products in high dr. However, substitution at the central carbon of 
the allylating agent substantially decreased the enantioselectivity of the reaction 
(entry 7). 
 
Entry Allylic acetate Product 28 R 
Yield linear /% 
(Yield branched /%) 
[dr linear] 
er linear 
(er branched) 
1 
 
 
Bn 
Me 
iPr 
72 (23) 
55 (13) 
57 (–) 
99:1 (60:40) 
98:2 (57:43) 
97:3 (–) 
2 
 
 
Bn 
Me 
iPr 
78 (12) 
67 (17) 
47 (–) 
99:1 (63:37) 
99:1 (60:40) 
95:5 (–) 
3 
 
 
Bn 
Me 
91 (–) 
74 (–) 
95:5 (–) 
93:7 (–) 
4 
 
 
Bn 45 (47a) 95:5 
5b 
 
 
Bn 
Me 
iPr 
74 [92:8] 
90 [90:10] 
77 [>95:5] 
99:1 
99:1 
97:3 
6 
 
 
Bn 
Me 
iPrb 
75 [90:10] (6) 
60 [87:13] (9) 
88 [>95:5] (4) 
99:1 (98:2) 
99:1 (98:2) 
99:1 (–) 
28 
 
 
Entry Allylic acetate Product 28 R 
Yield linear /% 
(Yield branched /%) 
[dr linear] 
er linear 
(er branched) 
7 
 
 
Bn 79c 55:45 
Table 5 Selected examples of Trost’s asymmetric allylic alkylations of azlactones.107,108  
a68:32 mixture of diastereomers. bReaction performed at 0-5 °C. cReaction performed in MeCN. 
 
2.2.2 Benchmarking the asymmetric allylic alkylation (AAA) of azlactones 
We sought to establish the suitability of the Tsuji-Trost reaction for meeting the 
requirements of our lead-oriented synthesis programme. In particular we 
envisioned an overall three-component coupling strategy to prepare building 
blocks for LOS (Figure 12), whereby following the AAA of azlactones, a range of 
different nucleophiles could be utilised to introduce additional functionality into 
the building blocks. Deprotection and cyclisation reactions would then furnish 
scaffolds. 
 
Figure 12 Proposed strategy for LOS by using the AAA of azlactones as a connective reaction.  
The coloured dots highlight functionalities that may potentially be exploited to form scaffolds. 
 
To commence this study, we attempted the known cinnamylation (Table 5, 
entry 3) of azlactone 27a.108 Firstly, azlactone 27a was prepared from the 
N-benzoylated amino acid 29, which in turn was derived from L-phenylalanine 30 
(Scheme 9). Preparation of azlactone 27a by using EDCI as the dehydrating 
agent (route a) consistently gave 100% conversion to the desired product (as 
judged by analysis of the crude product by 1H NMR spectroscopy).109 However, 
the requirement for an aqueous work-up following the reaction invariably led to a 
significant amount of hydrolysis of azlactone 27a to reform N-benzoylated amino 
acid 29. In contrast, the use of acetic anhydride as the dehydrating agent (route b) 
gave a robust route to the desired azlactone 27a, because exposure to an 
aqueous work-up could be avoided following the reaction.110  
29 
 
 
 
Scheme 9 Synthesis of azlactone 27a. 
 
With azlactone 27a in hand, known Pd-catalysed cinnamylation was carried out 
(Scheme 10).108 Attempted isolation of quaternary azlactone 28a by silica gel 
flash chromatography led to low yields of impure product due to hydrolysis on 
SiO2. However, following alkylation, methanolysis of quaternary azlactone 28a 
furnished protected amino ester 31 in 71% yield and in 83:17 er (as determined 
by chiral HPLC). The transformation was not optimised further at this stage. 
 
Scheme 10 Pd-catalysed cinnamylation of azlactone 27a, followed by subsequent methanolysis. 
 
2.2.2.1 Optimisation of the Pd-catalysed AAA of azlactones 
Given that the conditions described above required 2.25 equivalents of azlactone 
27a, optimisation for use of 1 equivalent of azlactone 27a was sought in order to 
prevent the waste of any bespoke azlactone starting materials. One equivalent of 
cinnamyl acetate was reacted with the azlactone 27a in the presence of different 
quantities of triethylamine as base, which enolised the azlactone and enabled 
reaction with the allyl electrophile (Table 6). This study found that one equivalent 
of base (entry 2) gave the highest yield whilst maintaining high levels of 
enantioselectivity. Interestingly, while the reaction worked without any base, it 
was sluggish (reaction incomplete after 6 h, entry 4). The optimal conditions 
(entry 2) were extended to allyl acetate to afford compound 32 in 72% yield 
(entry 5).  
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Entry Allylic acetate Et3N /eq. Yield /% er* 
1 Cinnamyl acetate 2 76 95:5 
2 Cinnamyl acetate 1 78 95:5 
3 Cinnamyl acetate 0.2 75 95:5 
4a Cinnamyl acetate 0 68 94:6 
5 Allyl acetate 1 73 n.d. 
Table 6 Optimisation of the Pd-catalysed AAA of azlactones.  
*determined by chiral HPLC. a15 h reaction time. 
 
2.2.3 Substitution at the azlactone carbonyl 
Once conditions had been established for the Pd-catalysed AAA of azlactones, 
variation of the nucleophilic opening of the quaternary azlactone 28a was 
considered (Figure 13). This step affects which functionalities can be installed at 
the carbonyl of the building block, and hence any downstream possibilities for 
cyclisation to form scaffolds. 
 
Figure 13 Proposed nucleophilic addition to azlactones. 
 
2.2.3.1 Addition of N-centred nucleophiles 
Quaternary azlactone 28a was opened with benzylamine to give amide 33 in 87% 
yield (Scheme 11).111–113 
 
Scheme 11 Ring-opening of the quaternary azlactone 28a with benzylamine. 
 
Opening quaternary azlactone 28a with a cyclic secondary amine, morpholine, 
was also possible (Scheme 12). This reaction did not take place at room 
temperature, as judged by analysis of the crude reaction mixture by 1H NMR 
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spectroscopy, even following the addition of DMAP (0.1 eq.) as a nucleophilic 
catalyst. Fortunately, heating the resulting mixture to 90 °C gave access to the 
targeted secondary amide 34, which was isolated in 60% yield (Scheme 12). The 
opening of quaternary azlactones with secondary cyclic amines has not been 
widely exploited in the literature.114,115 
 
Scheme 12 Ring-opening of quaternary azlactone 28a with morpholine. 
 
2.2.3.2 Addition of C-centred nucleophiles 
Recent years have seen large increases in the number of methodologies 
available for trifluoromethylation.116 In medicinal chemistry, ready access to 
fluorinated compounds is desired as they can display better membrane 
permeability, increased bioavailability and increased metabolic stability, when 
compared to their non-fluorinated analogues. In 2012, two of the top thirty 
best-selling drugs in the US contained trifluoromethyl groups, whilst five more 
were fluorinated in some manner.117,118 
 
Bräse recently described the synthesis of trifluoromethylketones 35 through the 
fluoride-mediated addition of the Ruppert–Prakash reagent (TMS-CF3) to 
benzoxazinones 36 (Scheme 13).119 
 
Scheme 13 Bräse’s synthesis of trifluoromethylketones 35 from benzoxazinones 36.119 
 
Under rigorously anhydrous conditions it was found that quaternary 
azlactones 28 could be opened by applying an adaption of Bräse’s protocol, 
giving rise to trifluoromethyl ketones 37-38 (Table 7). Changing the solvent from 
DMSO to toluene (Table 7, entry 2) led to an increase in the yield of trifluoromethyl 
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ketone 37, however these are preliminary studies and further investigations may 
improve this procedure in the future. 
 
Entry Allylic acetate Product Solvent Yield /%* 
1 Cinnamyl acetate 37 DMSO 52 
2 Cinnamyl acetate 37 PhMe 63 
3 Allyl acetate 38 PhMe 43 
Table 7 Formation of trifluoromethyl ketones 37-38 from quaternary azlactones 28. *er n.d. 
 
2.2.4 Deprotection of N-amido protected amines 
One of the major limitations of the AAA of azlactones was the presence of the 
phenyl ring at the C-2 position of azlactone 27. Following the addition of a 
nucleophile to quaternary azlactone, the C-2 substituent goes on to form a 
benzamide 39 which can be regarded as an amine protecting group (Figure 14). 
Removal of this protecting group to release the free amine 40, under mild 
conditions, would be essential to fully realise the full potential of the AAA of 
azlactones in a LOS programme. 
 
Figure 14 The required route to free amines 40. The C-2 substituent (X) of azlactone 27 goes on to form an amine 
protecting group in compound 39, which must then be deprotected to reveal free amine 40. 
 
The C-2 substituent must be derived from an amide. While there are a limited 
number of accounts detailing the preparation of azlactones bearing atoms other 
than carbon at the C-2 position, for instance, O-benzyl and O-tert-butyl 
substituents (which form the corresponding carbamate derivatives following the 
opening of the azlactone), the routes to prepare them are low yielding and 
alkylation of these substrates remains unknown.120–123 
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2.2.4.1 Attempted deprotection of an N-benzamido protected amine 
Typical literature conditions for deprotection of the N-benzoyl protecting group 
are harsh, requiring the use of concentrated aqueous acid at reflux with extended 
reaction times.108,124,125 Since we were interested in preparing azlactones bearing 
potentially sensitive functionalities (for instance Boc-protected alkylamino chains, 
silyl protected alkylether chains etc.), application of such conditions would not be 
synthetically useful as they would potentially result in the simultaneous 
deprotection of the side-chain. 
 
In an attempt to hydrolyse the N-benzoyl protected amino ester 31 under mild 
conditions, it was stirred with dilute acid at room temperature (Scheme 14). 
However, only starting material was observed after 24 h (as judged by analysis 
of the crude reaction mixture by 1H NMR spectroscopy) when using 1 N, 2 N or 
6 N hydrochloric acid. 
 
Scheme 14 Attempted hydrolysis of benzamide 31 with hydrochloric acid at rt. 
 
2.2.4.2 AAA of azlactones bearing a CF3-substituent at C-2 
The N-trifluoroacetyl group can be readily cleaved by alkanolysis under basic 
conditions and we sought to harness this protecting group in our strategy.125 
Preparation of the azlactone 42 was attempted by heating L-phenylalanine 30 in 
refluxing trifluoroacetic anhydride, following a procedure by Ries (Scheme 15).126 
However, careful analysis of the reaction product contradicted Ries’ findings; the 
tautomeric pseudoazlactone 43 was identified as the only product. We 
subsequently found that this was consistent with the findings of several other 
research groups.127–129 
 
Scheme 15 Preparation of pseudoazlactone 43. 
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With pseudoazlactone 43 in hand we decided to attempt the asymmetric allylic 
alkylation reaction. Heimgartner previously reported that simple alkylation of 
pseudoazlactone 43 was possible. Benzylation proceeded with high selectivity 
for the C-4 alkylated product 44b. However, allylation gave a 1:1 mixture of the 
C-2 alkylated product 44a and the C-4  alkylated product 45a (Scheme 16).130 
 
Scheme 16 Alkylation of pseudoazlactone 43 by Heimgartner.130 
 
Exposure of pseudoazlactone 43 to Trost’s AAA protocol resulted in successful 
alkylation (as judged by analysis of the crude product by 1H NMR spectroscopy, 
Scheme 17). However, to our surprise only protected amino acid 46 was isolated. 
Attempts to prevent the formation of acid 46 by using a freshly-distilled batch of 
pseudoazlactone 43, and by performing the reaction under rigorously anhydrous 
conditions, failed. We therefore postulated that, following allylic alkylation, the 
resulting trifluoromethylated quaternary azlactone 47 was highly electrophilic 
towards nucleophilic attack by acetate. Treatment of the resulting anhydride 48 
with sodium methoxide then liberated the acid 46. It was clear that a significant 
amount of study and optimisation would be required to improve the suitability of 
this reaction for LOS, which was beyond the scope of the project. 
 
Scheme 17 Allylic alkylation of pseudoazlactone 43. 
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2.2.4.3 AAA and deprotection of azlactones bearing a 4-chlorobutyryl 
substituent at C-2 
We turned our attention to the possibility of using a protecting group which could 
be removed through a highly selective ‘triggered-release’ strategy. 
N-4-Chlorobutyryl protected amines can be deprotected through 
triggered-release reactions to give the corresponding free amine, and therefore 
we chose to investigate the use of this protecting group in our synthesis.131,132 
 
Azlactone 49 bearing a 4-chlorobutyryl substituent at C-2 was synthesised by 
following a procedure developed by Mandić to prepare the analogous 
phenylglycine-derived azlactone (Scheme 18).133 Protection of phenylalanine 30 
gave amide 50, which was cyclised to give azlactone 49 using acetic anhydride. 
Pd-catalysed allylic alkylation, followed by methanolysis, gave the protected 
amino esters 51-52. The cinnamylated product 51 was prepared using the 
aforementioned AAA protocol, whereas the allylated product 52 was prepared 
using Pd(PPh3)4 (see experimental for details). 
 
Scheme 18 Synthesis of protected amino esters 51-52. 
 
2.2.4.4 Attempted deprotection of an N-4-chlorobutyryl protected amine 
with butylamine 
Stirling reported the deprotection of amide 53 using distillation to drive off the 
aniline released during the formation of lactam 54 (Scheme 19).131 
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Scheme 19 Stirling’s amide deprotection via lactamisation.131 
 
In an attempt to see if lactamisation would take place thermally, without the need 
for distillation, chloride 52 was substituted with n-butylamine. The resulting 
amine 55 was heated to reflux in toluene but no reaction took place (Scheme 20). 
 
Scheme 20 Attempted deprotection of N-protected amino ester 55. 
 
As a result of the failure of this reaction we turned our attention towards an 
Ag-mediated deprotection. 
 
2.2.4.5 Deprotection of an N-4-chlorobutyryl protected amino ester with 
AgBF4 
In 1963, Peter described the Ag-mediated deprotection of N-4-chlorobutyrylated 
tyrosine methyl ester 56 (Scheme 21).132 Treatment of protected amino ester 56 
with AgClO4, followed by the addition of dilute hydrochloric acid, gave the 
ammonium salt 57 in 93% yield via the formation of iminolactone 58. Alternatively, 
the use of AgBF4 allowed the isolation of iminolactone 58, providing a safer 
alternative to the use of potentially explosive AgClO4. 
 
Scheme 21 Deprotection of protected amino ester 56 via formation of iminolactone 58 by Peter.132 
 
Using Peter’s protocol, protected amino ester 52 was treated with AgBF4 in THF 
(Table 8). Analysis of the crude reaction mixture by 1H NMR spectroscopy after 
2 h showed complete conversion to the iminolactone tetrafluoroborate salt 59. In 
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an attempt to isolate the iminolactone, Et3N•HCl was added in the work-up (as 
described by Peter), however only re-formed starting material 52 was isolated 
(entry 1). It was subsequently found that the iminolactone tetrafluoroborate salt 59 
could be isolated by simply filtering away the insoluble AgCl following the reaction 
(entry 2). Using Peter’s one-pot deprotection conditions (condition a, Scheme 
21), using AgBF4 in place of AgClO4, gave only partial conversion to the 
deprotected amine (entry 3). However, the use of a telescoped procedure where 
the iminolactone was first formed in anhydrous THF and then subsequently 
hydrolysed in acetone–water sucessfully furnished amine 60, which was isolated 
in 95% yield. 
 
Entry Reaction conditions Conversion* 
Isolated 
Product 
(Yield) 
1 
(i) AgBF
4 
(1.1 eq.), THF,  
−20 °C to rt, 3.5 h.  
(ii) Et
3
N•HCl (0.5 eq.) 
100% 59 52* 
2 
AgBF
4 
(1.1 eq.), THF,  
−20 °C to rt, 2 h. 
100% 59 59 (80%) 
3 
AgBF
4
 (1.1 eq.),  
1:1 acetone–H2O, 4 days. 
50% 60 
25% 59 
25% 52 
– 
4 
(i) AgBF4 (1.1 eq.),  
THF, 0 °C to rt, 2 h. 
(ii) 1:1 acetone–H2O, 15 h. 
100% 60 60 (95%) 
Table 8 Optimisation of the AgBF4 mediated deprotection of compound 52. 
*As judged by analysis of the crude reaction product by 1H NMR spectroscopy. 
 
Whilst the optimised conditions for this deprotection worked nearly quantitatively, 
the use of stoichiometric silver salts was undesirable as they are expensive 
(AgBF4 retails at £1411 mol-1!).* 
 
2.2.5 Critical analysis of the suitability of the AAA of azlactones for LOS 
The AAA of the model azlactone 27a with cinnamyl acetate was robust and gave 
good yields and high enantioselectivity. The resulting quaternary azlactone 28a 
could be opened with O-, N- and C-centred nucleophiles. However, ultimately all 
                                            
* Based on 50 g material, Sigma Aldrich, 
http://www.sigmaaldrich.com/catalog/product/aldrich/208361?lang=en&region=GB, accessed 01/26/2015. 
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of the methodologies investigated to introduce a readily removable protecting 
group into the AAA strategy either failed, needed considerable optimisation, or 
were not scalable. As a result of this, alternative methodologies for the 
construction of quaternary amino acid derivatives were sought. 
 
2.2.6 Preparation of quaternary amino esters by simple allylation 
Due to the limited applicability of the AAA of azlactones to LOS, the allylation of 
cheap and readily accessible Boc-protected cyclic secondary amines 61a-c and 
α-iminoester 61d using LiHMDS and allyl bromide was investigated (Scheme 
22).134 This methodology was found to be broadly applicable and scalable, giving 
compounds 62a-c in 80-96% yield. The Boc-groups of compounds 62a-c were 
readily removed using TFA to furnish amino esters 63a-c in 66-85% yield. 
Phenylalanine-derived amino ester 63d was furnished in 89% yield by using an 
aqueous acidic work-up following allylation of α-iminoester 61d. 
 
Scheme 22 Allylation of protected amino esters 61a-c (R2= Boc) and α-iminoester 61d (R2= benzamine).  
a Aqueous acidic work-up used.135 
 
The above reaction is more limited in terms of introducing functional handles into 
the building blocks 64 for cyclisation (this two component coupling lacks the final 
substitution step that the three-component AAA strategy offers, Figure 15). 
Nevertheless, the starting materials are readily available and this process also 
offers the advantage of being applicable to secondary cyclic amino esters 
(building in such rings using the AAA strategy may have taken several steps). 
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Figure 15 Differences between the points of potential connectivity available to form scaffolds when using the simple 
allylation methodology (method b) compared to the products of the AAA of azlactones (method a). The coloured dots 
highlight functionalities that may potentially be exploited to form scaffolds. 
 
2.3 Establishing a chemical tool-kit: Synthetic strategy 
Having established conditions for the connective reaction to synthesise 
quaternary amino esters 63a-d, a tool-kit of reliable cyclisation methodologies 
was sought for the construction of lead-like molecules. It was proposed that the 
amine could be armed with a functional group (red) which would tune the 
precursor for cyclisation with either the adjacent alkene (cyan, equation 1) or the 
adjacent ester (green, equation 2) to form diverse cyclic molecules (Figure 16). 
Widely applicable and robust reaction methodologies were sought. Variation of 
the derivative scaffolds would be achieved by exploiting acyclic or cyclic amino 
acid starting materials 63a-d; by varying the appended functionality (red); and by 
varying the cyclisation reaction. Methodologies were developed based on their 
potential ability to provide access to scaffolds that could generate expansive 
libraries of highly lead-like products as judged by using our computational 
protocol (as described in Section 2.1). In particular we sought to exploit the 
addition of nucleophilic tethers to alkenes and esters, and transition 
metal-catalysed reactions between the functional tether and the alkene. 
 
Figure 16 Proposed strategies for the cyclisation of quaternary amino esters. 
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For the synthetic transformations that were successfully developed, a detailed 
interrogation of their ability to provide access to lead-like space is provided 
towards the end of the chapter (Section 2.5). 
 
2.3.1 Cyclisations exploiting the electrophile-induced capture of tethered 
nucleophiles 
1,2-Amino alcohols and diamines and their functionalised derivatives are 
prevalent in many bioactive compounds.136,137 We therefore explored oxy- and 
aminoamination through the reaction of alkene-iodine π-complexes with tethered 
nucleophiles, followed by substitution of the resulting alkyl iodides.98–102,138 
 
2.3.1.1 Oxyiodinations 
Licini described the cyclisation of the Boc-protected amino ester 65 with both 
molecular iodine and N-iodosuccinimide to give cyclic carbamates 66-67 with 
high diastereoselectivity (Scheme 23).102  
 
Scheme 23 Iodine-mediated cyclic carbamate synthesis by Licini.102 
 
Pipeline pilot confirmed that it would be valuable to apply this methodology to 
building blocks 62a-d. In initial studies, the iodine-mediated cyclisation of the 
diallylated amino ester 63e was investigated (prepared by diallylation of glycine 
– see experimental for full details). Boc-protection of compound 63e, followed by 
treatment with iodine in 1:1 THF–H2O, gave 100% conversion to alkyl iodide 68e. 
Purification of compound 68e proved challenging as it was unstable on SiO2. 
However we saw this as an opportunity to displace the iodide with a range of 
nucleophiles which would either generate a point for further diversity, or introduce 
a decorative capping group which may be useful in the generation of derivative 
compound libraries (Table 9). Potassium phthalimide, a poor nucleophile, did not 
displace the iodide even when the reaction was heated (entries 1-2). Surprisingly, 
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the iodide decomposed in the presence of sodium and potassium phenolates 
(entries 3 and 5). Good nucleophiles such as sodium thiophenolate (entry 6) and 
sodium azide (entry 7) were found to readily displace the iodide to give 
compounds 69e and 70e respectively. We considered the azide functional handle 
to be particularly valuable as it had the potential to undergo reduction to the 
amine, or click reactions to introduce triazoles. 
 
Entry Nucleophile Base Solvent T /°C t /h 
Yield /%  
(Conversion)* 
No. 
1 
potassium phthalimide  
(2.0 eq.) 
− DMF rt 15 nr − 
2 
potassium phthalimide  
(2.0 eq.) 
− DMF 90 3 nr − 
3 PhOH (2.0 eq.) NaH (2.0 eq.) DMF rt 15 decomposition* − 
4 PhOH (2.0 eq.) K2CO3 (4.0 eq.) MeCN rt 15 nr − 
5 PhOH (2.0 eq.) K2CO3 (4.0 eq.) MeCN 82 15 decomposition* − 
6 PhSH (1.3 eq.) DBU (1.4 eq.) DMF rt 15 80 (100) 69e 
7 NaN3 (2.0 eq.) − DMF rt 15 78 (100) 70e 
Table 9 Displacement of alkyl iodide 68e with nucleophiles.  
*As judged by analysis of the crude reaction product by 1H NMR spectroscopy. 
 
Applying Licini’s protocol to building blocks 62a-d, followed by treatment of the 
resulting alkyl iodide with NaN3, provided an overall oxyamination reaction to 
provide the cyclic carbamates 70a,c-d (Scheme 24).  
 
Scheme 24 Oxyamination of the Boc-protected amino esters 62a-d. 
 
The relative configuration of the minor diastereomer of the phenylalanine-derived 
carbamate 70d was determined by an nOe enhancement between the benzylic 
protons and the proton alpha to the azidomethyl group (Figure 17). 
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Figure 17 Key nOe enhancement for compound 70d. 
 
Crystallographic studies confirmed the relative configuration of the major 
diastereomer of proline-derived carbamate 70a (Figure 18). 
 
Figure 18 X-ray crystal structure of the proline derived carbamate 70a. 
 
Whilst the reaction was successful for phenylalanine, proline and 
piperazine-derived starting materials 62a,c-d, the azetidine-derived starting 
material 62b only gave a trace of product (Figure 19). This is because 
azetidine 62b was undergoing a competing intermolecular hydroiodination 
process under the aqueous reaction conditions, giving rise to iodoalcohols 71-72 
(as judged by analysis of the crude residue by 1H NMR spectroscopy and LCMS). 
Since a trace of the targeted product 70b was observed by analysis of the crude 
product by both 1H NMR spectroscopy and LCMS (mass observed at 348.1, 
which corresponds to the [M+Na]+ ion of the targeted cyclic carbamate 70b) we 
can postulate that the required six-membered transition state 73b can form under 
these conditions. The hydroiodination products 71-72 may therefore arise 
through the intermolecular addition of H2O to the transition states 73a-b, although 
we cannot rule out neighbouring group participation of the ester functionality (as 
in transition state 74) and subsequent addition of H2O. The favourability of the 
intermolecular pathway may arise from increased strain in the transition state 
caused by the presence of the azetidine ring. 
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Figure 19 Attempted cyclisation of the Boc-protected azetidine 62b. 
 
The work of Licini also describes the use of anhydrous conditions of 
N-iodosuccinimide in CHCl3 to give alkyl iodides 66-67, albeit with poorer 
diastereoselectivity (Scheme 23). Applying these conditions to the Boc-protected 
azetidine 62b gave the desired alkyl iodide, which was subsequently displaced 
with sodium azide to give compound 70b (Scheme 25). Both steps of the reaction 
were extremely sluggish when compared with the analogous steps to prepare 
70a,c,d. in THF–H2O. 
 
Scheme 25 Oxyamination of the Boc-protected azetidine 62b. 
 
2.3.1.2 Aminoiodinations 
Following on from the success of the oxyiodination-displacement protocol, we 
chose to investigate analogous aminoiodination reactions to give access to 
biologically relevant cyclic ureas.139 Unprotected cyclic ureas have the advantage 
of having an additional site to diversify when compared with the analogous 
carbamates. However, one difficulty with the halocyclisation of ureas 75 with 
alkenes lies in the ambident nature of the urea nucleophile, where O-cyclised 
products 76 are typically favoured over N-cyclised products 77 (Figure 20).140,141 
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Figure 20 Typical regioselectivity in the iodocyclisation of ureas 75. R= H, alkyl, aryl. 
 
Taguchi reported the iodine-mediated cyclisation of carbamoyl ureas 78, using 
Li[Al(OtBu)4] as a base, which cyclised through nitrogen to give six-membered 
cyclic ureas 79 in 64-86% yields and with reasonable to high 
diastereoselectivities (Table 10).138 Taguchi postulates that the role of 
Li[Al(OtBu)4] is to act as a chelating agent between the two carbonyls of 
carbamoyl urea 78, locking these into a six-membered ring 80 to promote 
N-cyclisation of the otherwise ambident nucleophile. 
 
Entry R1 R2 R3 Yield /% cis/trans 
1 Ph(CH2)2 H H 80 2:1 
2 Ph(CH2)2 H PhCH2 64 1:30 
3 Ph(CH2)2 H Ph2CH 70 >1:100 
4 Me H Ph2CH 64 1:64 
5 CO2Et CO2Et H 86 N/A 
Table 10 Iodine-mediated N-cyclisation of ureas by Taguchi.138 
 
Taguchi’s conditions were applied to building blocks 63a-d. Carbamoyl 
ureas 81a-d were generated by reaction of amines 63a-d with ethyl 
isocyanatoformate. Ureas 81a-d were then treated with iodine and Li[Al(OtBu)4], 
giving rise to the bicyclic scaffolds 82a-c (Scheme 26). Phenylalanine-derived 
urea 81d gave a complex mixture of inseparable products under these reaction 
conditions. Analysis of the crude reaction mixture by 1H NMR spectroscopy 
suggests that this may be due to the formation of a mixture of N- and O-cyclised 
products and their de-carbamoylated derivatives. 
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Scheme 26 Aminoamination to form the cyclic ureas 82a-c. 
 
Crystallographic studies confirmed the relative configuration of the 
decarbomoylated derivatives 83 and 84, prepared by treating scaffolds 82a,c with 
sodium hydroxide (Figure 21) and sodium methoxide respectively (Figure 22). 
 
Figure 21 X-ray crystal structure of urea 83a. 
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Figure 22 X-ray crystal structure of urea 84c. Both molecules in the asymmetric unit exhibited disorder around the benzyl 
ester groups. For both molecules, this was modelled as two parts in a 60:40 ratio. Only one of the benzyl ester 
conformations is shown for clarity. 
 
2.3.2 Cyclisations between tethered N-centred nucleophiles and the 
adjacent ester 
In this section, the inherent susceptibility of the ester to cyclisations through 
nucleophilic attack is exploited. 
 
2.3.2.1 Hydantoin formations 
During our investigations to form cyclic ureas 82a-c, we also investigated the 
possibility of forming scaffold 85d by using an aminoarylation reaction, which 
would allow scaffold formation and decoration in one step.82,142 However, on 
exposure of urea 86d to typical basic conditions for aminoarylation, 
hydantoin 87d was observed as the major product (as judged by analysis of the 
crude product using 1H NMR spectroscopy, Scheme 27). 
 
Scheme 27 Attempted aminoarylation.142 
 
Hydantoins are known for their anticonvulsant biological activity (e.g. phenytoin, 
mephenytoin, nirvanol), and we saw an opportunity to harness this transformation 
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to give access to new classes of hydantoin scaffolds. Heating urea 86d with 
sodium tert-butoxide gave hydantoin 87d in 85% yield (Scheme 28). 
 
Scheme 28 Base-mediated hydantoin formation. 
 
For carbamoyl ureas 81a,c, it was possible to achieve a one-pot hydantoin 
formation and carbamoyl deprotection. Treatment of 81a,c with sodium 
methoxide gave hydantoins 88a,c. Urea 81b failed to cyclise (only 
decarbamoylation was observed by analysis of the crude reaction mixture using 
1H NMR spectroscopy), presumably due to the strained nature of the azetidine 
ring (Scheme 29). 
 
Scheme 29 One-pot hydantoin formation-deprotection. 
 
2.3.2.2 Lactamisations 
Arming the building blocks 63a-b with an alkylamino functional handle opened up 
the possibility of preparing scaffolds by lactamisation. Reductive amination with 
N-Boc glycinal gave the Boc-protected diamines 89a-b, which were carried 
forward crude, as they could not be separated from trace impurities during 
attempted purification using flash chromatography. Treatment of the protected 
diamines 89a-b with TFA, followed by base-mediated cyclisation afforded 
lactams 90a-b (Scheme 30). 
48 
 
 
 
Scheme 30 N-alkylation and lactamisation. 
 
Piperazine 63c failed to undergo reductive amination to generate the required 
precursor for lactamisation. The Nelson group has previously had success using 
cyclic sulfamidates as electrophilic coupling partners to alkylate amine 
nucleophiles.90,92 In a preliminary study, alkylation of proline-derived starting 
material 63a with commercially available cyclic sulfamidate 91 proceeded with 
complete conversion to give Boc-protected diamine 89a, following an acidic 
work-up (Scheme 31). However, extension of these conditions to piperazine 63c 
resulted in no reaction. 
 
Scheme 31 Alkylation with cyclic sulfamidate 91. 
 
 
Jarosz noted difficulties when trying to react α,α-disubstituted piperidine 92 with 
common electrophiles to give protected piperidine 93 (Panel A, Scheme 32).143 
The origin of the lack of reactivity of piperazine 63c may lie in the decreased bond 
angle between the iminium double bond and the α-substituents in intermediate 
94, compared with the analogous pyrrolidine-derived iminium intermediate 95, 
this results in steric hindrance and forces the equilibrium towards the starting 
amine 63c (Panel B). 
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Scheme 32 Panel A: attempted protection of amine 93 by Jarosz.143  
Panel B: rationale for the failure of the attempted reductive amination of piperazine 63c. 
 
It was also possible to prepare a diketopiperazine 96d through an analogous 
cyclisation strategy (Scheme 33). The precursor 97d to this reaction was first 
prepared through reaction of compound 63d with N-Boc glycine, mediated by 
EDCI. Amide 97d was treated with Cs2CO3 in refluxing DMF to furnish 
diketopiperazine 96d in 93% yield. 
 
Scheme 33 Synthesis of diketopiperazine 96d. 
 
2.3.3 Transition metal-catalysed cyclisations between the capping group 
and the allyl functionality 
There is a wealth of literature describing the synthesis of scaffolds (natural 
products or otherwise) through the transition metal-catalysed formation of C-C 
bonds. The value of these types of transformation cannot be understated; two 
Nobel prizes in the last decade have been awarded for the development of such 
transformations: metathesis and Pd-catalysed cross coupling reactions.144,145 
Due to the wealth of literature on these processes, we chose to investigate the 
use of selected amine capping groups that would enable scaffold formations 
through C-C bond formations.  
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2.3.3.1 Intramolecular Heck reactions 
The intramolecular Heck reaction has been extensively developed146 and has 
been shown to be of particular value in the preparation of natural product 
skeletons.147 Consequently, we endeavoured to harness this approach to prepare 
scaffolds. 
 
In preliminary studies, N-benzoylation of 63d using 2-bromobenzoyl chloride, 
followed by treatment of the resulting benzamide 98d with Pd(OAc)2 gave none 
of the targeted seven-membered Heck product 99d under either thermal or 
microwave conditions (Scheme 34). We postulated that this lack of reactivity was 
caused by the thermodynamically favoured, but unreactive, s-trans geometry of 
the amide bond (this would be akin to trying to form a seven-membered ring 
containing a trans C=C bond, which is geometrically unfavourable).148 
 
Scheme 34 Attempted Heck cyclisation of benzamide 98. 
 
We postulated that the increased flexibility of the analogous amines 100a-d would 
allow the required Heck cyclisations to take place. Firstly, 2-bromobenzylated 
amines 100a-d were prepared by reductive amination. Once again, the 
piperazine 100c was reluctant to undergo reductive amination (33% conversion 
in 24 h, 15% isolated yield). However, alkylation with 2-bromobenzyl bromide 
provided 100c in 83% yield (Scheme 35). 
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Scheme 35 Alkylation of the amines 63a-d to give precursors for the intramolecular Heck reaction. 
aThe TFA salt of 63b and 2.2 eq. K2CO3 were used (see experimental). 
bAlternative reaction conditions used: 
2-Br-C6H4-CHO (2.0 eq.), NaBH(OAc)3 (4.0 eq.), THF, 45 °C, 3 days. 
 
Treatment of precursors 100a-d under standard Heck conditions146 with 
5-10 mol% Pd(PPh3)4 at 125 °C in the microwave gave azepanes 101a-d, which 
bear an exocyclic alkene (Scheme 36). However the reaction of piperazine 100c 
was poorly regioselective under the reaction conditions; analysis of the crude 
product by 1H NMR spectroscopy showed that azocane 102c was favoured in a 
6:4 ratio to azepane 101c, which were isolated in 31% and 32% yields 
respectively. It is also worth noting that while 100c-d formed only the products 
isolated (101c/102c and 101d), 100a-b formed other unknown products (as 
judged by analysis of the crude reaction product using 1H NMR spectroscopy) 
which could not be recovered following purification using flash chromatography 
or SPE-SCX. We postulate that these side products may have arisen through the 
alkene ‘walking’ around the ring following the Heck reaction to give unstable 
intermediates which later decomposed during purification. 
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Scheme 36 Intramolecular Heck cyclisations. a92:8 mixture with the regioisomeric azocane (see experimental). 
b10 mol% Pd(PPh3)4 used. 
cAnalysis of the crude reaction product by 1H NMR showed 100% conversion to a 42:58 
mixture of 101c:102c. dPd(OAc)2 (10 mol%) and PPh3 (20 mol%) used. 
 
2.3.3.2 Ring-closing metathesis (RCM) 
In recent years, ring-closing metathesis has been an extremely valuable synthetic 
method for preparing ring systems in many bioactive natural products149 and it 
was thought that this methodology could potentially be applied to our building 
blocks to prepare scaffolds. 
 
Gracias reported that the ring-closing metathesis of unprotected amines 103 
could be achieved by treating the derived ammonium tosylate salts with Grubbs 
second generation catalyst (GII) to generate spirocyclic scaffolds 104 (Table 
11).150 The prior preparation of the ammonium salt ostensibly prevents the 
unwanted coordination of the nitrogen lone pair to the catalyst. 
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Entry Substrate 103 Product 104 Yield /% 
1 
 
 
88 
2 
 
 
95a 
3 
 
 
75 
4 
 
 
96 
Table 11 RCM of ammonium tosylate salts to give spirocyclic scaffolds 104 by Gracias. a1.0 eq. TsOH used.150 
 
N-Allylation of the amine building blocks 63a-d with allyl bromide in DMF 
furnished precursors 105a-d for ring-closing metathesis (Scheme 37). 
 
Scheme 37 Allylation of amines 63a-d to give precursors for ring-closing metathesis. aThe TFA salt of 63b and 2.2 eq. 
K2CO3 used (see experimental). 
b5.0 eq. allyl bromide used. 
 
Gracias’ reaction conditions were applied to substrates 105a-d to give bicyclic 
scaffolds 106a,c-d (Scheme 38). While these conditions worked well for 
phenylalanine-derived 105d it was found that reactions of cyclic 
substrates 105a,c were more efficient when conducted in toluene at reflux. 
Azetidine 105b gave a complex mixture of products under these reaction 
conditions. 
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Scheme 38 Ring-closing metathesis. a5 mol% GII used in CH2Cl2. 
 
To test whether the reaction worked in the absence of p-toluenesulfonic acid, two 
reactions were conducted using proline-derived 105a. Heating substrate 105a 
overnight with either Grubbs second generation (GII) or Hoveyda–Grubbs second 
generation (HGII) gave, in both instances, complete conversion to the target 
product 106a (Scheme 39, Panel A). Following the success of these reactions, 
the azetidine 105b was treated with Grubbs second generation catalyst. Using 
2.5 mol% catalyst loading resulted in no reaction, but increasing the catalyst 
loading to 7.5 mol% led to the formation of the target product 106b, which was 
isolated in 57% yield (Scheme 39, Panel B). 
 
Scheme 39 Ring-closing metathesis in the absence of p-toluenesulfonic acid. 
 
2.3.4 Cyclisation toolkit: A summary 
A focused toolkit of chemical transformations was developed to allow the parallel 
synthesis of scaffolds for LOS (Figure 23). Overall, 22 novel scaffolds were 
prepared from four building blocks 63a-d in a total of 49 synthetic operations.* 
                                            
* Defined as a process conducted in a single reaction vessel. 
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The toolkit consisted of just six reaction methodologies following an N-capping 
event. 
 
Figure 23 A summary of the methods used to prepare 22 scaffolds. A: iodine-mediated cyclic carbamate synthesis; 
B: iodine mediated cyclic urea synthesis; C: hydantoin formation; D: lactamisation; E: intramolecular Heck reaction; F: 
RCM. aPhenylisocyanate derived urea 86d used as the starting material (see experimental, Section 5.2.2). bStarting 
material 97d derived from N-Boc-glycine. cFormed as part of a separable mixture with the azocane 102c. 
 
2.4 Generation of sites for further diversification 
With the 22 scaffolds in hand we wanted to show that the scaffolds could be 
further functionalised to generate points that could be diversified to form 
derivative compound libraries. In particular, we wanted to show that oxidation of 
the alkene functional handles was possible in the presence of tertiary amines. 
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2.4.1 Oxidation of cyclic alkenes in the presence of tertiary amines 
In an initial attempt to oxidise cyclic alkene 106a to form the natural product-like 
diol 107, it was exposed to Upjohn dihydroxylation conditions using OsO4 and 
NMO (Scheme 40).143,151 Unexpectedly, no reaction was observed (by analysis 
of the crude reaction mixture using TLC and 1H NMR spectroscopy). 
 
Scheme 40 Attempted dihydroxylation of alkene 106a. 
 
We opted to prepare compound 108 (prepared in two steps – see experimental), 
bearing a tertiary amine and an alkene, to act as a model substrate to enable the 
development of suitable oxidation conditions. In addition to preventing the waste 
of bespoke scaffolds, the presence of the benzyl group added a chromophore 
which aided TLC analysis of the oxidation reactions. Curiously, the previously 
described Upjohn dihydroxylation conditions were successful when applied to 
model substrate 108 (Table 12, entry 1), diol 109 was isolated in 69% yield. 
Attempted dihydroxylations using modified Prevost−Woodward conditions152 
(entry 2) and attempted transition metal-free diboration153 (entry 3) gave only 
traces of the targeted products. Attempted epoxidation of alkene 108 using 
peracids (entries 4-7) gave mixtures of products including the N-oxide of starting 
material 108 and/or over-oxidation to the N-oxide of epoxide 110 (as judged by 
analysis of the crude reaction products by 1H NMR spectroscopy and LCMS). 
However, epoxidation could be achieved by a two-step sequence involving 
chlorohydrin formation, using N-chlorosuccinamide and TFA in water, followed by 
closure of the resulting chloroalcohol with sodium methoxide (entry 8). While this 
procedure gave a low isolated yield, complete conversion was observed in both 
steps of the reaction. 
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Entry Conditions 
Target 
product 
Products (isolated 
yield) 
1 
OsO4 (5.0 mol%), NMO (2.0 eq.),  
25:1 THF–H2O, 0 °C, 8 h 
143 
109 109 (69%) 
2 
NaIO4 (30 mol%), LiBr (20 mol%),  
AcOH, 95 °C, 18 h 152 
109 
Mainly 108*, trace of 
monoacetylated 109† 
3 
B2pin2 (1.1 eq.), NaOt-Bu (0.15 eq.),  
THF–MeOH, 70 °C, 16 h 153 
109 
Mainly 108*, trace of 
diborylated alkene† 
4 m-CPBA (1.50 eq.), CH2Cl2, 2 h 110 
Mainly the N-oxide of 108 
and the N-oxide of 110*† 
5 
m-CPBA (1.50 eq.), TFA (1.25 eq.), 
CH2Cl2, 15 h 
110 
Mixture of 108; 110; the 
N-oxide of 110*† 
6 
F3CCO2H, F3CCO3H, CH2Cl2,  
0 °C to rt, 16 h 154 
110 complex mixture* 
7 
H2O2, trichloroacetonitrile,  
TFA, CH2Cl2, 48 h 
155 
110 complex mixture* 
8 
(i) NCS (1.2 eq.), TFA (1.3 eq.),  
H2O, 70 °C, 4 h 
156  
(ii) K2CO3 (2.0 eq.), MeOH, 24 h 
110 110 (42%)‡ 
Table 12 Oxidation studies on model substrate 108. *By analysis of the crude reaction mixture using 1H NMR 
spectroscopy. †By analysis of the crude reaction mixture using LCMS. ‡100% conversion for each step as judged by 
analysis of the crude reaction products by 1H NMR spectroscopy. 
 
The hydroxychlorination conditions (Table 12, entry 8) were applied to the cyclic 
alkene 106a (Scheme 41). Two equivalents of NCS were required in order for the 
reaction to go to completion. A 60:40 mixture of the separable 
regioisomers 111-112 was formed (as judged by analysis of the crude reaction 
product using 1H NMR spectroscopy), which were isolated in 36% and 8% yields 
respectively. 
 
Scheme 41 Preparation of the chloroalcohols 111 and 112. 
 
Isolation of the products allowed assignment of their regio- and relative 
stereochemical configurations by NOESY and HMQC (Figure 24). 
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Figure 24 Assignment of regioisomers 111 (Panel A) and 112 (Panel B). 
 
Products 111-112 arise from the trans-diaxial ring opening of the interconverting 
chloronium-ion conformers 113-114 (Figure 25).157 
 
Figure 25 Rationale for the regiochemical outcome of the hydrochlorination reaction. 
 
Treatment of major chlorohydrin 111 with sodium methoxide gave access to 
epoxide 115, which was isolated in 43% yield (Scheme 42). Surprisingly, minor 
chlorohydrin 112 did not react under the same conditions (as judged by analysis 
of the crude reaction mixture using LCMS). 
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Scheme 42 Base-mediated epoxide formation. 
 
The hydrochlorination-epoxidation sequence provides a potential starting point 
for the oxidation of the cyclic alkene systems in the presence of the tertiary amine. 
Further optimisation is required to improve this process in the future. 
 
2.4.2 Oxidation of terminal alkenes in the presence of tertiary amines 
Due to the difficulties met when trying to oxidise the cyclic alkenes in the presence 
of the tertiary amine, we decided to start our investigations into the oxidation of 
terminal alkenes by using a suitable model system. Terminal alkene 116 was 
prepared by reductive amination (route not shown, see experimental). Oxidation 
systems were investigated to try to convert the alkene to a more readily 
functionalised group.  
 
Firstly, the aforementioned dihydroxylation conditions were attempted, resulting 
in successful formation of diol 117 (Scheme 43). Oxidative cleavage of diol 117 
with sodium periodate initially gave aldehyde 118 in <40 min (as judged by LCMS 
analysis of the crude reaction mixture). However, following the work-up the 
observed mass by LCMS agreed with the corresponding acid 119. In addition, 
analysis of the crude product using 13C NMR spectroscopy showed a peak at 
177.2 ppm which indicated that the carboxylic acid had formed. 
 
Scheme 43 Dihydroxylation of alkene 116 and attempted oxidative cleavage of the resulting diol 117. 
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Application of the above conditions to lactam 90a gave diol 120, however, 
subsequent cleavage with sodium periodate gave a complex mixture (as judged 
by analysis of the crude reaction mixture by 1H NMR spectroscopy after each 
step) and none of the targeted aldehyde 121 was isolated following purification 
(Scheme 44). 
 
Scheme 44 Dihydroxylation of compound 90a and attempted oxidative cleavage of the resulting diol 120. 
 
In contrast to the above result, one-pot dihydroxylation and oxidative cleavage of 
alkene 88a, which does not contain a free amine, delivered aldehyde 122 
(Scheme 45). Aldehyde 122 was reduced with NaBH4 to furnish alcohol 123, 
which was isolated in 27% yield, although this procedure needs to be optimised. 
 
Scheme 45 One-pot oxidative cleavage of alkene 88a and subsequent reduction of aldehyde 122. 
 
Returning to the model system 116, a hydroboration-oxidation sequence was 
attempted to investigate the possibility of preparing terminal alcohols in the 
presence of the amine (Scheme 46). Hydroboration using 9-BBN in dioxane gave 
complete conversion to the hydroborated intermediate, this was then oxidised 
under mild conditions with NaBO3•4H2O to give alcohol 124, which was isolated 
in 64% yield.158 
 
Scheme 46 Hydroboration-oxidation of terminal alkene 116. 
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A variant of the above oxidation conditions was successfully applied to lactam 
90a to give alcohol 125 in 52% yield (Scheme 47). 
 
Scheme 47 Hydroboration-oxidation of alkene 90a. 
 
Application of the hydroboration-oxidation conditions to exocyclic alkene 101a 
gave a complex mixture of products that could not be separated by flash 
chromatography (Scheme 48). 
 
Scheme 48 Attempted hydroboration-oxidation of exocyclic alkene 101a. 
 
2.4.3 Oxidation chemistry: Summary and outlook 
The identification of suitable conditions for the oxidation of the alkenes in the 
presence of tertiary amines was challenging and it is clear that we need to study 
this area further. However, we were able to gain some initial insights about which 
methods are best to achieve such transformations. A hydroboration-oxidation 
protocol was used to prepare terminal alcohol 125, whilst hydroxychlorination 
followed by base-mediated epoxidation furnished chlorohydrins 111-112 
(Scheme 49).  
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Scheme 49 Successful oxidations in the presence of tertiary amines. 
 
Since amines have such high prevalence in drug molecules,118 it is extremely 
important to develop more compatible oxidation methodologies in the future. 
 
2.5 Computational assessment of the scaffolds prepared 
Now that preliminary studies had demonstrated the generation of points for 
further decoration, we wanted to assess the novelty and diversity of the 
22 scaffolds and show that they could be virtually decorated to provide access to 
a computer-generated library of lead-like molecules. To achieve this we used 
several new computational protocols.95 
 
2.5.1 Novelty assessment 
To assess the novelty of these scaffolds, a structure search was performed for 
the 22 compounds prepared (carboxybenzyl and ethoxycarbonyl urea protecting 
groups were removed, Figure 26). None of the deprotected compounds were 
found in the ZINC database of commercially available compounds (9×106 
compounds). In addition, none of the deprotected compounds were found within 
the CAS registry, apart from 106a which has been previously reported. However, 
no yield for scaffold 106a or experimental procedure for its formation (including 
supporting analytical data) were given.159 
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The Murcko assemblies97 (with alpha attachments) were also generated and 
compared against the Murcko assemblies (with alpha attachments) of a random 
5% sample of the ZINC database (4.5×105 compounds). Only the assemblies 
derived from scaffold 90a (2 hits) and 106a (1 hit) were found as substructure 
matches. 
 
Figure 26 A summary of the deprotected scaffolds used in the computational analysis to generate a virtual library of 
compounds. 
 
2.5.2 Diversity assessment 
The skeletal diversity and relationship between the scaffolds were assessed 
using the ‘scaffold tree’ hierarchical analysis developed by Waldmann.160 This is 
based on deconstruction of the scaffolds by iterative removal of rings, until a final 
‘root’ ring is obtained. At each iteration step, prioritisation rules dictate which ring 
to remove next, typically retaining central and complex rings and removing 
peripheral rings.  
 
By applying Waldmann’s prioritisation rules to the 22 scaffolds, it was found that 
each scaffold comprised a unique (with respect to this work) molecular framework 
at the graph-node-bond (GNB) level. Thus, the scaffolds are not simple 
derivatives of each other, but represent a skeletally diverse collection. The results 
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are summarized in Figure 27 and the frameworks illustrated in Figure 28. The 22 
frameworks were represented at the graph-node-bond level, and were ultimately 
related to 7 parental frameworks. One of the particular advantages of our parallel 
approach to scaffold preparation is that, if any potential leads were identified in a 
screening campaign, one would be able to ‘scaffold hop’ to related structures, 
retaining the decorative groups from the lead, yet modifying the core scaffold.161 
 
Figure 27 The hierarchical relationship between the 22 distinct molecular frameworks at the graph-node-bond level (black) 
and the 7 parental frameworks (blue). Daughter frameworks are shown in red. 
 
 
Figure 28 The 22 distinct molecular frameworks at the graph-node-bond level (black), and the seven parental frameworks 
(blue). Daughter frameworks are shown in red. The scaffolds that represent each framework are indicated. See Figure 27 
for the relationship between scaffolds at each level of hierarchy. 
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2.5.3 Virtual decoration of the scaffolds 
To determine the potential ability of the scaffolds to provide access to lead-like 
screening compounds, a virtual library of compounds was enumerated using 
Accelrys Pipeline Pilot. 
 
The enumeration process illustrated in Figure 29 was applied to the 22 scaffolds. 
Firstly, removal of the carboxybenzyl and ethoxcarbonyl urea protecting groups 
was performed to give the deprotected scaffolds as shown in Figure 26. Certain 
functional groups were then manipulated to generate sites for further decoration 
(Table 13): (i) azides were both retained and reduced (entry 1); (ii) terminal 
alkenes were converted to aldehydes and carboxylic acids (entry 2) and; (iii) 
esters were saponified (entry 3). Decoration reactions (Table 14) were performed 
using 80 typical medicinal chemistry capping groups from a list provided by our 
industrial collaborators GlaxoSmithKline (see Appendix 1). Subsequent 
manipulation (Table 13, entries 4-5) reduced any aldehydes and acids to alcohols 
(entry 4) and converted any remaining azides and primary amines to 
dimethylamines (entry 5). The deprotected but underivatised scaffolds (i.e. the 
scaffolds as shown in Figure 26) were also retained in the final virtual library. 
Overall this process generated a library of 1110 virtual screening compounds.  
 
 
Figure 29 An overview of the process for the enumeration of the virtual library. 
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Entry 
Manipulation  
1 or 2 
Synthetic transformation Description 
1 1 
 
Azides reduced and 
retained 
2 1 
 
Terminal alkenes oxidised 
to aldehyde and acid 
3 1 
 
Esters saponified 
4 2 
 
Aldehydes and acids 
reduced to alcohols 
5 2 
 
Azides and primary 
amines converted to 
dimethylamines 
Table 13 Functional group manipulations of scaffolds (Manipulation 1) and final compounds (Manipulation 2). 
 
 
Entry 
Functional group 
decoration 
Synthetic transformation Description 
1 Acid 
 
Amide coupling 
(R1= H, alkyl, aryl) 
2 Aldehyde 
 
Reductive amination 
(R1= H, alkyl, aryl) 
3 Amide 
 
Alkylation 
4 Amide 
 
Arylation 
5 
Amine 
(R1= H, alkyl) 
 
Alkylation 
6 
Amine 
(R1= H, alkyl) 
 
Amide coupling 
7 
Amine 
(R1= H, alkyl) 
 
Arylation 
8 
Amine 
(R1= H, alkyl) 
 
Reductive amination 
(R3= H, alkyl, aryl) 
9 
Amine 
(R1= H, alkyl) 
 
Sulfonamide 
formation  
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Entry 
Functional group 
decoration 
Synthetic transformation Description 
10 
Amine 
(R1= H, alkyl) 
 
Urea formation 
11 Azide 
 
Click 
12 Carbamate 
 
Alkylation 
13 Carbamate 
 
Arylation 
14 Urea 
 
Alkylation 
15 Urea 
 
Arylation 
Table 14 Decoration reactions exploited in the enumeration of the virtual library. 
 
2.5.3.1 Molecular properties analysis 
The molecular properties (AlogP, heavy atom count [HA], Fsp3) of the compounds 
in the virtual library were calculated using the built-in tools in Pipeline Pilot and 
Dotmatics Vortex. The data which follow were visualised and analysed using 
Dotmatics Vortex. 
 
2.5.3.1.1 Lead-likeness assessment 
The highly interactive Dotmatics Vortex software allows analysis of the library 
from many standpoints. For instance, it is useful to consider the virtual compound 
library as a whole (for example to compare it to the rest of chemical space), on a 
scaffold basis (to determine which scaffold could prepare the most valuable 
screening libraries), and in addition it is useful to determine if there is any intrinsic 
bias towards more lead-like compounds depending upon which initial building 
block is used. 
 
The lead-likeness of the virtual compound library was assessed in accordance 
with the criteria designated by Churcher (Figure 30, boxed area):10 66% of 
compounds survived filtering by molecular size (14 ≤ heavy atom count ≤ 26), 
lipophilicity (−1 < AlogP < 3) and structural filters (see Appendix 1) – heavy atoms: 
μ= 22.8, σ= 3.57; AlogP: μ= 0.38, σ= 1.38. By comparison, just 23% of 9×106 
compounds from the ZINC database of commercially-available compounds96 
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survived this filtering process (Figure 31), with most compounds lying well outside 
lead-like chemical space (heavy atoms: μ= 25.9, σ= 5.4; AlogP: μ= 1.7, σ= 2.9).  
 
 
Figure 30 Distribution of the number of heavy atoms and AlogP for the 1110 decorated final compounds derived from the 
22 scaffolds using the virtual library enumeration process. Compounds that survive successive filtering are shown in green 
(734 compounds, 66%). Compounds that fail successive filtering by number of heavy atoms (red, 173 compounds, 16%), 
AlogP (yellow, 200 compounds, 18%) and structural liabilities (black, 3 compounds, 0.3%) are shown. The black box 
shows the limit of lead-like space as outlined by Churcher.10 A larger annotated version of this plot is included in 
Appendix 1. 
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Figure 31 The distribution of molecular properties of the virtual library of 1110 compounds, derived from the 22 scaffolds 
(orange, enlarged for clarity), compared with 90911 randomly selected compounds from the ZINC database (blue). Our 
virtual library is considerably more focused on lead-like space compared to the rest of commercially-available compound 
space. 
 
Remarkably, when decorated with the same set of 80 capping groups, each of 
the 22 scaffolds allow significant lead-like chemical space to be targeted. Each 
scaffold was ranked on its ability to provide access to lead-like compounds (see 
Appendix 1, Section 6.4.1 for individual AlogP vs heavy atom count plots). When 
deciding which scaffolds were the most valuable, both the percentage of lead-like 
compounds accessible from each scaffold (top histogram, Figure 32) and the 
absolute number of potentially accessible compounds are valuable to consider 
(middle histogram, Figure 32). Both of these were taken into consideration by 
calculating the weighted average (calculated as shown in equation below) to give 
an idea of which scaffolds can deliver the highest quantity of lead-like compounds 
(bottom histogram, Figure 32). 
𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = 100 × (
𝑛 × 𝑝
∑ (𝑛 × 𝑝)𝑎𝑙𝑙 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑𝑠
) 
where n= no. lead-like compounds and p= percentage of lead-like compounds 
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Figure 32 Histograms to show: the percentage of lead-like compounds derived from each scaffold (top); the absolute 
number of lead-like compounds that may be derived from each scaffold (middle); and the weighted average of the 
number of lead-like compounds and the percentage of lead-like compounds (bottom).  
 
Decoration of scaffolds 70a and 106c would generally give large numbers of 
high-quality lead-like compounds and would be ideal starting points for compound 
library synthesis (Figure 32). The poorest scaffolds for generating lead-like 
compounds were 87d and 101d, where respectively only 4 out of 10, and, 7 out 
of 21 compounds were lead-like. Virtual compounds derived from scaffold 101d 
generally suffered from high molecular weight (10 out of 21 fail the heavy atom 
filter), while compounds derived from 87d had high molecular weights and AlogP. 
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By contrast the other hydantoins 88a,c performed better (Panel A, Figure 33): for 
pyrrolidine-derived 88a, 24 out of 26 compounds would be lead-like; for 
piperazine-derived 88c 39 out of 78 derivatives would be lead-like.  
 
In the urea series, pyrrolidine-derived 82a and azetidine-derived 82b perform well 
(Panel B, Figure 33). While piperazine-derived 82c may be used to prepare many 
scaffolds (127), less than half of them would be lead-like (47%); most of these 
derivatives fail the AlogP filter (55 failures, which were generally too polar) with 
the remainder (25) failing the heavy atoms filter.  
 
Figure 33 Panel A: comparison of the ability of the urea scaffolds 82a-c to prepare lead-like compounds.  
Panel B: comparison of the ability of the hydantoin scaffolds 87d and 88a-c to prepare lead-like compounds. 
 
It is also possible to rank potential for each building block to provide access to 
lead-like compounds. This approach would be particularly useful when deciding 
which bespoke starting materials would be most valuable to synthesise and use 
for the generation of compound libraries (Figure 34, for full details see 
Appendix 1, Table 24). In terms of absolute numbers (top histogram, Figure 34), 
the piperazine-derived building block 63c would deliver the largest number of 
lead-like compounds (285). This result is not unexpected as the additional amine 
in the scaffold increases the number of sites available for decoration, allowing the 
generation of a large compound library. This compares with 193, 139 and 117 
lead-like compounds for the pyrrolidine-, azetidine- and phenylalanine-derived 
libraries respectively. However, in terms of the percentage of lead-like 
compounds that may be derived per scaffold (middle histogram, Figure 34), the 
pyrrolidine-derived scaffolds would return 90% lead-like compounds, whilst the 
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piperazine-derived scaffold scores lowest at 56%. Once again, it is useful to 
consider the weighted average of the two aforementioned parameters (calculated 
as shown below). This analysis suggests that it would be most synthetically 
valuable to pursue the synthesis of the pyrrolidine-derived compounds (bottom 
histogram, Figure 34). 
𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 = 100 × (
𝑛 × 𝑝
∑ (𝑛 × 𝑝)𝑎𝑙𝑙 𝑠𝑐𝑎𝑓𝑓𝑜𝑙𝑑𝑠
) 
where n= no. lead-like compounds per building block and p= percentage of lead-like compounds per building block. 
 
Whilst the pyrrolidine- and azetidine-derived scaffolds only differ by one 
methylene group, there is still value in preparing both sets of compound libraries, 
not least because analogous scaffolds in each series would explore different 
vectors in chemical space. In terms of physicochemical properties, the virtual 
compounds have similar average heavy atom counts (21.1 and 20.4 for the 
pyrrolidine-derived and azetidine-derived compounds respectively), but notably 
have different AlogP (0.24 and −0.30 respectively). 
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Figure 34 Histograms to show: the average number of lead-like compounds per scaffold for each building block (top); the 
percentage of lead-like compounds per building block (middle); and the weighted average of the number of lead-like 
compounds per scaffold and the percentage of lead-like compounds per building block (bottom).  
 
The virtual library has significantly higher sp3 content (Fsp3: µ= 0.57) than the 
commercially available compounds in the ZINC database (Fsp3: µ= 0.33). The 
phenylalanine-derived final compounds gave the lowest average Fsp3 (0.37), 
whilst the final compounds derived from the remaining building blocks had 
Fsp3 ≈ 0.6 (see Appendix 1, Table 24 for more details). This is not unexpected 
due to the inclusion of an aromatic ring in the phenylalanine-derived building 
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block 63a. However, the phenylalanine-derived scaffolds still performed very well 
in the PMI analysis (see next section). 
 
2.5.3.2 Principal moments of inertia study 
More three-dimensional compounds typically have lower attrition rates in drug 
discovery,19 and may serve as better leads. The shape diversity of the virtual 
library was compared with that of 90911 randomly selected compounds from the 
ZINC database (Figure 35). For each compound, the two normalised principal 
moments of inertia values were determined for a low energy conformation (for 
individual PMI plots for each scaffold see Appendix 1, Section 6.4.3).162  
  
Figure 35 A normalised principal moment of inertia plot to show the shapes of the 1110 virtual compounds in relation to 
three idealised molecular shapes: a rod, a disk and a sphere. A systematic shift away from the flat-linear edge of the 
graph towards more three-dimensional molecular space can be observed for the 1110 virtual library compounds derived 
from the 22 scaffolds (orange, enlarged for clarity) when compared with 90911 randomly selected compounds from the 
ZINC database (blue). A larger annotated version of this plot is included in Appendix 1, Section 6.4. 
 
By dividing the PMI plot into 20 bins (Figure 36, see Appendix 1, Section 6.3 for 
details of the associated calculation) and counting the number of compounds in 
each bin (Figure 37), we were able to semi-quantitatively determine the relative 
three-dimensionality of the virtual library compared with the rest of commercially 
available compounds. Notably, while 44% of ZINC compounds fall within the first 
bin (which lies along the flat-linear edge of the PMI plot), 0% of the virtual library 
compounds fall within the same space. In addition, a higher proportion of the 
virtual library compounds fall within the bins 3-11 which represent more 
three-dimensional space. 
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Figure 36 An axis rotation was performed, then the PMI plot was binned into 20 sections. The relative count of compounds 
in each bin was assessed for the virtual library compounds against 1% of the ZINC database (Figure 37). 
 
 
Figure 37 The relative proportions of the compounds found when the PMI was divided into twenty bins for the virtual 
library compounds versus 1% of the ZINC database (11 of 20 bins shown). 
 
It was also possible to bin the PMI plot with respect to which amino ester building 
block was used (Figure 38). Notably, the cyclic amino esters had reasonably 
similar distributions. However, for the phenylalanine-derived compounds, in 
addition to the absence of scaffolds in bin 1, these compounds also barely occupy 
the next bin (3% occupancy in bin 2). In contrast, the cyclic building blocks all 
have >23% occupancy in bin 2. This verifies the value of including a non-cyclic 
amino ester in our LOS strategy. 
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Figure 38 Relative distributions of the virtual library compounds in the PMI plot with respect to the amino ester building block 63a-d used. The associated PMI plots are shown in Appendix 1.
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2.5.4 Computational assessment: A summary 
Our studies have shown that the scaffolds prepared are novel and diverse. In 
addition, the computational protocol has shown that decoration of the scaffolds 
with typical medicinal chemistry capping groups would give access to large 
numbers of lead-like molecules. We therefore endeavoured to put theory into 
practice by preparing some exemplary lead-like molecules.  
 
2.6 Exemplar decorations of scaffolds 
The cyclic urea scaffold 82a could undergo a Cu-mediated 1,3-dipolar 
cycloaddition (click reaction) with phenyl acetylene to give compound 126 in 88% 
yield. Removal of the ethoxycarbonyl protecting group, by treatment with sodium 
hydroxide, led to precipitation of a white solid after two hours. Addition of 
Amberlite IR-120 H (hydrogen form), followed by filtration, gave compound 127 
as an 8:2 mixture of the ester:acid (Scheme 50). A longer reaction time is required 
in future to ensure that the starting material undergoes complete conversion to 
the targeted acid. 
 
Scheme 50 Click reaction of azide 82a and subsequent deprotection to give urea 127. 
 
Decarbamoylation of compound 82a with sodium methoxide, to give 
compound 128, followed by N-alkylation with 4-fluorobenzyl bromide gave 129 
(Scheme 51). 
 
Scheme 51 N-alkylation of urea 128. 
 
Reduction of the azide functionality was also investigated. Under Staudinger 
conditions the reaction gave complete conversion to amine 130 (as judged by 
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analysis of the crude with LCMS and 1H NMR spectroscopy, Scheme 52). 
However, purification to remove the triphenylphosphine oxide following the 
reaction proved difficult, even when the reaction was telescoped with subsequent 
benzoylation. The characteristic 1H NMR spectroscopy data for amine 130 and 
its benzoylated derivative 131 are reported in the experimental.  
 
Scheme 52 Staudinger reduction of azide 82a and subsequent benzoylation. 
 
Other conditions were investigated in an attempt to simplify purification of 
amine 130 including: (i) the use of polymer-supported triphenylphosphine, which 
gave a complex mixture of inseparable products; and (ii) the use of SnCl2 in 
methanol, which gave unwanted side products along with amine 130 (conditions 
not shown). Future experimentation may determine a more suitable purification 
method for products 130-131. 
 
2.6.1 Computational assessment of exemplar scaffolds 
The plot below shows where these compounds fall in the lead-likeness 
assessment compared to the computationally generated library (Figure 39). 
These molecules fall within the bounds of lead-like space (26 heavy atoms; 
AlogP ≈ 0.5-2.5) and therefore may be considered lead-like. The decorated 
scaffolds are also shown on a PMI plot (Figure 40). While N-alkylated urea 129 
was more spherical, the triazole 127 and amide 131 were more rod-like. 
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Figure 39 The distribution of molecular properties of compounds 127, 129 and 131 (green, enlarged for clarity), derived 
from scaffold 82a, compared with the virtual library of 1110 molecules derived from the 22 scaffolds (orange). 
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Figure 40 A PMI plot to show the relative shapes of compounds 127, 129 and 131 compared to the rest of the virtual library.  
The lowest energy three-dimensional representations were generated using OpenEye Omega by George Burslem.
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2.7 Conclusions and future work 
In summary, the careful selection of small, polyfunctional substrates in the form 
of quaternary allylated amino acid esters has facilitated a modular approach to 
the efficient synthesis of molecular scaffolds that are novel, diverse, and can 
specifically target lead-like chemical space.  
 
Two methods were investigated to prepare the quaternary allylated amino acid 
esters. Asymmetric allylic alkylation of azlactones was found to be robust and the 
resulting quaternary azlactones could be opened with O-, N- and C-centred 
nucleophiles. However, the compatibility of this method with a readily removable 
amide protecting group was elusive. Consequently, building blocks were 
prepared by allylation of Boc-protected amino esters. 
 
A strategy to prepare scaffolds was realised, relying upon the variation of amine 
capping groups to tune the amino ester building blocks for cyclisation. Six 
cyclisation methodologies were exploited, four of which enabled the 
intramolecular capture of pendant nucleophiles by the alkene or ester 
functionalities, and two of which used transition metal-catalysed reactions 
between the capping group and the alkene. The use of four building blocks 
allowed a library of 22 scaffolds to be prepared in only 49 synthetic operations. 
 
We attempted to generate sites on the scaffolds for further decoration. Oxidations 
in the presence of tertiary amines were found to be challenging. Some successes 
were met in the form of chlorohydrin formation and a hydroboration-oxidation 
protocol, but it is clear that more work is required to develop oxidations that work 
consistently in the presence of unprotected amines. 
 
Virtual decoration of the scaffolds with 80 medicinal chemistry capping groups 
showed that the library has the potential to access large numbers of lead-like 
molecules. Three exemplar decorative steps were applied to a bicyclic urea. 
 
This general approach should be applicable to many classes of polyfunctional 
substrate in the future, enabling the more efficient exploration of lead-like 
chemical space. 
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3.0 Results and discussion 2: A top-down approach to LOS 
 
In contrast to the bottom-up approaches to lead-oriented synthesis developed 
previously in the Marsden and Nelson groups, we proposed to investigate a 
‘top-down’ strategy (Figure 41). This strategy would depend on the synthetic 
accessibility of complex polycyclic assemblies 132, which would be 
pre-engineered to bear selectively cleavable and modifiable chemical bonds. 
A key requirement of this strategy is for any complexity-generating steps to take 
place in a single operation, avoiding laborious synthetic routes to bespoke 
starting materials. A toolkit of chemical methodologies would then be used to 
break apart the assemblies to generate multiple diverse lead-like molecules. 
 
Figure 41 The proposed strategy to prepare a polycyclic assembly and illustrations of key strategies that may be used to 
generate scaffolds. 
 
Ring-distortion strategies have previously been used to prepare specific classes 
of natural products163 and have also been used to modify natural product 
scaffolds in diversity-oriented synthesis approaches.164–169 However, this strategy 
remains unexplored within the framework of LOS. 
 
3.1 The selection of a connective reaction for LOS 
Intramolecular [5+2] cycloadditions were proposed as a class of connective 
reactions which may efficiently deliver complex polycyclic assemblies 133 (Figure 
42).163 While intramolecular [5+2] cycloadditions are known for both 
oxidopyridiniums 134a (X= N) and oxidopyryliums 134b (X= O), there is a wealth 
of literature on the latter whilst there are considerably fewer accounts detailing 
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use of the former.163,170 This may be due to difficulties in preparing the appropriate 
starting materials for oxidopyridinium cycloadditions.170 As a result of this we 
chose to begin our studies by investigating intramolecular [5+2] cycloadditions of 
oxidopyryliums. We were particularly interested in preparing cycloadducts 133b, 
derived from oxidopyryliums 134b, which bear amine-containing tethers (Y= N), 
as this would provide a potential point for diversification in any derived scaffolds. 
 
Figure 42 The proposed intramolecular [5+2] strategy to prepare polycyclic assemblies 133.163,170 
 
Inherent in the framework 135 are a variety of different functionalities which may 
potentially be cleaved in order to form scaffolds (Figure 43), for instance: alkenes 
can undergo oxidative cleavage (equation 1), while α-oxy-ketones may be 
cleaved with SmI2 (equation 2).171 There would also be the possibility of using 
‘break-and-make’ strategies, for instance, oxidative cleavage of the alkene, 
followed by double reductive amination of intermediate 136 (equation 3). Finally, 
the addition of further rings may provide access to new scaffolds, for instance 
through the use of a condensation reaction (equation 4).172 In this way, increasing 
or reducing the complexity of the initial cycloadduct 135 would provide access to 
a variety of novel scaffolds for use in a LOS programme. 
 
Figure 43 Potential strategies to realise the synthesis of scaffolds from polycyclic assembly 135. The examples shown 
here are used to illustrate the concept and do not necessarily represent feasible transformations. 
 
In order for the top-down strategy to be effective, preparation of any polycyclic 
frameworks would need to be short (≤5 steps), scalable and synthetically 
tractable. Following the establishment of a suitable methodology for the 
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cycloaddition, an appropriate toolkit for the cleavage of the framework would be 
investigated (see Section 3.2). 
 
3.1.1 Intramolecular oxidopyrylium [5+2] cycloadditions 
Intramolecular [5+2] oxidopyrylium cycloadditions have been used in the total 
synthesis of several natural products.163 While oxidopyryliums 137 bearing allylic 
and propargylic tethers that contain carbon, oxygen and sulfur atoms are known 
to work in this reaction (Figure 44, Panel A, see later for specific modes of 
activation),163,170 there is only one account detailing the use of an 
amine-containing tether. Jacobsen reported the preparation of four 
cycloadducts 138a-d, which contain protected amines (Panel B).173 However, no 
supporting analytical data was given for cycloadducts 138a-d or for the 
corresponding starting materials to prepare them. 
 
Figure 44 Panel A: intramolecular [5+2] cycloadditions of oxidopyryliums. 
Panel B: amine-containing cycloadducts 138a-d reported by Jacobsen.173 
 
3.1.1.1 Benchmarking of an intramolecular [5+2] cycloaddition of an 
oxidopyrylium generated by group elimination 
One of the main strategies to generate oxidopyryliums for [5+2] cycloadditions is 
through the thermally initiated elimination of an O-acyl group from 
α-hydroxypyranone derivatives 139, followed by subsequent enolisation (Figure 
45).163 
 
Figure 45 Intramolecular [5+2] cycloadditions of oxidopyryliums generated by group elimination.  
 
We proposed to prepare polycyclic assemblies 140a-b through the [5+2] 
cycloaddition of oxidopyryliums generated from α-acetoxypyranones 141a-b, 
which would bear N-allyl- and N-propargyl tethers respectively (Figure 46). Ideally 
for our purposes, alkylation of sulfonamide 142 with allyl and propagyl bromides 
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would provide late-stage divergence in the route, enabling different cycloaddition 
products 140a-b to be accessed. α-Acetoxypyranone 142 could be delivered by 
oxidative-rearrangement (Achmatowicz reaction)174 of furan 143, followed by 
acetylation. Furan 143 would be prepared via a known175  Henry reaction between 
furfural and nitromethane, to give adduct 144, followed by reduction and 
nosylation. 
 
Figure 46 Proposed retrosynthetic route to polycyclic assemblies 140a-b. 
 
Reaction of furfural with nitromethane in the presence of 10 mol% lithium 
aluminium hydride provided access to adduct 144 which was used without further 
purification in the following steps (Scheme 53).175 A catalytic nickel boride 
reduction176 gave amino alcohol 145. Subsequent protection with 
4-nitrobenzenesulfonyl chloride gave the protected amino alcohol 143, which was 
isolated in 32% yield over three steps. 
 
Scheme 53 Preparation of protected amino alcohol 143. 
  
Attempted Achmatowicz reaction of furan 143 using a range of oxidative 
conditions (NBS;177 m-CPBA;178 and VO(acac)2/TBHP173) gave the desired 
rearranged product 146 (the characteristic enone peaks were observed in the 
crude reaction mixture by 1H NMR spectroscopy) along with an unknown 
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aromatic side product (Scheme 54). However, the targeted product 146 could not 
be separated from the impurity using flash chromatography. Acetylation was also 
attempted, however this gave a complex mixture. 
 
Scheme 54 Attempted preparation of α-acetoxypyranone 142. 
 
We chose to investigate whether prior allylation of furan 143 followed by 
Achmatowicz reaction would prevent the formation of the unwanted side product 
(Scheme 55). This strategy was less attractive than our originally proposed route 
as the opportunity for a late-stage alkylation with allyl and propargyl bromides 
was lost, resulting in earlier divergence in our routes to cycloadducts 140a-b. 
Nonetheless, allylation using allyl bromide and potassium carbonate in acetone 
gave compound 147 in 50% yield. Compound 147 cleanly underwent the 
Achmatowicz rearrangement, mediated by N-bromosuccinimide. Acetylation of 
the intermediate hemiacetal gave the required cycloaddition precursors 141a as 
a 3:2 mixture of anomers. 
 
Scheme 55 Preparation of α-acetoxypyranone 141a. 
 
Heating α-acetoxypyranone 141a with quinuclidine in acetonitrile179 gave 100% 
conversion to cycloadduct 140a, which was isolated in 84% yield (Scheme 56). 
The relative configuration of cycloadduct 140a was determined by the key nOe 
enhancements shown. 
87 
 
 
 
Scheme 56 [5+2] cycloaddition of α-acetoxypyranone 141a. 
 
While the [5+2] oxidopyrylium cycloaddition was successful, the synthetic route 
to prepare starting material 141a was laborious (seven steps) and the opportunity 
for late stage divergence was removed by the need to introduce the allyl group 
early in the synthesis to ensure a clean Achmatowicz rearrangement. As a result 
of this we chose to investigate whether the generation of oxidopyryliums through 
a different mode of activation would enable a more rapid synthesis of a polycyclic 
assembly. 
 
3.1.2 Intramolecular [5+2] cycloadditions of oxidopyryliums generated by 
group transfer 
Oxidopyryliums 148-149 can be generated from β-alkoxy-γ-pyrones 150-151 
derivatives of the inexpensive commercially available natural products kojic 
acid 152 and maltol 153. On heating β-alkoxy-γ-pyrones 150-151, 1,2-migration 
of a labile group (R= H, SiR3, Ac, Bz) from O-3 to O-4 generates 
oxidopyryliums 148-149, which then undergoes [5+2] cycloaddition (Figure 
47).163 Early investigations by Garst relied upon a prototropic shift to generate 
oxidopyryliums 148-149 (R= H),180 whilst Wender and Mascareñas pioneered the 
use of silyl group transfer.170,181 Oxidopyryliums 148 generated by group 
migration are known to undergo intramolecular [5+2] cycloadditions when X= C, 
O and S.163,170 However, the corresponding amine-containing series (X= N) is not 
known (although two examples are known with tethers containing amides180). 
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Figure 47 Intramolecular [5+2] cycloadditions of kojic acid and maltol derivatives. R= H, SiR3, Ac, Bz etc. 
 
A summary of the known intramolecular [5+2] cycloadditions, using 
β-alkoxy-γ-pyrones as the starting materials, is detailed in Table 15. In initial 
studies, Garst showed that amide-containing 154-155 could undergo a 
prototropic shift followed by a intramolecular [5+2] cycloaddition (Table 15, 
entries 1-2).180 Under similar conditions, substrate 156, which bears a 
three-carbon tether between the alkene and the β-alkoxy-γ-pyrone, gave access 
to a fully carbocyclic cycloadduct 157 (entry 3). Increasing the carbon chain by 
one methylene gave cycloadduct 158, albeit at a slower rate (entry 4). The 
analogous two-carbon homologue 159 did not react (entry 5). However, heating 
compound 160, which bears a five-membered carbon tether, with methyl sulfonic 
acid in methanol furnished dimethylacetal 161 (entry 6). Aside from all-carbon 
tethers, Mascareñas showed that ethers 162 (entry 7),182,183 thioethers 163 
(entry 8)184 and sulfones 164 (entry 9)185 underwent [5+2] cycloaddition when 
tert-butyldimethylsilyl ethers were used as the migrating group at O-3. 
Conjugated diene 165 could undergo [5+2] cycloaddition, but required prior 
activation with methyl triflate to form the salt 166 (entry 10). Salt 166 was then 
heated with cesium fluoride, which removed the silyl group and generated the 
zwitterion required to effect the cycloaddition.186 
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Entry Substrate Conditions Product Yield /% 
1 
 
1. PhH, 80 °C, 12 h 
2. Ac2O, py
180 
 
55 
2 
 
1. MeCN, 82 °C, 60 h 
2. Ac2O, py
180 
 
42 
3 
 
1. PhH, 80 °C, 12 h 
2. Ac2O, py
180 
 
70 
4 
 
1. PhH, 110 °C , 48 h 
2. Ac2O, py
180 
 
65 
5 
 
A variety of thermal conditions180 
 
nr 
6 
 
(a) a variety of thermal conditions  
(b) MeSO3H (1.7 eq.), MeOH, 65 °C, 
12 h180 
 
(a) nr 
(b) 87 
7 
 
PhMe, 180 °C, 12 h182,183 
 
79 
8 
 
PhMe, 145 °C, 40 h184 
 
71 
9 
 
PhMe, 90 °C, 18 h185 
 
91 
90 
 
 
Entry Substrate Conditions Product Yield /% 
10 
 
(i) MeOTf, CH2Cl2 (gives 166) 
(ii) CsF (xs), CH2Cl2–DMF, 10 h
186 
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Table 15 Examples of known intramolecular [5+2] cycloadditions via oxidopyryliums generated from β-alkoxy-γ-pyrones.  
Z= CO2Me. 
 
An asymmetric variant of the intramolecular [5+2] cycloaddition of 
β-alkoxy-γ-pyrones has also been developed (Scheme 57). The use of 
enantiopure starting materials 167 bearing sulfinyl chiral auxiliaries allowed the 
cycloaddition to proceed with excellent diastereoselectivity.185,187–189 The auxiliary 
could subsequently be removed using Raney nickel. The use of sulfoximine 
auxiliaries in place of sulfinyl groups switches the diastereoselectivity of the 
reaction (not shown).190 
 
Scheme 57 Mascareñas’ diastereoselective intramolecular [5+2] cycloaddition.187 
 
It was also possible to generate cycloadduct 168 which has a nitrogen-containing 
bridge; embedded in this structure is the core scaffold of the tropane alkaloids 
(Scheme 58).182 The starting material 169 for the cycloaddition was generated 
through reaction of MOM-protected 170 with methylamine followed by a 
deprotection-reprotection sequence. The starting material 169 did not undergo 
[5+2] cycloaddition to give compound 171, even when heated at 190 °C for 
several hours. This lack of reactivity may be due to the greater aromatic character 
of the pyridine and pyridinium systems when compared with their O-containing 
analogues.170 However, methylation of compound 169, followed by treatment with 
2,2,6,6-tetramethylpiperidine (TMP), gave access to the cycloadduct 168 via 
zwitterion 172. The cycloadduct 168 was isolated as a single diastereomer in 
95% yield. 
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Scheme 58 Mascareñas’ synthesis of cycloadduct 168.182 
 
In summary, given the large reaction scope of the [5+2] cycloaddition of 
oxidopyryliums generated from β-alkoxy-γ-pyrones, we endeavoured to harness 
this methodology to prepare the targeted amine-containing polycyclic 
assemblies. 
 
3.1.2.1 Preparation of β-alkoxy-γ-pyrone starting materials 
In order to realise our top-down lead-oriented synthesis approach, our initial 
studies focused on assessing the synthetic accessibility cycloadducts 173 (Figure 
48). For our purposes, ideally the R-group would be H or a readily removable 
protecting group (Boc, Cbz etc.). 
 
Figure 48 Proposed route to cycloadducts 173. 
 
Mascareñas reported the preparation of the aforementioned thioether 163 
through chlorination of kojic acid to give compound 174. Silylation, and 
subsequent displacement of the chloride with allyl mercaptan gave compound 
163 (Scheme 59).184 
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Scheme 59 Mascareñas’ route to thioether 163.184 
 
We found that the chlorination step of the procedure (Scheme 59) gave an 
unsatisfactory yield (57%) and consequently we chose to investigate an 
alternative route (Scheme 60). The known silylation delivered protected kojic 
acid 175.191 Mesylation gave compound 176, and subsequent displacement 
furnished amines 177-178. Carboxybenzyl-protection of compound 178 gave 
carbamate 179.  
 
We later routinely used compounds 179-180 as substrates for our cycloaddition. 
Conveniently, it was found that the procedure to prepare compounds 179-180 
could be telescoped. No significant change in overall yield was found for the 
telescoped procedure to prepare compound 179. 
 
Scheme 60 Preparation of starting materials for the proposed cycloaddition.  
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3.1.2.2 [5+2] cycloaddition of oxidopyryliums generated from 
β-alkoxy-γ-pyrones 
With starting materials 177-180 in hand, we investigated the [5+2] cycloaddition 
(Scheme 61, Panel A). The diallylated starting material 177 was heated at 140 °C 
under microwave irradiation for two hours. Complete conversion to 
cycloadduct 181 was observed, which was isolated in 73% yield (equation 1). 
Foreseeing that the basic amine in cycloadduct 181 would be incompatible with 
some of the proposed scaffold-cleaving reactions (e.g. ozonolysis), we 
endeavoured to prepare a cycloadduct containing either a free amine 182 (which 
could subsequently be protected as required) or a readily removable protecting 
group (e.g. Cbz). However, amine 178 did not undergo cycloaddition at 140 °C 
or 180 °C under microwave irradiation (as judged by analysis of the crude 
reaction mixture by 1H NMR spectroscopy). Heating amine 178 in DMF under 
microwave irradiation at 250 °C for five minutes led to complete decomposition 
of the starting material. Consequently we chose to attempt the cycloaddition using 
the Cbz-protected starting material 179. The reaction was slower than for the 
analogous diallylated starting material 177, taking 6 h to go to completion at 
140 °C under microwave irradiation, but gave access to cycloadduct 183 in 89% 
yield (key nOe enhancements are shown in Panel B). Cycloaddition of the 
analogous propargyl starting material 180 (equation 2) required a higher reaction 
temperature of 180 °C (no reaction took place at 140 °C), furnishing cycloadduct 
184 in 64% yield. 
 
Scheme 61 Panel A: [5+2] cycloadditions of precursors 177-180. Panel B: key nOe enhancements for compound 183. 
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3.2 Establishing a chemical toolkit 
3.2.1 Previous work 
With scalable and synthetically tractable routes to cycloadducts 183-184 in hand, 
we wanted to explore the development of a toolkit of chemical methodologies that 
would transform these polycyclic intermediates into new scaffolds that would be 
able to systematically target the synthesis of derivative lead-like compound 
libraries. Once again, Mascareñas has carried out substantial research into the 
chemistry of the cycloadducts, converting them into other scaffolds (natural 
products or otherwise). This work will herein be discussed. 
 
3.2.1.1 Ring-constructing reactions 
3.2.1.1.1 Tandem cycloadditions 
A one-pot [5+2]/[4+2] tandem cycloaddition was developed by Mascareñas, 
providing rapid access to tricyclic systems 185-186 with complete 
diastereoselectivity (Scheme 62). Both kojic acid-derived (equation 1) and 
maltol-derived precursors (equation 2) were effective coupling partners in this 
reaction providing access to skeletons resembling dolastane and sphaeroane 
diterpenes.192 An analogous process has been developed for the analogous 
alkynyl systems (not shown).193 
 
Scheme 62 Mascareñas’ tandem [5+2]/[4+2] cycloaddition.192 
 
Attempts to open the ether bridge of compound 186a using SmI2 failed, instead 
giving rapid deoxygenation of the silyl ether (Scheme 63).192 Further treatment of 
compound 187 with SmI2 did not open the bridge, even when heated.170 
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Scheme 63 Mascareñas’ attempt to open the ether bridge using SmI2.
192 
 
Treatment of compound 186a with trimethylsilyl triflate in refluxing benzene gave 
ring-opening of the ether bridge along with aromatisation of the cyclohexene ring, 
furnishing compound 188 which contains a trans-cyclopentane ring (Scheme 
64).192  
 
Scheme 64 Mascareñas’ procedure to open the ether bridge using TMSOTf. 
The configuration of compound 188 was confirmed by x-ray crystallography studies.192 
 
3.2.1.1.2 Ring closing metathesis to form medium-sized rings 
Mascareñas exploited the electrophilic reactivity of the α-silyloxyenone in the rigid 
polycyclic framework 189 to append exo-alkenyl groups to the structure (Scheme 
65).183 Double alkylations were achieved in one-pot. First, axial nucleophilic 
addition of organolithiums, followed by silyl migration, generated the intermediate 
enolates 190a-b. Subsequent alkylation of the resulting enolates with allyl 
bromide gave dialkenes 191a-b. Treatment of dialkenes 191a-b with Grubbs’ first 
generation catalyst (GI) furnished medium-sized rings 192a-b. Following 
hydrogenation of the products, an oxidative ring-cleavage was employed to give 
nine-membered carbocycles 193a-b, a structural motif found in terpenoids.170 
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Scheme 65 Ring-closing metathesis to form medium and large rings by Mascareñas.183 
 
3.2.1.2 Ring-cleaving reactions 
3.2.1.2.1 Semi-permanent tethers 
The sluggish and poor yielding nature of the intermolecular variant of the [5+2] 
cycloadditions of β-alkoxy-γ-pyrones170 led Mascareñas to design new substrates 
bearing selectively cleavable tethers for use in the more efficient intramolecular 
cycloaddition. For instance, following the [5+2] cycloaddition of 
dimethylvinylsilane-protected alcohol 194, an oxidative work-up liberated diol 195 
in 78% yield (Scheme 66).184 
 
Scheme 66 Mascareñas’ temporary tethering strategy using a silyloxy tether.184 
 
The thioether-containing cycloadduct 196 could be cleaved using Raney 
nickel.183,194 Surprisingly, this procedure also reduces the ketone to furnish the 
silylated α-hydroxyketone 197 following rearrangement (Scheme 67). 
Mascareñas cleaved α-silyloxyketone 197 by using a deprotection-oxidation 
sequence to provide access to highly substituted tetrahydrofuran 198. A similar 
protocol was applied in the synthesis of (±)-nemorensic acid 199.183,194 
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Scheme 67 Mascareñas’ reductive cleavage of thioether 196 and subsequent oxidative cleavage of compound 197.183,194 
 
3.2.1.2.2 Cleavage of the ether bridge 
It was possible to open the ether bridge of polycyclic assemblies 200 through the 
nucleophilic addition of organolithiums, which, following silyl migration, generated 
lithium enolate 201 (Scheme 68). The enolate 201 undergoes fragmentation 
when treated with excess boron trifluoride diethyl etherate. Mascareñas 
postulated that this reaction proceeds through coordination of boron trifluoride to 
the ether bridge, which is subsequently ejected through beta-elimination initiated 
by the lithium enolate 202a. However, given that five equivalents of boron 
trifluoride are used in this reaction, the beta-elimination step may take place via 
the boron enolate 202b. Notably, Mascareñas stated that the same 
transformation could not be achieved by heating the lithium enolate alone in 
THF.195 
 
Scheme 68 Opening of the ether bridge of cycloadducts 200 by Mascareñas.188,195 
Specific examples are given in Table 16. 
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Alkyl, alkenyl and alkynyl organolithiums were all tolerated in the bridge-opening 
procedure when applied to the thioether substrate 196 (Table 16, entry 1). 
Ethers 203, carbocycles 204 and esters 205 were all tolerated under the reaction 
conditions using methyllithium (entries 2-4). The corresponding maltol-derived 
cycloadducts 206-207 could also be opened to give regioisomeric tertiary 
alcohols (entries 6 and 7).170,188 However, maltol-derived diester 210 did not open 
(entry 5), whilst in contrast the related kojic acid-derived cycloadduct 205 
successfully underwent ring-opening (entry 4). 
 
Entry Starting material Product R Yield /% 
1 
 
 
Me 
Bu 
-CH=CH2 
-C≡C-TMS 
88 
78 
75 
67 
2 
 
 
Me 77 
3 
  
Me 71 
4 
  
Me 79 
5 
 
− Me 0 
6 
  
Me 80 
7 
  
Me 72 
Table 16 Opening of the ether bridge of cycloadducts derived from kojic acid and maltol by Mascareñas.188,195 
 
3.2.1.3 Previous work: A summary 
Mascareñas has developed many synthetic strategies that enable efficient 
access to new scaffolds from cycloadducts 208-209 (Figure 49). Mascareñas has 
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focused on modifications that allow access to specific classes of natural products 
(or natural product-like scaffolds), and consequently there remain multiple 
scaffold-altering reactions that could be developed and used in a LOS 
programme. 
 
Figure 49 A summary of the scaffolds prepared by Mascareñas.170 
 
3.2.2 Functional group interconversions (FGI) of α-silyloxyenones 
To identify suitable methodologies for a top-down approach to LOS from 
cycloadducts 183-184, the reactivity of the α-silyloxyenone functionality was 
probed to investigate whether useful functionalities could be accessed that may 
enable scaffold preparation. Reactions of the allylamine-derived cycloadduct 183 
were investigated by the candidate, whilst reactions of the 
propargylamine-derived cycloadduct 184 were herein investigated by 
Richard Doveston. 
 
3.2.2.1 Reductions 
Studies commenced with the investigation of conditions for chemo- and 
stereoselective reductions of the α-silyloxyenone. Treatment of cycloadduct 183 
with sodium borohydride in methanol gave a mixture of regioisomeric 
monosilylated diols 211-212 (Scheme 69), which were carried on to the next step 
without further purification. These products presumably arose through silyl 
migration following reduction of cycloadduct 183 to generate the silylated 
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α-hydroxyketone 213. Compound 213 is then reduced further, leading either to 
remigration of the silyl group to form compound 212, or protonation from the 
solvent to form compound 211. 
 
Scheme 69 NaBH4 reduction of cycloadduct 183 to give a 2:3 mixture of the regioisomeric monosilylated diols (as 
judged by analysis of the crude reaction product by 1H NMR spectroscopy). 
 
Deprotection of the silyl protected diols 211-212 with TBAF proceeded with 
complete conversion (as judged by analysis of the crude product using 1H NMR 
spectroscopy, Scheme 70). However, it was difficult to separate diol 214 from the 
tetrabutylammonium-containing side product using column chromatography, 
leading to a poor isolated yield (41%). The procedure needs further optimisation 
in future. NOESY analysis of compound 214 showed that the diol was in the 
cis configuration and located on the bottom face of the molecule. 
 
Scheme 70 Panel A: preparation of diol 214. Panel B: key nOe assignments of diol 214. 
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Richard Doveston showed that application of the aforementioned reduction 
conditions to cycloadduct 184, followed by a one-pot deprotection-reprotection 
sequence, gave acetonide 215 (Scheme 71). 
 
Scheme 71 Preparation of acetonide 215.95 
 
Reduction of cycloadduct 183 using L-selectride in THF resulted in silyl migration 
to form silylated α-hydroxyketone 216 (Scheme 72, Panel A, equation 1). 
However, under Luche conditions the reduction proceeded without silyl migration 
to give α-silyloxyenol ether 217 (equation 2). Both of the products 216-217 formed 
through the axial addition of the hydride reagent. NOESY analysis confirmed the 
relative configuration of products 216-217 (Panel B). Presumably the hardness 
of the oxyanion generated following the addition of the hydride reagent affects 
whether the silyl migration takes place. Mascareñas has previously noted that the 
nucleophilic addition of organolithium reagents to analogous cycloadducts results 
in silyl migration, whilst the addition of Grignard reagents does not lead to silyl 
migration.170 
 
Scheme 72 Panel A: selective reductions. Panel B: key nOe enhancements. 
 
Exposure of the cycloadduct 183 to hydrogenation conditions using Pd/C as the 
catalyst led to reductive rearrangement of the ketone (along with reductive 
removal of the Cbz protecting group) to give amine 218 (Scheme 73). Attempted 
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Boc-protection to give compound 219 was sluggish and did not go to completion 
after 15 h, this requires further optimisation in the future.  
 
Scheme 73 Hydrogenation of cycloadduct 183. 
 
Richard Doveston investigated whether hydrogenation of cycloadduct 184 would 
provide access to the diastereomeric scaffold 220, bearing a trans-fused 
five-membered ring, which would in turn offer downstream access to a 
diastereomeric scaffold series (Scheme 74). However, following a 
reprotection-deprotection sequence the resulting product was found to be 
identical to the previously prepared diol 214. Presumably the added ring-strain 
associated with the potential formation of a trans-fused five membered ring 
renders reduction from the top face unfavourable. 
 
Scheme 74 Hydrogenation of cycloadduct 184 and subsequent formation of diol 214.95 
 
Reductive amination of α-silyloxyketone 221, derived from cycloadduct 183, was 
also investigated. First, addition of methyllithium to the cycloadduct 183 resulted 
in silyl migration to form the lithium enolate, this then tautomerised upon aqueous 
work-up to form the silyl protected α-silyloxyketone 221 as a single diastereomer. 
Attempted reductive amination of ketone 221 with benzylamine and sodium 
triacetoxyborohydride resulted in no reaction (Scheme 75, equation 1). However, 
an alternative sequence was realised (equation 2). Treatment of ketone 221 with 
methanolic ammonia in the prescence of titanium isopropoxide, followed by the 
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addition of sodium borohydride,196 gave protected aminoalcohol 222 in 90% yield. 
The configuration of product 222 was confirmed by analysing the NOESY 
correlations. 
 
Scheme 75 Preparation and reductive amination of ketone 221. 
 
3.2.2.2 Silyl deprotection 
In an attempt to reveal 1,2-diketone 223, cycloadduct 183 was treated with TBAF, 
however, this led to a complex mixture (Scheme 76, equation 1). Treating 
cycloadduct 183 with (±)-camphorsulfonic acid (CSA) in methanol gave access 
to dimethyl acetal 224 which was isolated in 79% yield (Scheme 76, equation 2). 
NOESY studies confirmed the regiochemistry of dimethylacetal 224. 
 
Scheme 76 Equation 1: attempted formation of 1,2-diketone 223.  
Equation 2: formation of 1,2-dimethylacetal 224. 
 
3.2.2.3 FGI summary 
A range of reduction conditions have been explored which allow access to diols 
(both protected 211-212 and unprotected 214), protected α-hydroxyketones 216, 
218, 219 and 221, a protected α-silyloxyenol ether 217, a protected 
aminoalcohol 222 and a dimethylacetal 224. This toolkit of functional group 
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interconversions enabled us to understand the reactivity of the α-silyloxyenone 
functionality and provided access to a range of useful motifs which may be 
exploited in the synthesis of new scaffolds (Figure 50). Unfortunately, 
hydrogenation of acetonide 215 did not provide access to the targeted 
diastereomeric series of compounds. Nonetheless, acetonide 215 later proved 
useful in the formation of novel scaffolds (see Sections 3.2.3.2.1 and 3.2.3.2.2). 
 
Figure 50 A summary of the FGIs investigated using cycloadducts 183-184. 
 
3.2.3 Synthesis of new scaffolds from polycyclic assemblies 
With a clear understanding of the reactivity of the α-silyloxyenone functionality, 
we sought to exploit this knowledge in the preparation of scaffolds. 
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3.2.3.1 Ring-constructing reactions 
We commenced our studies to prepare new scaffolds by exploring 
ring-constructing reactions. We exploited the latent 1,2-diketone functionality of 
cycloadduct 183 for use in modified versions of known 
condensation-aromatisation reactions (Scheme 77). Heating cycloadduct 183 in 
acetic acid with 1,2-diaminobenzene at 180 °C in the microwave for ten minutes 
gave rapid access to the quinoxaline 225, which was isolated in 89% yield.197,198 
Quinoxalines are known to have biological activity against multiple targets.198,199 
Alternatively, cycloadduct 183 underwent condensation with ammonium acetate 
and benzaldehyde (Debus-Radziszewski reaction) to form imidazole 226, which 
was isolated in 91% yield.200 
 
Scheme 77 Condensation-aromatisation reactions. 
 
3.2.3.2 Ring-cleaving reactions 
This section explores the preparation of new scaffolds through ring-cleaving 
reactions. 
 
3.2.3.2.1 Cleavage of the ether bridge 
Our initial attempts to open the ether bridge of cycloadduct 183 focused on the 
application of Mascareñas’ previously developed conditions (see 
Section 3.2.1.2.2). However, these conditions failed to open the ether bridge; the 
only product formed was the previously prepared protected α-hydroxyketone 221 
(Table 17, entry 1). A range of modifications to the procedure were applied to 
compound 221 including heating the presumed boron enolate (entry 2); heating 
the lithium enolate (entry 3); the use of TMSOTf as the Lewis acid in place of 
BF3•Et2O (entry 4); and heating the substrate in sodium hydroxide, all to no avail. 
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Entry Substrate Conditions Reaction Outcome 
1 
 
1. MeLi (1.05 eq.), THF, 
−78 °C, 10 min 
2. BF3•OEt2 (5.0 eq.), 
0.5 h, −78 °C 
100% conversion to 221 
 
2 
 
1. LiHMDS (1.5 eq.), THF, 
−78 °C, 10 min 
2. BF3•OEt2 (5.0 eq.), 
PhMe, −78 °C to reflux 
No reaction at −78 °C, 0 °C or rt. 
Decomposition after 15 h at 
reflux. 
2 
 
1. LiHMDS (1.5 eq.), THF, 
−78 °C, 10 min 
2. −78 °C to reflux 
No reaction at −78 °C, 0 °C or rt.  
After 15 h at reflux: mixture of 
unreacted starting material and 
an unknown decomposition 
product.a 
4 
 
1. LiHMDS (1.5 eq.), THF, 
−78 °C, 10 min 
2. TMSOTf (5.0 eq.), 
PhMe, −78 °C to rt 
No reaction at −78 °C or 0 °C.  
5 
 
NaOH (5.0 eq.), 
MeOH, reflux, 2 days  
Global deprotection only 
Table 17 Attempts to open the ether bridge of cycloadduct 183 and derivative 221.aThe unknown product did not contain 
an alkenyl proton (by analysis of the crude reaction mixture by 1H NMR spectroscopy). 
 
Having exhausted attempts to open the ether bridge of the allylamine-derived 
cycloadduct 183 we turned our attention to propargylamine-derived 
cycloadduct 184. Richard Doveston showed that heating acetonide 215 with 
excess lithium aluminium hydride at reflux opened the ether bridge (with 
concurrent reduction of the Cbz group) to give amino alcohol 227, which was 
isolated in 75% yield (Scheme 78, Panel A). Interestingly, treatment of 
acetonide 215 with DIBAL at rt led to formation of the isopropyl ether 228, which 
was isolated in 46% yield (Panel B). The reduction using lithium aluminium 
hydride may take place via an internal delivery mechanism. By constrast, DIBAL 
is Lewis acidic and promotes reduction at the acetonide. 
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Scheme 78 Opening of the ether bridge of acetonide 215.95 
 
3.2.3.2.2 Oxidative cleavages and subsequent reductive aminations 
Oxidative cleavage of the polycyclic assemblies was investigated to prepare 
scaffolds. Initially ozonolysis of the α-silyoxyenone of cycloadduct 183 was 
attempted, however, this led to decomposition (as judged by analysis of the crude 
reaction mixture by 1H NMR spectroscopy, Scheme 79). 
 
Scheme 79 Attempted ozonolysis of cycloadduct 183. 
 
To provide an alternative route to the same bicyclic scaffold core, oxidative 
cleavage of 1,2-diols was investigated (Scheme 80). First, deprotection of 
α-silyloxyketone 221 (see Section 3.2.2.1 for preparation) with TBAF gave 
precursor 230. Reduction with sodium borohydride, followed by cleavage of the 
resulting diol with sodium periodate, gave complete conversion to 
ketoaldehyde 231 (as judged by analysis of the crude product by 1H NMR 
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spectroscopy), which was isolated in 46% yield. Double reductive amination of 
ketoaldehyde 231 using benzylamine and sodium triacetoxyborohydride gave a 
1:1 mixture of diastereomers of cyclic amines 232 (as judged by analysis of the 
crude reaction product using 1H NMR spectroscopy). However, during 
purification, only one amine diastereomer was isolated cleanly, in 23% yield. 
NOESY studies to determine the configuration of amine 232 proved inconclusive. 
 
Scheme 80 Preparation of the ketoaldehyde scaffold 231 and subsequent reductive amination to form cyclic amine 232. 
 
The lack of diastereoselectivity in the reductive amination of ketoaldehyde 231 
prompted us to consider reductive amination of the analogous dialdehyde 233 in 
order to avoid the creation of a new stereocentre. Starting with diol 214 (synthesis 
described in Section 3.2.2.1), oxidative cleavage with sodium periodate provided 
access to dialdehyde 233 (Scheme 81). Pleasingly, double reductive amination 
with benzylamine delivered cyclic amine 234, which was isolated in 32% yield 
over two steps. Alternatively, reduction of dialdehyde 233 with sodium 
borohydride gave access to diol 235, which was isolated in 38% yield, however, 
the purification procedure requires optimisation. 
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Scheme 81 Formation of cyclic amine 234 and diol 235. 
 
Richard Doveston investigated the oxidative cleavage of acetonide 215 (Scheme 
82, Panel A). Ozonolysis gave access to ketoaldehyde 236 which was 
subsequently reduced with NaBH4 to give diol 237 as 92:8 mixture of 
diastereomers. Notably, in order to achieve high diastereoslectivity in the 
formation of diol 237, dimethylsulfide had to be used to reduce the intermediate 
ozonides, as using NaBH4 to directly reduce the ozonides gave diol 237 as a 2:1 
mixture of diastereomers. The erosion of diastereoselectivity presumably arises 
through the stepwise reduction of the ozonides. The configuration of diol 237 was 
inferred from the NOESY correlations (Panel B); enhancements between the 
proton alpha to the secondary alcohol and two tetrahydropyran methylene 
protons were observed, suggesting that the secondary alcohol points away from 
the tetrahydropyran ring. The conformation 237a is presumably preferred over 
the conformation 237b, which would lead to a sterically unfavoured 1,3,5-triaxial 
arrangement of non-hydrogen ring substituents. For conformation 237b we would 
not expect to observe an nOe enhancement between the proton alpha to the 
secondary alcohol and the axial methylene proton on the tetrahydropyran ring. 
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Scheme 82 Panel A: ozonolysis to form ketoaldehyde 236 and subsequent reduction to diol 237. 
Panel B: configurational and conformational assignment of diol 237.95 
 
3.2.3.3 Scaffold synthesis: A summary 
Including the cycloadducts themselves, a total of eight scaffolds (at the 
graph-node-bond framework level) have been prepared so far using the top-down 
approach (Figure 51). Four unique scaffolds were prepared from the 
allylamine-derived cycloadduct 183, whilst two were prepared from the 
propargylamine-derived cycloadduct 184. Notably, each scaffold was delivered 
in ≤3 steps from a preceding scaffold. 
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Figure 51 A summary of the scaffolds prepared in this study.  
*Not considered to constitute a new scaffold in our analysis. 
 
3.3 Computational assessment of the scaffolds prepared 
To assess the novelty, diversity and lead-likeness of the library, nine compounds 
were chosen for virtual decoration and computational analysis. This study 
included six scaffolds (225, 226, 227, 231, 234 and 237) derived from 
cycloadducts 183-184, and three representative derivatives (214, 216 and 230) 
based on the cycloadduct framework 183 (Figure 52). These nine compounds will 
be collectively referred to as scaffolds herein. 
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Figure 52 Scaffolds chosen for virtual decoration. Acetonides were included to prevent decoration of any diols. Acetonides 
were removed following the decoration step in the computational studies (see Section 3.3.3). 
 
3.3.1 Novelty assessment 
To assess the novelty of the scaffolds, a structure search was performed for the 
nine compounds as shown above (Figure 52, acetonide protecting groups were 
removed). None of the compounds were found in the ZINC database (9×106 
compounds). In addition, none of the compounds were found in the CAS registry. 
 
The Murcko assemblies97 (with alpha attachments) were also generated and 
compared against the Murcko assemblies (with alpha attachments) of a random 
5% sample of the ZINC database (4.5×105 compounds). Only the Murcko 
assembly derived from compound 231 was found as a substructure match 
(308 hits). 
 
3.3.2 Diversity assessment 
The skeletal diversity and relationship between the scaffolds was assessed using 
the ‘scaffold tree’ hierarchical analysis developed by Waldmann.160 By applying 
Waldmann’s prioritisation rules to the graph-node-bond (GNB) frameworks of the 
nine scaffolds, it was found that the scaffolds were ultimately related to five 
parental frameworks. The results are summarized in Figure 53 and the 
frameworks are illustrated in Figure 54. The lack of similarity between the 
scaffolds is significant given that synthetically all the scaffolds derive from two 
common cycloadduct frameworks.  
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Figure 53 The hierarchical relationship between the seven distinct molecular frameworks at the graph-node-bond level 
(black) and the five parental frameworks (blue). Daughter frameworks are shown in red and green. 
 
 
Figure 54 The seven distinct molecular frameworks of the nine scaffolds in the analysis are shown at the graph-node-bond 
level (black) along with the five parental frameworks (blue). Daughter frameworks are shown in green and red. The 
scaffolds which represent each framework are indicated. See Figure 27 for the relationship between scaffolds at each 
level of hierarchy. 
 
3.3.3 Virtual decoration of the scaffolds 
To determine the ability of the scaffolds to provide potential access to lead-like 
screening compounds, a virtual library of compounds was enumerated using 
Accelrys Pipeline Pilot. The enumeration process is illustrated in Figure 55. Nine 
scaffolds (Figure 52) were used in the analysis (n.b. acetonides were removed in 
manipulation 2). Before decoration, ketones and aldehydes were converted to the 
corresponding alcohols (Table 18, entry 1). Decoration reactions (Table 19) were 
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performed using the same set of 80 typical medicinal chemistry capping groups 
as was used for the allylic-alkylation derived scaffolds (Appendix 1). Notably, 
decoration of alcohols (Table 19, entries 1-3) was included in the enumeration 
process (cf. the enumeration process for the allylic alkylation-derived scaffolds). 
The deprotected but underivatised scaffolds (i.e the scaffolds as shown in Figure 
52) were also retained in the final virtual library. This process generated a library 
of 798 virtual screening compounds. 
 
Figure 55 An overview of the process for enumeration of the virtual library. 
 
Entry Manipulation 1 or 2 Synthetic transformation Description 
1 1 
 
Aldehydes and 
ketones reduced to 
alcohols 
2 2 
 
Acetonides 
converted to diols 
Table 18 Functional group manipulations of the scaffolds (Manipulation 1). 
 
Entry 
Functional group 
decoration 
Synthetic transformation Description 
1 Alcohol 
 
Alkylation 
2 Alcohol 
 
Arylation 
3 Alcohol 
 
SN2 
4 
Amine 
(R1= H, alkyl) 
 
Alkylation 
5 
Amine 
(R1= H, alkyl) 
 
Amide coupling 
6 
Amine 
(R1= H, alkyl) 
 
Arylation 
7 
Amine 
(R1= H, alkyl) 
 
Reductive amination 
(R3= H, alkyl, aryl) 
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Entry 
Functional group 
decoration 
Synthetic transformation Description 
8 
Amine 
(R1= H, alkyl) 
 
Sulfonamide 
formation  
9 
Amine 
(R1= H, alkyl) 
 
Urea formation 
Table 19 Decoration reactions exploited in the enumeration of the virtual library. 
 
3.3.3.1 Molecular properties analysis 
3.3.3.1.1 Lead-likeness assessment 
The lead-likeness of the virtual compound library was assessed in accordance 
with the criteria designated by Churcher (Figure 56, boxed area):10 72% of virtual 
library compounds survived filtering by molecular size (14 ≤ heavy atom count 
≤ 26), lipophilicity (−1 < AlogP < 3) and structural filters – heavy atoms: μ= 22.2, 
σ= 3.36; AlogP: μ= 0.03, σ= 1.15. The next chapter will compare the properties of 
the virtual compound libraries derived from the top-down and bottom-up 
strategies.  
 
Figure 56 Distribution of the number of heavy atoms and AlogP values for the 798 decorated final compounds derived 
from the nine scaffolds using the virtual library enumeration process. Compounds that survive successive filtering are 
shown in green (571 compounds, 72%). Compounds that fail successive filtering by number of heavy atoms (red, 82 
compounds, 10%), AlogP (yellow, 145 compounds, 18%) are shown. The black box shows the limit of lead-like space as 
outlined by Churcher.10 A larger annotated version of this plot is included in Appendix 1. 
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When decorated with the same set of 80 capping groups, all nine scaffolds would 
allow lead-like chemical space to be targeted (Figure 57). Decoration of scaffolds 
226 and 234 and would generally give large numbers of high-quality lead-like 
compounds and would be ideal starting points for compound library synthesis. 
The versatility of being able to essentially perform a decoration step whilst 
preparing the imidazole-containing scaffold 226 enables a large library of final 
compounds to be prepared (294 compounds).  
 
Scaffolds 225 and 237 perform relatively poorly in the lead-likeness assessment 
(Figure 58, Panel A). Scaffold 225 suffers from having only one site for further 
decoration, limiting the number of derivatives that can be prepared 
(15 compounds). Compounds derived from scaffold 237 generally suffer from low 
AlogP values (78 out of 89 fail the AlogP filter); this is hardly unexpected as some 
of the final compounds are tetra- and penta-alcohols (Figure 58, Panel B). In 
practice we could carefully modify these polyalcohol compounds (e.g. global 
methylation) to tune them within lead-like space. However, it is also worth noting 
that they may also find use as carbohydrate mimetics.201 
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Figure 57 Histograms to show: the percentage of lead-like compounds derived from each scaffold (top); the absolute 
number of lead-like compounds that may be derived from each scaffold (middle); and the weighted average of the number 
of lead-like compounds and the percentage of lead-like compounds (bottom).  
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Figure 58 Exemplar final compounds derived from scaffold 237. Compound 237a is lead-like, while 237b-c fail the 
AlogP filter. 
 
The virtual library derived from the top-down approach had higher sp3 content 
(Fsp3: µ= 0.68) than the commercially available compounds in ZINC (Fsp3: 
µ= 0.33). 
 
3.3.3.2 Principal moments of inertia study 
The shape diversity of the virtual library was compared with that of 90911 
randomly-selected compounds from the ZINC database (Figure 59). Dividing the 
PMI plot into 20 bins (as described in Section 2.5.3.2 and Appendix 1, 
Section 6.3.1, Figure 60) showed that 16% of compounds derived from the 
top-down approach are found at the extreme flat-linear edge of the plot. However, 
of the 16% (128 compounds) of the derivatives found in bin 1, 96% are derived 
from scaffolds containing aromatic rings; the imidazole scaffold 226 (93%, 119 
compounds) and quinoxaline scaffold 225 (3%, 4 compounds). 
 
Figure 59 A normalised principal moment of inertia plot to show the shapes of the 798 virtual compounds (orange, 
enlarged for clarity) compared with 90911 randomly selected compounds from the ZINC database (blue). An annotated 
version is given in Appendix 1. 
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Figure 60 The relative proportions of the compounds found when the PMI was divided into twenty bins for the virtual 
library versus ZINC and the allylic alkylation-derived compounds (9 of 20 bins shown). 
 
3.3.4 Conclusions and future work  
In summary, the preparation of key polyfunctionalised cycloadducts has enabled 
a downstream synthetic programme in which these precursors are converted into 
new molecular scaffolds which can systematically target lead-like chemical 
space.  
 
Two different types of intramolecular oxidopyrylium [5+2] cycloaddition were 
investigated to prepare polycyclic assemblies. While the [5+2] cycloaddition of an 
oxidopyrilium generated from an α-acetoxypyranone was successful, it suffered 
from a long synthetic sequence to prepare the required starting material for the 
cycloaddition. However, investigation of the [5+2] cycloaddition of oxidopyriliums 
generated from β-alkoxy-γ-pyrones allowed rapid and scalable preparation of 
polycyclic assemblies. 
 
We established understanding of the reactivity of the α-silyloxyenone functionality 
by investigating its reaction with reducing agents and nucleophiles. A strategy to 
prepare scaffolds was then realised, relying upon both ring-constructing 
(condensation-aromatisations, double reductive aminations) and ring-cleaving 
reactions (oxidative cleavage of alkenes, ether bridge opening) providing access 
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to six unique new scaffolds. Each scaffold was prepared in three or fewer steps 
from a preceding scaffold, and in several instances just one step was required.  
 
There remain a number of reactivity pathways which could still be investigated in 
order to prepare new scaffolds. In future it would be particularly interesting to 
investigate whether some of the methodologies developed could be used in 
sequence to maximise their utility. For instance, condensation-aromatisation on 
the propargylamine derived cycloadduct 184, followed by ozonolysis and 
reduction, would give access to a unique spirocyclic framework 238 (Figure 61). 
This methodology would provide a way of removing the prevalence of alcohol 
functionality found in scaffold 237.  
 
Figure 61 An example of how the established methodologies could be used in sequence. 
 
 
Application of the established methodologies to the readily accessible 
maltol-derived cycloadducts may allow rapid access to a complementary, but 
structurally unique, series of compounds (Figure 62). 
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Figure 62 The methodologies applied to the kojic acid series (Panel B) may also be applicable to the isomeric 
maltol-derived series (Panel A). 
 
It may also be possible to exploit variants of the intramolecular [5+2] 
oxidopyrylium cycloaddition to provide access to novel scaffolds (Figure 63). For 
instance, cycloadduct 239, containing a six-membered ring, could be prepared 
from the homoallylic starting material 240 (equation 1), and would provide access 
to a novel set of scaffolds using the established methodologies. Cycloadduct 241, 
which contains a benzylic amine, may be cleaved by hydrogenation (equation 2). 
Alternatively, preparation of cycloadducts 242-243, containing N-N and N-O 
bonds, may allow cleavage by hydrogenation to form aminoalcohols and 
diamines 244-245 (equations 3 and 4). 
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Figure 63 Potential cycloadducts which may be prepared to enable the synthesis of new scaffolds. 
 
It may also be valuable to prepare aza-bridged scaffolds 246a-b via 
intramolecular [5+2] oxidopyridinium cycloadditions (Figure 64, Panel A). A 
similar strategy to that used to prepare the allylic alkylation-derived scaffolds 
could then be applied (Panel B). This would involve capping the bridging amine 
with a variety of different functionalised handles, which may then facilitate 
cyclisation reactions. There would also be the option to apply many of the 
established methodologies used so far in our top-down approach. 
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Figure 64 Panel A: the proposed intramolecular oxidopyridinium cycloaddition to prepare cycloadducts 246a-b. Panel B: a 
potential strategy to prepare scaffolds from cycloadducts 246a-b. The amine bridge would be capped with a variety of 
different functional handles to facilitate cyclisations, such as an intramolecular Heck reaction (equation 1) and/or a 
ring-closing metathesis reaction (equation 2). 
 
In summary, we have demonstrated the feasibility of a top-down approach to 
LOS. This paradigm should be applicable to many different classes of polycyclic 
assemblies in the future and represents a streamlined and synthetically efficient 
approach to LOS. 
124 
 
 
4.0 Comparison of approaches to LOS 
 
This chapter compares the LOS strategies developed so far in the Marsden and 
Nelson groups, and assesses their ability to systematically, and efficiently, target 
lead-like space. This assessment compares the libraries derived from the two 
bottom-up approaches to LOS (the allylic amination82 [see Section 1.5.3.3] and 
allylic alkylation connective reactions) with the top-down approach to LOS 
(intramolecular [5+2] cycloaddition, Table 20). 
 
4.1 Lead-likeness assessment  
We have demonstrated that all of the approaches we have developed would allow 
significant lead-like space to be accessed through the preparation of derivative 
compound libraries (Table 20, entry 1). The virtual library enumerated from the 
‘top-down’ scaffolds would give the highest proportion of lead-like compounds 
(72%, 571 compounds), followed by the allylic alkylation-derived compounds 
(66%, 734 compounds) and the allylic amination-derived virtual compounds82 
(59%, 11,468 compounds). It is worth noting that the allylic amination-derived 
compounds were typically decorated twice (except where a diversification step 
was used in the preparation of a scaffold, e.g. where scaffolds were derived from 
the Wolfe reaction – see Section 1.5.3.3 for full details) allowing access to a much 
larger virtual library of compounds. 
 
4.2 PMI assessment  
Overall, the allylic alkylation-derived compounds give the best PMI molecular 
shape distribution (Table 20, entry 2), both systematically avoiding the extreme 
flat-linear edge of the graph (bin 1, Figure 65) and penetrating further towards 
more three-dimensional space (compounds found as far as bin 17). In contrast, 
compounds derived from the top-down approach are weighted towards the 
rod-like edge of the plot. In addition, 16% of the top-down derived compounds 
are found at the extreme flat-linear edge (bin 1) of the plot, and are only found as 
far as bin 9. Compounds derived from the allylic amination are weighted towards 
the flat-linear edge of the graph (compounds are found as far as bin 12).  
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Entry Analysis Allylic amination* (OBC paper compounds)82 Allylic alkylation† [5+2] cycloaddition† 
1 AlogP 
vs. HA 
   
2 PMI 
 
µFsp3= 0.58 
 
µFsp3= 0.57 
 
µFsp3= 0.68 
Table 20 Comparison of AlogP vs. HA and PMI distributions for the three LOS approaches developed so far in the Marsden and Nelson groups. *Virtual library generated by Richard Doveston using 59 capping 
groups.82 Each scaffold was decorated twice except where aminoarylation reactions were used to prepare a scaffold (in which case they were decorated once). †80 capping groups used.
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Figure 65 The relative proportions of compounds found when the PMI plots were divided into twenty bins (see Section 
2.5.3.2 and Appendix 1, Section 6.3.1 for details). In general, all of the LOS approaches developed exhibit a systematic 
avoidance of the extreme flat-linear edge of the PMI plot (bin 1). 
 
4.3 Synthetic efficiency 
All of the approaches developed by the candidate allow rapid preparation of 
scaffolds. Including the key coupling step, scaffolds were prepared in an average 
of two steps, regardless of the synthetic strategy used (Table 21, entry 5). 
Notably, however, if the key coupling step is not included in the step count, the 
allylic amination-derived building blocks provide more rapid access to scaffolds 
(one step per scaffold, entry 7). This is probably due to the large number of 
aminoarylations (one step) that were carried out post-coupling, but also because 
some of the coupling products were considered to be scaffolds in their own right 
(and therefore required zero steps to prepare). 
 
On average the allylic alkylation derived building blocks are predisposed to 
deliver the most scaffolds (six per building block, entry 3), followed by the allylic 
amination and the cycloaddition-derived scaffolds (four per building block 
respectively). Full investigation of the top-down approach may prove this 
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approach to be more productive (i.e. if the proposed future work in Section 3.3.4 
can be realised). 
 
 
Entry Parameter Allylic amination Allylic alkylation [5+2] Cycloaddition 
1 No. building blocks used 13 4 2 
2 No. scaffolds 52 22 7a 
3 
Av. no. scaffolds  
per building block 
4 6 4 
4 
No. stepsb,c to prepare library 
including the key coupling step 
83 53d 15 
5 Av. no. steps per scaffold 2 2 2 
6 
No. stepsa,c to prepare  
library post coupling 
74 49 13 
7 
Av. no. stepsa,c per  
scaffold post coupling 
1 2 2 
Table 21 Synthetic efficiency parameters for the LOS approaches developed. Numbers are rounded to the nearest integer. 
aCompound 216 was included as a representative derivative of the cycloadduct 183 framework (see Figure 66). bFor the 
purposes of this analysis, a synthetic operation is defined as a process conducted in a single reaction vessel. cSteps 
counted once per linear sequence (for examples of step counting see Figure 66). dTotal step count for preparation of the 
entire library (including synthesis of the building blocks) was 56. 
 
In order to directly compare the synthetic efficiency of the top-down approach 
with the two bottom-up approaches, it is perhaps fairer to compare the building 
blocks from each series that give rise to the most scaffolds (Figure 66). This 
analysis shows that (i) the building block 9a in the allylic amination series gives 
access to 5 scaffolds in 11 steps (average 2.2 steps per scaffold, Panel A); (ii) the 
proline-derived building block 63a gives 6 scaffolds in 13 steps (average 2.2 steps 
per scaffold, Panel B); and (iii) the cycloadduct 183 gives 5 scaffolds in 8 steps 
(average 1.6 steps per scaffold, Panel C). 
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Figure 66 Examples of the building blocks (blue) which provided access to the most scaffolds (black) from the allylic amination (Panel A),82 allylic alkylation (Panel B), and cycloaddition-derived (Panel C) 
precursors. Common intermediates are shown in red.
129 
 
 
The major conclusion that can be drawn from the two synthetic economy 
analyses above is that at present, there is no significant advantage in synthetic 
economy between any of the LOS strategies used (all average two steps per 
scaffold). Whether full exploration of the top-down approach will lead to an 
increase in synthetic economy can only be determined through full exploration of 
the strategy by preparing more scaffolds. 
 
4.4 Summary and outlook 
All of the LOS strategies developed so far give access to large numbers of 
scaffolds. Virtual decoration of the scaffolds suggests that ~65% of derivatives 
from all three approaches would be lead-like. The derivatives also systematically 
target three-dimensional space. The synthetic economy is excellent, on average 
it takes two steps to prepare novel scaffolds. Future strategies must focus on 
streamlined synthetic approaches so that fewer steps are required to access the 
building blocks for cyclisation. In addition, we aspire to design our syntheses in 
such a way that diverse scaffolds can be prepared in the fewest number of steps 
(ideally one) from a minimal number of readily available building blocks.11 
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5.0 Experimental 
 
5.1 General experimental 
All non-aqueous reactions were performed under an atmosphere of nitrogen 
unless otherwise stated. Water-sensitive reactions were performed in oven-dried 
glassware, cooled under nitrogen before use. THF, CH2Cl2, PhMe and MeCN 
were dried and purified by means of a Pure Solv MD solvent purification system 
(Innovative Technology Inc.). Anhydrous DMF was obtained in a SureSeal bottle 
from Sigma-Aldrich. All other solvents used were of chromatography or analytical 
grade. Petrol refers to petroleum spirit (b.p. 40-60 °C). Commercially available 
starting materials were obtained from Sigma-Aldrich, Fluka, Acros, Alfa-Aesar or 
Fluorochem and were used without purification. 
Thin layer chromatography (TLC) was carried out on aluminium backed silica 
plates (Merck silica gel 60 F254). Visualisation of the plates was achieved using 
an ultraviolet lamp (λmax = 254 nm) and KMnO4. Flash chromatography was 
carried out using silica gel 60 (60-63 µm particles) supplied by Merck. Columns 
with solvent gradients were carried out using a Biotage Flashmaster II on 
pre-packed Redisep normal-phase silica or cyanosilica cartridges (as specified). 
Strong cation exchange solid phase extraction (SCX-SPE) was carried out using 
pre-packed Discovery DSC-SCX cartridges supplied by Supelco, see general 
procedure R. 
Melting points were measured on a Reichert hot stage apparatus and are 
uncorrected. Optical rotation measurements were carried out at the sodium D-line 
(589 nm) on a Schmidt and Haensch H532; concentrations are in g/100 mL, 
temperatures are given in °C, optical rotations are given in deg dm−1cm3 g−1 (units 
are omitted). Infrared spectra were recorded on a Perkin-Elmer One FT-IR 
spectrometer or a Bruker Alpha Platinum-ATR, with absorption reported in 
wavenumbers (cm–1). High resolution mass spectra (HRMS) were recorded by 
the candidate or by Tanya Marinko-Covell on a Bruker Daltonics micrOTOF or 
Bruker MaXis Impact spectrometer with electrospray ionisation (ESI) source. 
Where EI ionisation was required, a Waters/Micromass GCT Premier 
spectrometer was used.  
Proton (1H) and carbon (13C) NMR spectral data were collected on a Bruker 
Advance 500 or Bruker DPX500 or DPX300 spectrometers. Chemical shifts (δ) 
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are quoted in parts per million (ppm) and referenced to the residual solvent peak. 
Coupling constants (J) are quoted in Hertz (Hz) and splitting patterns reported in 
an abbreviated manner: app. (apparent), s (singlet), d (doublet), t (triplet), q 
(quartet), m (multiplet). All fully characterised products were assigned with the 
aid of COSY, DEPT-135 and HMQC experiments. Where stated HMBC and 
NOESY experiments were also used to aid assignments. Compounds are 
numbered with respect to their IUPAC names. Where necessary, coloured text is 
used to distinguish similar protons and carbons. Diastereomeric ratios were 
calculated by analysis of the 1H NMR spectra and assigned through the 
interpretation of coupling constants, NOESY spectra, and through 
crystallographic studies. X-ray crystallography studies were performed by Helena 
Shepherd and Christopher Pask. 
  
5.2 Experimental for ‘bottom-up’ approach to LOS 
 
5.2.1 General procedures 
 
General procedure A: synthesis of azlactones 
 
Following a procedure by Taran,110 protected amino acids in acetic anhydride 
(0.3 M) were heated at 65 °C for 2 h. The resulting reaction mixture was 
concentrated in vacuo. The crude azlactones were used without further 
purification. 
 
General procedure B: asymmetric allylic alkylation of azlactones 
 
Following a modification of a procedure by Trost,108 a pre-stirred suspension of 
[(η3-C3H5)PdCl]2 (2.5 mol%) and (R,R)-DACH-phenyl L2 (7.5 mol%) in PhMe 
(0.02 M) was added via cannula to a stirred solution of cinnamyl acetate 
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(eq. stated), Et3N (eq. stated), and azlactone (eq. stated) in PhMe (0.25 M, 
1 volume). The reaction mixture was stirred for 3 h. Following complete 
consumption of the starting material (as determined by TLC and 1H NMR 
spectroscopy of an aliquot of the crude reaction mixture) a nucleophilic work-up 
(general procedures C-D or as stated) was then carried out. 
 
General procedure C: methanolysis of quaternary azlactones 
 
Following completion of general procedure B, MeOH (120 eq.) and 
K2CO3 (2.0 eq.) were added to the crude reaction mixture. The resulting mixture 
was stirred for 15 h. The reaction mixture was concentrated in vacuo, diluted in 
EtOAc (1 volume) and washed with H2O (1 volume) and brine (1 volume). The 
combined organic extracts were dried over Na2SO4, filtered and concentrated in 
vacuo. Compounds were purified by flash chromatography as stated. 
 
General procedure D: opening the quaternary azlactones with TMS-CF3 
 
Following completion of general procedure B, the reaction mixture was 
concentrated in vacuo, diluted in EtOAc (1 volume), and washed with pH 7 
phosphate buffer (1 volume). The organic phase was dried over Na2SO4 and 
concentrated in vacuo. Following a modification of a procedure by Bräse,119 the 
resulting residue was dissolved in PhMe (0.25 M, 1 volume). TBAF (1.0 M in THF, 
0.1 eq.) was added to the mixture, followed by TMS-CF3 (2.0 eq.). The resulting 
mixture was stirred for 1 h. The reaction mixture was concentrated in vacuo, 
diluted in EtOAc (1 volume) and washed with brine (1 volume). The organic phase 
was dried over MgSO4, filtered, then concentrated in vacuo. Compounds were 
purified by flash chromatography or crystallisation as stated. 
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General procedure E: Allylation of Boc-protected amino esters 
 
LiHMDS (1.0 M in THF, 1.1 eq.) was added dropwise to a stirred solution of 
Boc-protected amino ester 61a-c (1.0 eq.) in THF (0.45 M, 1 volume) at −78 °C. 
The reaction mixture was stirred for 15 min, then allyl bromide (1.5 eq.) was 
added dropwise. The reaction mixture was stirred for 1 h, the dry-ice bath was 
removed and the reaction mixture was warmed to rt and stirred for 15 h. Sat. aq. 
NH4Cl solution was added (0.1 volume), then the reaction mixture was partitioned 
between EtOAc (1 volume) and brine (1 volume). The aqueous layer was 
extracted with EtOAc (2 × 1 volume). The combined organic extracts were dried 
over MgSO4 and concentrated in vacuo. Compounds 62a-c were purified by flash 
chromatography. 
 
General procedure F: Boc-carbamate deprotection 
  
Boc-carbamate 62a-c (1.0 eq.) was diluted in 2:1 CH2Cl2–TFA (0.5 M) at 0 °C. 
The reaction mixture was stirred for 1 h at rt then concentrated in vacuo. 
Compounds 63a-c were purified by SCX, according to general procedure R. 
 
General procedure G: Cyclic carbamate synthesis 
 
Following a procedure by Licini,102 iodine (3.0 eq.) was added to Boc-carbamate 
62a-e (1.0 eq.) in 1:1 THF–H2O (0.04 M, 1 volume) and the reaction mixture was 
stirred for 2-3 h. Sat. aq. Na2S2O3 was added until the reaction mixture turned 
colourless. The reaction mixture was extracted with CH2Cl2 (2 × 0.25 volumes). 
134 
 
 
The combined organic phase was washed with brine (0.5 volume) then dried over 
Na2SO4, filtered, and concentrated in vacuo to give the crude iodide 68a-e. The 
iodide was diluted in DMF (0.1 M, 1 volume) and NaN3 (2.0 eq.) was added 
(CAUTION: azides are potentially explosive and should be handled with care – 
this reaction should be performed behind a blast shield. NaN3 is extremely toxic 
and should be weighed out inside a fumehood using a non-metal spatula). The 
reaction mixture was stirred for 15 h. H2O (0.5 volume) was added at 0 °C. The 
reaction mixture was extracted with EtOAc (3 × 0.25 volume). The organics were 
washed with brine (0.5 volume) then dried over Na2SO4, filtered, and 
concentrated in vacuo. Compounds 70a-e were purified by flash 
chromatography. 
 
General procedure H: Carbamoyl urea synthesis 
 
Following a procedure by Taguchi,138 ethyl isocyanatoformate (1.2 eq.) was 
added to a stirred solution of amino ester 63a-c (1.0 eq.) in CH2Cl2 (0.1 M). The 
reaction mixture was stirred for 0.5 h then concentrated in vacuo to give crude 
urea 81a-c. 
 
General procedure I: Cyclic urea synthesis 
 
Following a procedure by Taguchi,138 Li[Al(OtBu)4] (0.7 M in THF, 1.0 eq., 
prepared following general procedure Q) was added to the crude urea 81a-c in 
PhMe (0.1 M, 1 volume) at −5 °C. The reaction mixture was stirred for 0.5 h, then 
iodine (3.0 eq.) was added. The reaction mixture was stirred for 15 h at −5 °C, 
then quenched with ice-cold sat. aq. Na2S2O3 until colourless. The reaction 
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mixture was extracted with ice-cold EtOAc (3 × 0.5 volume). The organics were 
dried over Na2SO4 at 0 °C, filtered, then concentrated in vacuo to give the crude 
iodide. The residue was dissolved in DMF (0.2 M, 1 volume) and NaN3 (2.0 eq.) 
was added (CAUTION: azides are potentially explosive and should be handled 
with care – this reaction should be performed behind a blast shield. NaN3 is 
extremely toxic and should be weighed out inside a fumehood using a non-metal 
spatula). The reaction mixture was stirred for 15 h at rt. H2O (0.5 volume) was 
added at 0 °C. The reaction mixture was extracted with EtOAc (3 × 0.25 volume). 
The organics were washed with brine (0.5 volume) then dried, filtered, and 
concentrated in vacuo. Compounds 82a-c were purified by flash 
chromatography. 
 
General procedure J: Hydantoin synthesis 
 
NaOMe (25 wt% in MeOH, 1.0 eq.) was added to the crude urea 81a-c in 85:15 
PhMe–MeOH (0.1 M). The reaction mixture was heated at 65 °C for 2 h, then 
concentrated in vacuo. Compounds 88a-c were purified by SCX eluting with 
MeOH. 
 
General procedure K: Reductive amination with N-Boc glycinal 
 
A suspension of amino ester 63a-b (1.0 eq.), N-Boc glycinal (2.0 eq.) and 4 Å MS 
(50 mg for 2.5 mmol of amine) in CH2Cl2 (0.1 M, 1 volume) was stirred for 1 h. 
NaBH(OAc)3 (2.0 eq.) was added in one portion and the reaction mixture was 
stirred for 15 h. The reaction mixture was filtered through Celite then concentrated 
in vacuo. The residue was dissolved in EtOAc (0.5 volume) and washed with 
brine (0.5 volume). The aqueous phase was extracted with EtOAc 
(2 × 0.25 volume). The combined organic phase was dried over MgSO4, filtered, 
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and concentrated in vacuo. Compounds 89a-b were carried on crude without 
further purification. 
 
General procedure L: Lactamisation 
 
The crude N-Boc glycinated amino ester 89a-b (1.0 eq.) was deprotected, 
following general procedure F. The residue was diluted in DMF (0.04 M) and 
Cs2CO3 (2.0 eq.) was added. The reaction mixture was heated at reflux for 1 h, 
then concentrated in vacuo. Compounds 90a-b were purified by flash 
chromatography or by SCX, according to general procedure R. 
  
General procedure M: Reductive amination with 2-bromobenzaldehyde 
 
A suspension of amino ester 63a-d (1.0 eq.), 2-bromobenzaldehyde (2.0 eq.) and 
4 Å MS (50 mg for 2.5 mmol of amine) in CH2Cl2 (0.1 M) was stirred for 1 h. 
NaBH(OAc)3 (2.0 eq.) was added in one portion and the reaction mixture was 
stirred for 15 h. The reaction mixture was filtered through Celite then concentrated 
in vacuo. The residue was dissolved in EtOAc (0.5 volume) and washed with 
brine (0.5 volume). The aqueous phase was extracted with EtOAc (2 × 0.25 
volume). The combined organic phase was dried over MgSO4, filtered, and 
concentrated in vacuo. Compounds 100a-d were purified by flash 
chromatography or by SCX, according to general procedure R. 
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General procedure N: Intramolecular Heck reaction 
 
Et3N (2.5 eq.) was added to a stirred solution of amino ester 100a-d (1.0 eq.) and 
Pd(PPh3)4 (5 mol%) in MeCN (0.1 M). The mixture was heated at 125 °C under 
microwave irradiation for 1 h, then filtered through celite and concentrated in 
vacuo. Compounds 101a-d were purified by flash chromatography. 
 
General procedure O: N-Allylation of amines 
 
Allyl bromide (3.0 eq.) and K2CO3 (1.1 eq.) were added to a stirred solution of 
amino ester 63a-d (1.0 eq.) in DMF (0.2 M, 1 volume) and the reaction mixture 
was stirred for 15 h. The reaction mixture was diluted with H2O (0.5 volume) and 
extracted with EtOAc (3 × 0.25 volume). The organics were washed with brine 
(0.5 volume) then dried over MgSO4, filtered, and concentrated in vacuo. The 
compounds 105a-d were purified by SCX, according to general procedure R. 
 
General procedure P: Ring-closing metathesis 
 
Following a procedure by Gracias,150 p-TsOH (2.0 eq.) was added to a stirred 
solution of N-allyl amino ester 105a-d (1.0 eq.) in CH2Cl2 or PhMe as specified 
(0.03 M). The reaction mixture was heated at reflux for 0.5 h then cooled to rt. GII 
(2.5-7.5 mol%) was added, the mixture was heated at reflux and monitored by 
NMR until complete consumption of the starting material was observed. The 
reaction mixture was cooled to rt. Sat. aq. NaHCO3 (0.25 volume) solution was 
added. The reaction mixture was extracted with CH2Cl2 (for reactions performed 
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in CH2Cl2, 2 × 0.25 volume) or EtOAc (for reactions performed in PhMe, 2 × 
0.25 volume). The organics were washed with brine, dried over Na2SO4, filtered, 
then concentrated in vacuo. Compounds 106a-d were purified by flash 
chromatography or by SCX, according to general procedure R. 
 
General procedure Q: Preparation of a Li[Al(OtBu)4] solution in THF 
t-BuOH (4.0 eq.) was added dropwise to LiAlH4 in THF (1.0 M solution) at 0 °C 
(CAUTION: gas evolution). The reaction mixture was stirred for 0.5 h warming to 
rt and was considered to constitute a 0.7 M solution of Li[Al(OtBu)4]. 
 
General procedure R: SCX purification 
TfOH (0.5 M in MeOH, 10 mL / 5 g SPE-SCX) was dripped through the SPE-SCX 
cartridge prior to use. MeOH (20 mL) was then washed through using pressurised 
air (bellows). The crude residue was loaded (3.5 mmol / 5 g SPE-SCX silica) in 
the minimum amount of MeOH. The cartridge was washed with MeOH and the 
fractions were collected and monitored by TLC. The cartridge was then washed 
with sat. NH3/MeOH and the fractions were collected and monitored by TLC. 
Fractions containing product were combined and concentrated. 
 
5.2.2 Compound data for ‘bottom-up’ approach to LOS 
 
(2S)-3-Phenyl-2-(phenylformamido)propanoic acid 29 
 Following a procedure by Richards,202 benzoyl chloride (1.8 mL, 
16 mmol, 1.1 eq.) was added dropwise to a stirred solution of 
L-phenylalanine (2.5 g, 15 mmol, 1.0 eq.) and NaOH (1.8 g, 
45 mmol, 3.0 eq.) in H2O (250 mL) at 0 °C. The mixture was stirred 
for 3 h then acidified to neutral pH with conc. HCl. Filtration of the resulting solid 
gave the title compound 29 (2.6 g, 9.8 mmol, 65%) as a colourless powder. 
M.p. 185 °C, microcrystalline, acetone, (lit.203 185-186 °C, acetone). 1H NMR 
(300 MHz, CDCl3, CO2H not observed): δ 7.73-7.65 (2H, m, Ar-H), 7.57-7.48 (1H, 
m, Ar-H), 7.47-7.37 (2H, m, Ar-H), 7.37-7.24 (3H, m, Ar-H), 7.24-7.17 (2H, m, 
Ar-H), 6.57 (1H, d, J 7.2, NH), 5.16-5.03 (1H, m, CHCH2Ph), 3.38 (1H, dd, J 14.0, 
5.6, CHAHBPh), 3.27 (1H, dd, J 14.0, 5.9, CHAHBPh). 13C NMR (75 MHz, CDCl3): 
δ 174.3 (CO2H), 167.9 (CONH), 135.7 (Ar-Cq), 133.5 (Ar-Cq), 132.3 (Ar-C), 129.6 
(Ar-C), 129.0 (Ar-C), 128.9 (Ar-C), 127.5 (Ar-C), 127.2 (Ar-C), 53.8 (CHCH2), 37.3 
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(CHCH2). IR νmax(film)/cm−1 3029 (NH), 1725 (CO), 1634 (CO), 1532, 1490, 1216, 
755, 700. HRMS (ESI): C16H15NNaO3 [M+Na]+; calculated 292.0944, found 
292.0939. [α]26D +54.0° (c. 1.00, CHCl3) {lit.204 +45.9° (c. 1.60, dioxane)}. Spectra 
consistent with the literature values.202 
 
4-Benzyl-2-phenyl-4,5-dihydro-1,3-oxazol-5-one 27a 
 General procedure A was followed using benzoylated 
phenylalanine 29 (1.00 g, 3.71 mmol) to give the title compound 27a 
(914 mg, 3.60 mmol, 97%) as a colourless amorphous solid. 
M.p. 68-70 °C, colourless needles, petrol (lit.205 69-70 °C, hexane). 1H NMR 
(300 MHz, CDCl3): δ 7.95-7.89 (2H, m, Ar-H), 7.59-7.51 (1H, m, Ar-H), 7.50-7.41 
(2H, m, Ar-H), 7.31-7.16 (5H, m, Ar-H), 4.70 (1H, dd, J 6.7, 5.0, 4-H), 3.38 (1H, 
dd, J 14.0, 5.0, CHAHBPh), 3.19 (1H, dd, J 14.0, 6.7, CHAHBPh). 13C NMR 
(125 MHz, CDCl3): δ 177.7 (5-C), 161.9 (2-C), 135.4 (Ar-C), 132.9 (Ar-C), 129.7 
(Ar-C), 128.9 (Ar-C), 128.6 (Ar-C), 128.0 (Ar-C), 127.4 (Ar-C), 126.0 (Ar-C), 
66.7 (4-C), 37.5 (CH2Ph). IR νmax(film)/cm−1 1810, 1645, 1448, 1295, 1161, 1149, 
899, 691. HRMS (ESI): C16H13NNaO2 [M+Na]+; calculated 274.0838, found 
274.0832. Spectra consistent with the literature values.206 
 
Methyl (2R,4E)-2-benzyl-5-phenyl-2-(phenylformamido)pent-4-enoate 31 
General procedure B was followed using cinnamyl acetate 
(70 μL, 0.40 mmol, 1.0 eq), Et3N (60 μL, 0.40 mmol, 1.0 eq.), 
and azlactone 27a (100 mg, 0.400 mmol, 1.00 eq.). General 
procedure C was then followed. Flash chromatography eluting with pentane–
EtOAc (95:5) gave the title compound 31 (125 mg, 0.313 mmol, 78%, er 95:5) as 
a colourless oil. Rf 0.34 (4:1 pentane–EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.68 
(2H, d, J 7.4, Ar-H), 7.51-7.46 (1H, m, Ar-H), 7.42-7.38 (2H, m, Ar-H), 7.28-7.23 
(4H, m, Ar-H), 7.23-7.15 (4H, m, Ar-H), 7.09-7.04 (2H, m, Ar-H), 6.94 (1H, s, NH), 
6.48 (1H, d, J 15.6, CH=CHPh), 6.00 (1H, dt, J 15.6, 7.6, CH=CHPh), 4.01 (1H, 
d, J 13.5, CHAHBPh), 3.84 (3H, s, CO2CH3), 3.77 (1H, dd, J 14.0, 7.4, 
CHAHBCH=CHPh), 3.25 (1H, d, J 13.5, CHAHBPh), 2.88 (1H, dd, J 14.0, 7.7, 
CHAHBCH=CHPh). 13C NMR (75 MHz, CDCl3): δ 173.3 (CO2CH3), 167.3 (CONH), 
137.0 (Ar-Cq), 136.2 (Ar-Cq), 135.2 (Ar-Cq), 134.3 (CH=CHPh), 131.6 (Ar-C), 
129.7 (Ar-C), 128.7 (Ar-C), 128.5 (Ar-C), 128.3 (Ar-C), 127.5 (Ar-C), 127.0 (Ar-C), 
126.8 (Ar-C), 126.2 (Ar-C), 123.5 (CH=CHPh), 66.7 (Cq), 52.9 (CO2CH3), 40.4 
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(CH2Ph), 38.7 (CH2CH=CH). IR νmax(film)/cm−1 3410 (NH), 3029, 2950, 1737 
(CO), 1662 (CO), 1515, 1486, 1114. HRMS (ESI): C26H25NNaO3 [M+Na]+; 
calculated 422.1727, found 422.1738. [α]23D −2.3° (c. 1.37, MeOH). HPLC 
(Chiralpak AD column, 25 cm, 70:29.9:0.1 ethanol–nheptane–isopropylamine, 
1 mL/min flow rate, Rt (min) 13.80 (major), 21.44 (minor). 
 
Methyl (2R)-2-benzyl-2-(phenylformamido)pent-4-enoate 32 
General procedure B was followed using allyl acetate (40 μL, 
0.40 mmol, 1.0 eq.), Et3N (60 μL, 0.40 mmol, 1.0 eq.) and 
azlactone 27a (100 mg, 0.400 mmol, 1.00 eq.). General 
procedure C was then followed. Flash chromatography eluting with EtOAc–
pentane (4:1) gave the title compound 32 (94 mg, 0.29 mmol, 73%) as a 
colourless oil. 1H NMR (300 MHz, CDCl3): δ 7.73-7.65 (2H, m, Ar-H), 7.53-7.46 
(1H, m, Ar-H), 7.46-7.37 (2H, m Ar-H), 7.23-7.15 (3H, m, Ar-H), 7.10-7.00 (2H, 
m, Ar-H), 6.93 (1H, s, NH), 5.74-5.55 (1H, m, CH=CH2), 5.13 (1H, dd, J 17.0, 2.0, 
CH=CHAHB), 5.07 (1H, dd, J 10.1, 2.0, CH=CHAHB), 3.96 (1H, d, J 13.5, 
CHAHBPh), 3.83 (3H, s, CO2CH3), 3.61 (1H, dd, J 13.8, 7.2, CHAHBCH=CH2), 3.21 
(1H, d, J 13.5, CHAHBPh), 2.72 (1H, dd, J 13.8, 7.6, CHAHBCH=CH2). 13C NMR 
(75 MHz, CDCl3): δ 173.5 (CO2CH3), 167.0 (CONH), 136.3 (Ar-Cq), 135.4 (Ar-Cq), 
132.3 (CH=CH2), 131.6 (Ar-C), 129.8 (Ar-C), 128.7 (Ar-C), 128.4 (Ar-C), 127.1 
(Ar-C), 126.9 (Ar-C), 119.4 (CH=CH2), 66.6 (Cq), 52.9 (CO2CH3), 40.4 (CH2Ph), 
39.6 (CH2CH=CH2). IR νmax(film)/cm−1 3412 (NH), 2952, 1738 (CO), 1662, 1519, 
1446, 1351, 1082. HRMS C20H21NNaO3 [M+Na]+; calculated 346.1414, found 
346.1413. [α]24D −3.9° (c. 0.93, CHCl3). 
 
(2R,4E)-N,2-Dibenzyl-5-phenyl-2-(phenylformamido)pent-4-enamide 33 
 General procedure B was followed using cinnamyl acetate 
(60 μL, 0.35 mmol, 1.0 eq.), Et3N (0.10 mL, 0.70 mmol, 2.0 eq.) 
and azlactone 27a (200 mg, 0.800 mmol, 2.25 eq.). Following 
the completion of the reaction, benzylamine (60 μL, 0.53 mmol, 
1.5 eq.) was added and the mixture was stirred for 15 h. The reaction mixture 
was concentrated in vacuo, diluted in EtOAc (50 mL) and washed with H2O 
(2 × 25 mL) and brine (25 mL). The organic phase was dried over Na2SO4, filtered 
and concentrated in vacuo. Flash chromatography eluting with pentane–EtOAc 
(4:1) gave the title compound 33 (145 mg, 0.306 mmol, 87%) as a colourless oil. 
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Rf 0.15 (4:1 pentane–EtOAc). 1H NMR (300 MHz, CDCl3, one NH not observed): 
δ 7.68-7.58 (2H, m, Ar-H), 7.48-7.39 (1H, m, Ar-H), 7.39-7.30 (2H, m, Ar-H), 
7.29-7.10 (13H, m, Ar-H), 7.10-6.98 (2H, m, Ar-H), 6.83-6.67 (1H, m, NH), 6.40 
(1H, d, J 15.8, CH=CHPh), 6.02 (1H, ddd, J 15.8, 8.3, 7.2, CH=CHPh), 4.55 (1H, 
dd, J 14.6, 6.1, NHCHAHBPh), 4.40 (1H, dd, J 14.6, 5.4, NHCHAHBPh), 3.73 (1H, 
d, J 13.8, CqCHAHBPh), 3.42 (1H, dd, J 14.6, 8.3, CHAHBCH=CHPh), 3.35 (1H, d, 
J 13.8, CqCHAHBPh), 2.87 (1H, ddd, J 14.6, 7.2, 0.7, CHAHBCH=CHPh). 13C NMR 
(75 MHz, CDCl3): δ 172.1 (CO), 167.6 (CO), 137.8 (Ar-Cq), 136.9 (Ar-Cq), 
135.8 (Ar-Cq), 135.2 (Ar-Cq), 134.8 (CH=CHPh), 131.8 (Ar-C), 130.2 (Ar-C), 
128.9 (Ar-C), 128.8 (Ar-C), 128.6 (Ar-C), 128.5 (Ar-C), 128.2 (Ar-C), 127.8 (Ar-C), 
127.7 (Ar-C), 127.2 (Ar-C), 127.0 (Ar-C), 126.4 (Ar-C), 123.6 (CH=CHPh), 64.9 
(Cq), 44.3 (NHCH2Ph), 41.1 (CqCH2Ph), 39.4 (CH2CH=CHPh). IR νmax(film)/cm−1 
3347 (NH), 3062, 3028, 1637 (CO), 1509, 1241, 1217, 966. HRMS (ESI): 
C32H30N2O2 [M+Na]+; calculated 497.2199, found 497.2200. [α]24D +1.9° (c. 3.97, 
CHCl3). 
 
N-[(2R,4E)-2-Benzyl-1-(morpholin-4-yl)-1-oxo-5-phenylpent-4-en-2-
yl]benzamide 34 
General procedure B was followed using cinnamyl acetate 
(60 μL, 0.35 mmol, 1.0 eq.), Et3N (0.10 mL, 0.70 mmol, 2.0 eq.) 
and azlactone 27a (200 mg, 0.800 mmol, 2.25 eq.). Following 
the completion of the reaction, morpholine (50 μL, 0.53 mmol, 
1.5 eq.) and DMAP (5.0 mg, 41 µmol, 0.1 eq.) were added and 
the mixture was heated at 90 °C for 15 h. The reaction mixture was concentrated 
in vacuo, diluted in EtOAc (50 mL) and washed with H2O (2 × 25 mL) and brine 
(25 mL). The organic phase was dried over Na2SO4, filtered and concentrated in 
vacuo. Flash chromatography eluting with a gradient of 0-100% EtOAc in CH2Cl2 
gave the title compound 34 (96 mg, 0.21 mmol, 60%) as a colourless oil. Rf 0.35 
(1:1 CH2Cl2–EtOAc). 1H NMR (300 MHz, CDCl3, NH not observed): δ 7.71-7.62 
(3H, m, Ar-H), 7.52-7.44 (1H, m, Ar-H), 7.43-7.34 (2H, m, Ar-H), 7.31-7.16 (7H, 
m, Ar-H), 7.14-7.07 (2H, m, Ar-H), 6.50 (1H, d, J 15.8, CH=CHPh), 6.06 (1H, dt, 
J 15.8, 7.2, CH=CHPh), 4.07 (1H, d, J 14.2, CHAHBPh), 3.92-3.68 (9H, m, all 
morpholine-H and CHAHBCH=CHPh), 3.27 (1H, d, J 14.2, CHAHBPh), 2.84 (1H, 
dd, J 15.0, 7.7, CHAHBCH=CHPh). 13C NMR (75 MHz, CDCl3): δ 169.8 (CO), 
166.5 (CO), 136.9 (Ar-Cq), 136.2 (Ar-Cq), 135.5 (Ar-Cq), 134.2 (CH=CHPh), 
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131.6 (Ar-C), 129.9 (Ar-C), 128.8 (Ar-C), 128.7 (Ar-C), 128.5 (Ar-C), 127.7 (Ar-C), 
127.2 (Ar-C), 127.0 (Ar-C), 126.4 (Ar-C), 123.8 (CH=CHPh), 66.8 (Cq), 65.6 
(NCH2), 46.0 (OCH2), 39.6 (CH2Ph), 38.3 (CH2CH=CHPh). IR νmax(film)/cm−1 
3278, 3027, 2856, 1642 (CO), 1534 (CO), 1421, 1218, 1115. HRMS (ESI): 
C29H30N2NaO3 [M+Na]+; calculated 477.2149, found 477.2152. [α]24D −1.3° 
(c. 1.70, CHCl3). 
 
N-[(3R,5E)-3-Benzyl-1,1,1-trifluoro-2-oxo-6-phenylhex-5-en-3-yl] 
benzamide 37 
 General procedure B was followed using cinnamyl acetate 
(210 μL, 1.23 mmol, 1.00 eq.), Et3N (0.18 mL, 1.3 mmol, 
1.0 eq.) and azlactone 27a (300 mg, 1.20 mmol, 1.00 eq.). 
General procedure D was then followed using one-sixth (0.20 mmol maximum) 
of the crude product. Flash chromatography eluting with pentane–EtOAc (4:1) 
gave the title compound 37 (55 mg, 13 µmol, 63%) as a pale oil. Rf 0.35 (4:1 
pentane–EtOAc). 1H NMR (300 MHz, CDCl3): δ 7.67-7.58 (2H, m, Ar-H), 
7.54-7.46 (1H, m, Ar-H), 7.44-7.35 (2H, m, Ar-H), 7.34-7.18 (8H, m, Ar-H), 
7.18-7.09 (2H, m, Ar-H), 6.46 (1H, d, J 15.7, CH=CHPh), 6.32 (1H, s, NH), 5.97 
(1H, dt, J 15.7, 7.6, CH=CHPh), 3.51 (1H, d, J 14.0, CHAHBPh), 3.39 (1H, d, 
J 14.0, CHAHBPh), 2.88 (2H, app. d, J 7.3, CH2CH=CHPh). 13C NMR (75 MHz, 
CDCl3): δ 189.3 (q, J 32.6, COCF3), 167.9 (CONH), 136.5 (Ar-C), 136.1 
(CH=CHPh), 134.6 (Ar-C), 132.6 (Ar-C), 132.5 (Ar-C), 130.9 (Ar-C), 129.0 (Ar-C), 
128.8 (Ar-C), 128.7 (Ar-C), 128.1 (Ar-C), 127.7 (Ar-C), 127.2 (Ar-C), 126.5 (Ar-C), 
121.3 (CH=CHPh), 116.3 (q, J 294.2, CF3), 65.6 (Cq), 37.8 (CH2Ph), 37.0 
(CH2CH=CHPh). IR νmax(film)/cm−1 3281 (NH), 3030, 1746 (CO), 1633, 1532, 
1199, 1151, 692. HRMS (ESI): C26H22F3NNaO2 [M+Na]+; calculated 483.1675, 
found 438.1696. [α]25D −2.2° (c. 1.73, CHCl3). 
 
N-[(3R)-3-Benzyl-1,1,1-trifluoro-2-oxohex-5-en-3-yl]benzamide 38 
 General procedure B was followed using allyl acetate (0.45 mL, 
4.2 mmol, 1.0 eq.), Et3N (0.58 mL, 4.2 mmol, 1.0 eq.) and 
azlactone 27a (1.00 g, 4.19 mmol, 1.00 eq.). General procedure D 
was then followed. Crystallisation of the crude residue from pentane–EtOAc (4:1) 
gave the title compound 38 (650 mg, 1.80 mmol, 43%) as a pale yellow solid. 
M.p. 163 °C, microcrystalline, EtOAc. 1H NMR (300 MHz, CDCl3): δ 7.60-7.51 
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(2H, m, Ar-H), 7.50-7.40 (1H, m, Ar-H), 7.37-7.28 (2H, m, Ar-H), 7.26-7.13 (2H, 
m, Ar-H), 7.13-6.97 (3H, m, Ar-H), 6.33 (1H, br. s, NH), 5.69-5.51 (1H, m, 
CH=CH2), 5.20-5.08 (2H, m, CH=CH2), 3.42 (1H, d, J 14.0, CHAHBPh), 3.26 (1H, 
d, J 14.0, CHAHBPh), 2.65 (2H, app. d, J 7.1, CH2CH=CH2). 13C NMR (75 MHz, 
CDCl3): δ 189.3 (q, J 32.4, COCF3), 167.8 (CONH), 134.6 (Ar-Cq), 132.6 (Ar-Cq), 
132.5 (Ar-C), 130.9 (CH=CH2), 130.1 (Ar-C), 128.9 (Ar-C), 128.7 (Ar-C), 
127.6 (Ar-C), 127.2 (Ar-C), 121.6 (CH=CH2), 118.2 (q, J 294.3, CF3), 65.3 (Cq), 
37.4 (CH2Ph and CH2CH=CH2). IR νmax(film)/cm−1 3263 (NH), 3031, 1746 (CO), 
1626, 1531, 1200, 1139, 701. HRMS C20H18F3NNaO2 [M+Na]+; calculated 
384.1182, found 384.1184. [α]23D +1.9° (c. 0.87, CHCl3).  
 
4-Benzyl-2-(trifluoromethyl)-2,5-dihydro-1,3-oxazol-5-one 43 
Following a modification of a procedure by Ries,126 L-phenylalanine 
(2.00 g, 12.0 mmol) in trifluoroacetic anhydride (19 mL) was heated 
at reflux for 36 h. The reaction mixture was concentrated in vacuo 
and the residue was washed through a pad of silica with EtOAc. 
The resulting solution was concentrated in vacuo. The residue was distilled at 
88-90 °C (5 mmHg) to give the title compound 43 (1.69 g, 6.95 mmol, 58%) as a 
yellow oil. Rf 0.32 (9:1 pentane–EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.38-7.28 
(5H, m, Ar-H), 6.11-6.07 (1H, m, 2-H), 4.06 (1H, dd, J 15.1, 1.4, CHAHBPh), 4.02 
(1H, dd, J 15.1, 1.8, CHAHBPh). 13C NMR (125 MHz, CDCl3): δ 167.5 (5-C), 163.4 
(4-C), 132.6 (Ar-Cq), 129.5 (Ar-C), 129.2 (Ar-C), 128.0 (Ar-C), 120.3 (q, J 281.7, 
CF3), 93.2 (q, J 35.3, 2-C), 34.7 (CH2Ph). 19F NMR (300 MHz, CDCl3, decoupled) 
δ 73.7 (CF3). IR νmax(neat)/cm−1 3035, 1808 (CO), 1651 (CN), 1497, 1372, 1272, 
1196, 1158. HRMS (ESI): C11H8F3NNaO2 [M+Na]+; calculated 266.0399, found 
266.0389. Spectral data consistent with the literature values.207 
 
(2R,4E)-2-Benzyl-5-phenyl-2-(trifluoroacetamido)pent-4-enoic acid 46 
General procedure B was followed using cinnamyl acetate 
(100 µL, 0.570 mmol, 1.0 eq.), Et3N (0.16 mL, 1.1 mmol, 
2.0 eq.) and pseudoazlactone 43 (312 mg, 1.28 mmol, 
2.25 eq.). General procedure C was then followed. Flash chromatography eluting 
with EtOAc−AcOH (98.5:1.5) gave the title compound 46 (102 mg, 0.270 mmol, 
47%) as a yellow oil. Rf 0.36 (98.5:1.5 EtOAc–AcOH). 1H NMR (300 MHz, CDCl3, 
CO2H and NH not observed): δ 7.34-7.18 (6H, m, Ar-H), 7.15-7.02 (4H, m, Ar-H), 
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6.52 (1H, d, J 15.8, CH=CHPh), 5.99-5.88 (1H, m, CH=CHPh), 3.77 (1H, d, 
J 13.8, CHAHBPh), 3.54 (1H, dd, J 14.3, 7.4, CHAHBCH=CHPh), 3.29 (1H, d, 
J 13.8, CHAHBPh), 2.93 (1H, dd, J 14.3, 7.0, CHAHBCH=CHPh). 13C NMR 
(125 MHz, CDCl3): δ 176.1 (CO2H), 156.5 (q, J 37.0, NHCOCF3), 136.8 (Ar-Cq), 
135.7 (CH=CHPh), 134.9 (Ar-Cq), 129.6 (Ar-C), 128.7 (Ar-C), 128.7 (Ar-C), 127.9 
(Ar-C), 127.7 (Ar-C), 126.5 (Ar-C), 121.7 (CH=CHPh), 115.5 (q, J 288.7, CF3), 
66.6 (Cq), 40.2 (CH2Ph), 38.3 (CH2CH=CHPh). IR νmax(film)/cm−1 3375 (br., 
CO2H), 1714 (CO), 1532, 1448, 1214, 1169, 739, 701. HRMS (ESI): C20H19F3NO3 
[M+H]+; calculated 377.1259, found 377.1239. [α]24D −0.2° (c. 1.17, MeOH). 
 
(2S)-2-(4-Chlorobutanamido)-3-phenylpropanoic acid 50 
 Following a modification of a procedure by Mandić,133 
TMSCl (1.8 mL, 15 mmol, 1.2 eq.) was added to a stirred 
solution of L-phenylalanine (2.0 g, 12 mmol, 1.0 eq.) in CH2Cl2 
(30 mL). The reaction mixture was cooled to 0 °C and Et3N 
(2.0 mL, 15 mmol, 1.2 eq.) was added dropwise. The resulting mixture was 
heated to reflux for 1 h. The reaction mixture was cooled to rt then further to 
−10 °C. 4-Chlorobutyryl chloride (1.4 mL, 12 mmol, 1.0 eq.) in CH2Cl2 (15 mL) 
was added dropwise to the reaction mixture. The reaction mixture was stirred at 
−10 °C for 2 h, at rt for 1 h, then filtered to remove the precipitated Et3N•HCl. The 
solution was concentrated in vacuo. The resulting residue was diluted in acetone–
H2O (20:80), acidified with conc. HCl to pH 1 (15 mL), and extracted with CH2Cl2 
(3 × 50 mL). The organic extracts were concentrated in vacuo to afford the title 
compound 50 as an off-white amorphous solid (2.1 g, 7.7 mmol, 64%), which was 
not purified further. M.p. 101 °C, microcrystalline, CH2Cl2. 1H NMR (300 MHz, 
CDCl3, CO2H not observed): δ 7.37-7.23 (3H, m, Ar-H), 7.23-7.13 (2H, m, Ar-H), 
5.99 (1H, d, J 7.4, NH), 4.90 (1H, app. q, J 6.5, CHCO2H), 3.61-3.43 (2H, m, 
CH2Cl), 3.25 (1H, dd, J 14.0, 5.4, CHAHBPh), 3.11 (1H, dd, J 14.0, 6.6, CHAHBPh), 
2.37 (2H, t, J 7.1, NH(CO)CH2), 2.13-1.99 (2H, m, CH2CH2Cl). 13C NMR (75 MHz, 
CDCl3, CONH not observed): δ 172.4 (CO2H), 135.6 (Ar-Cq), 129.4 (Ar-C), 
128.9 (Ar-C), 127.5 (Ar-C), 53.2 (CHCH2Ph), 44.3 (CH2Cl), 37.4 (CH2Ph), 33.1 
(NH(CO)CH2), 28.0 (CH2CH2Cl). IR νmax(film)/cm−1 3313 (br., CO2H), 2951, 1738, 
1660, 1506, 1446, 1228, 991. HRMS (ESI): C13H1635ClNaNO3 [M+Na]+; 
calculated 292.0711, found 292.0696. [α]24D +7.7° (c. 0.67, CHCl3). 
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4-Benzyl-2-(3-chloropropyl)-4,5-dihydro-1,3-oxazol-5-one 49 
General procedure A was followed using protected 
phenylalanine 50 (2.74 g, 10.1 mmol) to give the title 
compound 49 (2.55 g, 10.1 mmol, 99%) as a colourless oil. 
1H NMR (300 MHz, CDCl3): δ 7.38-7.21 (3H, m, Ar-H), 
7.21-7.13 (2H, m, Ar-H), 4.53-4.41 (1H, m, 4-H), 3.48-3.31 (2H, m, CH2Cl), 3.27 
(1H, dd, J 13.9, 5.1, CHAHBPh), 3.14 (1H, dd, J 13.9, 5.6, CHAHBPh), 2.61-2.41 
(2H, m, CH2CH2CH2Cl), 2.07-1.89 (2H, m, CH2CH2Cl). 13C NMR (75 MHz, 
CDCl3): δ 177.9 (5-C), 164.8 (2-C), 134.9 (Ar-Cq), 129.8 (Ar-C), 128.6 (Ar-C), 
127.5 (Ar-C), 65.9 (4-C), 43.4 (CH2Cl), 36.9 (CH2Ph), 27.6 (CH2CH2CH2Cl), 26.1 
(CH2CH2Cl). IR νmax(film)/cm−1 3031, 2928, 1820 (CO), 1678 (CN), 1496, 1454, 
1131, 1082. HRMS (EI+): C13H1435ClNO2 [M]+; calculated 251.0713, found 
251.0717. 
 
Methyl (4E)-2-benzyl-2-(4-chlorobutanamido)-5-phenylpent-4-enoate 51 
General procedure B was followed using cinnamyl acetate (0.23 
mL, 1.3 mmol, 1.0 eq.), Et3N (0.36 ml, 2.6 mmol, 2.0 eq.) and 
azlactone 49 (738 mg, 2.92 mmol, 2.25 mmol). General 
procedure C was then followed. Flash chromatography eluting 
with pentane–EtOAc (4:1) gave the title compound 51 (420 mg, 
1.05 mmol, 81%) as a straw-coloured oil. Rf 0.2 (4:1 pentane–EtOAc). 1H NMR 
(300 MHz, CDCl3): δ 7.28-7.10 (8H, m, Ar-H), 7.00-6.91 (2H, m, Ar-H), 6.38 (1H, 
d, J 15.7, CH=CHPh), 6.17 (1H, s, NH), 5.93-5.79 (1H, m, CH=CHPh), 3.80-3.68 
(4H, m, includes 1H, m, CHAHBPh and at δ 3.75: 3H, s, CO2CH3), 3.53-3.43 (3H, 
m, includes 1H, m, CHAHBCH=CHPh and at δ 3.50: 2H, t, J 6.3, CH2Cl), 3.11 (1H, 
d, J 13.5, CHAHBPh), 2.72 (1H, dd, J 13.9, 7.2, CHAHBCH=CHPh), 2.27 (2H, app. 
dd, J 10.6, 4.0, NH(CO)CH2), 2.06-1.95 (2H, m, CH2CH2Cl). 13C NMR (75 MHz, 
CDCl3): δ 173.3 (CO2CH3), 171.2 (CONH), 137.1 (Ar-Cq), 136.3 (Ar-Cq), 134.3 
(CH=CHPh), 129.7 (Ar-C), 128.7 (Ar-C), 128.5 (Ar-C), 127.6 (Ar-C), 127.2 (Ar-C), 
126.4 (Ar-C), 123.6 (CH=CHPh), 66.4 (Cq), 53.0 (CO2CH3), 44.5 (CH2Cl), 
40.6 (CH2Ph), 38.9 (CH2CH=CHPh), 34.0 (NH(CO)CH2), 28.2 (CH2CH2Cl). 
IR νmax(film)/cm−1 3402 (NH), 3030, 2249 (C=C), 1737 (CO), 1656 (CO), 1508, 
1445, 1220. HRMS (ESI): C23H2635ClNaNO3 [M+Na]+; calculated 422.1493, found 
422.1495. [α]25D +0.9° (c. 1.75, MeOH). 
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Methyl 2-benzyl-2-(4-chlorobutanamido)pent-4-enoate 52 
Pd(PPh3)4 (500 mg, 5 mol%) was added to a stirred solution of allyl 
acetate (1.1 mL, 10 mmol, 1.0 eq.), Et3N (1.4 mL, 10 mmol, 
1.0 eq.) and the azlactone 49 (2.55 g, 10.1 mmol, 1.00 eq.) in 
PhMe (100 mL). The reaction mixture was stirred at rt for 3 h. 
General procedure C was then followed. Flash chromatography 
eluting with a gradient of 0-100% EtOAc in pentane gave the title compound 52 
(2.57 g, 7.93 mmol, 79%) as a yellow oil. Rf 0.10 (4:1 pentane–EtOAc). 1H NMR 
(300 MHz, CDCl3): δ 7.35-7.18 (3H, m, Ar-H), 7.13-6.96 (2H, m, Ar-H), 6.26 (1H, 
s, NH), 5.72-5.49 (1H, m, CH=CH2), 5.18-5.08 (2H, m, CH=CH2), 3.82 (3H, s, 
CO2CH3), 3.77 (1H, d, J 13.5, CHAHBPh), 3.61 (2H, t, J 6.3, CH2Cl), 3.41 (1H, dd, 
J 13.8, 7.4, CHAHBCH=CH2), 3.18 (1H, d, J 13.5, CHAHBPh), 2.65 (1H, dd, J 13.8, 
7.3, CHAHBCH=CH2), 2.37 (2H, app. dd, J 10.7, 4.3, NH(CO)CH2), 2.18-2.03 (2H, 
m, CH2CH2Cl). 13C NMR (75 MHz, CDCl3): δ 173.2 (CO2CH3), 171.0 (CONH), 
136.2 (Ar-Cq), 132.2 (CH=CH2), 129.6 (Ar-C), 128.4 (Ar-C), 127.1 (Ar-C), 119.2 
(CH=CH2), 65.9 (Cq), 52.8 (CO2CH3), 44.4 (CH2Cl), 40.3 (CH2Ph), 39.5 
(CH2CH=CH2), 33.8 (NH(CO)CH2), 28.1 (CH2CH2Cl). IR νmax(film)/cm−1 
3342 (NH), 2917, 1699 (CO), 1615, 1548, 1268, 1231, 1207. HRMS 
C17H2335ClNO3 [M+H]+; calculated 324.1361, found 324.1361. 
 
Methyl 2-benzyl-2-[4-(butylamino)butanamido]pent-4-enoate 55 
4-Chlorobutyryl-protected amino ester 52 (109 mg, 0.340 mmol) in 
n-butylamine (2.5 mL) was heated at reflux for 3 h. The reaction 
mixture was cooled to rt and concentrated in vacuo. The resulting 
residue was dissolved in CH2Cl2 (50 mL) and washed with sat. aq. 
NaHCO3 solution (50 mL). The aqueous phase was extracted with 
CH2Cl2 (6 × 10 mL). The combined organic extracts were dried over MgSO4 then 
concentrated in vacuo to give the title compound 55 (124 mg, 0.34 mmol, 99%) 
as a colourless oil which was not purified further. Rf 0.67 (4:1 pentane–EtOAc). 
1H NMR (300 MHz, CDCl3, CH2NHCH2 not observed): δ 7.23-7.09 (3H, m, Ar-H), 
6.97-6.92 (2H, m, Ar-H) 6.39 (1H, s, NH), 5.62-5.41 (1H, m, CH=CH2), 
5.09-4.96 (2H, m, CH=CH2), 3.71 (3H, s, CO2CH3), 3.66 (1H, d, J 13.5, 
CHAHBPh), 3.29 (1H, dd, J 13.8, 7.3, CHAHBCH=CH2), 3.07 (1H, d, J 13.5, 
CHAHBPh), 2.61-2.44 (5H, m, CHAHBCH=CH2, NHCH2CH2CH2CH3 and 
NH(CO)CH2CH2CH2NH), 2.16 (2H, t, J 7.4, NH(CO)CH2), 1.81-1.62 (2H, m, 
147 
 
 
NH(CO)CH2CH2CH2NH), 1.45-1.31 (2H, m, CH2CH2CH3), 1.31-1.15 (2H, m, 
CH2CH3), 0.84 (3H, t, J 7.2, CH2CH3). 13C NMR (75 MHz, CDCl3): δ 173.4 (CO), 
172.3 (CO), 136.4 (Ar-Cq), 132.4 (CH=CH2), 129.8 (Ar-C), 128.3 (Ar-C), 127.0 
(Ar-C), 119.2 (CH=CH2), 65.9 (Cq), 52.7 (CO2CH3), 49.6 (NHCH2), 49.3 (NHCH2), 
40.3 (CH2Ph), 39.5 (CH2CH=CH2), 35.3 (NH(CO)CH2), 32.2 (CH2CH2CH3), 25.8 
(NH(CO)CH2CH2), 20.6 (CH2CH3), 14.1 (CH2CH3). IR νmax(film)/cm−1 3290, 2955, 
1739 (CO), 1651, 1539, 1446, 1226, 703. HRMS (ESI): C21H33N2O3 [M+H]+; 
calculated 361.2486 found 361.2503. 
 
(2Z*)-N-[(2R,4E)-2-Benzyl-1-methoxy-1-oxo-5-phenylpent-4-en-2-yl]oxolan-
2-iminium trifluoroborane fluoride 59 
Following a modification of a procedure by Peter,8 
4-chlorobutyryl-protected amino ester 52 (20 mg, 50 µmol, 
1.0 eq.) in THF (1.0 mL) was added via cannula to a stirred 
solution of AgBF4 (11 mg, 55 µmol, 1.1 eq.) in THF (1.0 mL) 
at −20 °C in the dark. The reaction mixture was warmed to rt and stirred 2 h. The 
reaction mixture was diluted in THF and washed through a plug of Celite. The 
resulting solution was concentrated in vacuo to give the title compound 59 
(18 mg, 40 µmol, 80%) as a colourless oil. 1H NMR (300 MHz, CDCl3): δ 9.96 
(1H, s, NH+), 7.33 (2H, d, J 7.3, Ar-H), 7.29-7.11 (6H, m, Ar-H), 7.08 (2H, d, J 7.0, 
Ar-H), 6.47 (1H, d, J 15.6, CH=CHPh), 6.12-5.92 (1H, m, CH=CHPh), 4.76-4.38 
(2H, m, 5-H), 3.71 (3H, s, CO2CH3), 3.43 (1H, d, J 14.0, CHAHBPh), 3.37-3.14 
(3H, m, includes 2H, m, 3-H and at δ 3.22: 1H, d, J 14.0, CHAHBPh), 2.93 (2H, 
app. d, J 7.3, CH2CH=CHPh), 2.29-2.04 (2H, m, 4-H). 13C NMR (75 MHz, CDCl3): 
δ 182.6 (2-C), 168.7 (CO2CH3), 136.4 (Ar-Cq), 136.1 (Ar-Cq), 133.9 (CH=CHPh), 
130.3 (Ar-C), 128.9 (Ar-C), 128.8 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 126.6 (Ar-C), 
121.1 (CH=CHPh), 81.4 (Cq), 70.2 (5-C), 53.5 (CO2CH3), 42.1 (CH2Ph), 40.3 
(CH2CH=CH2), 32.0 (3-C), 21.8 (4-C). IR νmax(film)/cm−1 2960, 1744 (CO), 1674, 
1449, 1258, 1223, 1065, 752. HRMS (ESI): C23H26NO3 [M]+; calculated 364.1907, 
found 364.1910. [α]25D +6.1° (c. 0.27, CHCl3). 
 
Methyl (2R,4E)-2-amino-2-benzyl-5-phenylpent-4-enoate 60 
Following a modification of a procedure by Peter,132 protected 
amino ester 52 (50 mg, 0.13 mmol, 1.0 eq.) in THF (1.0 mL) was 
added via cannula to a stirred solution of AgBF4 (28 mg, 
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0.14 mmol, 1.1 eq.) in THF (1.0 mL) at 0 °C in the dark. The reaction mixture was 
warmed to rt and stirred for 2 h. The reaction mixture was concentrated in vacuo. 
The residue was dissolved in 1:1 acetone–H2O (5 mL) and stirred for 15 h. The 
reaction mixture was concentrated in vacuo and purified by flash 
chromatography, eluting with pentane–EtOAc (4:6), to give the title compound 60 
(35 mg, 0.12 mmol, 95%) as a colourless oil. Rf 0.48 (2:3 pentane–EtOAc). 
1H NMR (300 MHz, CDCl3, NH2 not observed): δ 7.43-7.18 (8H, m, Ar-H), 
7.18-7.11 (2H, m, Ar-H), 6.53 (1H, d, J 15.7, CH=CHPh), 6.21-5.95 (1H, m, 
CH=CHPh), 3.72 (3H, s, CO2CH3), 3.23 (1H, d, J 13.1, CHAHBPh), 2.92-2.80 (2H, 
m, includes at δ 2.88: 1H, ddd, J 13.5, 6.4, 1.4, CHAHBCH=CHPh and at δ 2.83: 
1H, d, J 13.1, CHAHBPh), 2.47 (1H, dd, J 13.5, 8.7, CHAHBCH=CHPh). 13C NMR 
(75 MHz, CDCl3): δ 176.7 (CO2CH3), 137.1 (Ar-Cq), 136.3 (Ar-Cq), 
134.8 (CH=CHPh), 130.0 (Ar-C), 128.7 (Ar-C), 128.6 (Ar-C), 127.6 (Ar-C), 127.2 
(Ar-C), 126.4 (Ar-C), 124.0 (CH=CHPh), 62.4 (Cq), 52.2 (CO2CH3), 46.1 (CH2Ph), 
43.9 (CH2CH=CHPh). IR νmax(film)/cm−1 3377 (NH2), 3027, 2949, 1735 (CO), 
1494, 1197, 1066, 1026. HRMS (ESI): C19H22NO2 [M+H]+; calculated 296.1645, 
found 296.1653. [α]24D −0.7° (c. 0.23, CHCl3).  
 
1-tert-Butyl 2-methyl (2S)-pyrrolidine-1,2-dicarboxylate 61a 
Boc2O (5.20 g, 23.9 mmol, 1.03 eq.) and Et3N (9.7 mL, 70 mmol, 
2.9 eq.) were added to a stirred solution of L-proline methyl ester 
hydrochloride (3.84 g, 23.2 mmol, 1.00 eq.) in CH2Cl2 (230 mL). 
The reaction mixture was stirred for 1 h, then concentrated 
in vacuo. The residue was triturated with Et2O (3 × 50 mL) and filtered to remove 
the insoluble Et3N•HCl. The resulting solution was dry-loaded onto silica. Flash 
chromatography eluting with pentane–EtOAc (4:1) gave the title compound 61a 
(5.30 g, 23.1 mmol, 99%) as a colourless oil. Rf 0.19 (4:1 petrol–EtOAc). [α]27D 
−61.4 (c. 0.83, MeOH) {lit.208 -61.7 (c. 1.15, MeOH). 1H NMR (300 MHz, CDCl3, 
40:60 mixture of rotamers): δ 4.34 (0.4H, dd, J 8.5, 3.1, 2-H), 4.23 (0.6H, dd, 
J 8.5, 4.1, 2-H), 3.73 (3H, s, CO2CH3), 3.62-3.33 (2H, m, 5-H), 2.33-2.09 (1H, m, 
3-HA), 2.05-1.77 (3H, m, 3-HB and 4-H), 1.47 (3.6H, s, C(CH3)3), 1.42 (5.4H, s, 
C(CH3)3). 13C NMR (75 MHz, CDCl3, mixture of two rotamers): δ 173.8 (major, 
CO2CH3), 173.5 (minor, CO2CH3), 154.5 (minor, N(CO)O), 153.8 (major, 
N(CO)O), 79.9 (major and minor, Cq(CH3)3), 59.2 (major, 2-C), 58.8 (minor, 2-C), 
52.1 (minor, CO2CH3), 52.0 (major, CO2CH3), 46.6 (minor, 5-C), 46.4 (major, 
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5-C), 30.9 (major, 3-C), 30.0 (minor, 3-C), 28.5 (minor, Cq(CH3)3), 
28.3 (major, Cq(CH3)3), 24.4 (minor, 4-C), 23.7 (major, 4-C). IR νmax(film)/cm−1 
2977, 2882, 1747 (CO), 1694 (CO), 1393, 1201, 1121, 1088. HRMS (ESI): 
C11H19NNaO4 [M+Na]+; calculated 252.1212, found 252.1206. Spectra consistent 
with the literature values.209 
 
4-Benzyl 1-tert-butyl 2-methyl piperazine-1,2,4-tricarboxylate 61c 
Benzyl chloroformate (3.5 mL, 24 mmol, 1.3 eq.) was added 
dropwise to a stirred solution of 1-tert-butyl 2-methyl 
piperazine-1,2-dicarboxylate* (4.59 g, 18.8 mmol, 1.00 eq.) and 
Et3N (3.4 mL, 24 mmol, 1.3 eq.) in CH2Cl2 (50 mL) at 0 °C. The 
reaction mixture was warmed to rt and stirred for 15 h, then 
partitioned between H2O (50 mL) and CH2Cl2 (50 mL). The 
organics were dried over MgSO4, filtered, then concentrated in 
vacuo. Flash chromatography eluting with pentane–EtOAc (4:1) gave the title 
compound 61c (5.52 g, 14.6 mmol, 85%) as a straw-coloured oil. Rf 0.11 (4:1 
petrol–EtOAc). 1H NMR (500 MHz, d6-DMSO, 343 K): δ 7.40-7.29 (5H, m, Cbz 
Ar-H), 5.11 (1H, d, J 12.7, CHAHBPh), 5.07 (1H, d, J 12.7, CHAHBPh), 4.61 (1H, 
br. s, 2-H), 4.34 (1H, d, J 13.8, 3-HA), 3.92-3.85 (1H, m, NCHAHBCH2N), 3.74 (1H, 
dt, J 13.0, 3.4, NCHAHBCH2N), 3.60 (3H, s, CO2CH3), 3.27 (1H, dd, J 13.8, 4.5, 
3-HB), 3.16-3.07 (1H, m, NCHAHBCH2N), 3.04-2.03 (1H, m, NCHAHBCH2N), 
1.40 (9H, s, C(CH3)3). 13C NMR (125 MHz, d6-DMSO, 373 K): δ 169.9 (CO2CH3), 
154.0 (N(CO)O), 153.9 (N(CO)O), 136.3 (Ar-Cq), 127.8 (Ar-C), 127.2 (Ar-C), 
126.8 (Ar-C), 79.5 (Cq(CH3)3), 66.0 (CH2Ph), 53.7 (2-C), 51.3 (CO2CH3), 43.5 
(3-C and NCH2CH2N), 42.3 (NCH2CH2N), 27.4 (C(CH3)3). IR νmax(film)/cm−1 2976, 
1744 (CO), 1694, 1457, 1431, 1224, 1168, 1106. HRMS (ESI): C19H27N2O6 
[M+H]+; calculated 379.1864, found 379.1866. 
 
                                            
* Purchased from Fluorochem. 
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1-tert-Butyl 2-methyl 2-(prop-2-en-1-yl)pyrrolidine-1,2-dicarboxylate 62a 
General procedure E was followed using Boc-protected amino 
ester 61a (2.50 g, 10.9 mmol). Flash chromatography eluting with 
pentane–EtOAc (5:1) gave the title compound 62a (2.4 g, 8.8 mmol, 
81%) as a colourless oil. Rf 0.35 (4:1 petrol–EtOAc). 1H NMR 
(300 MHz, CDCl3, 33:67 mixture of rotamers): δ 5.89-5.64 (1H, m, 
CH=CH2), 5.22-5.05 (2H, m, CH=CH2), 3.76-3.54 (4H, includes 1H, m, 5-HA and 
at δ 3.72: 3H, s, CO2CH3), 3.50-3.28 (1H, m, 5-HB), 3.11 (0.33H, dd, J 14.1, 6.5, 
CHAHBCH=CH2), 2.92 (0.67H, dd, J 14.1, 6.5, CHAHBCH=CH2), 2.61 (1H, dd, 
J 14.1, 8.1, CHAHBCH=CH2), 2.20-1.96 (2H, m, 3-H), 1.96-1.72 (2H, m, 4-H), 1.46 
(3H, s, C(CH3)3), 1.43 (6H, s, C(CH3)3). 13C NMR (75 MHz, CDCl3, mixture of two 
rotamers): δ 175.4 (major and minor, CO2CH3), 154.2 (minor, N(CO)O), 
153.8 (major, N(CO)O), 134.0 (minor, CH=CH2), 133.6 (major, CH=CH2), 119.3 
(major, CH=CH2), 119.0 (minor, CH=CH2), 79.8 (Cq(CH3)3, major and minor), 
67.8 (minor, 2-C), 67.2 (major, 2-C), 52.5 (minor, CO2CH3), 52.4 (major, 
CO2CH3), 48.8 (minor, 5-C), 48.7 (major, 5-C), 39.9 (major, CH2CH=CH2), 38.6 
(minor, CH2CH=CH2), 37.3 (major, 3-C, major), 36.0 (minor, 3-C), 28.7 (minor, 
C(CH3)3), 28.6 (major, C(CH3)3), 23.4 (minor, 4-C), 22.9 (major, 4-C). 
IR νmax(film)/cm−1 2977, 2878, 1742 (CO), 1698 (CO), 1392, 1253, 1162, 1022. 
HRMS (ESI): C14H23NNaO4 [M+Na]+; calculated 292.1525, found 292.1519. 
Spectra consistent with the literature values.209,134 
 
1-tert-Butyl 2-methyl 2-(prop-2-en-1-yl)azetidine-1,2-dicarboxylate 62b 
General procedure E was followed using 1-tert-butyl 2-methyl 
azetidine-1,2-dicarboxylate* (2.4 g, 11 mmol). The residue was 
washed through a pad of silica with EtOAc to give the title compound 
62b (2.26 g, 8.85 mmol, 80%) as a yellow oil. Rf 0.07 (91:9 pentane–
EtOAc). 1H NMR (500 MHz, CDCl3, 33:67 mixture of rotamers): 
δ 5.97-5.84 (1H, m, CH=CH2), 5.23-5.16 (2H, m, CH=CH2), 4.00-3.86 (1H, m, 
4-HA), 3.77 (3H, s, CO2CH3), 3.69 (1H, m, 4-HB), 2.96-2.86 (0.33H, m, 
CHAHBCH=CH2), 2.76 (0.67H, m, dd, J 14.2, 6.0, CHAHBCH=CH2), 2.60 (1H, dd, 
J 14.2, 8.1, CHAHBCH=CH2), 2.29-2.21 (1H, m, 3-HA), 2.19-2.11 (1H, m, 3-HB), 
1.40 (9H, s, C(CH3)3). 13C NMR (125 MHz, CDCl3): δ 173.1 (CO2CH3), 155.1 
                                            
* Purchased from Fluorochem. 
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(N(CO)O), 132.6 (CH=CH2), 119.6 (CH=CH2), 80.0 (Cq(CH3)3), 70.3 (2-C), 52.4 
(CO2CH3), 44.9 (4-C), 38.8 (CqCH2CH=CH2), 28.4 (C(CH3)3), 24.3 (3-C). 
IR νmax(film)/cm−1 2977, 2895, 1739 (CO), 1713 (CO), 1392, 1257, 1157, 1112. 
HRMS (ESI): C13H22NO4 [M+H]+; calculated 256.1543, found 256.1541. 
 
4-Benzyl 1-tert-butyl 2-methyl 2-(prop-2-en-1-yl)piperazine- 
1,2,4-tricarboxylate 62c 
General procedure E was followed using Boc-protected amino 
ester 61c (3.5 g, 9.2 mmol). The residue was washed through 
a pad of silica with EtOAc to give the title compound 62c (3.7 g, 
8.8 mmol, 96%) was isolated as a yellow oil. 1H NMR (500 MHz, 
d6-DMSO, 340 K): δ 7.41-7.28 (5H, m, Cbz Ar-H), 5.85-5.71 
(1H, m, CH=CH2), 5.17-5.02 (4H, m, CH=CH2 and OCH2Ph), 
4.01-3.93 (1H, m, NCHAHBCH2N), 3.82-3.77 (1H, m, 3-HA), 
3.66-3.58 (1H, m, 3-HB), 3.56-3.47 (1H, m, NCHAHBCH2N), 3.43-3.36 (4H, m, 
includes NCHAHBCH2N and at δ 3.52: 3H, s, CO2CH3), 3.35-3.26 (1H, m, 
NCHAHBCH2N), 2.92 (1H, d, J 14.5, CHAHBCH=CH2), 2.53-2.44 (1H, m, 
CHAHBCH=CH2), 1.37 (9H, s, C(CH3)3). 13C NMR (125 MHz, d6-DMSO, 340 K, 
one carbamate CO peak not observed): δ 172.0 (CO2CH3), 153.1 (N(CO)O), 
136.5 (Ar-Cq), 132.1 (CH=CH2), 128.0 (Ar-C), 127.5 (Ar-C), 127.2 (Ar-C), 118.9 
(CH=CH2), 80.0 (Cq(CH3)3), 66.0 (CH2Ph), 63.1 (2-C), 51.6 (CO2CH3), 45.3 (3-C), 
43.2 (NCH2CH2N), 38.3 (NCH2CH2N or CH2CH=CH2), 37.6 (NCH2CH2N or 
CH2CH=CH2), 27.6 (C(CH3)3). IR νmax(film)/cm−1 2976, 1746 (CO), 1704 (CO), 
1417, 1394, 1366, 1270, 1219. HRMS (ESI): C22H31N2O6 [M+H]+; calculated 
419.2177, found 419.2181. 
 
Methyl 2-benzyl-2-[(tert-butoxycarbonyl)amino]pent-4-enoate 62d 
To a stirred solution of amino ester 63d (322 mg, 1.47 mmol, 1.00 eq.) 
in THF (10 mL) was added Boc2O (321 mg, 1.47 mmol, 1.00 eq.) and 
the reaction mixture was heated at reflux for 15 h. The reaction 
mixture was concentrated in vacuo, diluted with EtOAc (50 mL), 
washed with H2O (50 mL) then brine (50 mL). The organic phase was 
dried over MgSO4, filtered, then concentrated in vacuo to give the title 
compound 62d (470 mg, 1.47 mmol, 99%) as a yellow oil. Rf 0.35 (4:1 pentane–
EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.27-7.19 (3H, m, Ar-H), 7.07-7.04 (2H, m, 
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Ar-H), 5.70-5.59 (1H, m, CH=CH2), 5.33 (1H, br. s, NH), 5.14-5.06 (2H, m, 
CH=CH2), 3.75 (3H, s, CO2CH3), 3.61 (1H, d, J 13.6, CHAHBPh), 3.21 (1H, dd, 
J 13.7, 7.1, CHAHBCH=CH2), 3.12 (1H, d, J 13.6, CHAHBPh), 2.59 (1H, dd, J 13.7, 
7.4, CHAHBCH=CH2), 1.47 (9H, s, C(CH3)3). 13C NMR (125 MHz, CDCl3): δ 173.2 
(CO2CH3), 154.2 (NH(CO)O), 136.6 (Ar-Cq), 132.6 (CH=CH2), 130.0 (Ar-C), 
128.3 (Ar-C), 127.0 (Ar-C), 119.1 (CH=CH2), 79.4 (Cq(CH3)3), 65.1 (Cq), 52.6 
(CO2CH3), 40.9 (CH2Ph), 40.1 (CH2CH=CH2), 28.6 (C(CH3)3). IR νmax(film)/cm−1 
3430, 2978, 1739 (CO), 1714 (CO), 1495, 1447, 1348, 1232. HRMS (ESI): 
C18H25NNaO4 [M+Na]+; calculated 342.1681, found 342.1676. Spectra consistent 
with the literature values.210 
 
Methyl 2-(prop-2-en-1-yl)pyrrolidine-2-carboxylate 63a 
General procedure F was followed using Boc-protected amino ester 
62a (6.7 g, 25 mmol). Purification by SCX cartridge, eluting first with 
MeOH then sat. NH3/MeOH, gave the title compound 63a (3.10 g, 
18.3 mmol, 74%) as an orange oil. 1H NMR (500 MHz, CDCl3, NH not observed): 
δ 5.78-5.69 (1H, m, CH=CH2), 5.15-5.07 (2H, m, CH=CH2), 3.74 (3H, s, CO2CH3), 
3.14-3.02 (2H, m, 5-H), 2.61 (1H, ddt, J 13.7, 7.3, 1.1, CHAHBCH=CH2), 2.45 (1H, 
ddt, J 13.7, 7.2, 1.0, CHAHBCH=CH2), 2.27-2.18 (1H, m, 3-HA), 1.91-1.79 (2H, m, 
3-HB and 4-HA), 1.79-1.68 (1H, m, 4-HB). 13C NMR (125 MHz, CDCl3): δ 176.3 
(CO2CH3), 133.3 (CH=CH2), 119.0 (CH=CH2), 70.0 (2-C), 52.6 (CO2CH3), 
46.5 (5-C), 43.3 (CH2CH=CH2), 35.2 (3-C), 24.7 (4-C). IR νmax(film)/cm−1 3352 
(NH), 2953, 1732 (CO), 1435, 1217, 1200, 997, 918. HRMS (ESI): C9H16NO2 
[M+H]+; calculated 170.1181, found 170.1176. 
 
Methyl 2-(prop-2-en-1-yl)azetidine-2-carboxylate 63b 
General procedure F was followed using Boc-protected amino ester 
62b (1.93 g, 7.53 mmol). Purification by SCX cartridge, eluting first 
with MeOH then sat. NH3/MeOH, gave the title compound 63b 
(771 mg, 4.97 mmol, 66%) as an orange oil. 1H NMR (500 MHz, CDCl3, NH not 
observed): δ 5.80-5.68 (1H, m, CH=CH2), 5.14-5.07 (2H, m, CH=CH2), 3.78 (3H, 
s, CO2CH3), 3.51 (1H, app. q, J 7.9, 4-HA), 3.37-3.31 (1H, m, 4-HB), 2.63-2.51 
(2H, m, CH2CH=CH2), 2.49-2.39 (2H, m, 3-H). 13C NMR (125 MHz, CDCl3): 
δ 176.6 (CO2CH3), 132.2 (CH=CH2), 118.5 (CH=CH2), 67.4 (2-C), 52.3 (CO2CH3), 
43.8 (CH2CH=CH2), 41.5 (4-C), 30.0 (3-C). IR νmax(film)/cm−1 3329, 2954, 2879, 
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1732 (CO), 1436, 1266, 1216, 1140. HRMS (EI): C8H13NO2 [M]+; calculated 
155.0945, found 155.0946. 
 
1-Benzyl 3-methyl 3-(prop-2-en-1-yl)piperazine-1,3-dicarboxylate 63c 
General procedure F was followed using Boc-protected amino 
ester 62c (3.37 g, 8.05 mmol). Purification by SCX cartridge, 
eluting first with MeOH then sat. NH3/MeOH, gave the title 
compound 63c (2.19 g, 6.88 mmol, 85%) as a colourless oil. 
Rf 0.18 (3:2 pentane–EtOAc). 1H NMR (500 MHz, d6-DMSO, 
340 K): δ 7.41-7.28 (5H, m, Cbz Ar-H), 5.74-5.64 (1H, m, 
CH=CH2), 5.13-5.03 (4H, m, CH2Ph and CH=CH2), 4.19 (1H, d, J 12.8, 3-HA), 
3.70 (1H, d, J 12.5, NCHAHBCH2N), 3.58 (3H, s, CO2CH3), 3.00-2.92 (1H, m, 
NCHAHBCH2N), 2.90 (1H, d, J 12.8, 3-HB), 2.80-2.74 (1H, m, NCHAHBCH2N), 
2.73-2.66 (1H, m, NCHAHBCH2N), 2.65 (1H, br. s, NH), 2.32 (1H, dd, J 13.8, 7.2, 
CHAHBCH=CH2), 2.25 (1H, dd, J 13.8, 7.5, CHAHBCH=CH2). 13C NMR (125 MHz, 
d6-DMSO, 340 K): δ 173.2 (CO2CH3), 154.1 (N(CO)O), 136.7 (Ar-Cq), 131.7 
(CH=CH2), 128.0 (Ar-C), 127.4 (Ar-C), 127.0 (Ar-C), 118.4 (CH=CH2), 65.9 
(CH2Ph), 61.1 (2-C), 51.1 (CO2CH3), 49.0 (3-C), 43.2 (NCH2CH2), 41.0 
(CH2CH=CH2 or NCH2CH2N), 40.8 (CH2CH=CH2 or NCH2CH2N). 
IR νmax(film)/cm−1 3564, 3339, 2951, 1731 (CO), 1704 (CO), 1434, 1358, 1229, 
1122, 761. HRMS (ESI): C17H23N2O4 [MH+]; calculated 319.1652, found 
319.1658. 
 
Methyl 2-amino-2-benzylpent-4-enoate 63d 
Benzaldehyde (1.2 mL, 12 mmol, 1.0 eq.) was added to a stirred 
suspension of L-phenylalanine methyl ester hydrochloride (2.5 g, 
12 mmol, 1.0 eq.), Et3N (1.6 mL, 12 mmol, 1.0 eq.) and 4 Å MS 
(500 mg) in THF (60 mL). The reaction mixture was stirred for 15 h, 
then filtered to remove the insoluble Et3N•HCl and concentrated in vacuo to give 
the crude imine as a pale yellow oil. The residue was diluted in THF (60 mL) and 
LiHMDS (1.0 M in THF, 17.4 mL, 17.4 mmol, 1.50 eq.) was added dropwise at 
−78 °C. The reaction mixture was stirred for 15 min then allyl bromide (1.50 mL, 
17.4 mmol, 1.50 eq.) was added dropwise. After 1 h the dry-ice bath was 
removed, the reaction mixture was warmed to rt and stirred for 15 h. Aqueous 
citric acid (15 wt%, 100 mL) was added and the reaction mixture was stirred for 
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1 h, then partitioned with Et2O (100 mL). The aqueous layer was neutralised with 
solid NaHCO3, then extracted with CH2Cl2 (3 × 50 mL). The combined organics 
were dried over Na2SO4 and concentrated in vacuo. The title compound 63d 
(2.26 g, 10.3 mmol, 89%) was isolated as a yellow oil after flushing through a pad 
of silica with EtOAc–MeOH (9:1). Rf 0.14 (4:1 pentane–EtOAc). 1H NMR 
(300 MHz, CDCl3, NH2 not observed): δ 7.24-7.10 (3H, m, Ar-H), 7.10-7.02 (2H, 
m, Ar-H), 5.70-5.54 (1H, m, CH=CH2), 5.15-5.05 (2H, m, CH=CH2), 3.62 (3H, s, 
CO2CH3), 3.11 (1H, d, J 13.2, CHAHBPh), 2.71 (1H, d, J 13.2, CHAHBPh), 2.65 
(1H, ddt, J 13.4, 6.4, 1.2, CHAHBCH=CH2), 2.24 (1H, dd, J 13.4, 8.5, 
CHAHBCH=CH2). 13C NMR (75 MHz, CDCl3): δ 176.6 (CO2CH3), 136.2 (Ar-Cq), 
132.6 (CH=CH2), 129.9 (Ar-C), 128.5 (Ar-C), 127.1 (Ar-C), 119.9 (CH=CH2), 62.0 
(Cq), 52.1 (CO2CH3), 45.9 (CH2Ph), 44.6 (CH2CH=CH2). IR νmax(film)/cm−1 3378, 
2951, 1738 (CO), 1603, 1441, 1218, 1030, 922. HRMS C13H18NO2 [M+H]+; 
calculated 220.1332, found 220.1340. Spectra consistent with the literature 
values.211 
 
Methyl 2-amino-2-(prop-2-en-1-yl)pent-4-enoate 63e 
Et3N (5.6 mL, 40 mmol, 1.0 eq.) was added to a stirred solution of 
glycine methyl ester hydrochloride (5.0 g, 40 mmol, 1.0 eq.), 
benzaldehyde (4.1 mL, 40 mmol, 1.0 eq.) and 4 Å MS (1.5 g). The 
reaction mixture was stirred for 4 h, filtered, then concentrated in vacuo to give 
the crude α-imino ester (6.3 g, 62% mass recovery). A sample of the crude 
residue (2.5 g, 16 mmol, 1.0 eq.) was dissolved in THF (70 mL) and cooled to 
−78 °C. LiHMDS (1.0 M in THF, 34 mL, 34 mmol, 2.2 eq.) was added dropwise. 
The reaction mixture was stirred for 20 min then allyl bromide (3.7 mL, 42 mmol, 
2.7 eq.) was added dropwise. The reaction mixture was stirred for 1 h then 
warmed to rt. Aq. citric acid (5 wt%, 100 mL) was added and the reaction mixture 
was stirred for 2 h. Et2O (50 mL) was added and the phases were separated. The 
aqueous phase was neutralised with solid NaHCO3 then extracted with CH2Cl2 
(3 × 20 mL). The combined organic extracts were dried over MgSO4, filtered, then 
concentrated in vacuo to give the title compound 63e (1.35 g, 7.98 mmol, 51%) 
as an orange oil which was not purified further. 1H NMR (300 MHz, CDCl3, NH2 
not observed): δ 5.78-5.60 (2H, m, CH=CH2), 5.19-5.08 (4H, m, CH=CH2), 3.71 
(3H, s, CO2CH3), 2.56 (2H, dd, J 13.5, 6.5, CHAHBCH=CH2), 2.26 (2H, dd, J 13.5, 
8.4, CHAHBCH=CH2). 13C NMR (75 MHz, CDCl3): δ 176.9 (CO2CH3), 
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132.6 (CH=CH2), 119.7 (CH=CH2), 60.7 (Cq), 52.3 (CO2CH3), 44.2 
(CH2CH=CH2). IR νmax(film)/cm−1 3380 (NH2), 3078, 2980, 2952, 1738 (CO), 
1640, 1440, 1213. HRMS (ESI): C9H16NO2 [M+H]+; calculated 170.1176, found 
170.1198. 
 
Methyl (4R*,6R*)-6-(iodomethyl)-2-oxo-4-(prop-2-en-1-yl)-1,3-oxazinane-4-
carboxylate 68e 
Boc2O (1.0 g, 4.6 mmol, 1.0 eq.) was added to a stirred solution of 
amino ester 63e (775 mg, 4.60 mmol, 1.00 eq.) in THF (15 mL). The 
reaction mixture was stirred at rt for 15 h then concentrated 
in vacuo. General procedure G was then followed to give the title 
compound 68e (1.3 g, 3.8 mmol, 85%, dr 89:11) as a colourless amorphous solid 
which was not purified further. Rf 0.14 (4:1 pentane–EtOAc). 1H NMR (500 MHz, 
CDCl3, dr 89:11, major diastereomer peaks assigned): δ 5.66-5.55 (1H, m, 
CH=CH2), 5.48 (1H, s, NH), 5.29 (1H, d, J 9.9, CH=CHAHB), 5.25 (1H, dd, J 17.0, 
0.7, CH=CHAHB), 4.15-4.07 (1H, m, 6-H), 3.80 (3H, s, CO2CH3), 3.36 (1H, dd, 
J 10.7, 4.5, CHAHBI), 3.28 (1H, dd, J 10.7, 6.5, CHAHBI), 2.73-2.66 (2H, m, 
CHAHBCH=CH2 and 5-HA), 2.38 (1H, dd, J 13.7, 8.8, CHAHBCH=CH2), 1.73 (1H, 
dd, J 13.8, 11.8, 5-HB). Minor diastereomer characteristic peaks: δ 5.69 (1H, s, 
NH), 5.19 (1H, d, J 16.6, CH=CHAHB), 4.45-4.33 (1H, m, 6-H). 13C NMR 
(125 MHz, CDCl3, major diastereomer peaks assigned): δ 172.6 (CO2CH3), 151.9 
(2-C), 129.4 (CH=CH2), 122.4 (CH=CH2), 73.8 (6-C), 60.4 (4-C), 53.4 (CO2CH3), 
44.2 (CH2CH=CH2), 35.5 (5-C), 5.5 (CH2I). IR νmax(film)/cm−1 3251, 3130, 2953, 
2158, 1709, 1397, 1264, 1222. HRMS (ESI): C10H15INO4 [M+H]+; calculated 
340.0040, found 340.0040. 
 
Methyl (4R*,6R*)-2-oxo-6-[(phenylsulfanyl)methyl]-4-(prop-2-en-1-yl)-1,3-
oxazinane-4-carboxylate 69e 
Thiophenol (150 μL, 1.46 mmol, 1.30 eq.) and DBU (240 μL, 
1.60 mmol, 1.40 eq.) were added to a stirred solution of iodide 
68e (451 mg, 1.12 mmol, 1.00 eq.) in DMF (13 mL). The reaction 
mixture was diluted in EtOAc (150 mL), washed with H2O (50 mL) 
and brine (50 mL). The organic phase was dried over Na2SO4, filtered then 
concentrated in vacuo. Flash chromatography eluting with 0-100% EtOAc in 
pentane gave the title compound 69e (289 mg, 0.899 mmol, 80%, dr 93:7) as a 
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colourless amorphous solid. Rf 0.10 (3:2 petrol–EtOAc). M.p. 116-117 °C, 
colourless needles, hexane–EtOAc. 1H NMR (500 MHz, CDCl3, dr 93:7, major 
diastereomer peaks assigned): δ 7.42-7.37 (2H, m, Ar-H), 7.33-7.28 (2H, m, 
Ar-H), 7.27-7.22 (1H, m, Ar-H), 5.64-5.53 (1H, m, CH=CH2), 5.50 (1H, s, NH), 
5.26 (1H, d, J 10.1, CH=CHAHB), 5.21 (1H, dd, J 16.9, 1.1, CH=CHAHB), 4.21-4.14 
(1H, m, 6-H), 3.70 (3H, s, CO2CH3), 3.34 (1 H, dd, J 14.0, 4.4, CHAHBSPh), 
2.95 (1H, dd, J 14.0, 8.4, CHAHBSPh), 2.77 (1H, dt, J 13.9, 1.8, 5-HA), 2.67 (1H, 
dd, J 13.7, 6.0, CHAHBCH=CH2), 2.34 (1H, dd, J 13.7, 8.9, CHAHBCH=CH2), 
1.67 (1H, dd, J 13.9, 12.0, 5-HB). Minor diastereomer characteristic peaks: 
5.17 (1H, d, J 10.0, CH=CHAHB), 5.10 (1H, dd, J 17.3, 1.3, CH=CHAHB), 
4.43-4.36 (1H, m, 6-H), 3.40 (1H, dd, J 14.0, 4.5, CHAHBSPh), 3.10 (1H, dd, 
J 14.0, 7.4, CHAHBSPh), 2.54-2.40 (3H, m), 1.96 (1H, dd, J 14.3, 11.3). 13C NMR 
(75 MHz, CDCl3, major diastereomer peaks assigned): δ 172.6 (CO2CH3), 152.7 
(2-C), 134.5 (Ar-Cq), 130.9 (CH=CH2), 129.7 (Ar-C), 129.3 (Ar-C), 127.3 (Ar-C), 
121.9 (CH=CH2), 73.9 (6-C), 60.7 (4-C), 53.1 (CO2CH3), 43.9 (CH2CH=CH2), 
38.3 (CH2SPh), 33.8 (5-C). IR νmax(film)/cm−1 3245, 3121, 1711 (CO), 1403, 1288, 
1221, 1089, 742. HRMS (ESI): C16H19NNaO4S [M+Na]+; calculated 344.0927, 
found 344.0934. 
 
Methyl (3R*,4aR*)-3-(azidomethyl)-1-oxo-hexahydro-1H-pyrrolo[1,2-
c][1,3]oxazine-4a-carboxylate 70a 
General procedure G was followed using Boc-carbamate 62a 
(200 mg, 0.740 mmol). Flash chromatography eluting with 0-100% 
EtOAc in pentane gave the title compound 70a (99 mg, 0.39 mmol, 
53%, 95:5 mixture of diastereomers) as a yellow oil. Rf 0.05 (1:1 petrol–EtOAc). 
1H NMR (500 MHz, CDCl3): δ 4.30-4.21 (1H, m, 3-H), 3.79 (3H, s, CO2CH3), 
3.77-3.71 (1H, m, 7-HA), 3.67-3.61 (1H, m, 7-HB), 3.57 (1H, dd, J 13.0, 4.6, 
CHAHBN3), 3.46 (1H, dd, J 13.0, 4.5, HCHAHBN3), 2.63 (1H, dd, J 13.5, 2.6, 4-HA), 
2.55-2.43 (1H, m, 5-HA), 2.07-1.96 (1H, m, 6-HA), 1.90-1.79 (2H, m, 5-HB and 
6-HB), 1.74 (1H, dd, J 13.5, 12.3, 4-HB). 13C NMR (125 MHz, CDCl3): δ 173.5 
(CO2CH3), 151.5 (1-C), 74.1 (3-C), 67.1 (4a-C), 54.1 (CH2N3), 53.6 (CO2CH3), 
47.4 (7-C), 38.5 (5-C), 33.9 (4-C), 21.7 (6-C). IR νmax(film)/cm−1 2955, 2898, 2106 
(N3), 1738 (CO), 1416, 1302, 1210, 1171. HRMS (ESI): C10H15N4O4 [M+H]+; 
calculated 255.1093, found 255.1088. X-Ray Crystallography: CCDC 1008922 
contains the supplementary crystallographic data for this compound. Crystals 
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were grown by slow diffusion of Et2O into the sample dissolved in the minimum 
amount of CHCl3. 
 
Methyl (4R*,6R*)-4-(azidomethyl)-2-oxo-3-oxa-1-azabicyclo[4.2.0]octane-6-
carboxylate 70b 
Following a procedure by Licini,102 NIS (160 mg, 0.710 mmol, 
1.20 eq.) was added to a stirred solution of Boc-carbamate 62b 
(150 mg, 0.560 mmol, 1.00 eq.) in CHCl3 (6.0 mL). The reaction 
mixture was stirred for 4 days and monitored by TLC until complete. The reaction 
mixture was concentrated in vacuo, extracted with EtOAc (25 mL) and washed 
with sat. aq. Na2S2O3 until colourless. The aqueous layer was extracted with 
EtOAc (2 × 25 mL). The combined organics were dried over Na2SO4, filtered, 
then concentrated in vacuo to give the crude iodide. The iodide was dissolved in 
DMF (6.0 mL). NaN3 (114 mg, 1.76 mmol, 3.0 eq.) was added and the reaction 
mixture was stirred for 48 h. H2O (25 mL) was added at 0 °C. The reaction mixture 
was extracted with EtOAc (3 × 25 mL). The combined organic extracts were 
washed with brine (25 mL), dried over Na2SO4, filtered, then concentrated 
in vacuo. Flash chromatography eluting with 0-100% EtOAc in pentane gave 
co-elution of the title compound with succinimide. Trituration of the residue with 
Et2O gave the title compound 70b (53 mg, 0.22 mmol, 37%) as a colourless solid. 
Rf 0.09 (4:1 pentane–EtOAc). 1H NMR (500 MHz, CDCl3): δ 4.44-4.37 (1H, m, 
4-H), 4.33-4.25 (1H, m, 8-HA), 4.15 (1H, td, J 9.6, 4.8, 8-HB), 3.87 (3H, s, 
CO2CH3), 3.56 (1H, dd, J 13.1, 4.5, CHAHBN3), 3.45 (1H, dd, J 13.1, 4.5, 
CHAHBN3), 2.72-2.58 (2H, m, 7-H), 2.48 (1H, dd, J 13.5, 2.2, 5-HA), 2.02 (1H, dd, 
J 13.5, 11.9, 5-HB). 13C NMR (125 MHz, CDCl3): δ 172.3 (CO2CH3), 154.0 (2-C), 
75.9 (4-C), 69.3 (6-C), 53.9 (CH2N3), 53.4 (CO2CH3), 50.3 (8-C), 33.3 (7-C), 31.6 
(5-C). IR νmax(film)/cm−1 2959, 2107 (N3), 1713 (CO), 1392, 1293, 1208, 1155, 
762. HRMS (ESI): C9H13N4O4 [M+H]+; calculated 241.0931, found 241.0930. 
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2-Benzyl 9a-methyl (8R*,9aS*)-8-(azidomethyl)-6-oxo-
octahydropiperazino[1,2-c][1,3]oxazine-2,9a-dicarboxylate 70c 
General procedure G was followed using 
Boc-carbamate 62c (314 mg, 0.750 mmol). Flash 
chromatography eluting with 0-100% EtOAc in pentane 
gave the title compound 70c (195 mg, 0.480 mmol, 
64%, 93:7 mixture of diastereomers) as a brown oil. 
Rf 0.04 (4:1 petrol–EtOAc). 1H NMR (500 MHz, d6-DMSO, 319 K, major 
diastereomer peaks assigned): δ 7.42-7.29 (5H, m, Cbz Ar-H), 5.12 (1H, d, J 12.7, 
CHAHBPh), 5.08 (1H, d, J 12.7, CHAHBPh), 4.55 (1H, dd, J 13.4, 1.7, 1-HA), 
4.34-4.28 (1H, m, 8-H), 4.13-4.07 (1H, m, NCHAHBCH2N), 4.03-3.97 (1H, m, 
NCHAHBCH2N), 3.66 (3H, s, CO2CH3), 3.61 (1H, dd, J 13.5, 3.2, CHAHBN3), 3.44 
(1H, dd, J 13.5, 5.3, CHAHBN3), 3.01 (1H, d, J 13.4, 1-HB), 2.98-2.86 (2H, m, 
NCHAHBCH2N and NCHAHBCH2N), 2.26 (1H, dd, J 14.0, 2.6, 9-HA), 2.02 (1H, dd, 
J 14.0, 12.4, 9-HB). 13C NMR (125 MHz, d6-DMSO, 319 K): δ 170.8 (CO2CH3), 
153.7 (N(CO)O), 151.0 (N(CO)O), 136.4 (Ar-Cq), 128.2 (Ar-C), 127.7 (Ar-C), 
127.3 (Ar-C), 71.8 (8-C), 66.4 (CH2Ph), 61.6 (9a-C), 53.0 (CO2CH3), 52.8 
(CH2N3), 49.9 (1-C), 42.4 (NCH2CH2N), 41.0 (NCH2CH2N), 30.8 (9-C). 
IR νmax(film)/cm−1 2953, 2107 (N3), 1741 (CO), 1701 (CO), 1432, 1421, 1280, 
1230. HRMS (ESI): C18H22N5O6 [M+H]+; calculated 404.1565, found 404.1580. 
 
Methyl (4R*,6R*)-6-(azidomethyl)-4-benzyl-2-oxo-1,3-oxazinane-4-
carboxylate 70d  
General procedure G was followed using Boc-carbamate 62d 
(100 mg, 0.310 mmol). The residue was washed through a pad 
of silica with EtOAc–MeOH (9:1) to give the title compound 70d 
(84 mg, 0.28 mmol, 88%, 87:13 mixture of diastereomers) as a 
yellow oil. Rf 0.08 (3:2 petrol–EtOAc). 1H NMR (500 MHz, CDCl3, dr 87:13, 
diastereomers assigned by NOESY) major diastereomer peaks: δ 7.37-7.30 (3H, 
m, Ar-H), 7.13-7.07 (2H, m, Ar-H), 5.42 (1H, br. s, NH), 4.29-4.22 (1H, m, 6-H), 
3.73 (3H, s, CO2CH3), 3.55 (1H, dd, J 13.2, 4.4, CHAHBN3), 3.45 (1H, dd, J 13.2, 
4.7, CHAHBN3), 3.31 (1H, d, J 13.4, CHAHBPh), 2.90 (1H, d, J 13.4, CHAHBPh), 
2.51 (1H, app. dt, J 13.9, 2.0, 5-HA), 1.94 (1H, dd, J 13.9, 12.2, 5-HB). Minor 
diastereomer characteristic peaks: 5.55 (1H, br. s, NH), 4.43-4.37 (1H, m, 6-H), 
3.74 (3H, s, CO2CH3), 3.58-3.47 (2H, m, CH2N3), 3.14 (1H, d, J 13.3, CHAHBPh), 
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3.04 (1H, d, J 13.3, CHAHBPh), 2.30 (1H, ddd, J 14.3, 2.5, 1.3, 5-HA), 2.14 (1H, 
dd, J 14.3, 11.6, 5-HB). 13C NMR (125 MHz, CDCl3, peaks of major diastereomer 
assigned): δ 172.6 (CO2CH3), 151.9 (2-C), 133.0 (Ar-Cq), 129.9 (Ar-C), 129.3 
(Ar-C), 128.3 (Ar-C), 73.6 (6-C), 61.9 (4-C), 53.7 (CH2N3), 53.2 (CO2CH3), 46.2 
(CH2Ph), 33.0 (5-C). IR νmax(film)/cm−1 3247, 2927, 2105 (N3), 1713 (CO), 1435, 
1403, 1284, 1214. HRMS (ESI): C14H16N4NaO4 [M+Na]+; calculated 327.1064, 
found 327.1076. The relative configuration of the minor diastereomer was 
determined by interpretation of the NOESY correlations. 
 
 
Methyl (4R*,6R*)-6-(azidomethyl)-2-oxo-4-(prop-2-en-1-yl)-1,3-oxazinane-4-
carboxylate 70e 
General procedure G was followed for iodide 68e (200 mg, 
0.49 mmol). Flash chromatography eluting with pentane−EtOAc 
(3:2) gave the title compound 70e (97 mg, 0.38 mmol, 78%, dr 
91:9) as a yellow oil. Rf 0.05 (3:2 petrol–EtOAc). 1H NMR 
(500 MHz, CDCl3, dr 91:9, major diastereomer peaks assigned): δ 5.67 (1H, s, 
NH), 5.65-5.56 (1H, m, CH=CH2), 5.28 (1H, d, J 10.1, CH=CHAHB), 5.24 (1H, dd, 
J 16.9, 1.1, CH=CHAHB), 4.35-4.23 (1H, m, 6-H), 3.79 (3H, s, CO2CH3), 3.55 (1H, 
dd, J 13.1, 4.4, CHAHBN3), 3.45 (1H, dd, J 13.1, 4.7, CHAHBN3), 2.68 (1H, dd, 
J 13.7, 6.1, CHAHBCH=CH2), 2.44-2.36 (2H, m, 5-HA and CHAHBCH=CH2), 1.84 
(1H, dd, J 13.9, 12.2, 5-HB). Minor diastereomer characteristic peaks: 5.78 (1H, 
s, NH), 5.18 (1H, dd, J 16.9, 1.4, CH=CHAHB), 4.52-4.46 (1H, m, 6-H), 3.80 (3H, 
s, CO2CH3), 3.36 (1H, dd, J 10.7, 4.5, CHAHBN3), 3.28 (1H, dd, J 10.7, 6.4, 
CHAHBN3), 2.59-2.50 (2H, m), 2.18 (1H, ddd, J 14.2, 3.0, 1.3, CHAHBCH=CH2), 
2.11 (1H, dd, J 14.2, 11.2, CHAHBCH=CH2), 1.73 (1H, dd, J 13.9, 11.8, 5-HB). 
13C NMR (75 MHz, CDCl3): δ 172.6 (CO2CH3), 152.5 (2-C), 129.7 (CH=CH2), 
121.9 (CH=CH2), 73.5 (6-C), 60.4 (4-C), 53.7 (CO2CH3), 53.2 (CH2N3), 43.8 
(CH2CH=CH2), 31.6 (5-C). IR νmax(film)/cm−1 3252, 2954, 2106 (N3), 1715 (CO), 
1403, 1291, 1224, 1109. HRMS (ESI): C10H15N4O4 [M+H]+; calculated 255.1093, 
found 255.1088. 
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2-Ethyl 4a-methyl (3R*,4aR*)-3-(azidomethyl)-1-oxo-octahydropyrrolo[1,2-
c]pyrimidine-2,4a-dicarboxylate 82a 
General procedures H and I were followed using amino ester 63a 
(1.1 g, 6.7 mmol). Flash chromatography on cyanosilica eluting with 
a gradient of 0-100% EtOAc in pentane gave the title 
compound 82a (1.17 g, 3.60 mmol, 54%) as a colourless oil. Rf 0.11 
(1:1 pentane–EtOAc). 1H NMR (500 MHz, CDCl3): δ 4.34-4.20 (3H, m, CH2CH3 
and 3-H), 3.75-3.67 (5H, includes 2H, m, 7-H and at δ 3.72: 3H, s, CO2CH3), 3.65 
(1H, dd, J 12.3, 5.6, CHAHBN3), 3.50 (1H, dd, J 12.3, 2.9, CHAHBN3), 2.89 (1H, 
dd, J 13.2, 8.5, 4-HA), 2.37-2.30 (1H, m, 5-HA), 2.06-1.92 (3H, m, 5-HB and 6-H), 
1.83 (1H, dd, J 13.2, 9.7, 4-HB), 1.31 (3H, t, J 7.1, CH2CH3). 13C NMR (125 MHz, 
CDCl3): δ 173.1 (CO2CH3), 154.3 (CO), 150.4 (CO), 65.8 (4a-C), 
63.1 (OCH2CH3), 54.5 (CH2N3), 53.1 (CO2CH3), 52.5 (3-C), 46.7 (7-C), 38.1 
(5-C), 37.6 (4-C), 22.8 (6-C), 14.5 (OCH2CH3). IR νmax(film)/cm−1 3597, 3507, 
2981, 2106 (N3), 1708 (CO), 1420, 1296, 1018. HRMS (ESI): C13H20N5O5 [M+H]+; 
calculated 326.1459, found 326.1462. 
 
3-Ethyl 6-methyl (4R*,6R*)-4-(azidomethyl)-2-oxo-1,3-
diazabicyclo[4.2.0]octane-3,6-dicarboxylate 82b 
General procedures H and I were followed using amino ester 63b 
(150 mg, 0.970 mmol, 1.00 eq.). Flash chromatography eluting with 
a gradient of 0-100% EtOAc in pentane gave the title compound 
82b (98 mg, 0.31 mmol, 32%, 97:3 mixture of diastereomers) as a 
pale yellow oil. Rf 0.17 (1:1 pentane–EtOAc). 1H NMR (500 MHz, CDCl3): 
δ 4.32-4.19 (3H, m, CH2CH3 and 4-H), 4.16 (1H, td, J 9.4, 6.8, 8-HA), 4.05 (1H, 
td, J 9.4, 5.7, 8-HB), 3.82-3.76 (4H, m, includes 1H, m, CHAHBN3 and at δ 3.80: 
3H, s, CO2CH3), 3.53 (1H, dd, J 12.4, 2.5, CHAHBN3), 2.75-2.68 (1H, m, 7-HA), 
2.63 (1H, dd, J 13.6, 6.5, 5-HA), 2.42-2.34 (1H, m, 7-HB), 2.25 (1H, dd, J 13.6, 
11.7, 5-HB), 1.31 (3H, t, J 7.1, CH2CH3). 13C NMR (125 MHz, CDCl3): δ 171.4 
(CO2CH3), 153.8 (CO), 153.3 (CO), 68.5 (6-C), 63.2 (OCH2CH3), 55.1 (4-C), 54.0 
(CH2N3), 53.2 (CO2CH3), 47.2 (8-C), 35.9 (5-C), 28.8 (7-C), 14.4 (OCH2CH3). 
IR νmax(film)/cm−1 2978, 2108 (N3), 1712 (CO), 1390, 1372, 1289, 1245, 1033. 
HRMS (ESI): C12H18N5O5 [M+H]+; calculated 312.1303, found 312.1307. 
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2-Benzyl 7-ethyl 9a-methyl (8R*,9aS*)-8-(azidomethyl)-6-oxo-octahydro-1H-
pyrimido[1,6-a]piperazine-2,7,9a-tricarboxylate 82c 
General procedures H and I were followed using amino 
ester 63c (150 mg, 0.470 mmol, 1.00 eq.). Flash 
chromatography eluting with a gradient of 0-100% 
EtOAc in pentane gave the title compound 82c (98 mg, 
0.21 mmol, 44%) as a pale yellow oil. Rf 0.15 
(1:1 pentane–EtOAc). 1H NMR (500 MHz, d6-DMSO, 
348 K): δ 7.40-7.30 (5H, m, Cbz Ar-H), 5.11 (2H, s, CH2Ph), 4.33-4.26 (1H, m, 
8-H), 4.22 (1H, d, J 13.8, 1-HA), 4.17 (2H, q, J 7.1, CH2CH3), 3.91-3.79 (2H, m, 
NCHAHBCH2N and NCHAHBCH2N), 3.62-3.57 (4H, m, includes 1H, m, CHAHBN3 
and at δ 3.59: 3H, s, CO2CH3), 3.49 (1H, dd, J 12.7, 5.5, CHAHBN3), 3.35 (1H, d, 
J 13.8, 1-HB), 3.35 (1H, d, J 13.9, NCHAHBCH2N) 3.33-3.25 (1H, m, 
NCHAHBCH2N), 2.57 (1H, dd, J 14.1, 8.5, 9-HA), 1.96 (1H, dd, J 14.1, 6.7, 9-HB), 
1.22 (3H, t, J 7.1, CH2CH3). 13C NMR (125 MHz, d6-DMSO, 348 K): δ 171.1 
(CO2CH3), 154.0 (CO), 153.0 (CO), 151.1 (CO), 136.3 (Ar-Cq), 128.0 (Ar-C), 
127.5 (Ar-C), 127.1 (Ar-C), 66.2 (CH2Ph), 61.9 (OCH2CH3), 60.9 (9a-C), 
53.0 (CH2N3), 52.4 (CO2CH3), 50.1 (8-C), 48.0 (1-C), 42.4 (NCH2CH2N), 38.6 
(NCH2CH2N), 33.5 (9-C), 13.6 (OCH2CH3). IR νmax(film)/cm−1 2106 (N3), 1740 
(CO), 1705 (CO), 1416, 1290, 1226, 1145, 769. HRMS (ESI): C21H27N6O7 [M+H]+; 
calculated 475.1936, found 475.1950. 
 
(3R*,4aR*)-3-(Azidomethyl)-1-oxo-octahydropyrrolo[1,2-c]pyrimidine-4a-
carboxylic acid 83a 
NaOH (14 mg, 0.35 mmol, 2.2 eq.) was added to a solution of urea 
82a (50 mg, 0.15 mmol, 1.0 eq.) in MeOH (0.3 mL) and the reaction 
mixture was stirred for 2 h by which point a colourless precipitate 
had formed. The reaction mixture was diluted with MeOH (10 mL), then Amberlite 
IR-120 (hydrogen form, 94 mg) was added at 0 °C. The reaction mixture was 
stirred for 0.5 h, then filtered through celite and concentrated in vacuo. The 
resulting residue was triturated with CHCl3 to give the title compound 83a (37 mg, 
0.15 mmol, 99%) as a colourless solid. 1H NMR (500 MHz, d6-DMSO, 343 K, 
CO2H not observed): δ 6.13 (1H, s, NH), 3.52-3.41 (2H, m, CHAHBN3, 7-HA), 
3.40-3.29 (3H, m, CHAHBN3, 3-H, 7-HB), 2.46-2.40 (1H, m, 4-HA), 2.34-2.28 (1H, 
m, 5-HA), 1.89-1.76 (2H, m, 5-HB and 6-HA), 1.75-1.63 (1H, m, 6-HB), 1.46 (1H, 
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app. t, J 12.2, 4-HB). 13C NMR (125 MHz, d6-DMSO): δ 175.1 (CO2H), 153.8 (1-C), 
65.6 (4a-C), 53.5 (CH2N3), 48.5 (3-C), 44.9 (7-C), 37.4 (5-C), 33.6 (4-C), 21.1 
(6-C). IR νmax(film)/cm−1 3265, 2105 (N3), 1685 (CO), 1530, 1453, 1308, 1233, 
1078. HRMS (ESI): C9H14N5O3 [M+H]+; calculated 240.1091, found 240.1091. 
X-Ray Crystallography: CCDC 1008923 contains the supplementary 
crystallographic data for this compound. Crystals were grown by slow diffusion of 
Et2O into the sample dissolved in the minimum amount of CHCl3. 
 
2-Benzyl 9a-methyl (8R*,9aS*)-8-(azidomethyl)-6-oxo-octahydro-1H-
pyrimido[1,6 a]piperazine-2,9a-dicarboxylate 84c 
NaOMe (25 wt% in MeOH, 18 µL, 80 µmol, 1.0 eq.) was 
added to a stirred solution of urea 82c (37 mg, 80 µmol, 
1.0 eq.) in MeOH (0.8 mL). The reaction mixture was 
stirred at rt for 0.5 h, then concentrated in vacuo. The 
residue was redissolved in MeOH (10 mL) and 
Amberlite IR-120 (hydrogen form, 50 mg) was added. After stirring for 1 h the 
reaction mixture was filtered and concentrated to give the title compound 84c 
(28 mg, 70 µmol, 88%) as a pale yellow oil. Rf 0.16 (4:1 pentane−EtOAc). 1H NMR 
(500 MHz, d6-DMSO, 319 K): δ 7.42-7.28 (5H, m, Cbz Ar-H), 6.68 (1H, s, NH), 
5.11 (1H, d, J 12.7, CHAHBPh), 5.06 (1H, d, J 12.7, CHAHBPh), 4.50 (1H, d, J 13.2, 
1-HA), 4.04 (1H, d, J 12.1, NCHAHBCH2N), 3.96 (1H, d, J 13.1, NCHAHBCH2N), 
3.60 (3H, s, CO2CH3), 3.53-3.45 (1H, m, CHAHBN3), 3.33-3.24 (2H, m, 8-H and 
CHAHBN3), 3.01-2.84 (2H, m, 1-HB and NCHAHBCH2N), 2.83-2.73 (1H, m, 
NCHAHBCH2N), 2.14 (1H, d, J 12.7, 9-HA), 1.78 (1H, app. t, J 12.7, 9-HB). 
13C NMR (125 MHz, d6-DMSO, 319 K): δ 171.5 (CO2CH3), 154.9 (CO), 
153.8 (CO), 136.5 (Ar-Cq), 128.2 (Ar-C), 127.7 (Ar-C), 127.3 (Ar-C), 66.3 
(CH2Ph), 61.3 (9a-C), 53.2 (CH2N3), 52.5 (CO2CH3), 50.2 (1-C), 46.6 (8-C), 42.8 
(NCH2CH2N), 39.3 (NCH2CH2N), 32.2 (9-C). IR νmax(film)/cm−1 2107 (N3), 1738 
(CO), 1704 (CO), 1664 (CO), 1432, 1284, 1234, 1122. HRMS (ESI): C18H23N6O5 
[M+H]+; calculated 403.1724, found 403.1728. X-Ray Crystallography: CCDC 
1008924 contains the supplementary crystallographic data for this compound. 
Crystals were grown by slow diffusion of Et2O into the sample dissolved in the 
minimum amount of CHCl3. 
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Methyl 2-benzyl-2-[(phenylcarbamoyl)amino]pent-4-enoate 86d 
Phenyl isocyanate (180 µL, 1.61 mmol, 1.05 eq.) was added to a 
stirred solution of amino ester 63d (337 mg, 1.54 mmol, 1.0 eq.) in 
PhMe (20 mL). Flash chromatography eluting with pentane–EtOAc 
(4:1) gave the title compound 86d (271 mg, 0.80 mmol, 52%) as a 
colourless solid. Rf 0.46 (4:1 pentane−EtOAc). 1H NMR (500 MHz, 
CDCl3): δ 7.32-7.18 (7H, m, Ar-H), 7.13-7.04 (3H, m, Ar-H), 6.23 (1H, 
br. s., NH), 5.75-5.61 (1H, m, CH=CH2), 5.5 (1H, br. s., NH), 5.17-5.03 (2H, m, 
CH=CH2), 3.84-3.75 (4H, m, includes 1H, m, CHAHBPh and at δ 3.78: 3H, s, 
CO2CH3), 3.42 (1H, dd, J 13.9, 7.1, CHAHBCH=CH2), 3.18 (1H, d, J 13.5, 
CHAHBPh), 2.65 (1H, dd, J 13.9, 7.6, CHAHBCH=CH2). 13C NMR (125 MHz, 
CDCl3): δ 173.8 (CO2CH3), 154.3 (CO), 138.6 (Ar-Cq), 136.6 (Ar-Cq), 132.7 
(CH=CH2), 130.0 (Ar-C), 129.4 (Ar-C), 128.4 (Ar-C), 127.0 (Ar-C), 124.0 (Ar-C), 
121.1 (Ar-C), 119.1 (CH=CH2), 65.8 (Cq), 52.7 (CO2CH3), 41.1 (CH2Ph), 40.3 
(CH2CH=CH2). IR νmax(film)/cm−1 3355, 3030, 1742 (CO), 1651 (CO), 1599, 1549, 
1497, 1441. HRMS (ESI): C20H22N2NaO3 [M+Na]+; calculated 361.1523, found 
361.1525. 
 
5-Benzyl-3-phenyl-5-(prop-2-en-1-yl)imidazolidine-2,4-dione 87d 
To a solution of urea 86d (47 mg, 0.14 mmol, 1.0 eq.) in PhMe 
(1.5 mL) was added NaOtBu (14 mg, 0.14 mmol, 1.0 eq.) and 
the reaction mixture was heated at 100 °C for 15 h. The reaction 
mixture was cooled to rt then concentrated in vacuo. Flash 
chromatography eluting with 0-100% EtOAc in pentane gave the 
title compound 87d (36 mg, 0.12 mmol, 85%) as a colourless oil. 1H NMR 
(500 MHz, CDCl3): δ 7.41-7.36 (2H, m, Ar-H), 7.35-7.29 (4H, m, Ar-H), 7.24-7.18 
(2H, m, Ar-H), 6.99-6.94 (2H, m, Ar-H), 6.30 (1H, s, NH), 5.94-5.84 (1H, m, 
CH=CH2), 5.31-5.21 (2H, m, CH=CH2), 3.21 (1H, d, J 13.6, CHAHBPh), 2.96 (1H, 
d, J 13.6, CHAHBPh), 2.75 (1H, dd, J 13.9, 7.7, CHAHBCH=CH2), 2.56 (1H, dd, 
J 13.9, 7.1, CHAHBCH=CH2). 13C NMR (125 MHz, CDCl3): δ 174.2 (4-C), 155.9 
(2-C), 134.1 (Ar-Cq), 131.4 (Ar-Cq), 130.4 (2 × C; CH=CH2 and Ar-C); 129.2 
(Ar-C), 128.7 (Ar-C), 128.5 (Ar-C), 127.7 (Ar-C), 126.5 (Ar-C), 121.4 (CH=CH2), 
66.0 (5-C), 42.9 (CH2Ph), 41.1 (CH2CH=CH2). IR νmax(film)/cm−1 3290, 1778, 
1715 (CO), 1502, 1414, 1123, 919, 703. HRMS (ESI): C19H19N2O2 [M+H]+; 
calculated 307.1441, found 307.142 
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7a-(Prop-2-en-1-yl)-hexahydro-1H-pyrrolo[1,2-c]imidazolidine-1,3-dione 
88a 
General procedures H and J were followed using amino ester 63a 
(200 mg, 1.18 mmol). Purification by SCX, eluting with MeOH, gave 
the title compound 88a (200 mg, 1.11 mmol, 94%) as a colourless oil. 
1H NMR (500 MHz, CDCl3): δ 8.14 (1H, br. s, NH), 5.81-5.71 (1H, m, 
CH=CH2), 5.22-5.15 (2H, m, CH=CH2), 3.83-3.75 (1H, m, 5-HA), 3.21-3.14 (1H, 
m, 5-HB), 2.58 (1H, dd, J 14.0, 7.7, CHAHBCH=CH2), 2.41 (1H, dd, J 14.0, 6.8, 
CHAHBCH=CH2), 2.17-2.03 (2H, m, 6-H), 2.02-1.89 (2H, m, 7-H). 
13C NMR (125 MHz, CDCl3): δ 176.3 (1-C), 159.5 (3-C), 131.0 (CH=CH2), 120.6 
(CH=CH2), 73.8 (7a-C), 44.9 (5-C), 39.6 (CH2CH=CH2), 32.2 (7-C), 26.3 (6-C). 
IR νmax(film)/cm−1 3210, 3074, 2978, 1771 (CO), 1715 (CO), 1391, 1332, 1208. 
HRMS (EI): C9H12N2O2 [M]+; calculated 180.0899, found 180.0897. 
 
Benzyl 1,3-dioxo-8a-(prop-2-en-1-yl)-octahydroimidazolidino[1,5-
a]piperazine-7-carboxylate 88c 
General procedures H and J were followed using amino 
ester 63c (141 mg, 0.440 mmol). Purification by SCX, 
eluting with MeOH, gave the title compound 88c (139 mg, 
0.420 mmol, 96%). 1H NMR (500 MHz, d6-DMSO, 319 K): 
δ 10.98 (1H, s, NH), 7.42-7.28 (5H, m, Cbz Ar-H), 5.57-5.44 
(1H, m, CH=CH2), 5.18-5.03 (4H, m, CH=CH2 and CH2Ph), 4.02-3.91 (1H, m, 
NCHAHBCH2N), 3.93 (1H, d, J 13.1, 8-HA), 3.83 (1H, dd, J 13.2, 3.0, 
NCHAHBCH2N), 3.19-3.01 (1H, m, 8-HB), 2.98-2.92 (2H, m, NCHAHBCH2N and 
NCHAHBCH2N), 2.56 (1H, dd, J 14.3, 7.3, CHAHBCH=CH2), 2.34 (1H, dd, J 14.3, 
6.9, CHAHBCH=CH2). 13C NMR (125 MHz, d6-DMSO, 319 K, one Cq peak not 
observed): δ 174.1 (1-C), 154.4 (CO), 136.4 (Ar-Cq), 130.4 (CH=CH2), 128.2 
(Ar-C), 127.8 (Ar-C), 127.5 (Ar-C), 119.7 (CH=CH2), 66.7 (CH2Ph), 62.8 (8a-C), 
47.5 (8-C), 42.8 (NCH2CH2N), 35.8 (NCH2CH2N), 34.0 (CH2CH=CH2). 
IR νmax(film)/cm−1 3199, 1772 (CO), 1708 (CO), 1455, 1428, 1353, 1267, 1244. 
HRMS (ESI): C17H20N3O4 [M+H]+; calculated 330.1448, found 330.1449. 
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8a-(Prop-2-en-1-yl)-octahydropyrrolo[1,2-a]piperazin-1-one 90a 
General procedures K and L were followed using amino ester 63a 
(400 mg, 2.36 mmol). The residue was purified by SCX, eluting first 
with MeOH then sat. NH3/MeOH, to give the title compound 90a 
(270 mg, 1.50 mmol, 62%) as a brown oil. 1H NMR (500 MHz, CDCl3): 
δ 5.95-5.84 (1H, m, CH=CH2), 5.76 (1H, br. s, NH), 5.16-5.07 (2H, m, CH=CH2), 
3.72-3.62 (1H, m, 3-HA), 3.32-3.18 (2H, m, 3-HB and 4-HA), 3.09-3.02 (1H, m, 
6-HA), 2.96-2.82 (2H, m, 4-HB and 6-HB), 2.62 (1H, dd, J 13.9, 6.6, 
CHAHBCH=CH2), 2.43 (1H, dd, J 13.9, 7.9, CHAHBCH=CH2), 2.20-2.12 (1H, m, 
8-HA), 2.01-1.93 (1H, m, 8-HB), 1.83-1.69 (2H, m, 7-H). 13C NMR (125 MHz, 
CDCl3): δ 176.3 (1-C), 134.4 (CH=CH2), 117.8 (CH=CH2), 68.4 (8a-C), 51.9 (6-C), 
43.4 (4-C), 42.6 (CH2CH=CH2), 38.5 (3-C), 34.9 (8-C), 22.8 (7-C). 
IR νmax(film)/cm−1 3218, 3074, 2944, 1655 (CO), 1487, 1447, 915, 753. 
HRMS (ESI): C10H17N2O [M+H]+; calculated 181.1341, found 181.1335. 
 
6-(Prop-2-en-1-yl)-1,4-diazabicyclo[4.2.0]octan-5-one 90b 
General procedures K and L were followed using the TFA salt of the 
amino ester 63b (404 mg, 1.50 mmol). Flash chromatography on 
eluting with a gradient of 0-100% EtOAc in pentane containing 1% Et3N 
gave the title compound 90b (54 mg, 0.32 mmol, 22%) as a pale yellow 
oil. Rf 0.19 (1:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3): δ 6.97 (1H, br. s, NH), 
5.83-5.72 (1H, m, CH=CH2), 5.29-5.19 (2H, m, CH=CH2), 4.39-4.32 (1H, m, 
8-HA), 4.28-4.20 (1H, m, 8-HB), 3.47-3.34 (2H, m, 3-H), 2.94-2.86 (1H, m, 2-HA), 
2.77-2.70 (1H, m, 2-HB), 2.52 (1H, dd, J 14.0, 7.2, CHAHBCH=CH2), 2.38 (1H, dd, 
J 14.0, 7.5, CHAHBCH=CH2), 2.29-2.19 (2H, m, 7-H). 13C NMR (125 MHz, CDCl3): 
δ 178.4 (5-C), 131.1 (CH=CH2), 121.0 (CH=CH2), 65.0 (8-C), 61.8 (6-C), 
41.6 (2-C), 40.1 (2 × C; 3-C and CH2CH=CH2), 32.1 (7-C). IR νmax(film)/cm−1 
3325 (NH), 2982, 1763 (CO), 1719, 1560, 1183, 1024, 927. HRMS (EI): 
C9H14N2O [M]+; calculated 166.1106, found 166.1133. 
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Methyl 1-(2-{[(tert-butoxy)carbonyl]amino}ethyl)-2-(prop-2-en-1- 
yl)pyrrolidine-2-carboxylate 89a 
3-Boc-1,2,3-oxathiazolidine 2,2-dioxide* (1.19 g, 5.32 mmol, 
1.20 eq.) was added to a stirred solution of the amino ester 63a 
(750 mg, 4.43 mmol, 1.00 eq.) and K2CO3 (674 mg, 4.87 mmol, 
1.10 eq.) in DMF (22 mL). The reaction mixture was stirred for 
15 h. 1 N HCl (25 mL) was added and the reaction mixture was 
stirred for 1 h. The reaction mixture was neutralised with solid 
NaHCO3. EtOAc (75 mL) was added and the phases were separated. The 
organic phase was washed with brine (25 mL), dried over MgSO4, filtered, and 
concentrated in vacuo. Purification by SCX, eluting first with MeOH then 
NH3/MeOH, gave the title compound 89a (566 mg, 1.81 mmol, 37%) as an orange 
oil. Rf 0.48 (1:4:0.05 petrol–EtOAc–Et3N). 1H NMR (500 MHz, CDCl3): δ 5.85-5.72 
(1H, m, CH=CH2), 5.16-5.03 (2H, m, CH=CH2), 4.98 (1H, br. s, NH), 3.67 (3H, s, 
CO2CH3), 3.31-3.20 (1H, m, NHCHAHB), 3.11-3.02 (2H, m, NHCHAHB and 5-HA), 
2.82-2.73 (1H, m, NHCH2CHAHB), 2.68-2.61 (1H, m, 5-HB), 2.58 (1H, dd, J 14.2, 
6.9, CHAHBCH=CH2), 2.51-2.43 (1H, m, NHCH2CHAHB), 2.31 (1H, dd, J 14.2, 7.3, 
CHAHBCH=CH2), 2.15-2.07 (1H, m, 3-HA), 1.90-1.71 (3H, m, 3-HB and 4-H), 1.44 
(9H, s, C(CH3)3). 13C NMR (125 MHz, CDCl3): δ 175.0 (CO2CH3), 156.2 
(NH(CO)O), 134.2 (CH=CH2), 118.3 (CH=CH2), 79.1 (Cq(CH3)3), 70.3 (2-C), 51.4 
(5-C), 51.1 (CO2CH3), 48.6 (NCH2CH2), 39.1 (2 peaks, CH2CH=CH2 and 
NHCH2), 34.1 (3-C), 28.6 (C(CH3)3), 22.1 (4-C). IR νmax(film)/cm−1 3076, 2821, 
1712 (CO), 1502, 1365, 1245, 1165, 754. HRMS (ESI): C16H29N2O4 [M+H]+; 
calculated 313.2122, found 313.2126. 
 
                                            
* Purchased from Sigma Aldrich. 
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Methyl 2-benzyl-2-(2-{[(tert-butoxy)carbonyl]amino}acetamido)pent-4-
enoate 97d 
Amino ester 63d (535 mg, 2.44 mmol, 1.0 eq.) was added to a 
stirred solution of N-Boc-glycine (855 mg, 4.88 mmol, 2.0 eq.), 
EDCI (936 mg, 4.88 mmol, 2.0 eq.) and Et3N (0.85 mL, 6.10 mmol, 
2.50 eq.) in CH2Cl2 (20 mL). The reaction mixture was stirred for 
15 h. Additional N-Boc-glycine (855 mg, 4.88 mmol, 2.00 eq.) and 
EDCI (936 mg, 4.88 mmol, 2.00 eq.) were added and the reaction 
mixture was stirred for 3 h, then concentrated in vacuo. The 
residue was diluted with EtOAc (50 mL) and washed with H2O (50 mL) and brine 
(50 mL). The organic layer was dried over MgSO4, filtered, then concentrated in 
vacuo. Flash chromatography eluting with pentane–EtOAc–Et3N (80:20:1) gave 
the title compound 97d (790 mg, 2.09 mmol, 86%) as a colourless oil. Rf 0.22 
(4:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.28-7.20 (3H, m, Ar-H), 7.01 
(2H, dd, J 7.9, 1.4, Ar-H), 6.66 (1H, br. s, NH), 5.65-5.55 (1H, m, CH=CH2), 
5.13-5.06 (2H, m, CH=CH2), 5.03 (1H, br. s, NH), 3.78 (3H, s, CO2CH3), 3.76-3.72 
(3H, m, includes 2H, m, CH2NHBoc and at δ 3.74: 1H, d, J 13.6, CHAHBPh), 3.38 
(1H, dd, J 13.9, 7.1, CHAHBCH=CH2), 3.14 (1H, d, J 13.6, CHAHBPh), 2.64 (1H, 
dd, J 13.9, 7.7, CHAHBCH=CH2), 1.44 (9H, s, C(CH3)3). 13C NMR (125 MHz, 
CDCl3): δ 172.9 (CO2CH3), 168.8 (NH(CO)CH2), 155.9 (NH(CO)O), 136.1 (Ar-Cq), 
132.1 (CH=CH2), 129.7 (Ar-C), 128.4 (Ar-C), 127.1 (Ar-C), 119.3 (CH=CH2), 80.1 
(Cq(CH3)3), 66.0 (Cq), 52.7 (CO2CH3), 44.9 (CH2NHBoc), 40.5 (CH2CH=CH2), 
39.6 (CH2Ph), 28.3 (C(CH3)3). IR νmax(film)/cm−1 3385, 2978, 1740 (CO), 1716 
(CO), 1679, 1514, 1448, 1367. HRMS (ESI): C20H28N2NaO5 [M+Na]+; calculated 
399.1890, found 399.1895. 
 
3-Benzyl-3-(prop-2-en-1-yl)piperazine-2,5-dione 96d 
General procedure L was followed using amide 97d (50 mg, 
0.13 mmol, 1.0 eq.). Flash chromatography eluting with a gradient 
of 0-10% MeOH in CH2Cl2 gave the title compound 96d 
(30 mg, 0.12 mmol, 93%) as a colourless solid. Rf 0.33 
(5:95 CH2Cl2–MeOH).1H NMR (500 MHz, CD3OD, 2 × NH not observed): 
δ 7.34-7.30 (3H, m, Ar-H), 7.27-7.22 (2H, m, Ar-H), 5.85-5.75 (1H, m, CH=CH2), 
5.28-5.18 (2H, m, CH=CH2), 3.46 (1H, d, J 17.9, 6-HA), 3.27 (1H, d, J 13.3, 
CHAHBPh), 2.95 (1H, dd, J 13.8, 6.6, CHAHBCH=CH2), 2.80 (1H, d, J 13.3, 
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CHAHBPh), 2.62 (1H, d, J 17.9, 6-HB), 2.43 (1H, dd, J 13.8, 7.8, CHAHBCH=CH2). 
13C NMR (125 MHz, CD3OD): δ 170.8 (CO), 168.8 (CO), 136.5 (CH=CH2), 133.1 
(Ar-Cq), 131.8 (Ar-C), 129.4 (Ar-C), 128.4 (Ar-C), 120.4 (CH=CH2), 65.4 (3-C), 
47.4 (6-C), 44.9 (CH2Ph), 44.6 (CH2CH=CH2). IR νmax(film)/cm−1 3192, 3071, 
2917, 2332, 1673 (CO), 1451, 1316, 1108. HRMS (ESI): C14H16N2NaO2 [M+Na]+; 
calculated 267.1104, found 267.1092. 
 
Methyl 2-benzyl-2-[(2-bromophenyl)formamido]pent-4-enoate 98d 
Oxalyl chloride (51 µL, 0.60 mmol, 1.2 eq.) was added to a stirred 
solution of 2-bromobenzoic acid (100 mg, 0.500 mmol, 1.00 eq.) 
and DMF (4 drops) in CH2Cl2 (3.3 mL) (CAUTION: gas 
evolution). The reaction mixture was stirred at rt for 3 h then 
concentrated in vacuo to give the crude acid chloride. The 
residue was dissolved in CH2Cl2 (3.3 mL) and amino ester 63d (110 mg, 
0.500 mmol, 1.00 eq.) and Et3N (77 µL, 0.55 mmol, 1.1 eq.) were added. The 
reaction mixture was stirred for 15 h then the reaction mixture was quenched with 
sat. aq. NaHCO3 solution (50 mL). The phases were separated and the aqueous 
phase was extracted with CH2Cl2 (2 × 50 mL). The combined organic phase was 
washed with brine (50 mL), dried over MgSO4 and concentrated in vacuo. The 
residue was filtered through a pad of silica with EtOAc to give the title 
compound 98d (200 mg, 0.50 mmol, 99%) as a colourless oil. 1H NMR (500 MHz, 
CDCl3): δ 7.49 (1H, dd, J 7.9, 1.2, Ar-H), 7.27-7.11 (6H, m, Ar-H), 7.10-7.05 (2H, 
m, Ar-H), 6.67 (1H, s, NH), 5.75-5.64 (1H, m, CH=CH2), 5.12 (1H, ddd, J 17.0, 
2.0, 1.2, CH=CHAHB), 5.05 (1H, dd, J 10.1, 2.0, CH=CHAHB), 3.86 (1H, d, J 13.6, 
CHAHBPh), 3.75 (3H, s, CO2CH3), 3.53 (1H, dd, J 13.9, 7.2, CHAHBCH=CH2), 3.19 
(1H, d, J 13.6, CHAHBPh), 2.65 (1H, dd, J 13.9, 7.6, CHAHBCH=CH2). 13C NMR 
(125 MHz, CDCl3): δ 173.2 (CO2CH3), 166.8 (CONH), 137.9 (Ar-Cq), 136.2 
(Ar-Cq), 133.8 (Ar-C), 132.4 (CH=CH2), 131.4 (Ar-C), 129.9 (Ar-C), 129.4 (Ar-C), 
128.5 (Ar-C), 127.5 (Ar-C), 127.2 (Ar-C), 119.8 (Ar-Cq-Br), 119.6 (CH=CH2), 67.0 
(Cq), 52.9 (CO2CH3), 40.7 (CH2Ph), 39.7 (CH2CH=CH2). IR νmax(film)/cm−1 3393 
(NH), 3029, 2951, 1738 (CO), 1664, 1507, 1230, 748. HRMS (ESI): C20H21BrNO3 
[M+H]+; calculated 402.0705, found 402.0699. 
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Methyl 1-[(2-bromophenyl)methyl]-2-(prop-2-en-1-yl)pyrrolidine-2-
carboxylate 100a 
General procedure M was followed using amino ester 63a 
(250 mg, 1.48 mmol). The residue was purified by SCX cartridge, 
eluting first with MeOH then sat. NH3/MeOH, to give the title 
compound 100a (392 mg, 1.16 mmol, 78%) as a colourless oil. 
Rf 0.26 (4:1 pentane–EtOAc). 1H NMR (300 MHz, CDCl3): δ 7.52 
(1H, dd, J 7.9, 1.1, Ar-H), 7.47 (1H, dd, J 7.6, 1.1, Ar-H), 7.31-7.23 (1H, m, Ar-H), 
7.09 (1H, td, J 7.6, 1.6, Ar-H), 5.96-5.78 (1H, CH=CH2), 5.14-5.06 (2H, CH=CH2), 
3.98 (1H, d, J 15.0, CHAHBAr), 3.76 (3H, s, CO2CH3), 3.67 (1H, d, J 15.0, 
CHAHBAr), 2.97 (1H, td, J 8.5, 3.5, 5-HA), 2.77-2.58 (2H, m, 5-HB and 
CHAHBCH=CH2), 2.46 (1H, dd, J 14.1, 6.6, CHAHBCH=CH2), 2.24-2.16 (1H, m, 
3-HA), 1.95-1.82 (2H, m, 3-HB and 4-HA), 1.81-1.72 (1H, m, 4-HB). 13C NMR 
(125 MHz, CDCl3): δ 174.9 (CO2CH3), 139.1 (Ar-Cq), 134.4 (CH=CH2), 
132.7 (Ar-C), 130.2 (Ar-C), 128.2 (Ar-C), 127.3 (Ar-C), 124.0 (Ar-Cq-Br), 
118.1 (CH=CH2), 70.7 (2-C), 53.2 (CH2Ar), 51.9 (5-C), 51.4 (CO2CH3), 39.7 
(CH2CH=CH2), 34.0 (3-C), 22.0 (4-C). IR νmax(film)/cm−1 2949, 1727 (CO), 1439, 
1219, 1193, 1171, 1025, 916. HRMS (ESI): C16H2179BrNO2 [M+H]+; calculated 
338.0756, found 338.0750. 
 
Methyl 1-[(2-bromophenyl)methyl]-2-(prop-2-en-1-yl)azetidine-2-
carboxylate 100b 
Method 1: General procedure M was followed using amino ester 
63b (175 mg, 1.13 mmol). The residue was purified by SCX 
cartridge, eluting first with MeOH then sat. NH3/MeOH, to give the 
title compound 100b (246 mg, 0.759 mmol, 67%) as a colourless 
oil. Method 2: To a stirred solution of the TFA salt of the amino 
ester 63b (404 mg, 1.50 mmol, 1.00 eq.) in DMF (7.5 mL) was added 
2-bromobenzyl bromide (0.01 M in THF, 0.45 mL, 0.45 mmol, 3.00 eq.) and 
K2CO3 (456 mg, 3.30 mmol, 2.20 eq.) and the reaction mixture was heated at 
60 °C for 15 h. The reaction mixture was diluted with H2O (20 mL) and extracted 
with EtOAc (2 × 20 mL). The combined organics were washed with brine (20 mL) 
then dried over MgSO4, filtered, and concentrated in vacuo. Purification by SCX 
cartridge, eluting first with MeOH then sat. NH3/MeOH, gave the title 
compound 100b (358 mg, 1.10 mmol, 74%) as a colourless oil. 1H NMR 
170 
 
 
(500 MHz, CDCl3): δ 7.51 (1H, dd, J 8.0, 1.2, Ar-H), 7.43 (1H, dd, J 7.7, 1.2, Ar-H), 
7.28-7.24 (1H, m, Ar-H), 7.08 (1H, td, J 7.7, 1.7, Ar-H), 5.84-5.74 (1H, m, 
CH=CH2), 5.17-5.07 (2H, m, CH=CH2), 3.86-3.76 (5H, m includes 2H, dd, J 14.3, 
CH2Ar and at δ 3.77: 3H, s, CO2CH3), 3.31-3.25 (1H, m, 4-HA), 3.25-3.19 (1H, m, 
4-HB), 2.71 (1H, dd, J 13.7, 7.3, CHAHBCH=CH2), 2.65 (1H, dd, J 13.7, 6.9, 
CHAHBCH=CH2), 2.58-2.51 (1H, m, 3-HA), 2.15-2.07 (1H, m, 3-HB). 13C NMR 
(125 MHz, CDCl3): δ 173.7 (CO2CH3), 138.0 (Ar-Cq), 132.9 (Ar-C or CH=CH2), 
132.8 (Ar-C or CH=CH2), 130.3 (Ar-C), 128.4 (Ar-C), 127.4 (Ar-C), 124.2 
(Ar-Cq-Br), 118.6 (CH=CH2), 72.0 (2-C), 55.6 (CH2Ar), 51.7 (CO2CH3), 50.3 (4-C), 
38.9 (CH2CH=CH2), 25.9 (3-C). IR νmax(film)/cm−1 2950, 2843, 1728 (CO), 1440, 
1214, 1146, 1025, 751. HRMS (ESI): C15H1979BrNO2 [M+H]+; calculated 
324.0594, found 324.0598. 
 
1-Benzyl 3-methyl 4-[(2-bromophenyl)methyl]-3-(prop-2-en-1-yl)piperazine-
1,3-dicarboxylate 100c 
To a stirred solution amino ester 63c (225 mg, 0.71 mmol, 
1.00 eq.) in DMF (3.6 mL) was added 2-bromobenzyl bromide 
(10.4 M in THF, 200 µL, 2.13 mmol, 3.00 eq.) and K2CO3 
(108 mg, 0.780 mmol, 1.10 eq.). The reaction mixture was 
heated at 60 °C for 24 h, then diluted with H2O (20 mL) and 
extracted with EtOAc (2 × 20 mL). The combined organics were 
washed with brine (20 mL) then dried over MgSO4, filtered, and 
concentrated in vacuo. Purification by SCX cartridge, eluting first with MeOH then 
sat. NH3/MeOH, gave the title compound 100c (288 mg, 0.591 mmol, 83%) as an 
orange oil. 1H NMR (500 MHz, d6-DMSO, 319 K): δ 7.61 (1H, d, J 7.0, Ar-H), 7.57 
(1H, dd, J 7.9, 0.9, Ar-H), 7.42-7.29 (6H, m, Ar-H), 7.19 (1H, td, J 7.9, 1.5, Ar-H), 
5.82-5.71 (1H, m, CH=CH2), 5.14-5.01 (4H, m, CH=CH2 and OCH2Ph), 4.27 (1H, 
d, J 13.4, 2-HA), 4.12 (1H, d, J 16.6, NCHAHBAr), 3.84 (1H, d, J 12.9, 
NCHAHBCH2N), 3.79 (1H, d, J 16.6, NCHAHBAr), 3.59 (3H, s, CO2CH3), 3.09 (1H, 
d, J 13.4, 2-HB), 3.05-2.95 (1H, m, NCHAHBCH2N), 2.71 (1H, td, J 11.8, 3.5, 
NCHAHBCH2N), 2.65-2.53 (2H, m, CH2CH=CH2), 2.53-2.46 (1H, m, 
NCHAHBCH2N). 13C NMR (125 MHz, d6-DMSO, 319 K): δ 172.5 (CO2CH3), 154.0 
(N(CO)O), 138.1 (Ar-Cq), 136.8 (Ar-Cq), 132.3 (Ar-C or CH=CH2), 132.2 (Ar-C or 
CH=CH2), 129.2 (Ar-C), 128.3 (Ar-C), 128.2 (Ar-C), 127.6 (Ar-C), 127.5 (Ar-C), 
127.2 (Ar-C), 122.9 (Ar-Cq-Br), 118.7 (CH=CH2), 66.0 (OCH2Ph), 64.5 (3-C), 53.3 
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(NCH2Ar), 51.2 (CO2CH3), 49.6 (2-C), 46.6 (NCH2CH2N), 43.2 (NCH2CH2N), 38.0 
(CH2CH=CH2). IR νmax(film)/cm−1 2950, 1732 (CO), 1704, 1456, 1435, 1284, 
1228, 1212. HRMS (ESI): C24H2879BrN2O4 [M+H]+; calculated 487.1227, found 
487.1233. 
 
Methyl 2-benzyl-2-[(2-bromobenzyl)amino]pent-4-enoate 100d 
General procedure M was followed using amino ester 63d 
(268 mg, 1.22 mmol) with two changes; the reaction was 
performed in THF at 45 °C. After heating for 3 days, additional 
NaBH(OAc)3 (518 mg, 2.44 mmol, 2.0 eq.) was added and the 
reaction mixture was stirred for 3 h. Flash chromatography eluting 
with a gradient of 0-20% EtOAc in hexane gave the title compound 
100d (327 mg, 0.842 mmol, 69%) as a colourless oil. Rf 0.68 (4:1 petrol–
EtOAc).1H NMR (500 MHz, CDCl3): δ 7.53 (1H, dd, J 8.0, 1.2, Ar-H), 7.47 (1H, d, 
J 7.5, Ar-H), 7.26 (4H, m, Ar-H), 7.16 (2H, d, J 6.9, Ar-H), 7.11 (1H, td, J 7.7, 1.6, 
Ar-H), 6.00-5.88 (1H, m, CH=CH2), 5.23-5.13 (2H, m, CH=CH2), 3.89-3.79 (2H, 
m, NHCH2Ar), 3.67 (3H, s, CO2CH3), 3.09 (1H, d, J 13.7, CHAHBPh), 3.01 (1H, d, 
J 13.7, CHAHBPh), 2.65 (1H, dd, J 14.8, 6.1, CHAHBCH=CH2), 2.52 (1H, dd, 
J 14.8, 7.6, CHAHBCH=CH2). 13C NMR (125 MHz, CDCl3, one Ar-C peak not 
observed): δ 175.3 (CO2CH3), 139.5 (Ar-Cq), 136.4 (Ar-Cq), 133.3 (Ar-C), 132.8 
(CH=CH2), 130.3 (Ar-C), 128.7 (Ar-C), 128.3 (Ar-C), 127.7 (Ar-C), 127.0 (Ar-C), 
124.0 (Ar-Cq-Br), 118.8 (CH=CH2), 66.2 (Cq), 51.8 (CO2CH3), 47.3 (NHCH2Ar), 
42.3 (CH2Ph), 38.1 (CH2CH=CH2). IR νmax(film)/cm−1 2949, 1732 (CO), 1465, 
1439, 1213, 1197, 1206, 750. HRMS (ESI): C20H2379BrNO2 [M+H]+; calculated 
388.0907, found 388.0913. 
 
Methyl 9-methylidene-3-azatricyclo[8.4.0.03,7]tetradeca-1(10),11,13-triene-7-
carboxylate 101a and methyl (9Z)-3-azatricyclo[9.4.0.03,7]pentadeca-
1(11),9,12,14-tetraene-7-carboxylate 102a 
General procedure N was followed using amino 
ester 100a (105 mg, 0.310 mmol, 1.0 eq.). Flash 
chromatography eluting with pentane–EtOAc (4:1) gave 
the title compound 101a (43 mg, 0.17 mmol, 54%, 92:8 
mixture of 101a:102a) as a yellow oil. Rf 0.21 (4:1 petrol–
EtOAc). 1H NMR (500 MHz, CDCl3, peaks for 101a): δ 7.37-7.30 (1H, m, Ar-H), 
172 
 
 
7.25-7.18 (2H, m, Ar-H), 7.17-7.11 (1H, m, Ar-H), 5.33 (1H, d, J 1.6, C=CHAHB), 
5.12 (1H, s, C=CHAHB), 4.54 (1H, d, J 16.0, 2-HA), 3.89 (1H, d, J 16.0, 2-HB), 3.73 
(3H, s, CO2CH3), 3.13 (1H, d, J 13.6, 8-HA), 3.05 (1H, td, J 8.4, 2.4, 4-HA), 2.76 
(1H, app. q, J 8.4, 4-HB), 2.58 (1H, d, J 13.6, 8-HB), 2.26-2.16 (1H, m, 6-HA), 
2.10-2.00 (1H, m, 6-HB), 1.95-1.83 (1H, m, 5-HA), 1.81-1.69 (1H, m, 5-HB). 
Characteristic peaks for 102a: 6.79 (1H, d, J 10.6, 10-H), 5.94-5.87 (1H, m, 9-H), 
4.09 (1H, d, J 14.8, 2-HA), 4.02 (1H, d, J 14.8, 2-HB), 3.77 (3H, s, CO2CH3), 
2.74-2.67 (1H, m), 2.46 (1H, dd, J 13.4, 7.5, 8-HA), 2.37-2.30 (1H, m). 13C NMR 
(125 MHz, CDCl3, peaks for 101a assigned): δ 175.7 (CO2CH3), 145.5 (9-C), 
141.3 (Ar-Cq), 136.8 (Ar-Cq), 129.3 (Ar-C), 127.5 (Ar-C), 127.4 (Ar-C), 
127.2 (Ar-C), 116.9 (C=CH2), 69.9 (7-C), 52.9 (2-C), 52.0 (CO2CH3), 50.7 (4-C), 
41.8 (8-C), 36.1 (6-C), 22.3 (5-C). IR νmax(film)/cm−1 2949, 2902, 1727 (CO), 
1433, 1256, 1209, 1157, 1111. HRMS (EI): C16H19N2O [M]+; calculated 257.1409, 
found 257.1416. 
 
Methyl 8-methylidene-3-azatricyclo[7.4.0.03,6]trideca-1(9),10,12-triene-6-
carboxylate 101b 
General procedure N was followed using amino ester 100b (163 mg, 
0.500 mmol). After heating at 125 °C under microwave irradiation for 
2 h, additional Pd(PPh3)4 (29 mg, 25 µmol, 5.0 mol%) was added and 
the reaction mixture heated for a further 2 h. Flash chromatography 
eluting with a gradient of 0-100% EtOAc in pentane (containing 1% Et3N) gave 
the title compound 101b (35 mg, 0.14 mmol, 29%) as a yellow oil. 
Rf 0.07 (4:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.49-7.43 (1H, m, Ar-H), 
7.30-7.18 (2H, m, Ar-H), 7.15-7.10 (1H, m, Ar-H), 5.50 (1H, s, C=CHAHB), 5.23 
(1H, d, J 1.0, C=CHAHB), 4.22 (1H, d, J 15.2, 2-HA), 3.89 (1H, d, J 15.2, 2-HB), 
3.60 (3H, s, CO2CH3), 3.35-3.28 (1H, m, 4-HA), 3.25-3.15 (2H, m, 4-HB and 7-HA), 
3.06 (1H, d, J 15.1, 7-HB), 2.65-2.55 (1H, m, 5-HA), 2.29-2.26 (1H, m, 5-HB). 
13C NMR (125 MHz, CDCl3): δ 175.5 (CO2CH3), 144.7 (8-C), 139.8 (Ar-Cq), 135.8 
(Ar-Cq), 129.8 (Ar-C), 128.2 (Ar-C), 127.8 (Ar-C), 127.6 (Ar-C), 117.2 (C=CH2), 
69.2 (6-C), 54.9 (2-C), 52.2 (CO2CH3), 46.6 (4-C), 39.6 (7-C), 26.7 (5-C). 
IR νmax(film)/cm−1 2921, 1736 (CO), 1484, 1435, 1257, 1235, 1104, 775. 
HRMS (ESI): C15H18NO2 [M+H]+; calculated 244.1332, found 244.1335. 
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13-Benzyl 11-methyl 9-methylidene-1,13-diazatricyclo[9.4.0.03,8]pentadeca-
3(8),4,6-triene-11,13-dicarboxylate 101c and 14-benzyl 12-methyl (9Z)-1,14-
diazatricyclo[10.4.0.03,8]hexadeca-3(8),4,6,9-tetraene-12,14-
dicarboxylate 102c 
General procedure N was 
followed using amino ester 
100c (280 mg, 0.570 mmol, 
1.00 eq.). Flash 
chromatography eluting with a 
gradient of 0-100% EtOAc in 
pentane gave the separable title compounds 101c (74 mg, 0.18 mmol, 32%) and 
102c (72 mg, 0.18 mmol, 31%) as pale yellow oils.* 13-Benzyl 11-methyl 9-
methylidene-1,13-diazatricyclo[9.4.0.03,8]pentadeca-3(8),4,6-triene-11,13-
dicarboxylate 101c: Rf 0.11 (4:1 petrol–EtOAc). 1H NMR (500 MHz, d6-DMSO, 
319 K): δ 7.42-7.29 (6H, m, Ar-H), 7.21-7.14 (2H, m, Ar-H), 7.13-7.08 (1H, m, 
Ar-H), 5.40 (1H, s, C=CHAHB), 5.12 (1H, s, C=CHAHB), 5.12-5.03 (2H, m, 
OCH2Ph), 4.49 (1H, d, J 17.0, 2-HA), 4.22 (1H, d, J 12.8, 12-HA), 3.79 (1H, d, 
J 12.8, NCHAHBCH2N), 3.64 (1H, d, J 17.0, 2-HB), 3.58 (3H, s, CO2CH3), 
3.28-3.18 (1H, m, NCHAHBCH2N), 3.15 (1H, d, J 12.8, 12-HB), 2.90 (1H, br. s, 
NCHAHBCH2N), 2.78 (1H, d, J 13.8, 10-HA), 2.69 (1H, d, J 11.4, NCHAHBCH2N), 
2.63 (1H, d, J 13.8, 10-HB). 13C NMR (125 MHz, d6-DMSO, 319 K): 
δ 172.7 (CO2CH3), 154.2 (N(CO)O), 143.9 (9-C), 139.4 (Ar-Cq), 139.1 (Ar-Cq), 
136.7 (Ar-Cq), 128.2 (Ar-C), 127.6 (Ar-C), 127.5 (Ar-C), 127.3 (Ar-C), 
127.0 (Ar-C), 126.8 (Ar-C), 126.2 (Ar-C), 115.9 (C=CH2), 66.1 (OCH2Ph), 
64.8 (11-C), 56.6 (2-C), 51.2 (CO2CH3), 49.0 (12-C), 48.8 (NCH2CH2N), 
43.4 (NCH2CH2N), 41.2 (10-C). IR νmax(film)/cm−1 2946, 1732 (CO), 1702, 1461, 
1432, 1277, 1223, 1128. HRMS (ESI): C24H27N2O4 [M+H]+; calculated 407.1965, 
found 407.1975. 14-Benzyl 12-methyl (9Z)-1,14-
diazatricyclo[10.4.0.03,8]hexadeca-3(8),4,6,9-tetraene-12,14-dicarboxylate 
102c: Rf 0.21 (4:1 petrol–EtOAc). 1H NMR (500 MHz, d6-DMSO, 319 K): δ 7.45 
(1H, d, J 7.0, Ar-H), 7.40-7.30 (5H, m, Ar-H), 7.29-7.22 (2H, m, Ar-H), 7.16 (1H, 
d, J 7.1, Ar-H), 6.78 (1H, d, J 10.7, 9-H), 5.78 (1H, app. q, J 9.1, 10-H), 5.13-5.00 
(2H, m, OCH2Ph), 4.23 (1H, d, J 13.0, 13-HA), 3.93-3.81 (2H, m, NCHAHBCH2N 
                                            
* Analysis of the crude product by 500 MHz NMR spectroscopy showed 100% conversion to a 42:58 mixture of 101c:102c. 
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and 2-HA), 3.65-3.51 (4H, m, includes 1H, m, 2-HB and at δ 3.57: 3H, s, CO2CH3), 
3.42 (1H, td, J 11.5, 3.3, NCHAHBCH2N), 3.06-2.90 (2H, m, NCHAHBCH2N and 
NCHAHBCH2N), 2.73 (1H, d, J 13.0, 13-HB), 2.40 (1H, dd, J 13.2, 7.6, 11-HA), 
1.66 (1H, dd, J 13.2, 9.3, 11-HB). 13C NMR (125 MHz, d6-DMSO, 319 K): 
δ 171.6 (CO2CH3), 153.8 (N(CO)O), 138.7 (Ar-Cq), 136.6 (Ar-Cq), 135.3 (Ar-Cq), 
132.5 (9-C), 130.9 (Ar-C), 128.2 (2 × Ar-C), 127.6 (Ar-C), 127.2 (3 peaks, 3 × C; 
10-C and 2 × Ar-C), 126.5 (Ar-C), 66.1 (OCH2Ph), 60.4 (12-C), 55.8 (2-C), 52.4 
(13-C), 51.1 (NCH2CH2N and CO2CH3), 44.0 (NCH2CH2N), 35.3 (11-C). 
IR νmax(film)/cm−1 3010, 2948, 1733 (CO), 1701, 1456, 1432, 1284, 1232. 
HRMS (ESI): C24H27N2O4 [M+H]+; calculated 407.1965, found 407.1980.  
 
Methyl 3-benzyl-5-methylidene-2,3,4,5-tetrahydro-1H-2-benzazepine-3-
carboxylate 101d 
Et3N (90 µL, 0.65 mmol, 2.5 eq.) was added to a stirred solution 
of amino ester 100d (100 mg, 0.260 mmol, 1.00 eq.), Pd(OAc)2 
(3.0 mg, 13 µmol, 5.0 mol%) and PPh3 (7.0 mg, 27 µmol, 
10 mol%) in MeCN (4 mL). The reaction mixture was heated at 
125 °C under microwave irradiation for 1 h. Additional Pd(OAc)2 
(3.0 mg, 13 µmol, 5.0 mol%) and PPh3 (7.0 mg, 27 µmol, 10 mol%) was added 
and the reaction mixture heated for 1 h. The reaction mixture was filtered through 
celite then concentrated in vacuo. Flash chromatography eluting with 80:20:1 
pentane–EtOAc–Et3N gave the title compound 101d (72 mg, 0.23 mmol, 90%) 
as a colourless oil. Rf 0.29 (4:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3): 
δ 7.38-7.29 (1H, m, Ar-H), 7.24-7.14 (4H, m, Ar-H), 7.13-7.04 (4H, m, Ar-H), 
7.00-6.95 (1H, m, NH), 5.37 (1H, s, C=CHAHB), 5.06 (1H, s, C=CHAHB), 3.97-3.87 
(2H, m, 1-H), 3.59 (3H, s, CO2CH3), 3.02-2.97 (3H, m, 4-H and CHAHBPh), 2.72 
(1H, d, J 13.5, CHAHBPh). 13C NMR (125 MHz, CDCl3): δ 175.4 (CO2CH3), 144.8 
(5-C), 140.3 (Ar-Cq), 139.8 (Ar-Cq), 136.3 (Ar-Cq), 130.1 (Ar-C), 128.4 (Ar-C), 
128.1 (Ar-C), 128.0 (Ar-C), 127.5 (Ar-C), 127.1 (Ar-C), 126.9 (Ar-C), 
116.0 (C=CH2), 67.5 (3-C), 51.9 (CO2CH3), 48.8 (1-C), 44.3 (4-C or CH2Ph), 43.8 
(4-C or CH2Ph). IR νmax(film)/cm−1 2949, 1733 (CO), 1454, 1435, 1196, 909, 735, 
701. HRMS (ESI): C20H22NO2 [M+H]+; calculated 308.1645, found 308.1635. 
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Methyl 1,2-bis(prop-2-en-1-yl)pyrrolidine-2-carboxylate 105a 
General procedure O was followed using amino ester 63a (1.0 g, 
5.9 mmol). Purification by SCX cartridge, eluting first with MeOH then 
sat. NH3/MeOH, gave the title compound 105a (1.0 g, 4.8 mmol, 
81%) as an orange oil. Rf 0.27 (1:1 pentane–EtOAc). 1H NMR 
(300 MHz, CDCl3): δ 5.92–5.67 (2H, m, CqCH2CH=CH2 and NCH2CH=CH2), 
5.22-4.96 (4H, m, CqCH2CH=CH2 and NCH2CH=CH2), 3.67 (3H, s, CO2CH3), 
3.38 (1H, dd, J 13.7, 5.0, NCHAHBCH=CH2), 3.15-2.97 (1H, m, 5-HA), 2.84 (1H, 
dd, J 13.7, 7.5, NCHAHBCH=CH2), 2.69-2.48 (2H, m, 5-HB and 
CqCHAHBCH=CH2), 2.31 (1H, dd, J 14.0, 6.8, CqCHAHBCH=CH2), 2.19-1.99 (1H, 
m, 3-HA), 1.92-1.65 (3H, m, 3-HB and 4-H). 13C NMR (75 MHz, CDCl3): δ 174.6 
(CO2CH3), 136.9 (NCH2CH=CH2 or CqCH2CH=CH2), 134.3 (NCH2CH=CH2 or 
CqCH2CH=CH2), 118.0 (NCH2CH=CH2 or CqCH2CH=CH2), 116.2 (NCH2CH=CH2 
or CqCH2CH=CH2), 70.2 (2-C), 52.5 (NCH2CH=CH2), 51.8 (5-C), 51.2 (CO2CH3), 
39.4 (CqCH2CH=CH2), 33.9 (3-C), 21.6 (4-C). IR νmax(film)/cm−1 3077, 2978, 
2951, 2814, 1738 (CO), 1642, 1445, 1434. HRMS (ESI): C12H20NO2 [M+H]+; 
calculated 210.1494, found 210.1489. 
 
Methyl 1,2-bis(prop-2-en-1-yl)azetidine-2-carboxylate 105b 
General procedure O was followed using the TFA salt of the amino 
ester 63b (404 mg, 1.50 mmol, 1.0 eq.) and K2CO3 (2.2 eq.). 
Purification by SCX cartridge, eluting first with MeOH then sat. 
NH3/MeOH, gave the title compound 105b (183 mg, 0.937 mmol, 
62%) as an orange oil. 1H NMR (500 MHz, CDCl3): δ 5.81-5.65 (2H, m, 
NCH2CH=CH2 and CqCH2CH=CH2), 5.19-5.02 (4H, m, NCH2CH=CH2 and 
CqCH2CH=CH2), 3.74 (3H, s, CO2CH3), 3.25-3.18 (1H, m, 4-HA), 3.18-3.12 (3H, 
m, 4-HB and NCH2CH=CH2), 2.66 (1H, dd, J 13.6, 7.3, CqCHAHBCH=CH2), 2.55 
(1H, m, CqCHAHBCH=CH2), 2.52-2.47 (1H, m, 3-HA), 2.08-2.00 (1H, m, 3-HB). 
13C NMR (125 MHz, CDCl3): δ 173.7 (CO2CH3), 134.9 (NCH2CH=CH2 or 
CqCH2CH=CH2), 132.8 (NCH2CH=CH2 or CqCH2CH=CH2), 118.5 (NCH2CH=CH2 
or CqCH2CH=CH2), 117.1 (NCH2CH=CH2 or CqCH2CH=CH2), 71.5 (2-C), 54.9 
(NCH2CH=CH2), 51.6 (CO2CH3), 49.4 (4-C), 38.7 (CqCH2CH=CH2), 25.8 (3-C). 
IR νmax(film)/cm−1 2952, 2848, 1728 (CO), 1640 (CO), 1435, 1259, 1200, 1146. 
HRMS (ESI): C11H18NO2 [M+H]+; calculated 196.1338, found 196.1328. 
 
176 
 
 
1-Benzyl 3-methyl 3,4-bis(prop-2-en-1-yl)piperazine-1,3-dicarboxylate 105c 
General procedure O was followed using amino ester 63c 
(230 mg, 0.720 mmol). Purification by SCX cartridge, eluting 
first with MeOH then sat. NH3/MeOH, gave the title 
compound 105c (212 mg, 0.591 mmol, 82%) as an orange oil. 
1H NMR (500 MHz, d6-DMSO, 319 K): δ 7.42-7.27 (5H, m, 
Cbz Ar-H), 5.86-5.66 (2H, m, NCH2CH=CH2 and 
CqCH2CH=CH2), 5.22-5.01 (6H, m, CH2Ph, NCH2CH=CH2 and 
CqCH2CH=CH2), 4.15 (1H, dd, J 13.3, 1.5, 2-HA), 3.85 (1H, d, J 13.0, 
NCHAHBCH2N), 3.62-3.56 (1H, m, NCHAHBCH=CH2), 3.54 (3H, s, CO2CH3), 
3.00-2.85 (3H, m, 2-HB, NCHAHBCH=CH2 and NCHAHBCH2N), 2.72-2.54 (3H, m, 
NCH2CH2N, and CqCHAHBCH=CH2), 2.50 (1H, m, CqCHAHBCH=CH2). 13C NMR 
(125 MHz, d6-DMSO, 319 K): δ 172.5 (CO2CH3), 154.0 (N(CO)O), 136.8 (Ar-Cq), 
136.5 (NCH2CH=CH2 or CqCH2CH=CH2), 132.6 (NCH2CH=CH2 or 
CqCH2CH=CH2), 128.2 (Ar-C), 127.6 (Ar-C), 127.2 (Ar-C), 118.1 (NCH2CH=CH2 
or CqCH2CH=CH2), 116.0 (NCH2CH=CH2 or CqCH2CH=CH2), 66.0 (CH2Ph), 63.9 
(3-C), 52.4 (NCH2CH=CH2), 51.0 (CO2CH3), 49.2 (2-C), 45.6 (NCH2CH2N), 43.2 
(NCH2CH2N), 37.8 (CqCH2CH=CH2). IR νmax(film)/cm−1 2950, 1734 (CO), 1706 
(CO), 1458, 1431, 1283, 1225, 1124. HRMS (ESI): C20H27N2O4 [M+H]+; 
calculated 359.1965, found 359.1975. 
 
Methyl 2-benzyl-2-[(prop-2-en-1-yl)amino]pent-4-enoate 105d 
General procedure O was followed using amino ester 63d (400 mg, 
1.82 mmol) and allyl bromide (0.8 mL, 9 mmol, 5 eq.). The reaction 
mixture was stirred for 2 days at rt. Purification by SCX cartridge, 
eluting first with MeOH then sat. NH3/MeOH, gave the title 
compound 105d (297 mg, 1.15 mmol, 63%) as a pale yellow oil. 
1H NMR (500 MHz, CDCl3, NH not observed): δ 7.18-7.07 (3H, m, Ar-H), 6.99 
(2H, m, Ar-H), 5.87-5.67 (2H, m, NHCH2CH=CH2 and CqCH2CH=CH2), 5.16-5.02 
(4H, m, NHCH2CH=CH2 and CqCH2CH=CH2), 3.52 (3H, s, CO2CH3), 3.12 (1H, 
dd, J 13.0, 5.8, NHCHAHBCH=CH2), 3.05 (1H, dd, J 13.0, 6.1, 
NHCHAHBCH=CH2), 2.88 (1H, d, J 13.6, CHAHBPh), 2.81 (1H, d, J 13.6, 
CHAHBPh), 2.41 (1H, dd, J 14.8, 6.5, CqCHAHBCH=CH2), 2.31 (1H, dd, J 14.8, 
7.8, CqCHAHBCH=CH2). 13C NMR (125 MHz, CDCl3, Ar-Cq not observed): δ 175.3 
(CO2CH3), 136.4 (NCH2CH=CH2 or CqCH2CH=CH2), 133.0 (NCH2CH=CH2 or 
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CqCH2CH=CH2), 130.0 (Ar-C), 128.2 (Ar-C), 126.8 (Ar-C), 118.7 (NCH2CH=CH2 
or CqCH2CH=CH2), 116.0 (NCH2CH=CH2 or CqCH2CH=CH2), 66.0 (Cq), 
51.7 (CO2CH3), 46.0 (NHCH2CH=CH2), 41.8 (CH2Ph), 38.1 (CqCH2CH=CH2). 
IR νmax(film)/cm−1 2949 (NH), 1731 (CO), 1495, 1454, 1119, 917, 701, 614. 
HRMS (ESI): C16H22NO2 [M+H]+; calculated 260.1645, found 260.1647. 
 
Methyl 1,2,3,5,8,8a-hexahydroindolizine-8a-carboxylate 106a 
Method A: General procedure P was followed using amino ester 
105a (266 mg, 1.27 mmol) with GII (27 mg, 32 µmol, 2.5 mol%) in 
PhMe. The residue was washed through a pad of silica with EtOAc–
MeOH (9:1) to give the title compound 106a (191 mg, 1.05 mmol, 83%) as a 
red-brown oil. Method B: General procedure P was followed using amino 
ester 105a (1.89 g, 9.03 mmol) with two changes; the addition of p-TsOH was 
omitted and HGII (245 mg, 0.290 mmol, 3.20 mol%) was used as the catalyst. 
The residue was washed through a pad of silica with EtOAc–MeOH (9:1) to give 
the title compound 106a (1.12 g, 6.18 mmol, 69% [100% conversion based on 
crude 1H NMR study]) as a red-brown oil. Rf 0.28 (1:1 pentane–EtOAc). 1H NMR 
(500 MHz, CDCl3): δ 5.74-5.67 (2H, m, 6-H and 7-H), 3.67 (3H, s, CO2CH3), 
3.55-3.48 (1H, m, 5-HA), 3.40-3.33 (1H, m, 5-HB), 3.18-2.98 (2H, m, 3-H), 
2.86-2.71 (1H, m, 8-HA), 2.23-2.08 (2H, m, 1-HA and 8-HB), 1.98-1.70 (3H, m, 
1-HB and 2-H). 13C NMR (125 MHz, CDCl3): δ 175.6 (CO2CH3), 125.9 (6-C or 
7-C), 123.9 (6-C or 7-C), 65.5 (8a-C), 51.5 (CO2CH3), 50.9 (3-C), 47.4 (5-C), 36.8 
(1-C), 33.8 (8-C), 20.6 (2-C). IR νmax(film)/cm−1 3033, 2949, 2853, 1935 (C=C), 
1731 (CO), 1447, 1192, 1175. HRMS (ESI): C10H16NO2 [M+H]+; calculated 
182.1181, found 182.1176. 
 
Methyl 1-azabicyclo[4.2.0]oct-3-ene-6-carboxylate 106b 
General procedure P was followed using amino ester 105b (100 mg, 
0.510 mmol) with GII (33 mg, 38 µmol, 7.5 mol%) in PhMe. Flash 
chromatography eluting with a gradient of 0-10% MeOH in CH2Cl2, 
gave the title compound 106b (49 mg, 0.29 mmol, 57%) as a red-brown oil. 
Rf 0.35 (10:1 CH2Cl2–MeOH). 1H NMR (500 MHz, CDCl3): δ 6.05-5.98 (1H, m, 
3-H), 5.94-5.88 (1H, m, 4-H), 3.73 (3H, s, CO2CH3), 3.48-3.37 (2H, m, 2-HA and 
8-HA), 3.18-3.11 (1H, m, 8-HB), 2.95-2.88 (1H, m, 2-HB), 2.69-2.60 (1H, m, 7-HA), 
2.43-2.39 (2H, m, 5-H), 2.03-1.96 (1H, m, 7-HB). 13C NMR (125 MHz, CDCl3): 
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δ 175.8 (CO2CH3), 127.0 (4-C), 124.1 (3-C), 64.2 (6-C), 52.3 (CO2CH3), 49.0 
(8-C), 47.4 (2-C), 30.5 (7-C), 28.5 (5-C). IR νmax(film)/cm−1 2952, 2928, 1734 
(CO), 1437, 1267, 1225, 1202, 1156. HRMS (ESI): C9H14NO2 [M+H]+; calculated 
168.1019, found 168.1022. 
 
2-Benzyl 9a-methyl 1H,2H,3H,4H,6H,9H,9aH-pyrido[1,2-a]piperazine-2,9a-
dicarboxylate 106c 
General procedure P was followed using amino ester 105c 
(211 mg, 0.590 mmol) with GII (13 mg, 15 µmol, 2.5 mol%) 
in PhMe. Flash chromatography eluting with a gradient of 
0-100% EtOAc in pentane (containing 1% Et3N) gave the 
title compound 106c (176 mg, 0.533 mmol, 90%) as a pale yellow oil. Rf 0.15 (3:2 
petrol–EtOAc). 1H NMR (500 MHz, d6-DMSO, 319 K): δ 7.42-7.26 (5H, m, Cbz 
Ar-H), 5.69-5.58 (2H, m, 7-H and 8-H), 5.12-4.99 (2H, m, CH2Ph), 4.25 (1H, dd, 
J 13.1, 2.1, 1-HA), 3.98-3.90 (1H, m, NCHAHBCH2N), 3.47 (3H, s, CO2CH3), 
3.38-3.30 (1H, m, 6-HA), 3.19-3.13 (1H, m, 6-HB), 3.10-2.99 (2H, m, 
NCHAHBCH2N and NCHAHBCH2N), 2.86 (1H, d, J 13.1, 1-HB), 2.65-2.55 (1H, m, 
NCHAHBCH2N), 2.44-2.33 (1H, m, 9-HA), 2.11-2.02 (1H, m, 9-HB). 13C NMR 
(125 MHz, d6-DMSO, 319 K): δ 172.3 (CO2CH3), 153.8 (N(CO)O), 136.7 (Ar-Cq), 
128.2 (Ar-C), 127.6 (Ar-C), 127.2 (Ar-C), 125.1 (7-C or 8-C), 121.2 (7-C or 8-C), 
66.1 (CH2Ph), 59.8 (9a-C), 51.6 (1-C), 50.9 (CO2CH3), 49.8 (6-C), 
47.6 (NCH2CH2N), 43.4 (NCH2CH2N), 32.2 (9-C). IR νmax(film)/cm−1 3034, 2949, 
1732 (CO), 1704 (CO), 1463, 1434, 1286, 1228. HRMS (ESI): C18H23N2O4 
[M+H]+; calculated 331.1652, found 331.1652. 
 
Methyl 2-benzyl-1,2,3,6-tetrahydropyridine-2-carboxylate 106d 
General procedure P was followed using amino ester 105d (38 
mg, 0.15 mmol) with GII (7.0 mg, 7.5 µmol, 5.0 mol%) in CH2Cl2. 
Flash chromatography eluting with pentane–EtOAc (4:1) gave the 
title compound 106d (24 mg, 0.10 mmol, 69%) as an orange oil. Rf 0.06 (4:1 
petrol–EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.31-7.22 (3H, m, Ar-H), 7.12-7.08 
(2H, m, Ar-H), 5.74-5.69 (1H, m, 4-H), 5.69-5.64 (1H, m, 5-H), 3.62 (3H, s, 
CO2CH3), 3.54-3.48 (1H, m, 6-HA), 3.43-3.36 (1H, m, 6-HB), 3.04 (1H, d, J 13.2, 
CHAHBPh), 2.91 (1H, d, J 13.2, CHAHBPh), 2.68-2.61 (1H, m, 3-HA), 2.31-2.24 
(1H, m, 3-HB). 13C NMR (125 MHz, CDCl3): δ 175.3 (CO2CH3), 135.7 (Ar-Cq), 
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130.0 (Ar-C), 128.5 (Ar-C), 127.2 (Ar-C), 125.3 (5-C), 123.3 (4-C), 61.7 (2-C), 
51.8 (CO2CH3), 46.5 (CH2Ph), 42.7 (6-C), 33.3 (3-C). IR νmax(film)/cm−1 3030 
(NH), 2949, 1730, (CO), 1454, 1435, 1200, 1110, 1084, 1041. HRMS (ESI): 
C14H18NO2 [M+H]+; calculated 232.1332, found 232.1342.  
 
2-Benzyl-2,3,3a,4,7,7a-hexahydro-1H-isoindole-1,3-dione S1 
Benzylamine (3.8 mL, 36 mmol, 1.1 eq.) was added to a stirred 
solution of cis-1,2,3,6-tetrahydrophthalic anhydride (5.0 g, 
33 mmol, 1.0 eq.) and Et3N (2.75 mL, 37.4 mmol, 1.10 mmol) in 
PhMe (27 mL). The reaction mixture was heated at reflux for 15 h 
then concentrated in vacuo. The crude residue was diluted in EtOAc (50 mL) and 
washed with sat. aq. NaHCO3 (50 mL) and brine (50 mL). The organic phase was 
dried over MgSO4, filtered and concentrated in vacuo. The residue was filtered 
through a pad of silica, washed with 9:1 EtOAc–MeOH to give the title compound 
S1 (6.86 g, 28.4 mmol, 86%) as a colourless solid. Rf 0.57 (1:1 pentane–EtOAc). 
1H NMR (500 MHz, CDCl3): δ 7.32-7.22 (5H, m, Ar-H), 5.92-5.82 (2H, m, 5-H and 
6-H), 4.63 (2H, s, CH2Ph), 3.13-3.05 (2H, m, 3a-H and 7a-H), 2.64-2.57 (2H, m, 
4-HA and 7-HA), 2.28-2.18 (2H, m, 4-HB and 7-HB). 13C NMR (125 MHz, CDCl3): 
δ 179.9 (1-C and 3-C), 136.0 (Ar-Cq), 128.7 (Ar-C), 128.5 (Ar-C), 127.9 (2 peaks, 
Ar-C, 5-C and 6-C), 42.6 (CH2Ph), 39.3 (3a-C and 7a-C), 23.7 (4-C and 7-C). 
IR νmax(film)/cm−1 1689 (CO), 1399, 1367, 1313, 1195, 928, 901, 737. HRMS 
(ESI): C15H16NO2 [M+H]+; calculated 242.1176, found 242.1176. Spectral data 
consistent with the literature values.212  
 
2-Benzyl-2,3,3a,4,7,7a-hexahydro-1H-isoindole 108 
LiAlH4 (3.2 g, 85 mmol, 6.0 eq.) was added to a stirred solution of 
imide S1 (3.4 g, 14 mmol, 1.0 eq.) in THF (200 mL) at −78 °C. The 
reaction mixture was warmed to rt over 0.5 h, then heated at 60 °C 
for 2 h. The reaction mixture was cooled to rt and H2O (5 mL) was added dropwise 
followed by 1 N NaOH (5 mL) and H2O (10 mL). The resulting suspension was 
stirred vigorously for 1 h. MgSO4 (ca. 15 g) was added and the reaction mixture 
was filtered through a pad of Celite, washed with EtOAc. The filtrate was washed 
with EtOAc (2 × 50 mL). The resulting solution was concentrated in vacuo. The 
residue was filtered through a pad of silica, washed with 9:1 EtOAc–MeOH to 
give the title compound 108 (3.0 g, 41 mmol, 99%) as a pale yellow oil. Rf 0.06 
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(1:1 pentane–EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.35-7.20 (5H, m, Ar-H), 
5.86-5.78 (2H, m, 5-H and 6-H), 3.62 (2H, s, CH2Ph), 2.92 (2H, dd, J 8.8, 7.0, 
1-HA and 3-HA), 2.44-2.34 (2H, m, 3a-H and 7a-H), 2.21 (1H, dd, J 8.8, 7.0, 1-HB 
and 3-HB), 2.15 (2H, dd, J 15.2, 4.6, 4-HA and 7-HA), 1.87 (2H, d, J 15.2, 2.7, 4-HB 
and 7-HB). 13C NMR (125 MHz, CDCl3, one Ar-Cq not observed): δ 128.9 (Ar-C), 
128.3 (Ar-C), 128.0 (5-C and 6-C), 126.9 (Ar-C), 61.2 (CH2Ph or 1-C and 3-C), 
61.0 (CH2Ph or 1-C and 3-C), 35.9 (3a-C and 7a-C), 26.6 (4-C and 7-C). 
IR νmax(film)/cm−1 3085, 2920, 2783, 1494, 1452, 1147, 1130, 908. HRMS (ESI): 
C15H19NNa [M+Na]+; calculated 236.1410, found 236.1401. 
 
(3aR*,5R*,6S*,7aS*)-2-benzyl-octahydro-1H-isoindole-5,6-diol  
or (3aR*,5S*,6R*,7aS*)-2-benzyl-octahydro-1H-isoindole-5,6-diol 109 
4-Methylmorpholine N-oxide monohydrate 
(254 mg, 1.88 mmol, 2.00 eq.) and OsO4 
(0.1 M in tBuOH, 0.47 mL, 47 µmol, 
2.5 mol%) were added to a stirred solution of alkene 108 (200 mg, 0.940 mmol, 
1.00 eq.) in 25:1 THF–H2O at 0 °C. The reaction mixture was stirred at this 
temperature for 8 h, by which time all of the starting material had been consumed 
(TLC monitoring). Sat. aq. Na2SO3 (2 mL) was added and the reaction mixture 
was stirred for 30 min. EtOAc (20 mL) and H2O (10 mL) were added and the 
phases were separated. The aqueous phase was washed with EtOAc 
(2 × 25 mL). The combined organic extracts were dried over MgSO4 and 
concentrated in vacuo. The residue was filtered through a pad of silica, washed 
with 9:1 EtOAc–MeOH to give the title compound 109 (160 mg, 0.65, 69%) as a 
pale yellow oil. Rf 0.25 (9:1 CH2Cl2–MeOH). 1H NMR (500 MHz, CDCl3): 
δ 7.37-7.17 (5H, m, Ar-H), 3.89 (2H, dd, J 5.8, 3.1, 5-H and 6-H), 3.70 (2H, s, 
CH2Ph), 2.73 (2H, dd, J 9.3, 7.2, 1-HA and 3-HA), 2.58 (2H, dd, J 9.3, 5.0, 1-HB 
and 3-HB), 2.43-2.35 (2H, m, 3a-H and 7a-H), 1.95-1.87 (2H, m, 4-HA and 7-HA), 
1.68 (2H, ddd, J 14.1, 6.4, 3.9, 4-HB and 7-HB). 13C NMR (125 MHz, CDCl3): 
δ 140.1 (Ar-Cq), 128.6 (Ar-C), 128.3 (Ar-C), 126.9 (Ar-C), 68.9 (5-C and 6-C), 61.0 
(CH2Ph), 57.8 (1-C and 3-C), 34.5 (3a-C and 7a-C), 31.0 (4-C and 7-C). 
IR νmax(film)/cm−1 3303 (OH), 2898, 2798, 1685, 1451, 1073, 1027, 698. HRMS 
(ESI): C15H22NO2 [M+H]+; calculated 248.1646, found 248.1648. 
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(1aR*,2aR*,5aS*,6aS*)-4-benzyl-octahydro-1aH-oxireno[2,3-f]isoindole or 
(1aR*,2aS*,5aR*,6aS*)-4-benzyl-octahydro-1aH-oxireno[2,3-f]isoindole 110 
Following a procedure by Young,156 TFA 
(90 µL, 1.2 mmol, 1.3 eq.) was added to a 
stirred suspension of the alkene 108 (200 mg, 
0.94 mmol, 1.00 eq.) in H2O (1.0 mL) in a sealed screw-topped vial. NCS (150 mg, 
1.13 mmol, 1.20 eq.) was added and the reaction mixture was heated at 70 °C 
for 4 h. The reaction mixture was cooled to rt and quenched with sat. aq. NaHCO3 
(2 mL), then extracted with EtOAc (25 mL). The organic phase was washed with 
brine (25 mL). The combined aqueous phase was extracted with EtOAc 
(2 × 25 mL). The combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo to give a colourless oil (232 mg). The residue was 
dissolved in MeOH (10 mL) and K2CO3 (260 mg, 1.88 mmol, 2.00 eq.) was added. 
The reaction mixture was stirred for 24 h then concentrated in vacuo. The residue 
was diluted in EtOAc (25 mL) and washed with sat. aq. NaHCO3 (25 mL). The 
aqueous phase was extracted with EtOAc (2 × 25 mL). The combined organic 
phase was dried over MgSO4, filtered and concentrated in vacuo to give the title 
compound 110 (90 mg, 0.39 mmol, 42%) as a yellow oil which was not purified 
further. Rf 0.11 (9:1 CH2Cl2–MeOH). 1H NMR (500 MHz, CDCl3): δ 7.35-7.20 (5H, 
m, Ar-H), 3.63 (2H, s, CH2Ph), 3.17-3.10 (2H, m, 1a-H and 6a-H), 2.98-2.86 (2H, 
m, 3-HA and 5-HA), 2.38-2.26 (4H, m, 2a-H, 3-HB, 5-HB and 5a-H), 2.00 (2H, dd, 
J 15.3, 5.4, 2-HA and 6-HA), 1.83 (2H, dd, J 15.3, 1.4, 2-HB and 6-HB). 13C NMR 
(125 MHz, CDCl3): δ 139.2 (Ar-Cq), 129.1 (Ar-C), 128.4 (Ar-C), 127.1 (Ar-C), 
61.8 (3-C and 5-C), 60.6 (CH2Ph), 50.7 (1a-C and 6a-C), 31.1 (2a-C and 5a-C), 
24.3 (2-C and 6-C). IR νmax(film)/cm−1 2910, 2809, 1495, 1453, 1229, 1155, 936, 
699. HRMS (ESI): C15H20NO [M+H]+; calculated 230.1539, found 230.1543. 
 
Methyl (6R*,7R*,8aR*)-7-chloro-6-hydroxy-octahydroindolizine-8a-
carboxylate 111 and methyl (6S*,7S*,8aR*)-6-chloro-7-hydroxy- 
octahydroindolizine-8a-carboxylate 112 
Following a procedure by Young,156 TFA (0.21 mL, 
2.8 mmol, 1.0 eq.) was added to a stirred suspension 
of amine 106a (500 mg, 2.76 mmol, 1.00 eq.) in H2O 
(2.8 mL) in a sealed screw-topped vial. NCS (442 mg, 
3.31 mmol, 1.2 eq.) was added and the reaction 
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mixture was heated at 70 °C for 24 h. Additional NCS (300 mg, 2.25 mmol, 
0.80 eq.) was added and the reaction mixture was heated for a further 15 h. The 
reaction mixture was cooled to rt and quenched with solid NaHCO3 until 
neutralised. NaCl was added until the solution was saturated, then the mixture 
was extracted with EtOAc (5 × 2 mL). The combined organics were dried, filtered, 
and concentrated. Flash chromatography on cyanosilica eluting with a gradient 
of 0-10% EtOAc in pentane, gave the title compounds 111 (231 mg, 0.988 mmol, 
36%) and 112 (52 mg, 0.22 mmol, 8%) as colourless oils. Methyl (6R*,7R*,8aR*)-
7-chloro-6-hydroxy-octahydroindolizine-8a-carboxylate 111: Rf 0.11 
(1:1 petrol−EtOAc). 1H NMR (500 MHz, CDCl3, OH not observed): δ 4.11 (1H, dd, 
J 3.3, 3.0, 7-H), 3.79 (1H, app. br. s, 6-H), 3.73 (1H, d, J 12.7, 5-HA), 3.68 (3H, s, 
CO2CH3), 3.25-3.12 (1H, m, 3-HA), 3.05-2.98 (1H, m, 3-HB), 2.79 (1H, dd, J 12.7, 
2.7, 5-HB), 2.72 (1H, dd, J 14.7, 2.8, 8-HA), 2.19-2.06 (2H, m, 1-HA and 8-HB), 
1.94-1.78 (1H, m, 2-HA), 1.77-1.64 (2H, m, 1-HB and 2-HB). 13C NMR (125 MHz, 
CDCl3): 175.4 (CO2CH3), 69.0 (6-C), 64.3 (8a-C), 57.2 (7-C), 51.6 (CO2CH3), 
50.5 (3-C), 47.3 (5-C), 38.2 (1-C), 37.0 (8-C), 20.4 (2-C). IR νmax(film)/cm−1 2952, 
2855, 1731 (CO), 1309, 1196, 1068, 907, 725. HRMS (ESI): C10H1735ClNO3 
[M+H]+; calculated 234.0891, found 234.0896. Methyl (6S*,7S*,8aR*)-6-chloro-
7-hydroxy-octahydroindolizine-8a-carboxylate 112: Rf 0.18 (1:1 
petrol−EtOAc). 1H NMR (500 MHz, CDCl3): δ 3.86 (1H, ddd, J 11.2, 9.9, 5.1, 6-H), 
3.74 (3H, s, CO2CH3), 3.52 (1H, ddd, J 11.8, 9.9, 4.5, 7-H), 3.28 (1H, dd, J 13.3, 
5.1, 5-HA), 3.19-3.12 (1H, m, 3-HA), 3.09-2.97 (2H, m, includes 1H, m, 3-HB and 
at δ 3.06: 1H, dd, J 13.3, 11.2, 5-HB) 2.61 (1H, dd, J 13.0, 4.5, 8-HA), 2.53 (1H, 
br. s, OH), 2.15-2.05 (1H, m, 1-HA), 1.95-1.77 (3H, m, 1-HB and 2-H), 1.49 (1H, 
dd, J 13.0, 11.8, 8-HB). 13C NMR (125 MHz, CDCl3): δ 174.8 (CO2CH3), 72.9 
(7-C), 67.8 (8a-C), 61.2 (6-C), 52.3 (CO2CH3), 51.4 (5-C), 50.0 (3-C), 38.7 (8-C), 
37.3 (1-C), 21.9 (2-C). IR νmax(film)/cm−1 2951, 2853, 1727 (CO), 1447, 1194, 
1174, 1149, 1023. HRMS (ESI): C10H1735ClNO3 [M+H]+; calculated 234.0891, 
found 234.0888. 
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Methyl (1aR*,6aR*,7aS*)-octahydrooxireno[2,3-f]indolizine- 
6a-carboxylate 115 
NaOMe (25 wt% in MeOH, 146 µL, 0.640 mmol, 2.00 eq.) was added 
to a stirred solution of the major chlorohydrin 111 (75 mg, 0.32 mmol, 
1.0 eq.) in MeOH (3.2 mL). The reaction mixture was stirred for 15 h 
then concentrated in vacuo. The residue was washed through a pad 
of silica with 9:1 EtOAc−MeOH. Flash chromatography on cyanosilica eluting with 
a gradient of 0-100% EtOAc in pentane, gave the title compound 115 (27 mg, 
0.14 mmol, 43%) as a colourless oil. Rf 0.17 (1:1 petrol−EtOAc). 1H NMR 
(500 MHz, CDCl3): δ 3.70 (3H, s, CO2CH3), 3.39 (1H, d, J 13.9, 2-HA), 3.33 (1H, 
dd, J 5.8, 4.1, 7a-H), 3.15 (1H, app. d, J 4.1, 1a-H), 3.07 (1H, td, J 8.5, 3.9, 4-HA), 
2.86-2.78 (2H, m, includes 1H, m, 4-HB and at δ 2.81: 1H, d, J 13.9, 1.2, 2-HB), 
2.63 (1H, dd, J 14.9, 5.8, 7-HA), 2.12-2.05 (1H, m, 6-HA), 1.95-1.80 (2H, m, 5-H), 
1.77 (1H, app. d, J 14.9, 7-HB), 1.67-1.59 (1H, m, 6-HB). 13C NMR (125 MHz, 
CDCl3): δ 174.8 (CO2CH3), 64.7 (6a-C), 51.5 (2 × C, 1a-C and CO2CH3), 51.1 
(4-C), 50.8 (7a-C), 46.2 (2-C), 36.4 (6-C), 33.1 (7-C), 21.4 (5-C). IR νmax(film)/cm−1 
2951, 2841, 1723 (CO), 1447, 1433, 1195, 1173, 1111. HRMS (ESI): C10H16NO3 
[M+H]+; calculated 198.1125, found 198.1127. 
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1-(Pent-4-en-1-yl)-4-phenylpiperidine 116 
NaBH(OAc)3 (4.2 g, 30 mmol, 2.0 eq.) was added to a stirred solution of 
4-phenylpiperidine (1.6 g, 9.9 mmol, 1.0 eq.), 4-penten-1-al (1.2 mL, 
12 mmol, 1.2 eq.) and 4 Å MS in CH2Cl2 (50 mL). The reaction mixture 
was stirred for 2 days then filtered. The resulting solution was washed 
with sat. aq. NaHCO3 (50 mL) and brine (50 mL). The organic phase was 
dried over MgSO4 and filtered through Celite, washed with EtOAc. The 
residue was filtered through a pad of silica, washed with 9:1 EtOAc–MeOH to 
give the title compound 116 (2.1 g, 9.0 mmol, 91%) as a pale brown oil which was 
not purified further. 1H NMR (500 MHz, CDCl3): δ 7.34-7.16 (5H, m, Ar-H), 
5.91-5.72 (1H, m, CH=CH2), 5.03 (1H, dd, J 17.1, 1.6, CH=CHAHB), 4.97 (1H, d, 
J 10.2, CH=CHAHB), 3.06 (2H, app. d, J 11.5, 2-HA and 6-HA), 2.57-2.44 (1H, m, 
4-H), 2.43-2.33 (2H, m, NCH2), 2.12-2.00 (4H, m, 2-HB, 6-HB and CH2CH=CH2), 
1.87-1.75 (4H, m, 3-H and 5-H) , 1.68-1.60 (2H, m, NCH2CH2). 13C NMR 
(125 MHz, CDCl3): δ 146.6 (Ar-Cq), 138.7 (CH=CH2), 128.5 (Ar-C), 127.0 (Ar-C), 
126.2 (Ar-C), 114.7 (CH=CH2), 58.7 (NCH2), 54.6 (2-C and 6-C), 43.0 (4-C), 33.6 
(3-C and 5-C), 32.0 (CH2CH=CH2), 26.4 (NCH2CH2). IR νmax(film)/cm−1 2933, 
2801, 2763, 1130, 992, 908, 754, 697. HRMS (ESI): C16H23NNa [M+Na]+; 
calculated 252.1723, found 252.1717. 
 
7a-(2-Hydroxyethyl)-hexahydro-1H-pyrrolo[1,2-c]imidazolidine- 
1,3-dione 123 
NaIO4 (193 mg, 0.900, 2.00 eq.) and K2OsO4•2H2O (4.0 mg, 1.0 µmol, 
2.5 mol%) were added to a stirred solution of hydantoin 88a (81 mg, 
0.45 mmol, 1.0 eq.) in 4:1 acetone–H2O (5.0 mL). The reaction mixture 
was stirred at rt for 24 h. Na2SO3 (500 mg) was added and the reaction 
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mixture stirred for 0.5 h, then diluted with acetone (25 mL) and filtered through 
Celite. The solution was concentrated in vacuo to give a brown oil. The residue 
was dissolved in MeOH (5.0 mL) and NaBH4 (34 mg, 0.90 mmol, 2.0 eq.) was 
added at 0 °C. The reaction mixture was stirred for 5 h. Sat. aq. NH4Cl (0.2 mL) 
was added and the reaction mixture was filtered through Celite then concentrated 
in vacuo. Flash chromatography eluting with 85:14:1 CH2Cl2−EtOH−NH3* gave 
the title compound 123 (22 mg, 0.12 mmol, 27%) as a colourless oil. Rf 0.44 (1:1 
85:14:1 CH2Cl2−EtOH−NH3). 1H NMR (500 MHz, CD3OD, NH and OH not 
observed): δ 3.78-3.71 (1H, m, CHAHBOH), 3.70-3.60 (2H, m, 5-H), 3.27-3.19 
(1H, m, CHAHBOH), 2.27-2.09 (3H, m, 6-H and CHAHBCH2OH), 2.01-1.85 (3H, 
m, 7-H and CHAHBCH2OH). 13C NMR (125 MHz, CD3OD): δ 179.7 (1-C), 162.8 
(3-C), 73.4 (7a-C), 58.7 (CH2OH), 45.6 (5-H), 37.9 (CH2CH2OH), 34.1 (7-C), 26.8 
(6-C). IR νmax(film)/cm−1 3418, 3233, 1766 (CO), 1714, 1393, 1094, 1044, 773. 
HRMS (ESI): C8H13N2O3 [M+H]+; calculated 185.0921, found 185.0915. 
 
5-(4-Phenylpiperidin-1-yl)pentan-1-ol 124 
9-BBN dimer (106 mg, 0.440 mmol, 0.50 eq.) was added to a stirred 
solution of alkene 116 (200 mg, 0.870 mmol, 1.00 eq.) in 1,4-dioxane 
(1.6 mL) in a screw-topped vial. The reaction mixture was heated at 
60 °C for 15 h. Additional 9-BBN dimer (53 mg, 0.22 mmol, 0.25 eq.) 
was added and the reaction mixture was stirred for a further 3 h. H2O 
(1.6 mL) was added, followed by NaBO3•4H2O (400 mg, 2.60 mmol, 
3.00 eq.). The reaction mixture was stirred for 15 h, then partitioned between 
EtOAc (25 mL) and brine (25 mL). The phases were separated and the aqueous 
phase was extracted with EtOAc (2 × 25 mL). The combined organic phase was 
dried over MgSO4, filtered and concentrated in vacuo. The residue was purified 
by SCX, eluting first with MeOH then sat. NH3/MeOH, to give the title compound 
124 (138 mg, 0.56 mmol, 64%) as a yellow wax. 1H NMR (500 MHz, CDCl3, OH 
not observed): 7.35-7.13 (5H, m, Ar-H), 3.66 (2H, t, J 6.4, CH2OH), 3.06 (2H, app. 
d, J 11.3, 2-HA and 6-HA), 2.57-2.43 (1H, m, 4-H), 2.39 (2H, t, J 7.6, NCH2), 2.04 
(2H, app. td, J 11.3, 4.1, 2-HB and 6-HB), 1.87-1.76 (5H, m, 3-H and 5-H and 
NCH2CHAHB), 1.65-1.54 (3H, m, NCH2CHAHB, NCH2CH2CHAHB and 
NCH2CH2CH2CHAHB), 1.47-1.39 (2H, m, NCH2CH2CHAHB and 
                                            
* Sat. NH3 in MeOH used. 
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NCH2CH2CH2CHAHB). 13C NMR (125 MHz, CDCl3): δ 146.5 (Ar-Cq), 128.5 (Ar-C), 
127.0 (Ar-C), 126.3 (Ar-C), 62.8 (CH2OH), 59.0 (NCH2), 54.6 (2-C and 6-C), 42.9 
(4-C), 33.5 (3-C and 5-C), 32.5 (NCH2CH2) 26.7 (NCH2CH2CH2CH2), 23.8 
(NCH2CH2CH2). IR νmax(film)/cm−1 2929, 2765, 1450, 1374, 1119, 1066, 754, 697. 
HRMS (ESI): C16H26NO [M+H]+; calculated 248.2009, found 248.2017. 
 
8a-(3-Hydroxypropyl)-octahydropyrrolo[1,2-a]piperazin-1-one 125 
9-BBN (0.5 M in THF, 5.0 mL, 2.5 mmol, 3.0 eq.) was added to a stirred 
solution of lactam 90a (147 mg, 0.820 mmol, 1.00 eq.) in THF (0.8 mL). 
The reaction mixture was heated at reflux for 24 h then cooled to rt. 
NaBO3•4H2O (630 mg, 4.10 mmol, 5.00 eq.) and H2O (1.0 mL) were 
added and the reaction mixture was stirred for 15 h, then cooled to 
0 °C, dried over MgSO4, filtered through Celite and concentrated in vacuo. Flash 
chromatography on cyanosilica eluting with a gradient of 0-100% EtOAc in 
pentane, gave the title compound 125 (84 mg, 0.42 mmol, 52%) as a yellow oil. 
Rf 0.02 (9:1 EtOAc−MeOH). 1H NMR (500 MHz, CDCl3, OH not observed): δ 5.81 
(1H, s, NH), 3.58 (2H, t, J 5.3, CH2OH), 3.56-3.49 (1H, m, CHAHB), 3.45-3.37 (1H, 
m, CHAHB), 3.19-3.08 (2H, m, CHAHB and CHAHB), 2.95-2.86 (2H, m, CHAHB and 
CHAHB), 2.24-2.16 (1H, m, CHAHB), 2.14-2.06 (1H, m, CHAHBCH2CH2OH), 
2.03-1.96 (1H, m, CHAHB), 1.93-1.79 (3H, m, CHAHBCH2CH2OH and CH2), 
1.79-1.59 (2H, m, CH2CH2OH). 13C NMR (125 MHz, CDCl3): δ 175.5 (CONH), 
69.6 (8a-C), 63.5 (CH2OH), 52.1 (CH2), 44.5 (CH2), 39.0 (CH2), 36.4 (CH2), 34.5 
(CH2CH2CH2OH), 28.3 (CH2), 22.3 (CH2CH2OH). IR νmax(film)/cm−1 3290 (NH), 
2936, 2874, 1645 (CO), 1487, 1446, 1358, 1059. HRMS (ESI): C10H19N2O2 
[M+H]+; calculated 199.1441, found 199.1442. 
 
5.2.3 Synthesis of scaffold derivatives 
 
2-Ethyl 4a-methyl (3R*,4aR*)-1-oxo-3-[(4-phenyl-1H-1,2,3-triazol-1-
yl)methyl]-octahydropyrrolo[1,2-c]pyrimidine-2,4a-dicarboxylate 126 
Phenyl acetylene (70 µL, 0.62 mmol, 2.0 eq) was added 
to a stirred solution of azide 82a (100 mg, 0.31 mmol, 
1.0 eq.), Cu(OAc)2 (11 mg, 60 µmol, 20 mol%) and sodium 
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ascorbate (24 mg, 0.12 mmol, 40 mol%) in degassed* tBuOH–H2O (1:1, 2.0 mL). 
After 15 h the reaction mixture was extracted with EtOAc (25 mL) and washed 
with brine (25 mL). The aqueous layer was extracted with EtOAc (2 × 10 mL). 
The combined organics were dried over MgSO4, filtered and concentrated 
in vacuo. Flash chromatography on cyanosilica eluting with a gradient of 0-100% 
EtOAc in pentane, gave the title compound 126 (117 mg, 0.27 mmol, 88%) as 
colourless oil. Rf 0.29 (EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.88 (1H, s, triazole 
5-H), 7.83 (2H, d, J 7.1, Ar-H), 7.41 (2H, t, J 7.6, Ar-H), 7.35-7.30 (1H, m, Ar-H), 
4.69 (2H, app. d, J 4.4, CH2Ar), 4.59-4.51 (1H, m, 3-H), 4.39-4.20 (2H, m, 
CH2CH3), 3.70 (3H, s, CO2CH3), 3.58-3.51 (1H, m, 7-HA), 3.43-3.37 (1H, m, 
7-HB), 2.86 (1H, dd, J 13.6, 8.7, 4-HA), 2.28-2.21 (1H, m, 5-HA), 1.96-1.72 (4H, 
m, 4-HB; 5-HB and 6-H), 1.33 (3H, t, J 7.1, CH2CH3). 13C NMR (125 MHz, CDCl3): 
δ 172.8 (CO2CH3), 154.5 (CO), 150.0 (CO), 148.5 (triazole 4-C), 130.5 (Ar-Cq), 
129.0 (Ar-C), 128.4 (Ar-C), 126.1 (Ar-C), 121.2 (triazole 5-C), 65.6 (4a-C), 
63.4 (CH2CH3), 53.2 (CH2Ar), 53.2 (3-C), 53.1 (CO2CH3), 46.7 (7-C), 37.8 (5-C) 
36.7 (4-C), 22.7 (6-C), 14.5 (CH2CH3). IR νmax(film)/cm−1 2981, 1703 (CO), 1419, 
1288, 1230, 1171, 835, 767. HRMS (ESI): C21H26N5O5 [M+H]+; calculated 
428.1928, found 428.1930.  
 
(3R*,4aR*)-1-oxo-3-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]-
octahydropyrrolo[1,2-c]pyrimidine-4a-carboxylic acid 127 
NaOH (6.0 mg, 0.14 mmol, 2.0 eq.) was added to a stirred 
solution of urea 126 (30 mg, 70 µmol, 1.0 eq.) in MeOH 
(0.3 mL). The reaction mixture was stirred for 2 h, by 
which point a colourless solid had preciptiated from the solution. The reaction 
mixture was diluted with MeOH (15 mL). Amberlite IR-120 (hydrogen form, 
100 mg) was added and the mixture was stirred for 0.5 h, then filtered and 
concentrated. The residue was triturated with CHCl3 to give the title compound 
127 (20 mg, 83:17 mixture of ester:acid, 56 µmol, 80%) as colourless solid. 
1H NMR (500 MHz, d6-DMSO, 318 K, ester peaks assigned): δ 8.52 (1H, s, 
triazole 5-H), 7.85-7.81 (2H, m, Ar-H), 7.46 (2H, t, J 7.7, Ar-H), 7.34 (1H, t, J 7.4, 
Ar-H), 6.49 (1H, s, NH), 4.56 (1H, dd, J 14.0, 4.5, CHAHBAr), 4.44 (1H, dd, J 14.0, 
6.3, NCHAHBAr), 3.66 (3H, s, CO2CH3), 3.64-3.56 (1H, m, 3-H), 3.43-3.34 (1H, 
                                            
* Degassed by bubbling N2 through the solvent. 
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m, 7-HA), 3.33-3.26 (1H, m, 7-HB), 2.40-2.33 (1H, m, 4-HA), 2.30-2.23 (1H, m, 
5-HA), 1.85-1.75 (2H, m, 5-HB and 6-HA), 1.68-1.57 (1H, m, 6-HB), 1.40 (1H, t, 
J 12.4, 4-HB). Carboxylic acid characteristic peaks: δ 8.53 (1H, s, triazole 5-H), 
6.40 (1H, s, NH). 13C NMR (125 MHz, d6-DMSO, 318 K, ester peaks assigned): 
δ 173.6 (CO2CH3), 153.3 (1-C), 146.3 (triazole 4-C), 130.5 (Ar-Cq), 128.7 (Ar-C), 
127.7 (Ar-C), 125.0 (Ar-C), 122.1 (triazole 5-C), 65.8 (4a-C), 52.5 (CH2Ar and 
CO2CH3), 48.5 (3-C), 44.9 (7-C), 37.3 (5-C), 33.8 (4-C), 20.8 (6-C). 
IR νmax(film)/cm−1 1737 (CO), 1649 (CO), 1488, 1473, 1221, 1170, 712, 693. 
HRMS (ESI): C18H22N5O3 [M+H]+; calculated 356.1717, found 356.1723. 
 
Methyl (3R*,4aR*)-3-(azidomethyl)-1-oxo-octahydropyrrolo[1,2-
c]pyrimidine-4a-carboxylate 128 
NaOMe (25 wt% in MeOH, 82 µL, 37 µmol, 1.0 eq.) was added to 
a stirred solution of urea 82a (120 mg, 0.370 mmol, 1.00 eq.) in 
MeOH (3.0 mL). The reaction mixture was stirred at rt for 1.5 h, then 
concentrated in vacuo. The residue was redissolved in MeOH 
(10 mL) and Amberlite IR-120 (hydrogen form, 240 mg) was added. After stirring 
for 0.5 h the reaction mixture was filtered and concentrated to give the title 
compound 128 (72 mg, 0.28 mmol, 76%) as a white solid which was carried on 
crude to the next step. Rf 0.84 (9:1EtOAc–MeOH). 1H NMR (300 MHz, CDCl3, 
characteristic peaks): δ 5.47 (1H, s, NH), 3.74 (3H, s, CO2CH3), 3.67-3.53 (2H, 
m), 3.49 (1H, dd, J 11.5, 4.2), 3.44-3.34 (1H, m), 3.25 (1H, dd, J 11.5, 7.1), 2.57 
(1H, dd, J 12.8, 2.4), 2.48-2.32 (1H, m), 2.01-1.69 (3H, m), 1.47-1.34 (1H, m). 
 
Methyl (3R*,4aR*)-3-(azidomethyl)-2-[(4-fluorophenyl)methyl]-1-oxo-
octahydropyrrolo[1,2-c]pyrimidine-4a-carboxylate 129 
To a stirred solution of urea 128 (72 mg, 0.28 mmol, 1.0 eq.) in 
DMF (2.0 mL) was added NaH (60% dispersion in oil, 13 mg, 
0.31 mmol, 1.1 eq.). The reaction mixture was stirred for 10 min 
then 4-fluorobenzyl bromide (70 µL, 0.56 mmol, 2.0 eq.) was 
added. The reaction mixture was stirred for 1 h then H2O (0.1 mL) 
was added. The reaction mixture was diluted with Et2O (10 mL) and washed with 
brine (10 mL). The aqueous layer was extracted with Et2O (10 mL), then the 
combined organic layers were dried over MgSO4, filtered, and concentrated 
in vacuo. Flash chromatography on cyanosilica eluting with a gradient of 0-100% 
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EtOAc in pentane, gave the title compound 129 (53 mg, 0.15 mmol, 52%) as 
colourless oil. Rf 0.26 (EtOAc–petrol). 1H NMR (500 MHz, CDCl3): δ 7.21 (2H, 
app. dd, J 8.4, 5.5, Ar 2-H), 6.99 (2H, app. t, J 8.7, Ar 3-H), 5.32 (1H, d, J 15.9, 
CHAHBAr), 3.99 (1H, d, J 15.9, CHAHBAr), 3.74-3.63 (5H, m includes 2H, m, 7-H 
and at δ 3.66: 3H, s, CO2CH3), 3.48 (1H, dd, J 12.9, 5.2, CHAHBN3), 3.31 (1H, dd, 
J 12.9, 2.8, CHAHBN3), 3.23-3.17 (1H, m, 3-H), 2.60 (1H, dd, J 13.0, 5.0, 4-HA), 
2.42-2.36 (1H, m, 5-HA), 1.98-1.75 (4H, m, 4-HB; 5-HB and 6-H). 13C NMR 
(125 MHz, CDCl3): δ 174.3 (CO2Me), 162.1 (d, J 245.6, Ar 4-C), 155.3 (1-C), 
133.5 (Ar 1-C), 129.4 (d, J 7.8, Ar 2-C), 115.5 (d, J 21.3, Ar 3-C), 65.0 (4a-C), 
52.8 (CO2CH3), 52.4 (CH2N3), 51.2 (3-C), 46.5 (7-C or CH2Ar), 46.3 (7-C or 
CH2Ar), 38.6 (5-C), 35.8 (4-C), 21.7 (6-C). IR νmax(film)/cm−1 2953, 2101 (N3), 
1733 (CO), 1635, 1509, 1450, 1350,1218. HRMS (ESI): C17H21FN5O3 [M+H]+; 
calculated 362.1623, found 362.1630. 
 
2-Ethyl 4a-methyl (3R*,4aR*)-3-{[(3-cyanophenyl)formamido]methyl}-1-
oxo-octahydropyrrolo[1,2-c]pyrimidine-2,4a-dicarboxylate 131 
To a stirred solution of azide 82a (50 mg, 0.15 mmol, 1.0 eq.) 
in THF–H2O (1.0 mL) was added PPh3 (43 mg, 0.17 mmol, 
1.1 eq.). The reaction mixture was stirred for 15 h then 
concentrated in vacuo to give the crude amine 130 
[characteristic 1H NMR peaks (300 MHz, CDCl3): δ 6.45 (1H, 
s), 5.98-5.88 (1H, m, 3-H), 4.12 (2H, q, J 6.9, CO2CH2CH3), 3.76 (3H, s, CO2CH3), 
3.68-3.58 (2H, m), 3.50 (1H, dd, J 14.0, 7.1), 3.44-3.33 (1H, m), 3.13-2.99 (1H, 
m), 2.55 (1H, dd, J 12.5, 3.0), 2.49-2.41 (1H, m), 1.99-1.88 (1H, m), 1.81 (2H, dd, 
J 6.6, 4.1), 1.38 (1H, t, J 12.5), 1.25 (3H, t, J 6.9, CO2CH2CH3)]. The residue was 
dissolved in CH2Cl2 (1.0 mL). A pre-stirred solution of 3-cyanobenzoyl chloride 
(55 mg, 0.33 mmol, 2.2 eq.) and Et3N (0.12 mL, 0.60 mmol, 4.0 eq.) was added 
via cannula. The reaction mixture was stirred for 15 h. The reaction mixture was 
concentrated in vacuo to give the crude benzamide 131 [characteristic 1H NMR 
peaks (300 MHz, CDCl3): δ 8.41-8.25 (m), 7.95-7.81 (m), 5.24-5.10 (1H, m, NH), 
4.51-4.36 (1H, m, 3-H), 4.11 (2H, q, J 7.1, CO2CH2CH3), 3.84 (3H, s, CO2CH3), 
3.75-3.61 (1H, m), 3.54 (1H, ddd, J 14.4, 7.1, 3.5), 3.03 (1H, dd, J 13.8, 8.9), 
2.51-2.31 (1H, m), 2.22-1.89 (5H, m), 1.35-1.17 (4H, m, includes at δ 1.23: 3H, t, 
J 7.1, CO2CH2CH3). Attempted purification using flash chromatography and SCX 
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failed to remove the triphenylphosphine oxide biproduct (optimisation of the 
purification step is required). 
 
5.3 Experimental for ‘top-down’ approach to LOS 
 
5.3.1 A note on NMR assignments 
For polycyclic assemblies that were assigned using NOESY, protons labelled ‘A’ 
are on the bottom face of the molecule, while protons labelled ‘B’ are on the top 
face of the molecule, e.g. see compound 214 below as an example.  
 
 
Where polycyclic assemblies were not assigned using NOESY the ‘A’ and ‘B’ 
descriptors are reported arbitrarily. 
 
5.3.2 General procedures 
 
General procedure S: Amination of mesylate 176 
 
Et3N (1.0 eq.) was added to a stirred solution of the mesylate 176 (1.0 eq.) in 
THF (0.5 M, 1 volume). Amine (2.0-3.0 eq., as specified) was added and the 
reaction mixture was stirred for 15 h, then concentrated in vacuo. The resulting 
residue was diluted in EtOAc (1 volume) and washed with sat. aq. NaHCO3 
(1 volume). The phases were separated and the aqueous phase was extracted 
with EtOAc (2 volumes). The combined organics were washed with brine, dried 
over MgSO4, filtered and concentrated in vacuo. Compounds were purified by 
flash chromatography. 
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General procedure T: Carboxybenzyl protection of amines 
 
Benzyl chloroformate (1.5 eq.) was added dropwise to a stirred solution of the 
amine (1.0 eq.) in 9:1 CH2Cl2–NaHCO3 (sat. aq., 0.2 M, 1 volume). The reaction 
mixture stirred for 0.25 h. Sat. NaHCO3 (0.5 volume) was then added and the 
phases separated. The aqueous phase was extracted with CH2Cl2 (0.5 volume). 
The combined organic phase was dried over Na2SO4 and concentrated in vacuo. 
Compounds were purified by flash chromatography. 
 
General procedure U: Intramolecular [5+2] cycloaddition of 
oxidopyryliums generated from β-alkoxy-γ-pyrones 
 
A stirred solution of the starting material in PhMe (1.0 M) was heated at 
140-180 °C (as specified) under microwave irradiation for 2-6 h (as specified). 
The reaction mixture was concentrated in vacuo. Compounds were purified by 
flash chromatography. 
 
5.3.3 Compound data for ‘top-down’ approach to LOS 
 
2-Amino-1-(furan-2-yl)ethan-1-ol 143 
Following a procedure by O’Doherty,175 nitromethane 
(27.1 mL, 500 mmol, 5.00 eq.) was added to a stirred 
solution of LiAlH4 (380 mg, 10.0 mmol, 0.10 eq.) in THF 
(200 mL) at 0 °C. The reaction mixture was stirred at 0 °C 
for 0.5 h, then furfural (8.30 mL, 100 mmol, 1.00 eq.) was added. The reaction 
mixture was warmed to rt and stirred for 3 days. The reaction mixture was filtered 
through Celite. The resulting solution was partitioned with sat. aq. NaHCO3 
(200 mL) and the phases were separated. The aqueous phase was extracted 
with EtOAc (2 × 100 mL). The combined organic phase was washed with brine 
(100 mL), then dried over MgSO4, filtered and concentrated in vacuo to give the 
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crude Henry adduct 144 as a brown oil (15.2 g, 96% mass recovery) which was 
not purified further [characteristic 1H NMR peaks (300 MHz, CDCl3): δ 7.44-7.41 
(1H, m, 5-H), 6.41 (1H, d, J 3.3, 3-H), 6.39 (1H, dd, J 3.3, 1.8, 4-H), 5.53-5.45 
(1H, m, CH(OH)), 4.81 (1H, dd, J 13.4, 9.2, CHAHBNO2), 4.68 (1H, dd, J 13.4, 
3.5, CHAHBNO2), 2.79 (1H, m, OH). Spectrum consistent with the literature 
values].175  
Following the modification of a procedure by Dixon,213 NiCl2•6H2O (75 mg, 0.32 
mmol, 5.0 mol%) was added to a stirred solution of Henry adduct 144 (1.0 g, 6.4 
mmol, 1.0 eq.) in 1:1 THF–MeOH (65 mL) at rt. The reaction mixture was stirred 
for 10 min then cooled to 0 °C. NaBH4 (962 mg, 25.4 mmol, 4.00 eq.) was added 
portionwise. The reaction mixture was stirred for 10 min then warmed to rt and 
stirred for 1 h. Purification by SCX cartridge, eluting first with MeOH then sat. 
NH3/MeOH, gave aminoalcohol 145 (588 mg) as a brown oil which was carried 
on to the next step without further purification [characteristic 1H NMR peaks 
(300 MHz, CDCl3, NH2 and OH not observed): δ 7.37 (1H, app. br. s, 5-H), 6.33 
(1H, app. br. s, 4-H), 6.26 (1H, d, J 2.7, 3-H), 4.63 (1H, br. s, CH(OH)), 3.04 (2H, 
br. s, CH2NH2). Spectrum consistent with the literature values].214 
Et3N (1.0 mL, 6.9 mmol, 1.5 eq.) was added to a stirred solution of 
aminoalcohol 145 (588 mg, 4.62 mmol, 1.00 eq.) in CH2Cl2 (10 mL). The reaction 
mixture was stirred for 5 min then cooled to 0 °C. 4-Nitrobenzenesulfonyl chloride 
(1.23 g, 5.54 mmol, 1.20 eq.) was added and the reaction mixture was stirred for 
15 h at rt. The reaction partitioned with sat. aq. NaHCO3 (10 mL) and the phases 
were separated. The aqueous phase was extracted with CH2Cl2 (2 × 10 mL). The 
combined organic phases were washed with brine (20 mL), then dried over 
MgSO4, filtered and concentrated in vacuo. Flash chromatography eluting with 
0-100% EtOAc in pentane gave the title compound 143 (627 mg, 2.00 mmol, 32% 
over three steps) as a pale brown oil. Rf 0.65 (1:1 petrol–EtOAc). 
1H NMR (500 MHz, CDCl3): δ 8.37 (2H, d, J 8.9, Ar 3-H), 8.05 (2H, d, J 8.9, 
Ar 2-H), 7.36-7.35 (1H, m, furyl 5-H), 6.34 (1H, dd, J 3.3, 1.8, furyl 4-H), 6.30 (1H, 
d, J 3.3, furyl 3-H), 5.08-5.03 (1H, m, NH), 4.86-4.81 (1H, m, CH(OH)CH2), 
3.50-3.44 (1H, m, CHAHBNH), 3.37-3.30 (1H, m, CHAHBNH), 2.22 (1H, d, J 4.4, 
OH). 13C NMR (125 MHz, CDCl3): δ 152.9 (furyl 2-C), 150.4 (Ar-Cq-NO2), 146.0 
(Ar-Cq-SO2), 142.9 (furyl 5-C), 128.5 (Ar 2-C), 124.6 (Ar 3-C), 110.7 (furyl 4-C), 
107.8 (furyl 3-C), 66.6 (CH(OH)), 47.3 (CH2NH). IR νmax(film)/cm−1 3296 (OH), 
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3107, 1529, 1350, 1310, 1163, 1092, 1012. HRMS (ESI): C12H11N2O6S [M-H]−; 
calculated 311.0343, found 311.0339. 
  
N-Allyl-N-[2-(furan-2-yl)-2-hydroxyethyl]-4-nitrobenzenesulfonamide 147 
Following a procedure by Moitessier,215 allyl bromide 
(39 µL, 0.44 mmol, 1.20 eq.) was added to a stirred 
solution of the protected aminoalcohol 143 (115 mg, 
0.370 mmol, 1.00 eq.) and K2CO3 (512 mg, 3.70 mmol, 
10.0 eq.) in acetone (20 mL). The reaction mixture was 
stirred for 15 h then concentrated in vacuo. The resulting residue was extracted 
with CH2Cl2 (20 mL) and washed with H2O (20 mL). The organic phase was dried 
over MgSO4, filtered, then concentrated in vacuo. Flash chromatography eluting 
with 0-100% EtOAc in pentane gave the title compound 147 (65 mg, 2.0 mmol, 
50%) as a colourless oil. Rf 0.69 (1:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3): 
δ 8.36 (2H, d, J 8.9, Ar 3-H), 8.04 (2H, d, J 8.9, Ar 2-H), 7.38 (1H, m, furyl 5-H), 
6.36 (1H, dd, J 3.2, 1.8, furyl 4-H), 6.33 (1H, d, J 3.2, furyl 3-H), 5.62-5.52 (1H, 
m, CH2CH=CH2), 5.23-5.15 (2H, m, includes at δ 5.19: 1H, dd, J 10.1, 1.0, 
CH=CHAHB; and at δ 5.18: 1H, dd, J 17.0, 1.0, CH=CHAHB), 4.99-4.92 (1H, m, 
CH(OH)), 3.91 (1H, dd, J 15.8, 6.5, CHAHBCH=CH2), 3.86 (1H, dd, J 15.8, 6.4, 
CHAHBCH=CH2), 3.62 (1H, dd, J 14.9, 8.3, NCHAHBCH(OH)), 3.48 (1H, dd, 
J 14.9, 4.2, NCHAHBCH(OH)), 2.52 (1H, s, OH). 13C NMR (125 MHz, CDCl3): 
δ 153.4 (furyl 2-C), 150.2 (Ar-Cq-NO2), 145.9 (Ar-Cq-SO2), 142.6 (furyl 5-C), 131.9 
(CH=CH2), 128.7 (Ar 2-C), 124.5 (Ar 3-C), 120.4 (CH=CH2), 110.7 (furyl 4-C), 
107.7 (furyl 3-C), 66.8 (CH(OH), 52.0 (CH2CH=CH2), 51.6 (NCH2CH(OH)). 
IR νmax(film)/cm−1 1529, 1350, 1311, 1160, 1090, 1011, 922, 743. HRMS (ESI): 
C15H15N2O6S [M-H]−; calculated 351.0647, found 351.0656. 
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(2R*,6R*)-5-Oxo-6-{[N-(prop-2-en-1-yl)4-nitrobenzenesulfonamido]methyl}-
5,6-dihydro-2H-pyran-2-yl acetate 141amajor and (2R*,6S*)-5-oxo-6-{[N-(prop-
2-en-1-yl)4-nitrobenzenesulfonamido]methyl}-5,6-dihydro-2H-pyran-2-yl 
acetate 141aminor 
Following a procedure by 
O’Doherty,175 NBS (50 mg, 
0.28 mmol, 1.0 eq.) was 
added to a stirred solution of 
furan 147 (100 mg, 
0.28 mmol, 1.0 eq.), 
NaHCO3 (47 mg, 0.56 mmol, 2.0 eq.) and NaOAc•3H2O (38 mg, 0.28 mmol, 
1.0 eq.) in 5:1 THF–H2O (6.0 mL) at 0 °C. The reaction mixture was stirred at this 
temperature for 1 h then diluted with sat. aq. NaHCO3 solution (10 mL). The 
reaction mixture was extracted with EtOAc (3 × 10 mL). The combined organic 
phases were washed with sat. aq. Na2SO3 (10 mL) and brine (10 mL). The 
organic phases was then dried, filtered and concentrated in vacuo to give a yellow 
oil (115 mg). The crude residue was dissolved in pyridine (5.0 mL) and Ac2O 
(0.1 mL, 1.0 mmol, 3.8 eq.) was added at 0 °C. The reaction mixture was stirred 
at 0 °C for 0.5 h then warmed to rt and concentrated in vacuo. Flash 
chromatography eluting with 0-100% EtOAc in pentane gave coelution of the title 
compounds 141amajor and 141aminor (52 mg, 0.13 mmol, 45% over two steps, 3:2 
mixture of anomers) as a pale brown oil. Rf 0.22 (1:1 petrol–EtOAc). 1H NMR 
(500 MHz, CDCl3, 60:40 mixture of anomers): δ 8.36 (2H, 2 × d, J 9.0, major and 
minor Ar 3-H), 8.05 (2H, app. t, J 9.0, major and minor Ar 2-H), 6.91-6.85 (1H, m, 
major and minor 4-H), 6.52-6.50 (0.4H, m, minor 2-H), 6.40 (0.6H, d, J 3.6, major 
2-H), 6.25 (0.4H, dd, J 10.4, 1.2, minor 3-H), 6.20 (0.6H, app. d, J 10.3, major 
3-H), 5.66-5.53 (1H, m, major and minor CH2CH=CH2), 5.23-5.15 (2H, m, major 
and minor CH2CH=CH2), 4.76 (0.6H, dd, J 8.6, 2.8, major 6-H), 4.42 (0.4H, dd, 
J 8.6, 3.2, minor 6-H), 4.04-3.92 (2.6H, m, includes 2H, major and minor 
CH2CH=CH2; and 0.6H, major CHCHAHBN), 3.90 (0.4H, dd, J 15.3, 3.2, minor 
CHCHAHBN), 3.65 (0.4H, dd, J 15.3, 8.6, minor CHCHAHBN), 3.42 (0.6H, dd, 
J 15.5, 8.6, major CHCHAHBN), 2.17 (1.2H, s, minor CH3), 2.12 (1.8H, s, major 
CH3). 13C NMR (125 MHz, CDCl3, mixture of two rotamers): δ 192.9 (major, 5-C), 
192.8 (minor, 5-C), 169.4 (major, (CO)CH3), 169.2 (minor, (CO)CH3), 150.2 
(major and minor, Ar-Cq-NO2), 146.2 (minor, Ar-Cq-SO2), 146.0 (major, 
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Ar-Cq-SO2), 144.6 (minor, 4-C), 142.0 (major, 4-C), 132.0 (major, CH=CH2), 
131.9 (minor, CH=CH2), 129.1 (minor, 3-C), 128.8 (major, 3-C or Ar 2-C), 128.7 
(major, 3-C or Ar 2-C), 128.4 (minor, Ar 2-C), 124.5 (minor, Ar 3-C), 124.4 (major, 
Ar 3-C), 120.2 (minor, CH=CH2), 120.1 (major, CH=CH2), 88.0 (minor, 2-C), 86.0 
(major, 2-C), 78.3 (minor, 6-C), 75.5 (major, 6-C), 51.7 (major, CH2CH=CH2), 
51.3 (minor, CH2CH=CH2), 48.0 (minor, CqCH2N), 46.6 (major, CqCH2N), 21.1 
(minor, CH3), 21.0 (major, CH3). IR νmax(film)/cm−1 1755 (CO), 1697 (CO), 1531, 
1312, 1217, 1162, 1090, 1010. HRMS (APCI): C15H15N2O6S* [M+H]+; calculated 
351.0651, found 351.0645. 
 
 
(1R*,5R*,7R*)-3-(4-Nitrobenzenesulfonyl)-11-oxa-3-
azatricyclo[5.3.1.01,5]undec-8-en-10-one 140a 
Following a modified procedure by Mitchell,179 
quinuclidine (15 mg, 0.13 mmol, 4.0 eq.) was added to 
a stirred solution of acetoxypyranone 141a (14 mg, 
34 µmol, 1.0 eq.) in MeCN (0.3 mL) in a 1 mL 
screw-topped vial. The reaction mixture was heated at 80 °C for 15 h then 
concentrated in vacuo. Flash chromatography eluting with 0-100% EtOAc in 
pentane gave the title compound 140a (10 mg, 29 µmol, 84%) as a colourless oil. 
Rf 0.69 (1:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3): δ 8.40 (2H, d, J 8.7, 
Ar 3-H), 8.04 (2H, d, J 8.7, Ar 2-H), 7.20 (1H, dd, J 9.8, 4.5, 8-H), 5.97 (1H, d, 
J 9.8, 9-H), 4.92 (1H, dd, J 6.7, 4.5, 7-H), 4.12 (1H, d, J 12.0, 2-HA), 3.72 (1H, dd, 
J 10.5, 8.7, 4-HA), 3.46 (1H, d, J 12.0, 2-HB), 3.22 (1H, dd, J 10.5, 6.7, 4-HB), 
2.60-2.53 (1H, m, 5-H), 2.13 (1H, dd, J 12.3, 8.5, 6-HA), 1.99-1.93 (1H, m, 6-HB). 
13C NMR (125 MHz, CDCl3): δ 192.8 (10-C), 152.8 (9-C), 150.5 (Ar-Cq-NO2), 
142.5 (Ar-Cq-SO2), 129.1 (Ar 2-C), 125.8 (8-C), 124.5 (Ar 3-C), 96.2 (1-C), 76.9 
(7-C), 54.2 (4-C), 51.1 (2-C), 44.3 (5-C), 35.5 (6-C). IR νmax(film)/cm−1 1693 (CO), 
1528, 1350, 1307, 1164, 1100, 1013, 856. HRMS (APCI): C15H15N2O6S [M+H]+; 
calculated 351.0651, found 351.0643. 
                                            
* N.b. The pyran underwent [5 + 2] cycloaddition under all attempted MS conditions to give cycloadduct 140a.  
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5-[(tert-Butyldimethylsilyl)oxy]-2-(hydroxymethyl)-4H-pyran-4-one 175 
Following a procedure by Miyazaki,191 TBSCl (5.3 g, 35 mmol, 
1.0 eq.) was added to a stirred suspension of kojic acid (5.0 g, 
35 mmol, 1.0 eq.), Et3N (7.4 mL, 100 mmol, 2.90 eq.) and 
DMAP (5 mg, 0.04 mmol, 0.001 eq.) in CHCl3 at 0 °C. The 
reaction mixture was stirred at this temperature for 1 h then aqueous 5 wt% 
KHSO4 (50 mL) was added. The phases were separated and the organic phase 
was washed with brine (50 mL), dried, filtered and concentrated in vacuo. Flash 
chromatography eluting with 1:1 pentane–EtOAc gave the title compound 175 
(8.08 g, 31.5 mmol, 90%) as a colourless amorphous solid.* Rf 0.57 (1:1 petrol–
EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.65 (1H, s, 6-H), 6.47 (1H, s, 3-H), 4.46 
(2H, d, J 6.3, CH2OH), 3.13 (1H, t, J 6.3, OH), 0.95 (9H, s, SiC(CH3)3), 0.21 (6H, 
s, 2 × SiCH3). 13C NMR (125 MHz, CDCl3): δ 176.1 (4-C), 166.6 (2-C), 
144.6 (5-C), 144.2 (6-C), 112.4 (3-C), 61.1 (CH2), 25.8 (SiC(CH3)3), 18.7 (SiCq), 
−4.4 (2 × SiCH3). IR νmax(film)/cm−1 3358 (br., OH), 2954, 2857, 1651 (CO), 1629, 
1268, 1211, 874. LRMS† (HPLC-MS): C12H21O4Si; found 257.1 [M+H]+. Spectral 
data are consistent with the literature values.216 
 
{5-[(tert-Butyldimethylsilyl)oxy]-4-oxo-4H-pyran-2-yl}methyl 
methanesulfonate 176 
Et3N (3.3 mL, 23.4 mmol, 2.0 eq.) was added to a stirred 
solution of silyl protected kojic acid 175 (3.00 g, 11.7, 1.00 eq.) 
in CH2Cl2 (24 mL). The reaction mixture was cooled to 0 °C 
and MsCl (1.1 mL, 14 mmol, 1.2 eq.) was added dropwise. The 
reaction mixture was stirred at 0 °C for 0.5 h, then warmed to rt and partitioned 
with H2O (25 mL). The phases were separated and the aqueous phase was 
                                            
* This compound and all derivatives slowly decomposed in mildly acidic solvents (e.g. CHCl3) and should be stored in a 
freezer. N.b. the derived cycloadducts 181,183,184 were bench stable for weeks. 
† Compound decomposed before HRMS could be performed. 
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extracted with CH2Cl2 (25 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated in vacuo to give the title compound 176 (3.31 g, 
9.89 mmol, 85% mass recovery) which was used subsequently without further 
purification. Rf 0.62 (1:1 petrol–EtOAc). 1H NMR (300 MHz, CDCl3, characteristic 
peaks): δ 7.69 (1H, s, 6-H), 6.48 (1H, s, 3-H), 4.97 (2H, s, CH2), 3.11 (3H, s, 
SO2CH3), 0.95 (9H, s, SiC(CH3)3), 0.23 (6H, s, 2 × SiCH3). 
 
2-{[bis(Prop-2-en-1-yl)amino]methyl}-5-[(tert-butyldimethylsilyl)oxy]-4H-
pyran-4-one 177 
General procedure S was followed using mesylate 176 
(650 mg, 1.95 mmol, 1.00 eq.) and diallylamine (0.48 mL, 
3.9 mmol, 2.0 eq). Flash chromatography on cyanosilica, 
eluting with 0-50% EtOAc in pentane gave the title 
compound 177 (498 mg, 1.48 mmol, 76%) as a colourless 
oil. Rf 0.11 (95:5 petrol–EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.64 (1H, s, 6-H), 
6.40 (1H, s, 3-H), 5.87-5.77 (2H, m, 2 × NCH2CH=CH2), 5.23-5.15 (4H, m, 
2 × CH=CH2), 3.42 (2H, s, CqCH2N), 3.14 (4H, dt, J 6.3, 1.1, 2 × NCH2CH=CH2), 
0.96 (9H, s, SiC(CH3)3), 0.23 (6H, s, 2 × SiCH3). 13C NMR (125 MHz, CDCl3): 
δ 175.7 (4-C), 165.6 (2-C), 145.5 (5-C), 144.2 (6-C), 134.9 (2 × CH=CH2), 118.5 
(2 × CH=CH2), 114.6 (3-C), 57.2 (2 × NCH2CH=CH2), 54.2 (CqCH2N), 25.8 
(SiC(CH3)3), 18.7 (SiCq), −4.3 (2 × SiCH3). IR νmax(film)/cm−1 2954, 2929, 2857, 
1652 (CO), 1279, 1252, 1010, 922. HRMS (ESI): C18H30NO3Si [M+H]+; calculated 
336.1989, found 336.1994.  
 
5-[(tert-Butyldimethylsilyl)oxy]-2-{[(prop-2-en-1-yl)amino]methyl}-4H-
pyran-4-one 178 
General procedure S was followed using mesylate 176 (10 g, 
35 mmol, 1.0 eq.) and Et3N (3.5 mL, 35 mmol) and allylamine 
(8.0 mL, 0.1 mol, 3.0 eq.). The residue was washed through a 
pad of silica with 9:1 EtOAc–MeOH to give the title 
compound 178 (5.9 g, 20.0 mmol, 56%) as a dark brown oil. 
Rf 0.57 (1:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3): δ 7.64 (1H, s, 6-H), 6.36 
(1H, s, 3-H), 5.91-5.81 (1H, m, CH=CH2), 5.20 (1H, app. dq, J 17.2, 1.4, 
CH=CHAHB), 5.14 (1H, ddd, J 10.3, 2.7, 1.4, CH=CHAHB), 3.62 (2H, s, CqCH2NH), 
3.27 (2H, dt, J 6.0, 1.4, NHCH2CH=CH2), 0.96 (9H, s, SiC(CH3)3), 0.23 (6H, s, 
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2 × SiCH3). 13C NMR (125 MHz, CDCl3): δ 175.7 (4-C), 165.7 (2-C), 145.5 (5-C), 
144.2 (6-C), 135.9 (CH=CH2), 117.1 (CH=CH2), 113.7 (3-C), 51.5 (CH2CH=CH2), 
49.8 (CqCH2NH), 25.8 (SiC(CH3)3), 18.7 (SiCq), −4.3 (2 × SiCH3). 
IR νmax(film)/cm−1 2954, 2930, 2857, 1651 (CO), 1232, 919, 879, 786. 
LRMS* (HPLC-MS): C15H25NO3Si; found 296.1 [M+H]+. 
 
Benzyl N-({5-[(tert-butyldimethylsilyl)oxy]-4-oxo-4H-pyran-2-yl}methyl)-N- 
(prop-2-en-1-yl)carbamate 179 
Method A (from amine 178): Benzyl chloroformate 
(180 µL, 1.28 mmol, 2.6 eq.) was added to a stirred 
solution of the amine 178 (145 mg, 0.49 mmol, 
1.0 eq.) and Et3N (180 µL, 1.28 mmol, 2.6 eq.) in 
CH2Cl2 (5.0 mL) at 0 °C. The reaction mixture 
warmed to rt and stirred for 15 h, then concentrated in vacuo. Flash 
chromatography eluting with 9:1 EtOAc–MeOH gave the title compound 179 
(145 mg, 0.34 mmol, 69%) as a pale yellow oil. 
Method B (four-step telescoped procedure): Starting with kojic acid (5.0 g, 
35 mmol) the procedure to prepare 5-[(tert-butyldimethylsilyl)oxy]-2-
(hydroxymethyl)-4H-pyran-4-one 175 was followed. The crude silylated kojic 
acid 175 (35 mmol) was carried forward without further purification following the 
work-up. The procedure to prepare {5-[(tert-butyldimethylsilyl)oxy]-4-oxo-4H-
pyran-2-yl}methyl methanesulfonate 176 was then followed. The crude mesylate 
176 was carried on to the next step without further purification. General 
procedure S was followed using mesylate 176 (35 mmol) and allylamine (8.0 mL, 
106 mmol, 3.00 eq.) to give crude amine 178. General procedure T was followed 
using amine 178 (35 mmol). Flash chromatography eluting with 1:1 pentane–
EtOAc gave the title compound 179 (4.4 g, 10 mmol, 29% [over four steps]) as a 
pale yellow oil.† Rf 0.82 (1:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3, 330 K): 
δ 7.56 (1H, s, 6-H), 7.39-7.27 (5H, m, Cbz Ar-H), 6.23 (1H, s, pyran 3-H), 
5.81-5.70 (1H, m, CH=CH2), 5.21-5.10 (4H, m, CH=CH2 and CH2Ph), 4.26 (2H, 
s, CqCH2NH), 3.96 (2H, s, NCH2CH=CH2), 0.97 (9H, s, SiC(CH3)3), 0.24 (6H, s, 
2 × SiCH3). 13C NMR (125 MHz, CDCl3, 330 K): δ 175.3 (4-C), 163.3 (2-C), 156.1 
                                            
* Compound decomposed before HRMS could be performed. 
† This compound slowly decomposed in mildly acidic solvents (e.g. CHCl3) and should be stored in a freezer. 
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(N(CO)O), 145.8 (5-C), 144.0 (6-C), 136.5 (CH=CH2), 132.9 (Ar-Cq), 128.7 
(Ar-C), 128.4 (Ar-C), 128.2 (Ar-C), 118.2 (CH=CH2), 113.7 (3-C), 65.6 (CH2Ph), 
50.3 (CH2CH=CH2), 47.6 (CqCH2NH), 25.8 (SiC(CH3)3), 18.7 (SiCq), −4.3 
(2 × SiCH3). IR νmax(film)/cm−1 2953, 2929, 2857, 1702 (CO), 1649, 1460, 1410, 
1210. HRMS (ESI): C23H32NO5Si [M+H]+; calculated 430.2058, found 430.2044. 
 
Benzyl N-({5-[(tert-butyldimethylsilyl)oxy]-4-oxo-4H-pyran-2-yl}methyl)-N-
(prop-2-yn-1-yl)carbamate 180 
Starting with kojic acid (5.0 g, 35 mmol) the 
procedure to prepare 5-[(tert-butyldimethylsilyl)oxy]-
2-(hydroxymethyl)-4H-pyran-4-one 175 was 
followed. The crude silylated kojic acid 175 
(35 mmol) was carried forward without further 
purification following the work-up. The procedure to 
prepare {5-[(tert-butyldimethylsilyl)oxy]-4-oxo-4H-pyran-2-yl}methyl 
methanesulfonate 176 was then followed. The crude mesylate 176 was carried 
on to the next step without further purification. General procedure S was followed 
using mesylate 176 (35 mmol) and propargylamine (6.8 mL, 106 mmol, 3.00 eq.) 
to give the crude amine S2 [characteristic 1H NMR peaks (300 MHz, CDCl3): 
δ 7.65 (1H, s, 6-H), 6.39 (1H, s, 3-H), 3.73 (2H, s, CqCH2N), 3.47 (2H, d, J 2.4, 
NCH2C≡CH), 2.27 (1H, t, J 2.4, C≡CH), 0.95 (9H, s, SiC(CH3)3), 0.23 (6H, s, 
2 × SiCH3)]. General procedure T was followed using amine S2 (35 mmol). Flash 
chromatography eluting with 1:1 pentane–EtOAc gave the title compound 
180 (2.7 g, 6.3 mmol, 18% [over four steps]) as a pale yellow oil.* Rf 0.20 (4:1 
petrol–EtOAc). 1H NMR (500 MHz, CDCl3, 329 K): δ 7.57 (1H, s, 6-H), 7.38-7.29 
(5H, m, Cbz Ar-H), 6.28 (1H, s, 3-H), 5.19 (2H, s, OCH2Ph), 4.42 (2H, s, CqCH2N), 
4.18 (2H, br. s, NCH2C≡CH), 2.26 (1H, t, J 2.5, C≡CH), 0.97 (9H, s, SiC(CH3)3), 
0.24 (6H, s, 2 × SiCH3). 13C NMR (125 MHz, CDCl3, 329 K): δ 175.3 (4-C), 162.7 
(2-C), 155.5 (N(CO)O), 145.9 (5-C), 144.0 (6-C), 136.2 (Ar-Cq), 128.8 (Ar-C), 
128.5 (Ar-C), 128.3 (Ar-C), 114.0 (3-C), 78.1 (CH2C≡CH), 73.3 (CH2C≡CH), 68.5 
(CH2Ph), 47.5 (CqCH2N), 37.2 (CH2C≡CH), 25.9 (SiC(CH3)3), 18.7 (SiCq), 
−4.3 (2 × SiCH3). IR νmax(film)/cm−1 2953, 2930, 2857, 1708 (CO), 1650, 1498, 
                                            
* This compound slowly decomposed in mildly acidic solvents (e.g. CHCl3) and should be stored in a freezer. 
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1455, 1216. HRMS (ESI): C23H30NO5Si [M+H]+; calculated 428.1888, found 
428.1889. 
 
(1R*,5S*,7S*)-9-[(tert-Butyldimethylsilyl)oxy]-3-(prop-2-en-1-yl)-11-oxa-3-
azatricyclo[5.3.1.01,5]undec-9-en-8-one 181 
General procedure U was followed using amine 177 
(174 mg, 0.520 mmol), which was heated at 140 °C under 
microwave irradiation for 2 h. Flash chromatography 
eluting with 0-100% EtOAc in pentane gave the title 
compound 181 (127 mg, 0.379 mmol, 73%) as a colourless 
oil. Rf 0.31 (1:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3): δ 6.46 (1H, s, 10-H), 
5.95-5.85 (1H, m, CH2CH=CH2), 5.21 (1H, dd, J 17.1, 1.3, CH2CH=CHAHB), 5.13 
(1H, d, J 10.0, CH2CH=CHAHB), 4.76 (1H, d, J 8.0, 7-H), 3.21-3.12 (2H, m, 
CH2CH=CH2), 3.08-2.98 (2H, m, includes at δ 3.04, 1H, d, J 11.2, 2-HA; and at 
δ 3.00, 1H, d, J 8.5, 4-HA), 2.86 (1H, d, J 11.2, 2-HB), 2.75-2.67 (1H, m, 5-H), 2.39 
(1H, app. t, J 8.5, 4-HB), 2.20-2.08 (1H, m, 6-HB), 1.86 (1H, dd, J 13.1, 8.7, 6-HA), 
0.93 (9H, s, SiC(CH3)3), 0.15 (6H, s, 2 × SiCH3). 13C NMR (125 MHz, CDCl3): 
δ 194.3 (8-C), 147.7 (9-C), 134.9 (10-C), 131.1 (CH=CH2), 118.1 (CH=CH2), 90.7 
(1-C), 84.3 (7-C), 61.5 (2-C), 59.6 (4-C), 58.7 (CH2CH=CH2), 49.0 (5-C), 30.7 
(6-C), 25.7 (SiC(CH3)3), 18.5 (SiCq), −4.6 (2 peaks, 2 × SiCH3). IR νmax(film)/cm−1 
2952, 2929, 2857, 1702 (CO), 1613, 1471, 1341, 1252. HRMS (ESI): 
C18H30NO3Si [M+H]+; calculated 336.1989, found 336.1990.  
 
 
Benzyl (1R*,5S*,7S*)-9-[(tert-butyldimethylsilyl)oxy]-8-oxo-11-oxa-3-
zatricyclo[5.3.1.01,5]undec-9-ene-3-carboxylate 183 
General procedure U was followed using carbamate 
179 (1.0 g, 2.3 mmol), which was heated at 140 °C 
under microwave irradiation for 6 h. Flash 
chromatography eluting with EtOAc gave the title 
compound 183 (890 mg, 2.05 mmol, 89%) as a 
colourless amorphous solid. M.p. 96-98 °C, colourless 
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plates, hexane–EtOAc. Rf 0.18 (4:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3, 
50:50 mixture of rotamers): δ 7.41-7.29 (5H, m, Cbz Ar-H), 6.29 (0.5H, s, 10-H), 
6.26 (0.5H, s, 10-H), 5.15 (1H, d, J 12.0, OCHAHBPh), 5.12 (1H, d, J 12.0, 
OCHAHBPh), 4.78 (1H, d, J 8.2, 7-H), 4.04-3.90 (2H, m, 2-HB and 4-HA), 3.68 
(0.5H, d, J 12.8, 2-HA), 3.64 (0.5H, d, J 12.8, 2-HA), 3.22-3.13 (1H, m, 4-HB), 
2.84-2.74 (1H, m, 5-H), 2.34-2.21 (1H, m, 6-HB), 1.89 (1H, td, J 13.2, 8.2, 6-HA), 
0.94 (4H, s, SiC(CH3)3), 0.93 (5H, s, SiC(CH3)3), 0.16 (6H, m, 2 × SiCH3). 
13C NMR (125 MHz, CDCl3, mixture of two rotamers): δ 193.7 (8-C), 154.5 
(N(CO)O), 154.3 (N(CO)O), 148.1 (9-C), 136.8 (Ar 1-C), 138.7 (Ar 1-C), 128.7 
(Ar-C), 128.3 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 127.3 (10-C), 127.2 (10-C), 90.6 
(1-C), 89.8 (1-C), 83.4 (7-C), 67.2 (OCH2Ph), 53.9 (2-C or 4-C), 53.5 (2-C or 4-C), 
53.1 (2-C or 4-C), 52.7 (2-C or 4-C), 47.1 (5-C), 46.2 (5-C), 31.6 (6-C), 31.5 (6-C), 
25.7 (SiC(CH3)3), 18.6 (SiCq), −4.5 (2 × SiCH3) [27 of 36 expected peaks 
observed]. IR νmax(film)/cm−1 2954, 2953, 1703 (CO), 1652, 1419, 1347, 1163, 
919. HRMS (ESI): C23H32NO5Si [M+H]+; calculated 430.2044, found 430.2048. 
 
 
Benzyl (1R*,7R*)-9-[(tert-butyldimethylsilyl)oxy]-8-oxo-11-oxa-3-
azatricyclo[5.3.1.01,5]undeca-5,9-diene-3-carboxylate 184 
General procedure U was followed using 
carbamate 180 (377 g, 0.88 mmol), which was heated 
at 180 °C under microwave irradiation for 6 h. Flash 
chromatography eluting with 0-100% EtOAc in 
pentane gave the title compound 184 (240 mg, 
0.56 mmol, 64%) as a colourless powder. Rf 0.39 
(4:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3, 329 K): δ 7.40-7.30 (5H, m, Cbz 
Ar-H), 6.36 (1H, s, 10-H), 6.04 (1H, s, 6-H), 5.19 (2H, s, OCH2Ph), 5.17-5.15 (1H, 
m, 7-H), 4.25 (1H, d, J 16.7, 2-HA), 4.14 (1H, app. dd, J 16.7, 1.4, 2-HB), 4.05-3.87 
(1H, m, 4-HA), 3.51 (1H, d, J 11.3, 4-HB), 0.94 (9H, s, SiC(CH3)3), 0.17 (3H, s, 
SiCH3), 0.16 (3H, s, SiCH3). 13C NMR (125 MHz, CDCl3, mixture of two rotamers): 
δ 190.8 (2 peaks, 8-C), 156.4 (9-C), 155.6 (9-C), 154.7 (N(CO)O), 
154.5 (N(CO)O), 143.7 (5-C), 136.3 (Ar-Cq), 128.6 (Ar-C), 128.3 (Ar-C), 
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128.1 (Ar-C), 127.5 (10-C), 127.4 (10-C), 118.0 (6-C), 93.9 (7-C), 92.2 (1-C), 
91.4 (1-C), 67.4 (OCH2Ph), 51.9 (2 peaks, 4-C), 43.6 (2-C), 43.5 (2-C), 25.5 
(SiC(CH3)3), 18.4 (SiCq), −4.6 (SiCH3), −4.7 (SiCH3) [26 of 36 expected peaks 
observed]. IR νmax(film)/cm−1 2955, 2930, 2887, 2856, 1704, 1606, 1412, 1358. 
HRMS (ESI): C23H30NO5Si [M+H]+; calculated 428.1888, found 428.1889. 
 
Benzyl (1R*,5R*,7R*,8S*,9R*)-9-[(tert-butyldimethylsilyl)oxy]-8-hydroxy-11-
oxa-3-azatricyclo[5.3.1.01,5]undecane-3-carboxylate 211 and benzyl 
(1R*,5R*,7R*,8R*,9R*)-8-[(tert-butyldimethylsilyl)oxy]-9-hydroxy-11-oxa-3-
azatricyclo[5.3.1.01,5]undecane-3-carboxylate 212 
NaBH4 (44 mg, 1.2 mmol, 2.0 eq.) was added to a 
stirred solution of cycloadduct 183 (250 mg, 
0.58 mmol, 1.0 eq.) in MeOH (10 mL) at 0 °C. The 
reaction mixture was stirred at 0 °C for 0.5 h. H2O 
(1 mL) was added and the reaction mixture was 
warmed to rt. The reaction mixture was 
concentrated in vacuo to give a colourless oil 
which was carried on to the next step without 
further purification [Rf 0.29 and 0.45 (7:3 pentane–
EtOAc). Characteristic 1H NMR peaks (500 MHz, 
CDCl3, 40:60* mixture of regioisomers): δ 7.38-7.28 (major and minor, 5H, m, Cbz 
Ar-H), 5.15-5.07 (major and minor, 2H, m, OCH2Ph), 4.36 (minor, 0.4H, dd, J 7.3, 
4.6), 4.25-4.20 (major, 0.6H, dd, J 6.9, 5.2), 4.13-4.09 (minor, 0.4H, m), 3.98-3.93 
(major, 0.6H, m), 3.93-3.86 (major and minor, 1H, m), 3.84-3.79 (major, 0.6H, m), 
3.77-3.68 (major and minor, 1.4H, m), 3.44-3.32 (major and minor, 1H, m), 
3.24-3.13 (major and minor, 1H, m), 3.09-3.01 (major, 0.6H, m), 2.95-2.86 (minor, 
0.4H, m), 2.77 (major, 0.6H, d, J 4.5), 2.62 (major, 0.6H, td, J 13.2, 8.5), 2.57-2.50 
(minor, 0.4H, m), 2.49 (minor, 0.4H, d, J 10.6), 2.24-2.10 (major, 0.6H, m), 2.07 
(minor, 0.4H, dd, J 14.6, 3.7), 1.98 (major, 0.6H, dd, J 14.5, 7.9), 1.80 (minor, 
0.4H, dd, J 14.6, 9.3), 1.76-1.56 (major and minor, 1H, m), 0.94 (minor, 3.6H, s, 
SiC(CH3)3), 0.91 (major, 5.4H, s, SiC(CH3)3), 0.13-0.10 (major and minor, 6H, m, 
SiCH3)]. 
 
                                            
* The identity of the major/minor regioisomers (with respect to the structures 211/212) has not been determined. 
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Benzyl (1R*,5R*,7R*,8R*,9R*)-8,9-dihydroxy-11-oxa-3-
azatricyclo[5.3.1.01,5]undecane-3-carboxylate 214 
TBAF (1.0 M in THF, 1.2 mL, 1.2 mmol, 2.0 eq.) was 
added to a stirred solution of the crude silylated 
alcohols 211-212 (0.58 mmol) in THF. The reaction 
mixture was stirred for 2 h then concentrated in vacuo. 
Flash chromatography eluting with 0-10% MeOH in EtOAc gave a mixture of the 
title compound with TBAF. Further purification by SCX following general 
procedure R, eluting with MeOH gave the title compound 214 (76 mg, 0.24 mmol, 
41%) as a colourless oil. Rf 0.58 (9:1 EtOAc–MeOH). 1H NMR (500 MHz, CDCl3, 
50:50 mixture of rotamers): δ 7.41-7.27 (5H, m, Cbz Ar-H), 5.11 (2H, s, CH2Ph), 
4.35 (1H, dd, J 7.2, 4.8, 7-H), 4.15-4.10 (1H, m, 9-H), 3.93-3.85 (1H, m, includes 
at δ 3.91: 0.5H, d, J, 10.5; and at δ 3.87: 0.5H, d, J, 10.5, 4-HA), 3.86-3.80 (1H, 
m, 8-H), 3.79-3.71 (1H, m, includes at δ 3.76: 0.5H, d, J, 12.6; and at δ 3.74: 0.5H, 
d, J, 12.6, 2-HA), 3.41 (0.5H, d, J 12.6, 2-HB), 3.36 (0.5H, d, J 12.6, 2-HB), 
3.24-3.15 (1H, m, 4-HB), 3.08-3.00 (1H, m, 5-H), 2.63 (1H, td, J 12.7, 8.5, 6-HA), 
2.49 (2H, br. s, 2 × OH), 2.19 (0.5H, dd, J 14.7, 4.3, 10-HB), 2.13 (0.5H, dd, J 14.7, 
4.3, 10-HB), 1.97-1.90 (1H, m, includes at δ 1.95: 0.5H, d, J 14.7; and at δ 1.93: 
0.5H, d, J 14.7, 10-HA), 1.78-1.66 (1H, m, 6-HB). 13C NMR (125 MHz, d6-DMSO, 
mixture of two rotamers): δ 153.5 (N(CO)O), 153.4 (N(CO)O), 137.1 (Ar-Cq), 
128.4 (Ar-C), 127.7 (Ar-C), 127.5 (Ar-C), 88.7 (1-C), 87.7 (1-C), 79.0 (7-C), 
68.0 (8-C), 65.9 (9-C), 65.7 (CH2Ph), 54.8 (2-C or 4-C), 54.5 (2-C or 4-C), 54.2 
(2-C or 4-C), 54.0 (2-C or 4-C), 44.2 (5-C), 43.2 (5-C), 38.0 (10-C), 37.9 (10-C), 
32.7 (6-C), 32.6 (6-C) [22 of 30 expected peaks observed]. IR νmax(film)/cm−1 
3423 (OH), 2948, 2884, 1683 (CO), 1425, 1350, 1149, 1107. HRMS (ESI): 
C17H22NO5 [M+H]+; calculated 320.1495, found 320.1496. 
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Benzyl (1R*,5R*,7R*,8S*)-8-[(tert-butyldimethylsilyl)oxy]-9-oxo-11-oxa-
3-azatricyclo[5.3.1.01,5]undecane-3-carboxylate 216 
L-Selectride® (1.0 M in THF, 0.25 mL, 0.25 mmol, 
1.1 eq.) was added dropwise to a stirred solution of 
cycloadduct 183 (100 mg, 0.230 mmol, 1.00 eq.) in 
THF (10 mL) at −78 °C. The reaction mixture was 
stirred for 3.5 h at −78 °C, then quenched with sat. 
aq. NH4Cl (1 mL). The reaction mixture was warmed to rt then concentrated 
in vacuo. The resulting residue was dissolved in EtOAc (25 mL) and washed with 
brine (25 mL). The aqueous phase was extracted with EtOAc (2 × 10 mL). The 
combined organic extracts were dried over MgSO4, filtered and concentrated 
in vacuo. Flash chromatography eluting with 0-100% EtOAc in pentane gave the 
title compound 216 (61 mg, 0.14 mmol, 61%) as a colourless oil. Rf 0.77 (3:2 
petrol–EtOAc). 1H NMR (500 MHz, CDCl3, 50:50 mixture of rotamers): 
δ 7.38-7.28 (5H, m, Cbz Ar-H), 5.13 (1H, d, J 11.7, CHAHBPh), 5.11 (1H, d, J 11.7, 
CHAHBPh), 4.56 (1H, app. t, J 6.4, 7-H), 4.24-4.19 (1H, m, 8-H), 3.95-3.86 (2H, 
m, 2-HA and 4-HA), 3.44 (0.5H, d, J 12.7, 2-HB), 3.39 (0.5H, d, J 12.7, 2-HB), 
3.21-3.11 (1H, m, 4-HB), 2.87 (0.5H, dd, 15.1, 10-HB), 2.86 (0.5H, dd, 15.1, 
10-HB), 2.60-2.50 (1H, m, 5-H), 2.44 (1H, m, includes at δ 2.45: d, J 15.1; and at 
δ 2.44: d, J 15.1, 10-HA), 2.20 (1H, td, J 15.0, 8.6, 6-HA), 1.92-1.79 (1H, m, 6-HB), 
0.89 (9H, s, SiC(CH3)3), 0.14 (3H, s, SiCH3), 0.04 (3H, s, SiCH3). 13C NMR 
(125 MHz, CDCl3, mixture of two rotamers): δ 204.6 (9-C), 154.4 (N(CO)O), 136.8 
(Ar-Cq), 128.6 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 91.5 (1-C), 90.7 (1-C), 80.8 
(7-C), 77.6 (8-C), 67.2 (CH2Ph), 54.2 (2-C or 4-C), 53.9 (2-C or 4-C), 48.7 (10-C), 
45.9 (5-C), 45.0 (5-C), 31.9 (6-C), 31.7 (6-C), 25.9 (SiC(CH3)3), 18.5 (SiCq), 
−4.5 (SiCH3), −5.3 (SiCH3) [22 of 38 expected peaks observed]. IR νmax(film)/cm−1 
2953, 2856, 1701 (CO), 1417, 1347, 1251, 1104, 836. HRMS (ESI): C23H34NO5Si 
[M+H]+; calculated 432.2201, found 432.2205. 
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Benzyl (1R*,5S*,7S*,8R*)-9-[(tert-butyldimethylsilyl)oxy]-8-hydroxy-11-oxa-
3-azatricyclo[5.3.1.01,5]undec-9-ene-3-carboxylate 217 
NaBH4 (9 mg, 0.23 mmol, 1.0 eq.) was added to a 
stirred solution of cycloadduct 183 (100 mg, 
0.23 mmol, 1.00 eq.) and CeCl3•7H2O (95 mg, 0.25 
mmol, 1.1 eq.) in 2:1 CH2Cl2–MeOH (9 mL). The 
reaction mixture was stirred for 0.5 h. H2O (0.5 mL) 
was added then the mixture was concentrated in 
vacuo. The resulting residue was diluted in EtOAc (30 mL) and washed with brine 
(20 mL). The aqueous phase was extracted with EtOAc (2 × 10 mL). The 
combined organic phase was dried over MgSO4, filtered and concentrated 
in vacuo. Flash chromatography eluting with 0-10% MeOH in EtOAc gave the title 
compound 217 (80 mg, 0.19 mmol, 81%) as a colourless oil. 1H NMR (500 MHz, 
CDCl3, 50:50 mixture of rotamers): δ 7.38-7.27 (5H, m, Cbz Ar-H), 5.13 (1H, app. 
dd, J 12.5, 1.8, CHAHBPh), 5.10 (1H, d, J 12.5, CHAHBPh), 4.99 (0.5H, s, 10-H), 
4.99 (0.5H, s, 10-H), 4.70 (1H, app. t, J 6.4, 7-H), 4.51 (1H, app. t, J 5.4, 8-H), 
3.86-3.75 (2H, m, 2-HB and 4-HA), 3.43 (0.5H, d, J 12.6, 2-HA), 3.38 (0.5H, d, 
J 12.6, 2-HA), 3.12 (0.5H, d, J 10.5, 4-HB), 3.08 (0.5H, d, J 10.5, 4-HB), 2.75-2.65 
(1H, m, 5-H), 2.57-2.49 (1H, m, 6-HA), 2.35-2.26 (1H, m, OH), 1.87 (0.5H, dd, 
J 13.6, 7.6, 6-HB), 1.82 (0.5H, dd, J 13.6, 7.6, 6-HB), 0.94 (4.5H, SiCq(CH3)3), 0.93 
(4.5H, SiC(CH3)3), 0.21-0.16 (6H, m, 2 x SiCH3). 13C NMR (125 MHz, d6-DMSO, 
mixture of two rotamers): 153.6 (N(CO)O), 153.5 (N(CO)O), 151.8 (2 peaks, 9-C), 
137.0 (Ar-Cq), 128.4 (Ar-C), 127.7 (Ar-C), 127.5 (2 peaks, Ar-C), 107.3 (10-C), 
107.2 (10-C), 88.2 (1-C), 87.3 (1-C), 79.0 (7-C), 67.9 (8-C), 65.8 (2 peaks, 
CH2Ph), 53.1 (2-C or 4-C), 52.7 (2-C or 4-C), 52.6 (2-C or 4-C), 52.2 (2-C or 4-C), 
49.5 (5-C), 48.5 (5-C), 28.1 (6-C), 25.6 (SiC(CH3)3), 17.9 (SiCq), −4.4 (2 peaks, 
SiCH3), −4.6 (SiCH3), −4.7 (SiCH3) [30 of 38 expected peaks observed]. 
IR νmax(film)/cm−1 3443, (OH), 2952, 2884, 2857, 1686 (CO), 1650, 1419, 1358. 
HRMS (ESI): C23H34NO5Si [M+H]+; calculated 432.2201, found 432.2200. 
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tert-Butyl (1R*,5R*,7R*,8S*)-8-[(tert-butyldimethylsilyl)oxy]-9-oxo-11-oxa-3-
azatricyclo[5.3.1.01,5]undecane-3-carboxylate 219 
A stirred solution of cycloadduct 183 (100 mg, 
0.230 mmol, 1.00 eq.) and 10% Pd/C (10 mg) in 
MeOH (10 mL) was exposed to an atmosphere of H2 
(balloon) for 24 h. The reaction mixture was filtered 
through Celite then concentrated in vacuo to give amine 218 (69 mg) 
[characteristic 1H NMR peaks (300 MHz, CDCl3): δ 4.49 (1H, t, J 6.3), 4.16 (1H, 
d, J 5.9), 3.27 (1H, d, J 12.7), 3.09 (1H, dd, J 12.0, 8.4), 2.85 (1H, d, J 14.8), 2.72 
(1H, dd, J 12.1, 3.6), 2.63 (1H, d, J 12.7), 2.51-2.38 (3H, m), 2.37-2.19 (1H, m), 
1.77-1.61 (1H, m), 0.89 (9H, s, SiC(CH3)3), 0.14 (3H, s, Si(CH3)A), 0.03 (3H, s, 
Si(CH3)B)]. Boc2O (53 mg, 0.24 mmol, 1.1 eq.) Et3N (0.1 mL, 0.7 mmol, 3.0 eq.) 
and DMAP (5 mg, 0.04 mmol, 0.17 eq.) were added to a stirred solution of the 
crude amine 218 (0.23 mmol) in CH2Cl2 (10 mL). The reaction mixture was stirred 
for 15 h then concentrated in vacuo.* Flash chromatography eluting with 0-100% 
EtOAc in pentane gave the title compound 219 (48 mg, 0.12 mmol, 52%) as a 
colourless oil. Rf 0.85 (89:11 petrol–EtOAc). 1H NMR (500 MHz, CDCl3, 50:50 
mixture of rotamers): δ 4.56 (1H, app. t, J 6.3, 7-H), 4.25-4.17 (1H, m, 8-H), 
3.88-3.74 (2H, m, 2-HB and 4-HA), 3.38 (0.5H, d, J 12.5, 2-HA), 3.32 (0.5H, d, 
J 12.5, 2-HA), 3.13-3.01 (1H, m, 4-HB), 2.86 (0.5H, d, J 15.2, 10-HB), 2.81 (0.5H, 
d, J 15.2, 10-HB), 2.57-2.47 (1H, m, 5-H), 2.44 (1H, d, J 15.2, 10-HA), 2.24-2.14 
(1H, m, 6-HA), 1.91-1.78 (1H, m, 6-HB), 1.45 (9H, s, OC(CH3)3), 0.90 (9H, s, 
SiC(CH3)3), 0.14 (3H, s, SiCH3), 0.04 (3H, s, SiCH3). 13C NMR (125 MHz, CDCl3, 
mixture of two rotamers): δ 204.7 (9-C), 153.9 (N(CO)O), 91.5 (1-C), 90.7 (1-C), 
80.7 (7-C), 79.8 (CqtBu), 77.5 (8-C), 54.0 (2-C or 4-C), 53.7 (2-C or 4-C), 48.7 
(10-C), 45.7 (5-C), 44.8 (5-C), 31.8 (6-C), 31.5 (6-C), 28.5 (OC(CH3)3), 25.7 
(SiC(CH3)3), 18.4 (SiCq), −4.6 (SiCH3), −5.4 (SiCH3) [19 of 32 expected peaks 
observed]. IR νmax(film)/cm−1 2955, 2930, 2886, 2857, 1732, 1697 (CO), 1402, 
1365. HRMS (ESI): C20H35NNaO5Si [M+Na]+; calculated 420.2177, found 
420.2180. 
                                            
* n.b. incomplete conversion. 
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Benzyl (1R*,5R*,7R*,8S*)-8-[(tert-butyldimethylsilyl)oxy]-8-methyl-9-oxo-
11-oxa-3-azatricyclo[5.3.1.01,5]undecane-3-carboxylate 221 
MeLi (1.6 M in Et2O, 0.37 mL, 0.60 mmol, 1.30 eq.) 
was added to a stirred solution of cycloadduct 183 
(200 mg, 0.460 mmol, 1.00 eq.) in THF (15 mL) at 
−78 °C. The reaction mixture was stirred at this 
temperature for 0.5 h, then sat. aq. brine (1 mL. The 
reaction mixture was warmed to rt, then partitioned between EtOAc (25 mL) and 
brine (25 mL). The aqueous phase was extracted with EtOAc (2 × 10 mL). The 
combined organic extracts were dried, filtered and concentrated in vacuo. Flash 
chromatography eluting with 95:5 pentane–EtOAc gave the title compound 221 
(187 mg, 0.420 mmol, 91%) as a yellow oil. Rf 0.30 (3:1 petrol–EtOAc). 
1H NMR (500 MHz, CDCl3, 50:50 mixture of rotamers): δ 7.39-7.28 (5H, m, Cbz 
Ar-H), 5.12 (2H, s, OCH2Ph), 4.21-4.15 (1H, m, 7-H), 3.95-3.83 (2H, m, 2-HB and 
4-HA), 3.43 (0.5H, d, J 12.6, 2-HA), 3.38 (0.5H, d, J 12.6, 2-HA), 3.20-3.09 (1H, m, 
4-HB), 2.92 (0.5H, d, J 15.3, 10-HB), 2.86 (0.5H, d, J 15.3, 10-HB), 2.55-2.46 (1H, 
m, 5-H), 2.37 (0.5H, d, J 3.3, 10-HA), 2.34 (0.5H, d, J 3.3, 10-HA), 2.27-2.14 (1H, 
m, 6-HA), 1.91-1.76 (1H, m, 6-HB), 1.46 (1.5H, s, CqCH3), 1.45 (1.5H, s, CqCH3), 
0.85 (9H, s, SiC(CH3)3), 0.17 (3H, s, SiCH3), 0.13 (3H, s, SiCH3). 13C NMR 
(125 MHz, CDCl3, mixture of two rotamers): δ 208.0 (9-C), 207.9 (9-C), 
154.4 (N(CO)O), 136.8 (Ar-Cq), 128.6 (Ar-C), 128.2 (Ar-C), 128.12 (Ar-C), 91.5 
(1-C), 90.7 (1-C), 85.4 (7-C), 81.4 (8-C), 67.1 (OCH2Ph), 54.2 (2-C or 4-C), 53.8 
(2-C or 4-C), 53.7 (2-C or 4-C), 47.3 (10-C), 45.7 (5-C), 44.8 (5-C), 31.7 (6-C), 
31.4 (6-C), 26.0 (SiC(CH3)3), 24.4 (CqCH3), 18.5 (SiCq), −2.3 (SiCH3), 
−2.6 (SiCH3) [25 of 38 expected peaks observed]. IR νmax(film)/cm−1 2954, 2953, 
2930, 2887, 1702 (CO), 1629,1593, 1419 HRMS (ESI): C24H36NO5Si [M+H]+; 
calculated 446.2357, found 446.2360. 
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Benzyl (1R*,5R*,7R*,8R*,9R*)-9-amino-8-[(tert-butyldimethylsilyl)oxy]-8-
methyl-11-oxa-3-azatricyclo[5.3.1.01,5]undecane-3-carboxylate 222 
Ti(OiPr)4 (0.27 mL, 0.92 mmol, 2.0 eq.) was added to 
a stirred solution of ketone 221 (204 mg, 0.46 mmol, 
1.00 eq.) in sat. NH3/MeOH. The reaction mixture was 
stirred for 15 h then NaBH4 (26 mg, 0.7 mmol, 1.5 eq.) 
was added at 0 °C. The reaction mixture was warmed 
to rt, stirred for 2 h then concentrated in vacuo. The residue was diluted in EtOAc 
(10 mL) and sat. aq. brine (10 mL) and stirred vigorously. The phases were 
separated and the aqueous phase was extracted with EtOAc (2 × 10 mL). The 
combined organic phase was dried over MgSO4, filtered, and concentrated in 
vacuo. Flash chromatography eluting with 0-10% MeOH in EtOAc gave the title 
compound 222 (184 mg, 0.410 mmol, 90%) as a colourless oil. 1H NMR 
(500 MHz, CDCl3, 50:50 mixture of rotamers, NH2 not observed): δ 7.38-7.27 (5H, 
m, Cbz Ar-H), 5.10 (2H, s, CH2Ph), 4.00 (1H, d, J 7.5, 7-H), 3.92-3.82 (1H, m, 
4-HA), 3.75-3.68 (1H, m, includes at δ 3.72: d, J 12.5; and at δ 3.71: d, J 12.5, 
2-HB), 3.38 (0.5H, d, J 12.5, 2-HA), 3.33 (0.5H, d, J 12.5, 2-HA), 3.23-3.12 (2H, m, 
4-HB and 9-H), 3.11-3.03 (1H, m, 5-H), 2.96-2.87 (1H, m, 6-HA), 2.16 (0.5H, dd, 
J 14.2, 5.4, 10-HB), 2.11 (0.5H, dd, J 14.2, 5.4, 10-HB), 1.72-1.60 (1H, m, 6-HB), 
1.57-1.50 (1H, m, includes at δ 1.54: 0.5H, d, J 14.2; and at δ 1.53: 0.5H, d, J 14.2, 
10-HA), 1.37 (1.5H, s, CqCH3), 1.36 (1.5H, s, CqCH3), 0.91 (9H, s, SiC(CH3)3), 
0.13 (3H, s, SiCH3), 0.12-0.10 (3H, m, SiCH3). 13C NMR (125 MHz, d6-DMSO, 
mixture of two rotamers): δ 153.6 (N(CO)O), 153.4 (N(CO)O), 137.1 (Ar-Cq), 
128.4 (Ar-C), 127.7 (Ar-C), 127.5 (Ar-C), 89.3 (1-C), 88.4 (1-C), 83.2 (7-C), 73.1 
(8-C), 65.7 (CH2Ph), 54.7 (2-C or 4-C), 54.6 (2-C or 4-C), 54.1 (2-C or 4-C), 54.0 
(2-C or 4-C), 53.8 (9-C), 44.4 (5-C), 43.4 (5-C), 36.7 (10-C), 36.6 (10-C), 
32.9 (6-C), 32.8 (6-C), 27.5 (CqCH3), 25.8 (SiC(CH3)3), 18.0 (SiCq), −2.0 (SiCH3), 
−2.2 (SiCH3) [27 of 38 expected peaks observed]. IR νmax(film)/cm−1 2952, 2931, 
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2882, 2856, 1704 (CO), 1419, 1362, 1346. HRMS (ESI): C24H39N2O4Si [M+H]+; 
calculated 447.2674, found 447.2679. 
 
 
Benzyl (1R*,5R*,7R*)-8,8-dimethoxy-9-oxo-11-oxa-3-
azatricyclo[5.3.1.01,5]undecane-3-carboxylate 224 
(±)-Camphorsulfonic acid (196 mg, 0.844 mmol, 1.20 
eq.) was added to a stirred suspension of cycloadduct 
183 (303 mg, 0.705 mmol, 1.00 eq.) in MeOH (10 mL). 
The reaction mixture heated at 45 °C for 15 h, then 
concentrated in vacuo. The residue was partitioned between CH2Cl2 (20 mL) and 
sat. aq. NaHCO3 (20 mL) and the phases were separated. The aqueous phase 
was extracted with CH2Cl2 (2 × 20 mL). The combined organic phase was dried 
over Na2SO4 and concentrated in vacuo. Flash chromatography eluting with 
7:3 pentane–EtOAc gave the title compound 224 (201 mg, 0.556 mmol, 79%) as 
a colourless oil. Rf 0.46 (1:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3, 50:50 
mixture of rotamers): δ 7.38-7.29 (5H, m, Cbz Ar-H), 5.15-5.07 (2H, m, OCH2Ph), 
4.68 (1H, d, J 7.6, 7-H), 3.96 (1H, d, J 12.8, 2-HB), 3.95-3.88 (1H, m, 4-HA), 
3.47-3.35 (4H, m, includes 1H, m, 2-HA; and at δ 3.37: 3H, s, (OCH3), 3.26 (3H, 
s, (OCH3), 3.24-3.09 (1H, m, 4-HB), 3.09 (0.5H, d, 14.9, 10-HB), 3.02 (0.5H, d, 
14.9, 10-HB), 2.62-2.51 (1H, m, 5-H), 2.45-2.38 (1H, m, includes at δ 2.42: 0.5H, 
d, J 14.9; and at δ 2.41: 0.5H, d, J 14.9, 10-HA), 2.16-2.06 (1H, m, 6-HA), 2.02-1.89 
(1H, m, 6-HB). 13C NMR (125 MHz, CDCl3, mixture of two rotamers): 
δ 201.5 (9-C), 201.3 (9-C),154.3 (N(CO)O), 136.8 (Ar-Cq), 128.6 (Ar-C), 128.2 
(Ar-C), 128.1 (2 peaks, Ar-C), 99.7 (8-C), 91.5 (1-C), 90.8 (1-C), 79.3 (7-C), 67.2 
(OCH2Ph), 54.1 (2-C or 4-C), 54.0 (2-C or 4-C), 53.7 (2-C or 4-C), 53.6 (2-C or 
4-C), 50.6 (OCH3), 49.9 (OCH3), 48.3 (10-C), 48.2 (10-C), 45.4 (5-C), 44.5 (5-C), 
31.0 (6-C), 30.7 (6-C) [25 of 34 expected peaks observed]. IR νmax(film)/cm−1 
2947, 2886, 1734, 1698 (CO), 1416, 1347, 1143, 1107 HRMS (ESI): C19H24NO6 
[M+H]+; calculated 362.1598, found 362.1601. 
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Benzyl (1R*,13R*,15R*)-19-oxa-4,11,17-triazapentacyclo 
[11.5.1.01,15.03,12.05,10]nonadeca-3,5(10),6,8,11-pentaene-17-carboxylate 225 
1,2-Diaminobenzene (270 mg, 2.50 mmol, 1.1 eq.) 
was added to a stirred suspension of 
cycloadduct 183 (1.0 g, 2.3 mmol, 1.0 eq.) in AcOH 
(10 mL). The reaction mixture was heated under 
microwave irradiation at 180 °C for 10 min. The 
reaction mixture was concentrated in vacuo then partitioned between CH2Cl2 
(25 mL) and sat. aq. NaHCO3 (25 mL). The aqeuous phase was extracted with 
CH2Cl2 (2 × 10 mL). The combined organic phases were dried, filtered and 
concentrated in vacuo. Flash chromatography eluting with 0-100% EtOAc in 
pentane gave the title compound 225 (789 mg, 2.04 mol, 89%) as a colourless 
oil. Rf 0.51 (1:2 petrol–EtOAc). 1H NMR (500 MHz, CDCl3): δ 8.02-7.97 (2H, m, 
6-H and 9-H), 7.75-7.69 (2H, m, 7-H and 8-H), 7.42-7.30 (5H, m, Cbz Ar-H), 5.50 
(1H, d, J 6.8, 13-H), 5.18 (1H, d, J 12.9, CHAHBPh), 5.14 (1H, d, J 12.9, 
CHAHBPh), 4.14 (1H, d, J 12.7, 18-HA), 3.93 (1H, dd, J 11.3, 9.4, 16-HA), 
3.71-3.53 (2H, m, 2-HA and 18-HB), 3.53-3.37 (1H, m, 16-HB), 3.15 (1H, d, J 17.8, 
2-HB), 2.83-2.70 (1H, m, 15-H), 2.49-2.30 (2H, m, 14-H). 13C NMR (125 MHz, 
CDCl3, mixture of two rotamers): δ 154.9 (2 × Ar-Cq), 154.7 (N(CO)O), 150.0 
(Ar-Cq), 142.3 (Ar-Cq), 140.7 (Ar-Cq), 136.8 (Ar-Cq), 129.9 (2 peaks, 2 × Ar-C), 
129.0 (Ar-C), 128.7 (2 peaks, 2 × Ar-C), 128.2 (2 peaks, 2 × Ar-C), 91.4 (1-C), 
90.5 (1-C), 81.3 (13-C), 67.2 (CH2Ph), 55.3 (16-C or 18-C), 54.9 (16-C or 18-C), 
54.5 (16-C or 18-C), 54.2 (16-C or 18-C), 46.6 (15-C), 45.6 (15-C), 42.8 (2-C), 
42.4 (2-C), 40.4 (14-C) [27 of 42 expected peaks observed]. IR νmax(film)/cm−1 
2952, 2884, 1702 (CO), 1421, 1358, 1274, 1112, 769. HRMS (ESI): C23H22N3O3 
[M+H]+; calculated 388.1656, found 388.1660. 
 
211 
 
 
Benzyl (1R*,8R*)-5-phenyl-14-oxa-4,6,12-
triazatetracyclo[6.5.1.01,10.03,7]tetradeca-3(7),4-diene-12-carboxylate 226 
PhCHO (18 µL, 0.17 mmol, 1.0 eq.) and NH4OAc 
(135 mg, 1.70 mmol, 10.0 eq.) were added to a 
suspension of 183 (75 mg, 0.17 mmol, 1.0 eq.) in 
AcOH (3.0 mL). The resulting mixture was heated 
under microwave irradiation at 180 °C for 5 min. 
The reaction mixture was concentrated in vacuo, then partitioned between 
CH2Cl2 (25 mL) and NaHCO3 (25 mL). The phases were separated and the 
aqueous phase was extracted with CH2Cl2 (2 × 10 mL). The combined organic 
extracts were dried, filtered and concentrated in vacuo. Flash chromatography 
eluting with 0-100% EtOAc in pentane gave the title compound 226 (64 mg, 
0.16 mmol, 91%) as a pale brown oil. Rf 0.12 (1:1 petrol–EtOAc). 1H NMR 
(500 MHz, CDCl3, imidazole NH not observed): δ 7.76 (2H, d, J 7.3, Ar-H), 
7.43-7.28 (8H, m, Ar-H), 5.28 (1H, d, J 5.7, 8-H), 5.17 (1H, d, J 15.9, CHAHBPh), 
5.14 (1H, d, J 15.9, CHAHBPh), 4.07 (1H, d, J 12.6, 13-HA), 3.85-3.73 (1H, m, 
11-HA), 3.55-3.36 (2H, m, 11-HB and 13-HB), 3.28-3.16 (1H, m, 2-HA), 2.73-2.64 
(1H, m, 10-H), 2.61 (1H, d, J 15.4, 2-HB), 2.58-2.47 (1H, m, 9-HA), 2.16-2.05 (1H, 
m, 9-HB). 13C NMR (125 MHz, CDCl3, mixture of two rotamers, 2 × imidazole Cq 
not observed): δ 154.9 (N(CO)O), 145.6 (5-C), 136.7 (Ar-Cq), 130.4 (Ar-Cq), 129.1 
(Ar-C), 128.6 (Ar-C), 128.2 (Ar-C), 128.0 (2 peaks, Ar-C), 125.1 (Ar-C), 91.1 
(1-C), 90.1 (1-C), 77.4 (8-C), 67.2 (CH2Ph), 55.4 (13-C), 55.0 (13-C), 53.6 (11-C), 
53.5 (11-C), 47.1 (10-C), 46.1 (10-C), 45.8 (9-C), 45.6 (9-C), 32.8 (2-C) [23 of 40 
expected peaks observed]. IR νmax(film)/cm−1 3274, 2241, 1682 (CO), 1448, 
1418, 1348, 1116, 909. HRMS (ESI): C24H24N3O3 [M+H]+; calculated 402.1812, 
found 402.1825. 
 
Benzyl (1R*,5R*,7R*,8S*)-8-hydroxy-8-methyl-9-oxo-11-oxa-3-
azatricyclo[5.3.1.01,5]undecane-3-carboxylate 230 
TBAF (1.0 M in THF, 0.46 mL, 0.46 mmol, 2.0 eq.) was 
added to a stirred solution of compound 221 (102 mg, 
0.230 mmol, 1.0 eq) in THF (10 mL). the reaction mixture 
was stirred 0.5 h then concentrated in vacuo. Flash 
chromatography eluting with 0-100% EtOAc in pentane 
gave the title compound 230 (69 mg, 0.21 mmol, 91%) as a colourless oil. Rf 0.25 
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(1:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3, 50:50 mixture of rotamers): 
δ 7.39-7.28 (5H, m, Cbz Ar-H), 5.12 (2H, s, OCH2Ph), 4.39 (1H, d, J 7.4, 7-H), 
3.99-3.92 (1H, m, includes at δ 3.96: 0.5H, d, J 12.8; and at δ 3.94: 0.5H, d, J 12.8, 
2-HA), 3.92-3.84 (1H, m, 4-HA), 3.72 (1H, s, OH), 3.45 (0.5H, d, J 12.7, 2-HB), 
3.40 (0.5H, d, J 12.7, 2-HB), 3.21-3.10 (1H, m, 4-HB), 3.05 (0.5H, d, J 15.0, 10-HA), 
2.99 (0.5H, d, J 15.0, 10-HA), 2.54-2.42 (2H, m, 5-H and 10-HB), 2.15 (1H, td, 
J 14.5, 8.7, 6-HA), 1.91-1.78 (1H, m, 6-HB), 1.48 (1.5H, s, CH3), 1.47 (1.5H, s, 
CH3). 13C NMR (125 MHz, CDCl3, 329 K, mixture of two rotamers): δ 210.0 (9-C), 
154.4 (N(CO)O), 137.0 (Ar-Cq), 128.7 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 91.5 
(1-C), 91.4 (1-C), 84.7 (7-C), 78.5 (8-C), 67.2 (OCH2Ph), 54.1 (2-C and 4-C), 46.5 
(10-C), 45.9 (5-C), 45.0 (5-C), 31.5 (6-C), 24.5 (CH3) [17 of 34 expected peaks 
observed]. IR νmax(film)/cm−1 2954, 2887, 1703 (CO), 1454, 1422, 1350, 1108, 
771. HRMS (ESI): C18H22NO5 [M+H]+; calculated 332.1492, found 332.1491. 
 
Benzyl (2R*,3aR*,6aR*)-2-acetyl-6a-(2-oxoethyl)-hexahydro-2H-furo[2,3-
c]pyrrole-5-carboxylate 231 
NaBH4 (21 mg, 0.54 mmol, 1.0 eq.) was added to a 
stirred solution of α-hydroxyketone 230 (180 mg, 
0.54 mmol, 1.0 eq.) in MeOH at 0 °C. The reaction 
mixture was stirred for 2 h, warming to rt, then H2O (1 mL) 
was added. The reaction mixture was concentrated 
in vacuo then diluted in EtOAc (25 mL) and washed with brine (25 mL). The 
aqueous phase was extracted with EtOAc (2 × 10 mL). The combined organic 
phase was dried over MgSO4, filtered and concentrated in vacuo. Flash 
chromatography on cyanosilica eluting with 0-100% EtOAc in pentane gave the 
title compound 231 (82 mg, 0.25 mmol, 46%) as a colourless oil. Rf 0.14 (1:1 
petrol–EtOAc). 1H NMR (500 MHz, CDCl3): δ 9.81 (1H, t, J 2.0, CHO), 7.37-7.27 
(5H, m, Cbz Ar-H), 5.15-5.10 (2H, m, CH2Ph), 4.54 (1H, t, J 8.2, 2-H), 3.88 (1H, 
d, J 12.4, 6-HA), 3.75 (1H, dd, J 11.7, 8.7, 4-HA), 3.52 (1H, d, J 12.4, 6-HB), 3.39 
(1H, dd, J 11.7, 5.4, 4-HB), 2.82 (1H, dd, J 16.0, 2.0, CHAHBCHO), 2.79-2.65 (2H, 
m, 3a-H and CHAHBCHO), 2.18-2.12 (5H, m, includes 2H, m, 3-H; and at δ 2.16: 
3H, s, CH3). 13C NMR (125 MHz, CDCl3, 329 K): δ 207.5 (CHO), 199.2 (COCH3), 
154.7 (N(CO)O), 136.7 (Ar-Cq), 128.7 (Ar-C), 128.2 (Ar-C), 128.1 (Ar-C), 91.3 
(6a-C), 83.9 (2-C), 67.3 (CH2Ph), 56.6 (6-C), 51.2 (4-C or CH2CHO), 50.7 (4-C 
or CH2CHO), 46.5 (3a-C), 34.4 (3-C), 25.9 (CH3). IR νmax(film)/cm−1 2952, 2885, 
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1704 (CO), 1498, 1422, 1217, 1099, 769. HRMS (ESI): C18H21NNaO5 [M+Na]+; 
calculated 354.1312, found 354.1314. 
 
Benzyl (1R*,5R*,7R*)-9-benzyl-8-methyl-12-oxa-3,9- 
diazatricyclo[5.4.1.01,5]dodecane-3-carboxylate 232 
BnNH2 (18 µL, 0.16 mmol, 1.0 eq.) was added to a stirred 
solution of ketoaldehyde 231 (53 mg, 0.16 mmol, 1.0 eq.). 
The reaction mixture was stirred for 5 min then 
NaBH(OAc)3 (102 mg, 0.48 mmol, 3.0 eq.) was added. 
The reaction mixture was stirred for 2 h, by which time 
complete consumption of the starting material was 
observed by TLC. The reaction mixture was diluted in CH2Cl2 (15 mL) and 
washed with brine (25 mL). The aqueous phase was extracted with CH2Cl2 
(2 × 20 mL). The combined organic phases were dried over MgSO4, filtered and 
concentrated in vacuo. Analysis of the crude reaction product by 1H NMR 
spectroscopy identified a 1:1 mixture of diastereomers. Flash chromatography 
eluting with 0-100% EtOAc in pentane gave one diastereomer* of the 
title compound 232 (15 mg, 37 µmol, 23%) as a colourless oil. Rf 0.18 (3:2 petrol–
EtOAc). 1H NMR (300 MHz, CDCl3, 50:50 mixture of rotamers): 7.34-7.11 (10H, 
m, Ar-H), 5.03 (2H, s, OCH2Ph), 4.33-4.17 (1H, m, 7-H), 3.97 (1H, d, J 13.8, 
NCHAHBPh), 3.76 (1H, d, J 12.3, 2-HA), 3.71-3.62 (1H, m, includes at δ 3.68: 
0.5H, d, J 11.0; and at δ 3.65: 0.5H, d, J 11.0, 4-HA), 3.33-3.05 (3H, m, 2-HB, 4-HB 
and NCHAHBPh), 2.77-2.64 (1H, m, 8-H), 2.61-2.46 (3H, m, 5-H and 10-H), 
2.46-2.33 (1H, m, 6-HA), 1.84-1.64 (2H, m, 6-HB and 11-HA), 1.64-1.45 (1H, m, 
11-HB), 0.92 (3H, d, J 6.6, CH3). Characteristic peaks for the other diastereomer, 
as judged by analysis of crude product using 1H NMR spectroscopy (300 MHz, 
CDCl3): 4.16-4.07 (1H, m, 7-H), 3.80 (1H, d, J 12.5), 3.65-3.59 (1H, m), 2.94-2.78 
(1H, m), 2.30 (1H, ddd, J 11.7, 8.2, 3.3), 2.22-2.11 (1H, m), 0.91 (1H, d, J 6.5, 
CH3). 13C NMR (125 MHz, CDCl3, mixture of two rotamers, one Ar-C peak not 
observed): δ 154.8 (CO), 141.0 (Ar-Cq), 137.1 (Ar-Cq), 128.6 (Ar-C), 128.5 (Ar-C), 
128.4 (Ar-C), 128.0 (Ar-C), 126.9 (Ar-C), 90.7 (1-C), 89.7 (1-C), 85.3 (7-C), 66.9 
(OCH2Ph), 63.0 (8-C), 62.8 (8-C), 58.3 (NCH2Ph), 57.4 (2-C), 57.0 (2-C), 53.7 
(4-C), 53.4 (4-C), 51.1 (5-C), 50.1 (5-C), 49.4 (10-C), 38.2 (11-C), 30.3 (6-C), 
                                            
* Optimisation of the purification step is required in order to isolate the other diastereomer cleanly. 
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29.9 (6-C), 16.5 (CH3) [26 of 44 expected peaks observed]. IR νmax(film)/cm−1 
2943, 1699 (CO), 1416, 1348, 1099, 1029, 734, 700. HRMS (ESI): C25H31N2O3 
[M+H]+; calculated 407.2329, found 407.2334. 
 
Benzyl (1R*,5R*,7R*)-9-benzyl-12-oxa-3,9-diazatricyclo[5.4.1.01,5]dodecane-
3-carboxylate 234 
NaIO4 (105 mg, 0.490 mmol, 2.00 eq.) was added to a 
stirred solution of diol 214 (78 mg, 0.24 mmol, 1.0 eq.) in 
8:2 MeOH–H2O (10 mL) at 0 °C. The reaction mixture was 
warmed to rt an stirred for 2 h. The reaction mixture was 
concentrated in vacuo then the resulting crude dialdehyde 
233* was dissolved in CH2Cl2 (10 mL). BnNH2 (26 µL, 0.25 
mmol, 1.0 eq.), NaBH(OAc)3 (153 mg, 0.72 mmol, 3.0 eq.) and 4 Å MS (10 mg) 
were added. The reaction mixture was stirred 15 h then filtered through Celite 
and concentrated in vacuo. The resulting residue was diluted in EtOAc (25 mL) 
and washed with brine (25 mL). The aqueous phase was extracted with EtOAc 
(2 × 10 mL). The combined organic phase was dried over MgSO4, filtered and 
concentrated in vacuo. Flash chromatography eluting with 0-100% EtOAc in 
pentane gave the title compound 234 (30 mg, 76 µmol, 32%) as a colourless oil. 
Rf 0.74 (1:1 petrol–EtOAc). 1H NMR (500 MHz, CDCl3, 50:50 mixture of 
diastereomers): δ 7.39-7.21 (10H, m, Ar-H), 5.15-5.06 (2H, m, OCH2Ph), 
4.43-4.38 (1H, m, includes at δ 4.41: d, J 8.1; and at at δ 4.40: d, J 8.1, 7-H), 3.89 
(1H, d, J 12.3, 2-HA), 3.64-3.53 (3H, includes: 1H, m, 4-HA; at δ 3.61, 1H, d, J 13.3, 
NCHAHBPh; and at δ 3.55, 1H, d, J 13.3, NCHAHBPh), 3.52-3.33 (1H, m, 4-HB), 
3.22-3.06 (1H, m, 2-HB), 2.90-2.80 (1H, m, 5-H), 2.77-2.68 (1H, m, 10-HA), 
2.58-2.44 (2H, includes: 1H, m, 10-HB; and at δ 2.52, 1H, d, J 12.4, 8-HA), 
2.43-2.36 (1H, m, includes at δ 2.40: d, J 12.4; and at δ 2.39: d, J 12.4, 8-HB), 
2.28-2.21 (1H, m, 6-HA), 1.92-1.74 (3H, m, 6-HB and 11-H).13C NMR (125 MHz, 
CDCl3, mixture of two rotamers): δ 155.1 (N(CO)O), 139.9 (Ar-Cq) 137.1 (Ar-Cq), 
128.8 (Ar-C), 128.6 (Ar-C), 128.5 (Ar-C), 128.0 (2 peaks, 2 × Ar-C), 127.2 (Ar-C), 
93.2 (1-C), 92.2 (1-C), 80.2 (7-C), 66.9 (OCH2Ph), 64.3 (NCH2Ph), 63.6 (8-C), 
57.9 (2-C), 57.5 (2-C), 54.0 (4-C), 53.8 (4-C), 53.6 (10-C), 50.1 (5-C), 38.3 (11-C), 
36.6 (6-C) [23 of 40 expected peaks observed]. IR νmax(film)/cm−1 2930, 2865, 
                                            
* Characteristic 1H NMR peaks for the crude aldehyde 233 are given in the procedure for 235. 
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1702 (CO), 1451, 1419, 1360, 1217, 1143. HRMS (ESI): C24H29N2O3 [M+H]+; 
calculated 393.2173, found 393.2185. 
 
Benzyl (2R*,3aR*,6aR*)-6a-(2-hydroxyethyl)-2-(hydroxymethyl)-hexahydro-
2H-furo[2,3-c]pyrrole-5-carboxylate 235 
NaIO4 (56 mg, 0.26 mmol, 2.0 eq.) was added to a 
stirred solution of diol 214 (41 mg, 0.13 mmol, 1.0 eq.) 
in 8:2 MeOH–H2O (5 mL) at 0 °C. The reaction mixture 
was warmed to rt, stirred for 2 h, then concentrated 
in vacuo. The residue was diluted in EtOAc (10 mL) and 
washed with brine (10 mL). The aqueous phase was extracted with EtOAc 
(2 × 10 mL). The combined organic extracts were dried over MgSO4, filtered and 
concentrated in vacuo to give crude aldehyde 233 [characteristic 1H NMR peaks 
(300 MHz, CDCl3,): δ 9.82 (1H, t, J 1.9, CH2CHO), 9.64 (1H, d, J 1.4, CHCHO), 
7.42-7.28 (5H, m, Cbz Ar-H), 5.13 (2H, s, OCH2Ph)]. NaBH4 (12 mg, 0.33 mmol, 
2.5 eq.) was added to a stirred solution of the crude aldehyde 234 in MeOH (5 mL) 
at 0 °C. The reaction mixture was warmed to rt, stirred 1 h, then concentrated in 
vacuo. The residue was diluted in EtOAc (10 mL) and washed with brine (10 mL). 
The aqueous phase was extracted with EtOAc (2 × 10 mL). The combined 
organic phase was dried over MgSO4, filtered and concentrated in vacuo. Flash 
chromatography eluting with 9:1 EtOAc–MeOH gave the title compound 235 
(16 mg, 50 µmol, 38%) as a colourless oil. Rf 0.43 (9:1 EtOAc–MeOH). 1H NMR 
(500 MHz, CDCl3, 2 × OH not observed): δ 7.40-7.28 (5H, m, Cbz Ar-H), 5.13 
(2H, s, CH2Ph), 4.33-4.26 (1H, m, 2-H), 3.93-3.79 (4H, m, 6-HA, CHCHAHBOH 
and CH2CH2OH), 3.74 (1H, dd, J 11.4, 9.1, 4-HA), 3.50 (1H, dd, J 12.5, 3.0, 
CHCHAHBOH), 3.47-3.28 (2H, m, 4-HB and 6-HB), 2.71-2.64 (1H, m, 3a-H), 2.21 
(1H, ddd, J 12.8, 9.7, 7.3, 3-HA), 2.03-1.95 (1H, m, CHAHBCH2OH), 1.89-1.76 
(2H, m, 3-HB and CHAHBCH2OH). 13C NMR (125 MHz, CDCl3, one Cq not 
observed): δ 154.9 (N(CO)O), 137.1 (Ar-Cq), 128.7 (Ar-C), 128.2 (Ar-C), 128.1 
(Ar-C), 80.1 (2-C), 67.2 (CH2Ph), 64.1 (CHCH2OH), 60.2 (CH2CH2OH), 
57.1 (6-C), 51.6 (4-C), 47.2 (3a-C), 39.8 (3-C), 33.0 (CH2CH2OH). 
IR νmax(film)/cm−1 3401 (OH), 2938, 2880, 1684 (CO), 1422, 1351,1217, 1100. 
HRMS (ESI): C17H24NO5 [M+H]+; calculated 322.1649, found 322.1649. 
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6.0 Appendix 1: Computational tools and related data 
 
6.1 Capping groups for virtual library enumeration 
Decoration reactions were performed using the 80 capping groups shown in 
Figure 67. 
 
Figure 67 80 capping reagents used in the enumeration of the virtual libraries. 
 
6.2 Lead-likeness analysis 
Structural filtering was performed by interrogating SMARTS definitions against 
each of the final compounds using the substructure search tool within 
Pipeline Pilot. For full information on the filters used for our assessments see Org. 
Biomol. Chem. 2015, 13, 859 (filters can be found in the Supporting Information, 
Section S5, Tables S1-S3, pages 7-13).  
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AlogP and number of heavy atoms (HA) were calculated using the tools within 
Pipeline Pilot. The fraction of sp3-hybridised carbon atoms (Fsp3) was calculated 
using Dotmatics Vortex (Vortex v2013.12.25046). The data were visualized and 
analysed using Vortex. 
 
6.3 Shape analysis: Principal moments of inertia  
George Burslem generated the 3D structures from the 2D Pipeline Pilot output 
using OpenEye OMEGA (OMEGA 2.4.3, OpenEye Scientific Software, 2010) and 
the lowest energy conformer was selected.217 The 3D structures were used to 
generate the three principal moments of inertia (I1, I2 and I3) by the candidate, 
using Accelrys Pipeline Pilot (Pipeline Pilot v8.5.0.200, Accelrys© Software Inc., 
2011), which were then normalised by dividing the two lower values by the largest 
(I1/I3 and I2/I3). Normalised PMI plots were generated by the candidate to give 
triangular plots with the corners defined by a perfect sphere, a perfect disk and a 
perfect rod shape.162 
 
6.3.1 PMI plot binning 
This section describes how the PMI plots were divided in to 20 bins (see also 
Section 2.5.3.2) in which the number of virtual compounds were counted. The 
equations below were derived by the candidate and Stuart Warriner. 
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Figure 68 A PMI plot shown on an x,y axis. x,y coordinates are shown in blue; the calculated k,l coordinates (see below) 
are shown in green.  
 
An axis rotation was applied to the PMI plot (Figure 68); x,y coordinates were 
converted to k,l coordinates as follows: 
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x=I1 and y=I2 were substituted into equations 1 and 2 and k,l coordinates were 
calculated for all I1 and I2 values using Microsoft Excel (Figure 69, left hand side). 
The l axis was divided into 40 bins, of which 20 actually intersect the PMI plot 
(Figure 69, right hand side).  
 
Since lmax= √2; the upper limit of each bin is (n−1)*√2/40 (where n= 0, 1, 2…40).  
 
The number of compounds in each bin was counted using an array formula in 
Microsoft Excel. This was converted to a percentage as a fraction of the total 
number of compounds, allowing the generation of histogram plots (e.g. Figure 
32). 
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Figure 69 An axis rotation was applied to convert the PMI plot from x,y to k,l coordinates. The l axis was then divided into bins and the number of compounds in each bin were counted. 
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6.4 Data for the ‘bottom-up’ compound library 
 
6.4.1 Lead-likeness assessment: Per scaffold basis 
 
Filter 
ZINC Database 
(9046036) 
Random 1% of ZINC Database 
(90911) 
Virtual Library (1110) 
Successive 
Filtering 
Parallel 
Filtering 
Successive 
Filtering 
Parallel 
Filtering 
Successive 
Filtering 
Parallel 
Filtering 
 Fail  
14 ≤ nHA ≤ 
26 
4395739 
4395739 
(48%) 
43971 43971 (48%) 173 173 (16%) 
Fail  
–1 ≤ AlogP ≤ 
3 
1768807 
4478982 
(49%) 
17828 44746 (49%) 200 220 (20%) 
Fail 
Structural 
819652 
2805505 
(31%) 
8180 28147 (31%) 3 5 (0.5%) 
Pass All 
2061838 
(23%) 
n/a 20932 (23%) n/a 734 (66%) n/a 
Table 22 Filtering assessment data for the allylic alkylation-derived virtual library and the ZINC database. For comparison, 
data obtained from parallel filtering of all compounds using each filter in isolation is shown. 
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Entry Scaffold 
No. final 
compounds 
No. lead-like 
compounds 
% Lead-like 
Compounds 
Average 
number of 
lead-like 
compounds 
per scaffold 
Fail 
HA 
Fail 
AlogP 
Fail 
SS 
Most likely 
reason(s) for 
compound failure 
Average 
heavy atom 
count 
(standard 
deviation) 
Average 
AlogP 
(standard 
deviation) 
Average 
Fsp3 
(standard 
deviation) 
1 70a 64 62 97 
N/A 
2 0 0 HA too high 
22.3 
(2.54) 
0.42 
(0.75) 
0.66 
(0.15) 
2 70b 64 55 86 1 8 0 AlogP too low 
21.3 
(2.54) 
−0.17 
(0.75) 
0.63 
(0.16) 
3 70c 116 68 59 23 25 0 
AlogP too low/ 
HA too high 
24.2 
(2.73) 
−0.28 
(0.85) 
0.68 
(0.14) 
4 70d 71 37 52 34 0 0 HA too high 
26.1 
(2.65) 
1.69 
(0.74) 
0.42 
(0.10) 
5 82a 76 62 82 3 11 0 AlogP too low 
22.2 
(2.59) 
−0.15 
(0.75) 
0.67 
(0.14) 
6 82b 75 46 61 1 28 0 AlogP too low 
21.2 
(2.61) 
−0.75 
(0.74) 
0.64 
(0.15) 
7 82c 127 47 37 25 55 0 AlogP too low 
24.1 
(2.77) 
−0.92 
(0.83) 
0.68 
(0.14) 
8 88a 26 24 92 1 1 0 – 
18.5 
(2.63) 
−0.12 
(0.57) 
0.58 
(0.15) 
9 88c 78 39 50 2 37 0 AlogP too low 
21.3 
(2.90) 
−0.92 
 (0.72) 
0.57 
(0.15) 
10 87d 10 4 40 3 3 0 
AlogP too high/ 
HA too high 
26.0 
(1.76) 
2.72 
(0.52) 
0.28 
(0.06) 
11 90a 26 24 92 1 1 0 – 
18.5 
(2.63) 
0.03 
(0.57) 
0.69 
(0.15) 
12 90b 26 18 69 2 6 0 AlogP too low 17.5 −0.55 0.66 
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Entry Scaffold 
No. final 
compounds 
No. lead-like 
compounds 
% Lead-like 
Compounds 
Average 
number of 
lead-like 
compounds 
per scaffold 
Fail 
HA 
Fail 
AlogP 
Fail 
SS 
Most likely 
reason(s) for 
compound failure 
Average 
heavy atom 
count 
(standard 
deviation) 
Average 
AlogP 
(standard 
deviation) 
Average 
Fsp3 
(standard 
deviation) 
(2.63) (0.57) (0.16) 
13 96d 37 31 84 6 0 0 HA too high 
23.6 
(2.75) 
0.40 
(0.57) 
0.34 
(0.09) 
14 101a 15 14 93 0 0 1 Substructure 
22.0 
(2.20) 
1.94 
(0.49) 
0.47 
(0.12) 
15 101b 15 14 93 0 0 1 Substructure 
21.0 
(2.20) 
1.36 
(0.49) 
0.44 
(0.12) 
16 101c 67 40 60 26 0 1 HA too high 
25.6 
(2.83) 
1.33 
(0.75) 
0.45 
(0.10) 
17 101d 21 7 33 10 4 0 HA too high 
26.0 
(2.41) 
2.86 
(0.58) 
0.37 
(0.05) 
18 102c 60 33 55 26 1 0 HA too high 
25.9 
(2.77) 
2.23 
(0.78) 
0.42 
(0.09) 
19 106a 8 7 88 1 0 0 HA too low 
16.1 
(2.64) 
1.12 
(0.54) 
0.61 
(0.16) 
20 106b 8 6 75 2 0 0 HA too low 
15.1 
(2.64) 
0.54 
(0.54) 
0.57 
(0.17) 
21 106c 60 58 97 1 1 0 – 
19.9 
(2.77) 
0.71 
(0.78) 
0.59 
(0.14) 
22 106d 60 38 63 3 19 0 AlogP too high 
22.9 
(2.77) 
2.66 
(0.78) 
0.35 
(0.09) 
10 
Sum (22 
scaffolds) 
1110 734 66 33 173 200 3 AlogP too low 
22.8 
(3.57) 
0.38 
(1.38) 
0.57 
(0.18) 
Table 23 Lead-likeness assessment data for the allylic alkylation-derived virtual library.
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Figure 70 Distribution of number of heavy atoms (Num_Atoms) and AlogP for the virtual library based upon each scaffold. 
Compounds that survive successive filtering are shown in green. Compounds that fail successive filtering by number of 
heavy atoms (red), AlogP (yellow) and structural features (black) are shown as appropriate. 
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6.4.2 Lead-likeness assessment: Per building block basis 
 
Figure 71 Distribution of the number of heavy atoms (Num_Atoms) and AlogP for the allylic alkylation-derived virtual 
compound library based upon each building block. Red= pyrrolidine-derived; green= azetidine derived; blue= 
piperazine-derived; orange= phenylalanine derived. 
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Entry Building block 
No. 
scaffolds 
No. final 
compounds 
No. 
lead-like 
compounds 
% Lead-like 
Compounds 
Average 
number of 
lead-like 
compounds 
per scaffold 
Fail 
HA 
Fail 
AlogP 
Fail 
SS 
Most likely 
reason for 
compound 
failure 
Average 
heavy 
atom 
count 
(standard 
deviation) 
Average 
AlogP 
(standard 
deviation) 
Average 
Fsp3 
(standard 
deviation) 
1 Pyrrolidine-derived 63a 6 215 193 90 32 8 13 1 
No significant 
trend* 
21.1 
(3.15) 
0.24 
(0.88) 
0.64 
(0.15) 
2 Azetidine-derived 63b 5 188 139 74 28 6 42 1 ALogp too low 
20.4 
(3.06) 
−0.30 
(0.91) 
0.62 
(0.16) 
3 Piperazine-derived 63c 6 508 285 56 48 103 119 1 ALogp too low 
23.6 
(3.37) 
0.09 
(1.36) 
0.57 
(0.18) 
4 
Phenylalanine-derived 
63d 
5 199 117 59 23 56 26 0 
Heavy atoms 
too high 
24.7 
(3.01) 
1.92 
(1.11) 
0.37 
(0.10) 
5  All 22 1110 734 66 33 173 200 3 AlogP too low 
22.8 
(3.57) 
0.38 
(1.38) 
0.57 
(0.18) 
Table 24 Lead-likeness assessment data for the allylic alkylation-derived virtual library compounds with respect to the starting building block. *Where logP fails it was always because it was too low. 
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6.4.3 PMI assessment: Per scaffold basis  
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Figure 72 Normalised principal moment of inertia plots to show the shapes of the 1110 allylic alkylation-derived virtual 
compounds with respect to each scaffold. 
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6.4.4 PMI assessment: Per building block basis 
 
 
Figure 73 Normalised principal moment of inertia plots to show the shapes of the 1110 for the allylic alkylation-derived 
virtual library compounds, coloured by initial building block. Red= pyrrolidine-derived; green= azetidine derived; blue= 
piperazine-derived; orange= phenylalanine derived. 
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6.5 Data for the ‘top-down’ compound library 
6.5.1 Lead-likeness assessment: Per scaffold basis 
Filter 
Virtual Library (1110) 
Successive 
Filtering 
Parallel 
Filtering 
 Fail  
14 ≤ nHA ≤ 
26 
82 82 (10%) 
Fail  
–1 ≤ AlogP ≤ 
3 
145 151 (19%) 
Fail 
Structural 
0 0 
Pass All 571 (72%) n/a 
Table 25 Filtering assessment data for cycloaddition-derived virtual library and the ZINC database. For comparison, data 
obtained from parallel filtering of all compounds using each filter in isolation is shown. 
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Figure 74 Distribution of number of heavy atoms (Num_Atoms) and AlogP for the virtual library based upon each scaffold. 
Compounds that survive successive filtering are shown in green. Compounds that fail successive filtering by number of 
heavy atoms (red), AlogP (yellow) are shown. 
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Entry Scaffold 
No. final 
compounds 
No. lead-like 
compounds 
% Lead-like 
Compounds 
Average 
number of 
lead-like 
compounds 
per scaffold 
Fail 
HA 
Fail 
AlogP 
Fail 
SS 
Most likely reason 
for compound 
failure 
Average 
heavy atom 
count 
(standard 
deviation) 
Average 
AlogP 
(standard 
deviation) 
Average 
Fsp3 
(standard 
deviation) 
1 214 53 33 62 
N/A 
2 18 0 AlogP too low 
21.1 
(2.75) 
−0.57 
(0.77) 
0.73 
(0.16 
2 216 78 52 67 2 24 0 AlogP too low 
20.2 
(2.91) 
−0.59 
(0.69) 
0.75 
(0.16) 
3 225 15 12 80 3 0 0 HA too high 
24.5 
(2.59) 
1.72 
(0.61) 
0.54 
(0.04) 
4 226 294 227 77 67 0 0 HA too high 
24.3 
(2.96) 
0.85 
(0.86) 
0.57 
(0.01) 
5 227 19 19 100 0 0 0 N/A 
19.2 
(2.72) 
0.30 
(0.56) 
0.65 
(0.14) 
6 230 78 59 76 2 17 0 AlogP too low 
21.2 
(2.91) 
−0.39 
(0.69) 
0.76 
(0.15) 
7 231 67 60 90 2 5 0 HA too high 
21.4 
(2.88) 
−0.09 
(0.71) 
0.77 
(0.15) 
8 234 105 98 93 1 6 0 AlogP too low 
20.2 
(2.64) 
0.07 
(0.76) 
0.73 
(0.15) 
9 237 89 11 12 3 75 0 AlogP too low 
22.0 
(2.92) 
−1.7 
(0.68) 
0.75 
(0.16) 
10 
Sum (9 
scaffolds) 
798 571 72 63 82 145 0 AlogP too low* 
22.2 
(3.36) 
0.03† 
(1.15) 
0.68 
(0.16) 
Table 26 Lead-likeness assessment data for the cycloaddition-derived compounds.  
*There were 171 failures for too low AlogP and 76 of these can be attributed to scaffold 237. †Excluding scaffold 237 the average AlogP is 0.25.
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6.5.2 PMI assessment: Per scaffold basis 
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Figure 75 Normalised principal moment of inertia plots to show the shapes of the 798 cycloaddition-derived virtual library 
compounds with respect to each scaffold. 
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7.0 Appendix 2: NOESY and HMBC Spectra 
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